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Abstract 
Despite the success of antiretroviral therapy roll-out, one-million people still die with 
HIV-infection annually. In high-burden settings, tuberculosis remains the most common 
proximal cause of hospital admission and death in people living with HIV. In post-mortem 
series, 90% of fatal HIV-associated tuberculosis is ‘disseminated’. This is a form of 
tuberculosis which has been poorly characterised and, despite the high associated-
mortality, never been the subject of interventional trials to define optimal treatment 
strategies.  
This thesis contends that the mode of severe HIV-associated tuberculosis is blood stream 
infection. First it is argued with reference to historical literature that blood stream 
dissemination is part of the natural history of post-primary tuberculosis infection, and that 
HIV-associated M. tuberculosis blood stream infection (MTBBSI) can be conceived of as a 
reversion to, and exaggerated form of this natural history. Using data from a large cohort 
(n=571) of HIV-infected inpatients with CD4 cell count <350 cells/mm3 and a new TB 
diagnosis from Khayelitsha Hospital, South Africa (the KDHTB study), the extent and 
magnitude of MTBBSI is shown to be a major determinant of clinical phenotype and 
mortality risk. Systematic, quantitative markers of blood stream dissemination, including 
TB blood culture, urine-lipoarabinomannan (uLAM), and urine GeneXpert MTB/RIF 
testing (uXpert), can be combined into a ‘disseminated TB score.  KDHTB patients have 
high prevalence of abnormal sodium and fluid balance, metabolic acidosis associated with 
acute kidney injury, hyperlactataemia, infiltrative liver and splenic pathology, and 
anaemia. Each of these pathophysiologies in turn correlates to disseminated TB score, and 
to risk of death, suggesting bacterial burden and MTBBSI are central to the 
pathophysiology of severe HIV-associated tuberculosis.  
An individual patient data meta-analysis, with 20 independent data sets comprising over 
6000 patients, is used to establish the prevalence of TB blood culture positive disease 
amongst critically unwell HIV-infected inpatients. This shows that MTBBSI is more 
common than previous estimates suggest, is a strong independent association with 
vi 
 
mortality risk, and is also associated with specific increased risk of death if empirical 
treatment is delayed.  
The development of tools to identify and measure MTBBSI is described, including Xpert-
ultra testing of blood, and the use of a novel dye, DMN-trehalose, to perform direct 
microscopy on patient blood samples. These techniques are used to provide the first 
description of the pharmacodynamics of MTBBSI, by serially quantifying blood bacilli 
load over the first 72-hours of standard TB therapy, in 28 patients with high predicted 
probability of bacteraemia. In this cohort, risk of mortality is related to several summary 
measures of MTBBSI dynamics in the first 72-hours of therapy, suggesting this approach 
can be used to define biomarkers of treatment response. 
In conclusion, MTBBSI is a highly-specific diagnosis responsible for substantial mortality 
in hospitalised people living with HIV. Interventions with strengthened bacteriocidal 
activity, focussed on reducing bacterial burden, are warranted for MTBBSI. Tools 
developed in this thesis, including potential pharmacodynamic biomarkers, should 
facilitate such trials.  
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0 Introduction 
 
0.1 Background & motivation 
The roll-out of antiretroviral drugs has arguably been the greatest public health initiative 
of our time. The headline global figures are astonishing. Over 20 million people are 
accessing treatment.1 Millions of deaths have been avoided.2 Life expectancy on 
antiretroviral therapy is rising, up to 60-90% of that of the general population in different 
settings.3 But the pool of HIV infection continues to grow, with an estimated 37 million 
people living with HIV in 2016, and one million people still die with HIV infection 
annually.1,4  
Any complacency is dispelled with a review of recent evidence from the front-line of the 
HIV epidemic. In high-burden settings, the proportion of patients initiating antiretroviral 
therapy when already profoundly immunosuppressed is not declining despite changes to 
national and international guidelines.5-7 There is little evidence of shifting disease burden: 
people living with HIV still present and die from opportunistic infections.8-10 In South 
African district hospitals, 10-years after the start of antiretroviral scale-up, the majority of 
medical inpatients are HIV-infected, and there is no evidence the proportion has yet 
fallen.11 A marked burden of advanced HIV-disease and associated critical illness persists 
in high-prevalence settings. 
A greater part of this critical illness is caused by HIV-associated tuberculosis. TB is the 
leading cause of admission worldwide in people living with HIV; 25% of HIV-associated 
in-hospital deaths are in patients diagnosed with TB.12 The prevalence of TB in adult 
inpatients dying with HIV-infection is greater than 25% in most post mortem studies 
(pooled estimate, 40%).13 Patients hospitalised with HIV-TB have case fatality rates in the 
range 10 to 50% (depending on setting case-mix, definitions and follow-up, which are 
highly variable between studies).14-19  
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Critically unwell, HIV-infected inpatients with advanced immunosuppression do not have 
typical TB presentations. Symptom screens which are well established in ambulant 
outpatients,20 are unreliable in hospitalised people living with HIV.21,22 Radiology findings 
are atypical and non-specific at lower CD4 counts.23 Patients may be unable to produce 
sputum,24,25 and are more likely to have sputum smear or culture negative disease with 
advanced HIV infection, which is in turn associated with higher risk of mortality.26-29 
Extra-pulmonary TB is also more common at lower CD4 counts and associated with 
mortality. 30,31 In keeping with these clinical findings, meta-analysis of post-mortem data 
shows that HIV-associated tuberculosis is ‘disseminated’ in 90% of fatal cases, and is 
undiagnosed ante-mortem in half of these patients.13 The term ‘disseminated’ isn’t 
defined in this systematic review, but high rates of reticulo-endothelial, intestinal, renal 
and hepatic involvement are reported in the best described individual studies (figure 1A). 
In summary, HIV-associated tuberculosis in critically unwell inpatients is ‘atypical’ – 
often smear-negative, extra-pulmonary or disseminated. It is, however, managed with the 
same antimicrobial chemotherapy as other, ‘typical’ forms of tuberculosis: 6-month 
rifampicin-based regimen 2HRZE/4HR, with daily dosing, and rifampicin at ~10mg/Kg.32  
The systematic review and meta-analysis which supports standard therapy for 
tuberculosis in HIV co-infection found only trials which recruited pulmonary (>90% 
smear-positive) tuberculosis cases, with 24/27 trials specifically excluding patients who 
also had concomitant extra-pulmonary disease.33 This is standard practice in TB PK/PD 
studies which assess treatment response by clearance of bacilli from sputum. In addition, 
the primary outcome for anti-tuberculosis therapy phase III trials is sterilising cure, not 
mortality. Consequently, while on meta-analysis there are trends towards higher mortality 
for HIV-infected patients in lower rifampicin exposure arms (e.g. thrice weekly versus 
daily dosing), no comparisons are adequately powered for death end-points.33 There is a 
profound absence of evidence that standard TB therapy is adequate for critically unwell 
HIV-infected inpatients.  
Indeed, observational data is in keeping with therapeutic failure in this patient group, with 
evidence of significant mortality in patients despite receipt of anti-tuberculosis therapy 
(figure 1B). For comparison, it is hard to think of other common infections which are 
managed with the same antimicrobial regimen irrespective of whether the patient has a 
predicted probability of death of close to zero or approaching 50%. But no interventional 
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trials have ever been conducted that test adequacy of current standard therapy for 
preventing mortality in these high-risk patients. In this regard, it could be argued that the 
disseminated form of tuberculosis seen in critically unwell HIV-infected inpatients is a 
neglected disease, an overlooked clinical problem festering despite the successes of the 
public-health approach to the HIV in high-burden settings. HIV wasn’t historically a 
disease of poverty,34 and its major route of transmission – sex – is fairly evenly distributed 
in society. But like other neglected diseases, dying from HIV and tuberculosis in the 
antiretroviral-era is disproportionately a fate of disenfranchised people.35-38 
 
Figure 0-1. Post-mortem studies in HIV-associated adult inpatient deaths. 
A. Three of the best described post-mortem studies39-41 of patients dying with HIV-associated TB 
show the disseminated nature of this disease, with extensive reticulo-endothelial involvement. 
Categories without a bar were not assessed in the study. 
B. A study from Edendale Hospital in KwaZulu-Natal performed limited post-mortem 
examinations on a random sample of all adult inpatient deaths, excluding only trauma and obstetric 
cases.42 94% of cadavers were HIV sero-positive, half were culture positive for M. tuberculosis, and 
half had been diagnosed with TB prior to death. The overlap between culture positive and TB 
diagnosed ante-mortem cases was 58%. This means that 42% had died with undiagnosed TB (a 
diagnostic failure), but also that a substantial number of patients died despite being on anti-
tuberculosis therapy – evidence of a therapeutic failure. Median time from admission to death was 
only 4-days in these patients. 
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0.2 Thesis 
The central thesis presented in this volume is that severe HIV-associated tuberculosis 
needs to be better characterised to develop a rational basis for future interventional trials.  
It is argued that ‘atypical’, ‘smear-negative’, ‘extra-pulmonary’ or ‘disseminated’ HIV-
associated tuberculosis is better understood as a bacteraemic disease, fundamentally 
gauged by the bacilli burden and extent of blood stream infection.  This specific and 
mechanistic clinical characterisation allows novel exposition of disease phenotype and 
pathophysiology, makes a case for investigating therapies with intensified bactericidal 
activity, and provides tools which may facilitate testing these interventions.  
This thesis is not a case for expanding the use of blood cultures for diagnosing tuberculosis 
in advanced HIV-infection. TB blood culture is an expensive test of limited clinical value 
in low-resource settings. Even where available, the time to detection (averaging around 3 
weeks) means TB blood culture has limited scope to influence management. Calls to roll-
out TB blood culture were rightly dismissed by experts 20 years ago,43 and subsequent 
developments in TB-diagnostics22 make the case for blood culture even weaker now. 
Nonetheless, it will be shown in this thesis that, in research settings, TB blood culture is a 
useful tool for understanding severe HIV-associated tuberculosis. As an analogy, PET-CT 
scanning has been used to better characterise latent TB infection,44 but this does not 
imply that TB contacts should now be sent for PET-CT. Similarly, better clinical 
descriptions of M. tuberculosis blood stream infection (MTBBSI) empower clinicians to 
make empirical diagnoses, just as we don’t only rely on blood culture to diagnose bacterial 
endocarditis in a patient with myalgia, fever, and Osler’s nodes, or to diagnose blood-
stream embolic S. aureus in an intravenous drug user with sepsis and multiple peripheral 
lung abscesses on chest x-ray. 
This is a general theme of this work, that detailed clinical description of severe HIV-
associated tuberculosis – and specifically of M. tuberculosis blood stream infection – 
remains fruitful. Clinical descriptions may seem an anachronism at a time when clinical 
science increasingly looks to systems biology and the ‘omics for inspiration. But the power 
of these techniques rests on them being related to real-world phenotypes: without clinical 
metadata, big-data is just noise.  A second, related, theme in this thesis is that the 
dichotomy between a traditional clinical research approaches (data from observation and 
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description, e.g. the much-maligned case series) and ‘modern’ approaches (systematic, 
unbiased, high-resolution data, e.g. gene-expression analysis) is not as stark as it seems. 
Clinicians have always handled high-dimensional data, and are running causal models and 
classification algorithms intuitively every time they make a diagnosis. In this thesis, 
computationally intensive methods espoused by systems biology – such as hierarchical 
clustering and principle components analysis – are successfully applied to clinical data, to 
give a low-dimensional summary of clinical phenotypes and relate this to bacilli burden 
and extent of blood stream infection. 
The idea that bacilli burden – or indeed extent of blood stream dissemination – are the 
major axis determining clinical variation in tuberculosis disease is not new, but can be 
dated back to the early 20th century giants of TB pathology,45,46 or even Robert Koch.47 
Measuring and counting bacilli is a theme throughout this thesis. Novel techniques are 
developed and explored for quantifying mycobacteria in the lab and in blood or urine. 
Importantly, these methods allow systematic assessment of bacilli burden in the body and 
in the blood in a way which would have been unimaginable to Krause, Pagal, or Koch, but 
substantiates their ideas intently.   
 
0.3 Overview of chapters 
Chapter 1 reviews some of these historical ideas, reviewing the semantic classifications of 
disseminated and blood stream tuberculosis. It is argued that blood stream infection is a 
mode of tuberculosis infection, which has an exaggerated form in advanced-HIV co-
infection.  The clinical phenotype of advanced HIV-associated tuberculosis is then 
described using unprecedented detail afforded by the results of the KDHTB cohort study 
(detailed below), and it shown that a substantial portion of co-variance in clinical variables 
and death can be related to TB blood culture positivity, or the combined measure of blood 
culture, urine-Xpert and urine-lipoarabinomannan positivity, which are all hypothesised 
to be mechanistically related to total bacilli burden and blood stream dissemination.  
In chapter 2 the ability to predict TB blood culture positivity from baseline clinical 
variables available on day of admission to hospital is shown. Using training and test data 
sets from the KDHTB study, a variety of machine-learning techniques are employed to 
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develop a final model with area under ROC curve around 0.85 for TB blood culture 
positivity. This is validated in a prospective cohort, which is also used to show that the 
additional yield associated with doing more than one TB blood culture is similar to that 
established for other non-mycobacterial blood stream infections. The predictive modelling 
developed here is used to enrich recruitment to the KDHTB sub-study presented in 
chapter 5. 
The third chapter reports a 7000 patient individual participant data meta-analysis used to 
define rates of TB blood culture positivity in HIV-associated tuberculosis. The prevalence 
of MTBBSI has been underestimated in previous studies, and WHO danger-sign positive 
HIV-infected inpatients with tuberculosis and a CD4 count less than 100 cells/mm3 are 
more likely than not to be TB blood culture positive if at least 2 cultures are sent prior to 
start of TB therapy. It is argued that patients with MTBBSI are therefore an important 
group in which to validate the WHO ‘algorithm for managing people living with HIV and 
suspected of having TB (seriously ill)’.48 Evidence is presented to show that sputum 
diagnostics are unreliable rule-out tests for TB in patients with BSI, particularly if 
critically unwell. In addition, delay in empirical treatment is likely independently 
associated with mortality in MTBBSI patients.  
Chapter 4 reviews some of the difficulties of quantifying mycobacteria, and describes the 
development of a novel flow cytometry method for absolute counting of mycobacteria in 
in vitro broth cultures. This method is used to describe sub-populations of bacilli with 
differential response to antimicrobials – i.e. phenotypic heterogeneity related to 
antimicrobial action – and supports the idea that culturability gives a limited window on 
pharmacodynamics of mycobacteria.  
The flow cytometry method is used in the development of methods for identifying and 
quantifying M. tuberculosis in blood, described in chapter 5. A novel blood microscopy 
technique using mycobacterial dye 4-N,N-dimethylaminonaphthalimide-trehalose 
(DMN-tre), and a method for detecting TB in blood using GeneXpert-ulta cartridges, are 
shown to have equal or greater sensitivity compared to Myco/F lytic blood culture. All 
three methods are used to serially quantify MTBBSI over the first 24-hours of anti-
tuberculosis treatment in 28 HIV-infected inpatients. This shows marked variation in 
blood bacilli burden and response to treatment between patients, and provides evidence 
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that this in turn is related to mortality outcome. It is argued this can be the basis of a 
pharmacodynamic biomarker of treatment response, to facilitate future interventional 
trials focussed on MTBBSI.  
 
0.4 The KDHTB study 
All the work in this thesis is based on or nested within the “Defining interventions to 
reduce mortality in severe HIV-associated tuberculosis” (KDH-TB) study, PI Professor 
Graeme Meintjes. The study is referenced continually throughout so is summarised here.  
0.4.1 Study procedures  
KDHTB ran from January 2014 to October 2016 and recruited HIV-infected patients 
newly admitted to Khayelitsha Hospital aged 18-years or more, with CD4 count less than 
350 cells/mm3, and suspected of having TB (i.e. a new diagnosis). Pregnant patients and 
those in receipt of 3 or more doses of TB therapy within the preceding month were 
excluded.    
Consenting patients had extensive assessment and sample collection on day of 
recruitment, including unselected Myco/F lytic TB blood culture (5ml blood), collection 
of urine for lipoarabinomannan testing and concentrated urine GeneXpert testing, and 
sputum (with induction attempted if non-productive or absent cough) GeneXpert and 
culture. Patients were managed by non-study health care team at Khayelitsha Hospital, 
and followed-up by study team at 4 and 12 weeks to ascertain survival (by hospital visit, or 
failing this telephone or hospital record or death registry review).  
0.4.2 Setting  
Khayelitsha is a township near Cape Town, South Africa, with an official population 
estimate of approximately half-a-million residents; two-thirds of households have a 
monthly income less than R3200 (~US$200), half of households are informal settlements, 
and 61% have access to piped water.49 HIV-seroprevalence is ~34% in antenatal 
attendees,50 and TB notification rate was at least 1500/100,000 in 2011.51 Khayelitsha 
Hospital is a public sector district facility where patients too ill to be managed in the 
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community are referred from primary care clinics. It has approximately 150 inpatient 
medical beds but no high-dependency or intensive care unit.  
0.4.3 Cohort description 
For the purposes of analysis in this thesis, patients were classified as confirmed TB if they 
had M. tuberculosis identified on at least one culture sample or by GeneXpert. Patients 
were classified as having a clinical TB diagnosis if they had a compatible clinical picture,* 
were treated for TB, and no alternative diagnosis was made, or if they were urine-
lipoarabinomannan positive (≥1 on Alere lateral flow assay). A STROBE flow chart 
showing recruitment is shown in figure 2. Basic descriptions of the cohort are shown in 
table 1.  
 
Figure 0-2. STROBE flow diagram for KDHTB study. 
                                                             
* Exudative or lymphocytic pleural effusion; pericardial effusion; adenopathy greater than 2cm in 
diameter; compatible chest x-ray findings. 
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Table 0-1. Basic descriptors of KDHTB cohort by TB diagnosis category. 
  
Clinical TB 
(N=114) 
Proven MTB 
(N=482) 
Total 
(N=596) 
p value 
Male 43 (37.7%) 243 (50.4%) 286 (48.0%) 0.02 
Age, years 37.6 (31.0 to 43.6) 35.8 (30.8 to 43.3) 
35.9 (30.9 to 
43.4) 
0.674 
ART status    0.052 
   Defaulted 34 (30.1%) 111 (23.2%) 145 (24.5%)  
   Naive 33 (29.2%) 198 (41.3%) 231 (39.0%)  
   On ART 46 (40.7%) 170 (35.5%) 216 (36.5%)  
CD4 count, cells/mm3 97 (44 to 186) 53 (18 to 111) 59 (22 to 121) < 0.001 
Detectable plasma HIV 96 (85.0%) 414 (87.0%) 510 (86.6%) 0.68 
Previous TB history       0.012 
   None 47 (43.9%) 270 (57.9%) 317 (55.3%)   
   Previous TB 60 (56.1%) 196 (42.1%) 256 (44.7%)   
TB treatment doses prior to 
recruitment 
   0.71 
   0 100 (87.7%) 422 (87.6%) 522 (87.6%)  
   1 9 (7.9%) 46 (9.5%) 55 (9.2%)  
   2 5 (4.4%) 13 (2.7%) 18 (3.0%)  
   3 0 (0.0%) 1 (0.2%) 1 (0.2%)  
Any antibiotics prescribed  111 (97.4%) 460 (95.4%) 571 (95.8%) 0.505 
Ceftriaxone prescribed 104 (91.2%) 420 (87.1%) 524 (87.9%) 0.296 
Serum cryptococcal antigen test       0.296 
   Negative 109 (95.6%) 455 (94.8%) 564 (94.9%)   
   Positive 5 (4.4%) 16 (3.3%) 21 (3.5%)   
Detectable CMV viraemia    0.25 
   FALSE 73 (65.8%) 281 (59.3%) 354 (60.5%)  
   TRUE 38 (34.2%) 193 (40.7%) 231 (39.5%)  
Sputum TB culture       < 0.001 
Missing result 43 135 178   
   Negative 71 (100.0%) 38 (11.0%) 109 (26.1%)   
   Positive 0 (0.0%) 309 (89.0%) 309 (73.9%)   
Sputum Xpert     < 0.001 
Missing result 33 96 129  
   FALSE 80 (98.8%) 63 (16.3%) 143 (30.6%)  
   TRUE 1 (1.2%) 323 (83.7%) 324 (69.4%)  
Urine-Xpert       < 0.001 
Missing result 8 71 79   
   Positive 0 (0.0%) 227 (55.2%) 227 (43.9%)   
   Negative 106 (100.0%) 184 (44.8%) 290 (56.1%)   
Urine-LAM    < 0.001 
Missing result 7 65 72  
   Negative 55 (51.4%) 131 (31.4%) 186 (35.5%)  
   Positive 52 (48.6%) 286 (68.6%) 338 (64.5%)  
TB blood culture       < 0.001 
Missing result 12 12 24   
   Negative 102 (100.0%) 250 (53.2%) 352 (61.5%)   
   Positive 0 (0.0%) 220 (46.8%) 220 (38.5%)   
Rifampicin resistance isolate 0 (0.0%) 55 (11.4%) 55 (9.2%) < 0.001 
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12-week outcome       0.315 
   Died 19 (16.7%) 108 (22.4%) 127 (21.3%)   
   Loss to follow-up 1 (0.9%) 8 (1.7%) 9 (1.5%)   
   Survived 94 (82.5%) 366 (75.9%) 460 (77.2%)   
Days to death  6 (3 to 23) 15.5 (4 to 40) 13 (4 to 35) 0.097 
Improved overall by 12-weeks 71 (62.3%) 295 (61.2%) 366 (61.4%) 0.916 
 
Median (inter-quartile range), or frequency (%) shown; P-value is from Wilcox Rank-Sum test or 
Fisher’s exact test as appropriate. 
ART = Antiretroviral therapy; CMV = cytomegalovirus; Any antibiotics prescribed = any 
antibiotics prescribed at time of recruitment for treatment of bacterial infection (not including anti-
TB therapy); Rifampicin resistance isolate = any cultured isolate had rifampicin resistance on DST 
or any Xpert sample had rpoB probe result in keeping with rifampicin resistance.  
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1 Clinical description of HIV-
associated M. tuberculosis blood 
stream infection 
 
1.1 Introduction 
 
“If the names are unknown, knowledge of the things also perishes.”  
Carl Linnaeus, Philosophia Botanica (1751), aphorism 210. 
 
This chapter starts with a discussion of semantics. HIV-associated TB is often described 
as ‘disseminated’, but the term is ill-defined and used inconsistently: a vague name for a 
condition mostly considered non-specific. Here, it is claimed that this descriptive 
nihilism is unwarranted. It is argued that HIV-associated disseminated tuberculosis is 
essentially a spectrum, characterised by bacilli burden, and degree of ongoing, active 
blood stream infection. M. tuberculosis blood stream infection (MTBBSI) is an explicit 
name for this condition, and can, in fact, be considered highly specific. 
To support this, some compelling classical descriptions of bacteraemic dissemination of 
tuberculosis are reviewed and an attempt is made to summarise these mechanistically.  
The contention is that M. tuberculosis blood-stream dissemination is pivotal in TB’s 
natural history, and that HIV-associated MTBBSI can be conceived of as a reversion to, 
and exaggerated form of, the bacteraemic mode of tuberculosis infection. Modern 
descriptions of HIV-associated MTBBSI are also reviewed, but these are argued to be 
haphazard and superficial. A more comprehensive clinical description is attempted using 
data from the uniquely rich KDHTB dataset. Statistical data reduction techniques are 
employed to uncover fundamental patterns of covariance. Rather than being entirely data 
driven and descriptive, these findings are related to prior clinical theory and to the 
contemporary sepsis literature, making inferences about pathophysiology where possible. 
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1.2 What is disseminated TB? 
Classifications, definitions & 
mechanisms. 
 
1.2.1 The classification of disseminated tuberculosis 
 
The International Classification of Disease52 lists many forms of tuberculosis: respiratory 
(including pleural and laryngeal); 7 types of tuberculosis of the nervous system; 
tuberculosis of the heart; eye; ear; endocrine glands; musculoskeletal system; genito-
urinary system; lymph nodes; digestive tract or hepato-biliary system; cutaneous or 
mucous membrane (including, explicitly, the anal canal); the placenta; and the thymus 
gland. Miliary tuberculosis [sub-index term, disseminated tuberculosis] is noted as the 
“widespread dissemination of Mycobacterium tuberculosis via haematogenous spread” and 
defined as millet-like seeding on chest radiography. But there is no explicit mention of 
tuberculosis bacteraemia anywhere in this capacious classification.†  
HIV-associated tuberculosis is classified separately in the ICD (IC61.3: HIV infection 
clinical stage IV associated with tuberculosis, a stub, listed without further description or 
associated index terms), and tuberculosis BSI could reasonably be considered 
ontologically subsumed here. But even international standards on HIV-associated 
tuberculosis are reluctant to name tuberculosis bacteraemia. Like the ICD, World Health 
Organisation (WHO) guidelines on HIV-associated TB do not address MTB BSI directly, 
but instead refer to ‘disseminated TB’:  
“People living with HIV with extrapulmonary TB often have disseminated disease and 
are at high risk of rapid clinical deterioration and death. The commonest forms include 
lymph node (especially in the neck or under the arms), pleural (usually one-sided 
pleural effusion) and disseminated TB (disease that is not limited to one site in the 
                                                             
† The spleen and bone marrow are also conspicuously absent as explicit entities in the tuberculosis 
section. 
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body). Pericardial and meningeal TB are less frequent forms of extrapulmonary TB but 
are more likely to result in fatal outcomes.”48  
 
“HIV-related extrapulmonary tuberculosis is a WHO clinical stage 4 (advanced AIDS) 
diagnosis, and patients with HIV-related extrapulmonary tuberculosis often have 
disseminated disease and are at high risk of rapid clinical deterioration and death. The 
accurate diagnosis of extrapulmonary tuberculosis is complex and difficult…high rates 
of undiagnosed disseminated tuberculosis have been consistently identified in febrile, 
HIV-positive inpatients…”53 
 
Although the five citations given to support this last statement are all M. tuberculosis blood 
culture studies,54-58 tuberculosis bacteraemia isn’t directly mentioned in any WHO HIV-
TB guideline.‡ The definition of “disseminated TB” is left vague (“not limited to one site 
in the body”), and – in contrast to other forms of extra-pulmonary TB – disseminated TB 
is described as non-specific, characterised by an absence of clinical signs, and by negative 
test results.  
This uncertainty accurately reflects the wider literature. No consistent definition is used 
by studies reporting on disseminated, HIV-associated, tuberculosis (figure 1).   Few 
commentators have directly addressed the relationship between disseminated tuberculosis 
and blood stream infection.  
 
Figure 1-1. Definition of disseminated TB in n=50 random sample from PubMed 
Disseminated & TB & HIV [Title/Abstract] 
An exception is the work of John Crump et al., who consistently define disseminated 
tuberculosis as “isolation of Mycobacterium tuberculosis from blood or bone marrow, from a 
                                                             
‡ This apparent reticence to name TB bacteraemia is very likely partly because TB blood culture is 
an inappropriate diagnostic test for high-burden low-resource settings, due to its expense and 
limited role in clinical decision making. This point is well made in correspondence in the Lancet in 
1999-2000.43. Hudson CP, Maartens G, Wood R, et al. Unrecognised mycobacterium 
tuberculosis (multiple letters). Lancet 2000; 355(9198): 141-3. This thesis is categorically not 
arguing for greater use of blood culture in low resource settings. 
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liver biopsy specimen, or from specimens from ⩾2 non-contiguous organs”, making MTB 
BSI a subset of disseminated tuberculosis.59,60 Crump et al. go further, distinguishing 
bacteraemic from non-bacteraemic disease phenotypes in their retrospective case series 
(n=52, 46% HIV-infected) from Duke University Medical Centre: patients with 
bacteraemic disseminated tuberculosis less frequently had miliary chest x-ray (risk ratio = 
0.32) but higher 30-day mortality (risk ratio = 5.6).60  Others have specifically linked this 
clinical  diversity to different histo-pathology determined by immune-status:  
“While tubercules form in miliary TB in the tissues, they are not present in 
disseminated TB: nonreactive generalized TB. The fate of host in TB bacillemia is 
dictated by the immune status: in case of immunocompetency, miliary TB; in case of 
immunocompromisation, disseminated TB. Histopathological changes are related to 
the degree of cellular immunodeficiency. In patients with normal CD4 lymphocyte 
count, classical tubercules develop. In patients with severe lymphopenia… atypical 
foci… unorganized granulomas, scanty giant cells… necrosis and large amounts of 
bacilli.”61 
 
The implication is that, while all miliary TB is haematogenous, not all haematogenous TB 
is miliary. Established descriptions of miliary TB pre-dating HIV-coinfection are worth 
reviewing next. 
1.2.2 Classical descriptions of miliary tuberculosis 
The most classical description is of uncontained primary infection (typically in children 
and infants) resulting in acute haematogenous dissemination, followed by development of 
‘millet-like’ (1-3mm) well organised granulomas at the multitude of seeded sites.62,63 
Initially, development of chronic lung tuberculosis was thought to preclude miliary 
spread,64 but by the mid-20th century substantial case and post-mortem series reported 
acute miliary dissemination from (presumed reactivated) chronic pulmonary and extra-
pulmonary lesions in adults.64-66 The key features in all these reports were that multiple 
organs – invariably including the spleen, liver, bone marrow, and often meninges and 
choroid – demonstrated lesions of the same size and acute stage, suggesting a discrete 
bacteraemic event, and retained ability to form organised granulomas.  
A failure to form miliary granulomas after an acute haematogenous dissemination was also 
well recognised, under a variety of names:  
• non-reactive tuberculosis (because of the absence of cellular reaction at foci, favoured 
by pathologists, who generally made the diagnosis);67  
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• acute tuberculosis septicaemia (classically associated with blood dyscrasias);68-70 
• typhoidal form tuberculosis (described in detail by Osler: “the temperature increases, 
the pulse rapid and feeble, the tongue dry; delirium becomes marked and the cheeks 
are flushed… pulmonary symptoms may be slight… enlargement of the spleen 
occurs… [petechiae and] Cheyne-Stokes breathing occur towards the close”);71  
• Yersin type tuberculosis (Yersin recorded that rabbits injected intravenously with very 
large numbers of bacilli die with “septicaemic cachexy” before developing any 
macroscopic lesions);72 and 
• sepsis tuberculosa acutissima, sepsis tuberculosis gravissima, or Landouzy’s septicaemia, 
which are still sometimes used to specifically describe tuberculosis associated with 
acute septic shock or multi-organ failure.73-76  
Acute miliary disseminations of tuberculosis were distinguished from more chronic 
‘abortive dissemination’45 of tuberculosis: 
“68 per cent of… pulmonary tuberculosis at autopsy showed extrapulmonary foci of a 
chronic type… [these are] "benign generalizations" of pulmonary forms of 
tuberculosis… when occasional tubercle bacilli are released, producing isolated 
tubercles in one or two additional sites, the disease has in a sense become generalized 
but is still quite distinct from acute generalized miliary tuberculosis… One must 
recognise, therefore, that disseminated tuberculosis infection may appear in several 
forms. One extreme is the acute, progressive disease… [the other] chronic, 
nonprogressive extrapulmonary tuberculosis lesion, which seldom, if ever, causes 
death.”65 
 
In fact, sub-acute, non-miliary, TB blood stream infection was strongly suspected by 
pathologists in the pre-antibiotic era, but they lacked the tools to observe this 
antemortem. In 244/804 post-mortems of adults dying of tuberculosis, Lewison et al. 
found TB lesions in the spleen of varying “size and chronicity”, caused “in all 
probability, from repeated blood infection”,66 which doesn’t sound very benign or non-
progressive. 
With the roll-out of chest radiology it was established that chronic but progressive 
disseminated disease was not only possible, but common, with remissions and relapses, 
and even recurrent miliary episodes.77-79 This chronic course was noted to give rise to 
more heterogeneous pathology than was captured by the term ‘miliary’:  
“chronic miliary tuberculosis is a somewhat protean condition, which justifies the 
substitution of the name ‘chronic disseminated tuberculosis’…”80 
 
Subsequently, in the early-antibiotic, post-BCG era, a rapid decline in classic miliary TB 
in children was observed, and yet another category of disseminated TB came to the fore: 
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late generalised tuberculosis (LGT). This was defined as presence of miliary tubercles in 
multiple organs in the absence of an active primary Ghon complex.81,82 Curiously, TB 
meeting this definition can be found in all prior adult post-mortem series of miliary TB 
that I have seen, and the new term seems to have emerged more in response to the 
“radical change in miliary tuberculosis epidemiology”, which was now a disease of the 
elderly.82,83 Physicians at the time were particularly alarmed by the fact that “cryptic”84 
miliary disease was being detected on post-mortem histology, but undetected on chest x-
ray: 
“characterised by an insidious onset and progression and the absence of any reliable 
clinical pointers to the diagnosis… such forms of tuberculosis may even be missed on 
naked-eye examination of the organs at necropsy... the low rate of diagnosis in this 
group is disturbing.”83 
It was also clear from the post-mortem studies that some LGT was of the chronic, 
progressive type, where the “dissemination appeared episodic or protracted since acute 
lesions were admixed with tubercles showing partial or complete replacement fibrosis”.82 
Choroidal lesions and meningitis appeared rare compared to classic acute miliary 
tuberculosis.82-85 The insidious nature of LGT was specifically linked to waning “allergic 
response to the bacillus, as measured by skin tuberculin sensitivity… after the age of 50 
years”,84 and “indiscriminate use of [recently discovered] cortisone therapy”.86  
 How can we make sense of this shifting historical classification of disseminated TB? For a 
start, it’s clear that classifications are made to fit the prevailing epidemiology, and biased 
by the available technical windows onto disease process. When only post-mortem data 
was available to correlate with clinical observation, disseminated TB could only be acute 
and fatal, or, chronic and non-progressive; the advent of chest radiology revealed this to 
be a biased understanding. When the case mix shifted to be dominated by elderly patients 
with declining cell mediated immunity and heterogeneous TB lesions, the terms “late 
generalised”, “cryptic” and “anergic” TB were invented to emphasise a perceived 
departure from “classic” acute miliary presentations. If different diagnostic technologies 
– say, reliable blood culture, and PET-CT scans – had been available to clinicians working 
in the pre-antibiotic era, their classification of disseminated TB (which we have inherited) 
would have been different.  
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Further – and more speculatively – a mechanistic description of TB dissemination might 
help resolve some of the complexity. Specifically, how do TB bacilli end up in the blood 
stream?  
1.2.3 Mechanisms of TB bacillaemia 
I assert there are two pathophysiological processes described in the literature: (1) a 
sudden, stochastic event; and (2) bacillaemia as a regular event in the natural history of 
TB infection.  
The former is clearly linked to acute miliary disease. Weigert found evidence of caseous 
lymph node erosion into a pulmonary blood vessel in a majority of miliary TB cases at 
post-mortem – the Weigert focus.64,87 Similar cases have been made for rupture of 
tubercles in the vascular intima or thoracic duct, and emptying of a (pulmonary or extra-
pulmonary) caseous focus into the circulation.64,65 The sudden and stochastic nature of 
such dissemination events is illustrated by the rare but well described cases of miliary TB 
following surgical procedures or traumatic rupture§ of latent tubercles.88-93 
But acute miliary dissemination is an atypical process in TB’s natural history. By contrast, 
after initial inhalation of bacilli, infection and spread via the lymphatics is an essential step 
in establishing infection, with a natural extension via the thoracic lymph node trunk to the 
subclavian vein (a “lymphatic disease with a pulmonary portal”).94 TB bacteraemia 
during primary infection is extensively described in animal models,95-98 and has generally 
been accepted to occur in humans at least since the descriptions by Calmette.99,100 There 
is even some indirect clinical evidence of an extended period of “silent bacillaemia” 
through post-primary infection in some patients.101,102 In this conception, a “more general 
[haematogenous] distribution of infection [is] perhaps the mode of tuberculosis”. 103   
Is such dissemination the exception or the rule? In 49 immuno-competent Mexican 
patients who died of causes unrelated to tuberculosis, with no history of tuberculosis 
disease, Barrios-Payán et al. identified M. tuberculosis DNA in lung (72%), spleen (70%), 
kidney (68%), and liver (66%) tissue.104 In a post-mortem study of patients dying with 
                                                             
§ “A man, aged 33, received a blow on the left testicle, followed by local and general symptoms. 
Eight-days later he had a rigor, and seventeen days later he died of miliary tuberculosis. 
Necroscopy showed that the left epididymis contained a softened caseous nodule smaller than a 
small cherry.”88. May O. The Relation between Trauma and Tuberculosis: From the Point of 
View of Accident, Insurance. Br Med J 1928; 2(3545): 1090-1. 
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HIV-associated tuberculosis, genetic distance between bacilli isolated from different body 
sites in the same patient do not depend on spatial proximity: TB isolated from different 
lungs are no more genetically related than isolates from the same lung, and even bacilli 
from different organs are as likely to be closely related as those from two different ling 
sites.105 The authors logically conclude that “similar patterns of migration within and 
between organs suggest that dissemination of M. tuberculosis across the lungs… is no 
easier than dissemination across organs”.105 
This evidence implies that blood stream infection is a routine part of TB’s natural history, 
that bacteraemia is an inevitable result of progressive primary disease, and that all 
tuberculosis is disseminated to a greater or lesser extent. This was certainly the view of 
Walter Pagel, the last great TB pathologist of the pre-antibiotic era, who called post-
primary tuberculosis “haematogenous tuberculosis” (table 1).106,107 
Table 1-1. Principal forms of tuberculosis according to Pagel107 
Forms of tuberculosis Description 
Primary infection “When the bacillus enters the lung a small patch of caseous broncho-
pneumonia develops and later encapsulates… Before the primary 
focus is fully developed, a similar caseous lesion appears in one of the 
regional lymph nodes… The lymph nodes beyond the regional nodes 
first affected may become involved by lymphatic spread.” 
Post primary tuberculosis: 
haematogenous disseminated 
tuberculosis 
“Haematogenous dissemination can be mild and benign or may cause 
severe and fatal illness. All intermediate stages are observed… the 
number of bacilli reaching the blood stream and multiplying in the 
tissues is the main concern.” 
Bronchogenic tuberculosis: 
lesions limited to the lungs 
“Bronchogenic differs from primary tuberculosis in that the regional 
lymph nodes, though they may show some non-specific reactive 
changes… remain devoid of appreciable caseation. It differs from 
disseminated tuberculosis in that it is restricted to the lungs and the 
sputum draining channels (larynx and gut); further the lesions are 
asymmetrical and have a marked tendency to cavitation. As the 
condition progresses it is characterised by gradual destruction of the 
lungs by caseous and liquefying lesions produced by transmission of 
the bacilli along the bronchi.” 
 
All the various described classes of disseminated TB can be, tentatively, related to these 
two underlying processes then. Sudden releases of many bacilli into the blood stream can 
result in classic acute miliary tuberculosis or a non-reactive acute “typhoidal” 
tuberculosis septicaemia, depending on the number released and degree of 
hypersensitivity in the host. On the other hand, a spectrum of post-primary tuberculosis, 
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characterised by the “number of bacilli reaching the blood stream and multiplying in the 
tissues” (as a continuous process, not a discrete event) can encompass the other forms of 
disseminated TB. Paucibacillary extrapulmonary TB (for example, meningitis, adenitis, 
pleurisy – even if in “⩾2 noncontiguous” sites), “benign generalisations”, “abortive 
dissemination” are at one end of this spectrum. Late generalised tuberculosis, “anergic 
TB of the elderly”, and the disease often seen in post-mortem studies of HIV-associated 
tuberculosis, lie at the other extreme, representing failing immune containment of post-
primary disease. This is a reversion to, and exaggerated form of, the bacteraemic stage of 
TB’s natural history. 
What are the implications? First, blood stream infection isn’t an exotic addendum to 
HIV-associated disseminated TB, it’s the mode of HIV-associated disseminated TB.  The 
question is how much dissemination, i.e. what is the total body bacillary burden? And, is the 
bacteraemic dissemination ongoing? Blood culture – or other quantifications of bacilli in 
blood – give a direct and systematic answer to these questions. So, too, might urine based 
quantifications of bacilli burden and (renal) dissemination, like urine lipoarabinomannan 
and urine Xpert testing (discussed below). While Krause was frustrated that “native 
tissue reaction [is] the only visible process”103 by which to gauge TB dissemination, we 
don’t have to be.  
Second, by accepting advanced HIV-associated disseminated TB is, fundamentally, a 
blood stream infection, a more explicit clinical phenotype can be demarcated. While 
disseminated tuberculosis is ill-defined, non-specific, and characterised by negative test 
results, MTB BSI is positively and mechanistically defined, homogenous and 
reproducible. This chapter aims to give a rigorous clinical description of MTB BSI, and 
show its central clinical importance in advanced HIV-associated tuberculosis, starting 
with a review of the previous literature. 
 
1.3 Prior descriptions of HIV-associated 
MTBBSI 
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1.3.1 Clinical descriptions of HIV-associated MTB BSI 
By the end of the 1980s there were 11 publications reporting 59 cases of tuberculosis 
isolated from blood culture in HIV positive patients.108-118 These were all from high-
resource, low-TB burden settings, where modern, liquid media mycobacterial blood 
culture techniques were starting to be adopted. Those that gave clinical descriptions 
reported MTB BSI to be associated with advanced immunosuppression, lymph node 
disease, ‘atypical’ presentations (i.e. limited pulmonary features), and high mortality 
(table 2). These descriptions were, however, far from systematic, and tuberculosis was 
overshadowed by Mycobacterium avium complex as a cause of mycobacteraemia in most of 
these settings.112,113,115 
Table 1-2. Case series of MTBBSI from the first decade of the global HIV epidemic 
1st Author Year Country n Clinical features reported in MTB BSI 
Barnes109 1987 USA 6 cases Lymphadenitis; lymphopenia; concurrent candidiasis and PCP; 
pulmonary symptoms, CXR and sputum microbiology of limited 
diagnostic value; poor prognosis 
Prego115 1990 USA 2 cases Liver and bone marrow involvement in both cases 
Saltzman116 1986 USA 1 case Anorexia, weight loss; concurrent pulmonary TB and PCP; lymphopenia 
Shafer117 1989 USA 7 cases Concurrent AIDS defining illness; high fever; raised alkaline phosphatase 
and LDH; miliary CXR; high early mortality 
Bouza110 1988 Spain 16 
cases 
In 5 cases blood was the diagnostic sample; predominance of lymphatic 
disease; concurrent AIDS defining illnesses common; high early mortality. 
Barber108 1990 USA 9 cases Fever and severe weight loss; absence of pulmonary symptoms; 
lymphadenopathy; candidiasis; anaemia; abnormal LFTs and LDH; low 
CD4 counts; anergic skin tests; 4 patients had normal CXR at 
presentation; 2/9 cases sputum culture positive; 6 died within 7 months. 
Handwerger114 1987 USA 5 cases Generalised lymphadenopathy; candidiasis; chronic diarrhoea. 
CXR = chest x-ray; LDH= lactate dehydrogenase; LFTs = liver function tests; PCP = Pneumocystis carinii 
 
By contrast, when blood culture studies were subsequently carried out in low-resource, 
high-TB burden settings during the 1990s, tuberculosis was the more frequent blood 
pathogen.54,55,119-123 Studies in these settings have also been – particularly in the last 20 
years – increasingly systematic, with defined control groups allowing assessment of 
clinical features as ‘predictors’ of MTB BSI (table 3, figure 2). The most consistently 
identified predictors of MTBBSI have been low CD4 count and anaemia. Several other 
variables have a high ‘hit rate’, for example, hyponatraemia, lymphadenopathy, 
hypoalbuminaemia, and body mass index / mid upper arm circumference (figure 2).  
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Table 1-3. Cohort and case-control studies reporting clinical predictors of MTBBSI in PLWHIV 
 
 
 
 
 
 
 
 
 
IP = 
Inpatient; OP = Outpatient 
Studies identified from the 2375 abstracts screened for meta-analysis detailed in chapter 3. In these studies, patients with and without positive 
blood culture were compared within the population defined by the inclusion criteria. The two Lewis 2002 entries (57) are analyses from the same 
cohort using different inclusion criteria / control group as indicated. Associations with MTBBSI are shown in the next figure. 
 
1st Author 
Year 
published 
Design Inclusion MTBBSI n Algorithmic variable selection for multivariate testing 
Muchemwa124 2016 cohort HIV+ IP severe sepsis n 70/201 Stepwise 
Nakiyingi125 2015 cohort HIV+ IP&OP suspected sm-ve TB n 41/394 Univariate p<0.2 & stepwise 
Crump126 2015 nested case-
control 
Patients who had TB blood culture 
performed in ACTG STRIDE study 
n 18/90 Univariate p<0.1 & stepwise 
Jacob127 2013 cohort HIV+ IP severe sepsis n 86/368 Stepwise 
Feasey15 2013 cohort HIV+ IP suspected TB n 10/104 Univariate only presented 
Crump59 2012 cohort Febrile IP (157 HIV+) n 12/403 Univariate only presented 
Varma128 2010 cohort HIV+ OP n 
31/2013 
Univariate p<0.05 & stepwise 
Lewis57 2002 cohort Febrile or shock IP (285 HIV+) n 57/344 Adjusted for a priori set demographic factors (age, 
sex, urban dwelling, education, AIDS diagnosis) 
Lewis57 2002 cohort Febrile or shock IP with TB 
diagnosis  
n 57/116 Univariate only presented 
von 
Gottberg129 
2001 cohort IP suspected TB (58 HIV+) n 16/58 Univariate only presented 
McDonald58 1999 cohort Febrile IP (255 HIV+) n 34/344 Univariate only presented 
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Figure 1-2. Clinical predictors associated with MTBBSI from studies in preceding table 
Cells in matrix are coloured to indicate if an association was found (grey = none; yellow = univariate; blue = multivariate), with no colour (white) 
indicating the predictor was not assessed or not reported. In addition, predictors included in multivariate modelling are indicated by a black outline 
around the cell. There is substantial variation in what variables were assessed and adjusted for across studies. 
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There are several difficulties with interpreting these MTBBBSI clinical predictor studies: 
1. Variable selection is inconsistent. Mostly, these studies are secondary analyses of 
datasets designed to answer other questions, so predictors are likely assessed 
opportunistically. While several studies emphasise variables which are ‘independent’ 
predictors, choice of variables to adjust for in multivariate models has been even more 
inconsistent, and generally not explicitly justified. The implicit assumption is that 
‘independent predictors’ are ‘stronger’ predictors. But should we really conclude 
that, for example, CD4 count is not a strong predictor of MTBBSI because it becomes 
non-significant after adjusting for an apparently arbitrary set of co-variates?124 
Collinearity and small sample sizes increase this type II error risk. 
2. Inclusion criteria, and therefore comparison groups, vary widely between studies. In 
studies that include substantial numbers of patients without TB in the control group, 
variables associated with TB generally (rather than BSI specifically) may still be 
strongly associated with MTBBSI. Associations could differ, or even reverse, with 
different inclusion criteria (Simpson’s paradox130). For example, two of the best 
reported studies124,127 recruited inpatients with severe sepsis; associations with 
MTBBSI within this stratum of patients may not represent the wider population of 
patients with HIV-associated TB. Useful metrics of clinical predictors (for example 
likelihood ratios) are clearly heavily dependent on the comparison group. 
3. With one notable exception,127 the studies don’t report measures of predictive 
performance (like ROC AUC) or cross-validate their findings. Given the heavy use of 
automated variable selection (see table 3), overfitting is possible. This might not 
matter if the purpose is to assess the overall predictive performance of the (more 
parsimonious) model, but it likely misrepresents which individual predictors are 
‘important’. Is the aim a model that predicts MTBBSI in a specific population, or a 
model that explains clinical processes related to MTBBSI? 
In sum, several seminal studies have reported clinical findings which suggest HIV-associated 
MTBBSI, but a systematic, substantive clinical description is yet to be advanced.  Rather than 
relying on arbitrary or algorithmic variable selection procedures, co-variance of multiple 
predictors with MTBBSI could be related to “causal reasoning which relies on background 
24 
 
knowledge, not statistical criteria”.131 In addition to avoiding some of the above pitfalls,132 such 
an approach is more likely to reflect and inform clinical reasoning.133 The small number of 
previous papers which have tried to relate MTBBSI to causal processes are reviewed next. 
1.3.2 Observational studies of MTBBSI which explore pathophysiology  
As noted in the preceding section, anaemia has been consistently associated with MTBBSI. 
Hepcidin is an iron homeostasis cytokine released as part of the acute phase response, induced 
by type-1 interferon and IL-6 signalling and by microbial Toll-Like Receptor ligands as the 
mediator of a host-response restricting iron availability to invasive pathogens, with the 
potential to cause anaemia of chronic disease (ACD).134,135 ACD is the major driver of anaemia 
in HIV-associated tuberculosis disease, with iron-deficiency playing only a minor role.136,137 
Anti-tuberculosis treatment in these patients causes resolution of elevated hepcidin levels and 
anaemia.138,139 Kerkhoff et al. demonstrated a dose-response relationship between hepcidin 
concentration and anaemia severity in patients with TB and HIV infection in Cape Town, 
while HIV-infected patients without tuberculosis had no such relationship.140 Median hepcidin 
levels were 1.8-fold higher amongst hospitalised HIV-associated TB patients who had a 
positive TB blood culture (figure 3), and 4-fold higher in hospitalised patients that died 
compared to survivors.140  
 
Figure 1-3. Plasma hepcidin by site of positive TB microbiology, extracted from Kerkhoff 
et al. 2016.  
Median / IQR shown. Categories not mutually exclusive. 
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Two papers have been published from an early n=60 HIV-associated TB patient subset of the 
KDHTB cohort which examined haemostatic changes,141 innate immune activation142, and 
their relationship to mortality. Patients who died had higher whole-blood extracellular 
concentrations of pro-inflammatory (TNF-α, IL-6) and anti-inflammatory (IL-1RA) cytokines, 
plus higher proportion of CD16+ monocytes, but impaired monocyte activation after ex vivo 
stimulation with LPS and heat-killed pneumococcus.142 This analysis found no difference in 
monocyte cytokine expression by TB blood culture status, but it is notable that the pattern of 
monocyte function – comparing blood culture negative to positive – mirrors the pattern of 
monocyte function comparing survivors to those that died. Reproduced from the manuscript, 
figure 4 shows the median/IQR concentrations of 7 cytokines in supernatant after monocyte 
stimulation with LPS or heat-killed pneumococcus. The results are arranged to show 4 HIV-
TB patient groups: BC-, survived, BC+, died. Also shown is the median cytokine concentration 
across all the patients (dashed red line).  In 12/14 cases, median values for those that died and 
those that were blood culture positive co-localise relative to the overall median, while those 
that survived and those that were blood culture negative are on the ‘opposite side’ of the 
overall median. The probability of this occurring by chance is 0.006 (i.e. the probability of 12 
successes or more in 14 trials assuming BC and death are independent).  The absence of 
‘significant’ associations between blood culture status and innate-immune markers is very 
likely a type II error. 
In the same cohort, indicators of consumptive coagulopathy, endothelial activation and tissue 
damage were associated with decreased survival.141 TB blood culture status was not 
‘significantly’ associated with most of these markers, leading to the conclusion that 
“mycobacteraemia… did not affect markers of coagulation, anticoagulation extracellular 
matrix or tissue damage” but that MTBBSI was associated with some markers of endothelial 
activation and fibrinolysis.141 The data isn’t presented such that the comparison can be directly 
made, but, subjectively, I think the distributions of most markers in blood culture positive 
patients are more similar to patients who died than those that survived. 
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Figure 1-4. Ex vivo monocyte function in HIV-associated TB, data extracted from Janssen 
et al. 2017.142 
Median/IQR shown by patient group. Blood culture and outcome groupings are not mutually exclusive. 
Monocyte stimulation with Lipopolysaccharide (LPS) or heat-killed pneumococcus (S.pneumo). The overall 
median across all patients is shown with dashed red line. 
 
 
Confounding the under-powering in these analyses is the problem of suboptimal sensitivity of 
TB blood culture. Of the 60 patients analysed almost all had a single blood culture and some 
had anti-tuberculosis therapy initiated before time of blood culture. As shown in later chapters 
(2 and 3), this will have led to under-ascertainment of MTBBSI. This is a measurement error 
problem, adding noise to the mycobacteraemia variable, and reducing power in the analysis.143 
Potential solutions to measurement error include repeated measurement, and use of 
complementary or surrogate variables. The next section argues that urine-lipoarabinomannan 
and urine GeneXpert testing might be considered surrogate measures of MTBBSI. 
1.3.3 Urine-based assays as surrogate measures of MTBBSI  
In every study that has looked, a positive urine liparabinomannan (uLAM) or urine-GeneXpert 
(uGXP) result correlates with detection of M. tuberculosis by blood culture.24,125,144  
There are two competing explanations for how LAM ends up in urine. The first is that bacilli 
at any site in the body release free LAM into the blood stream, and this circulating LAM is 
then filtered through the glomeruli into the urine. The second is that urine-LAM results from 
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renal tuberculosis, possibly with intact bacilli shedding into urine. Lawn and Gupta-Wright145 
summarise a case for the latter, including:  
• LAM in plasma is bound to antibody146 and lipoproteins147, which are too large to filter 
through an intact glomerulus, but urine-LAM is unrelated to proteinuria and other 
markers of glomerular function148; 
• In a post-mortem study of adult inpatients dying with HIV infection in a Ugandan 
hospital,149 8/13 (62%) urine-LAM positive patients had histology compatible with renal 
TB, 6/8 with AFB detected by ZN staining. This study has significant limitations: no 
molecular or culture detection methods were used, and, while the urine-LAM negative 
control group had no evidence renal TB, this was only 3 patients. 
The alternative explanation – free LAM secretion into the blood stream followed by 
glomerular filtration – proposes that urine-LAM detection is not caused by occurrence of renal 
TB, but instead represents total body bacilli load. Proponents of this explanation therefore 
hypothesise that LAM is present in more immunocompetent patients, but is below limit of 
detection for current tests.150 Recent support for this hypothesis comes from a study where use 
of a novel high-affinity capture method allowed detection of LAM in urine of 46/48 HIV-
negative Peruvian pulmonary TB patients, quantified at levels an order of magnitude less than 
the limit of detection of previous uLAM assays.151 The test was positive in 1/13 hospitalised 
controls, and patients with abnormal urinalysis were excluded. 
 From a theoretical point-of-view, I don’t think this debate is an obstacle to use of uLAM as a 
surrogate for MTBBSI. This is based on the assumption that total body bacilli burden, 
bacteraemic dissemination, and renal tuberculosis are all causally related, so blood culture, 
uLAM and uGXP are all indicators of the same underlying latent spectrum of advanced post-
primary TB disease (figure 5). It is difficult to test this assumption directly with clinical data, 
but several lines of evidence supporting it will be presented in this chapter. 
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Figure 1-5. Theoretical schematic relating uLAM, uGXP and TB blood culture. 
 
Having laid a theoretical foundation, this chapter now turns to novel data analysis. 
 
1.4 Novel methods for describing the clinical 
phenotypes 
The preceding sections have argued that HIV-associated disseminated TB exists on a 
continuum of post-primary TB disease, a continuum characterised by total body bacilli burden 
and blood stream infection. Blood culture, urine LAM and Xpert are systematic windows on 
this spectrum of HIV-associated tuberculosis. The remaining sections use this formulation to 
facilitate a less ad hoc clinical description of severe HIV-associated tuberculosis, using the 
KDHTB dataset.  
This analysis will rely heavily on dimension reduction statistical techniques. To justify this 
approach, a motivating example is first presented. This shows the use of a dimension reduction 
technique (Principal Components Analysis) on data from a previous study of TB diagnostics in 
PLWHIV admitted to G. F. Jooste Hospital in Cape Town.**  
In brief, the Jooste study24 recruited unselected newly-admitted HIV-seropositive adults 
without a current TB diagnosis and systematically screened them for HIV-associated 
tuberculosis using  
• spot and induced sputum for fluorescent microscopy, liquid culture and Xpert testing; 
                                                             
** With thanks to Dr Andrew Kerkhoff and colleagues for access to this dataset. 
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• Myco/F lytic blood culture; 
• urine- LAM and urine-Xpert testing; 
as well as collecting results of routine care investigations for tuberculosis. In total 132 patients 
were recruited with a subsequent new diagnosis of HIV-associated tuberculosis based on this 
screening; mortality outcome was ascertained at 90-days in 119 of these patients. This cohort 
is therefore an unbiased representation of HIV-associated tuberculosis amongst inpatients in 
Cape Town with systematic ascertainment of TB blood culture, uLAM and uGXP status.  
1.4.1 Clinical variable dimension reduction: a motivating example 
The Jooste data can be analysed for associations with 90-day mortality using a standard 
approach adopted by previous TB blood culture studies. An a priori selection of clinical 
variables hypothesised to be important determinants of mortality, including blood culture 
status, are assessed for univariate association with mortality; those with a p value below an 
arbitrary threshold are then carried forward to a multivariate model to see if blood culture 
status is an ‘independent’ predictor in such a model. This approach is shown in table 4. 
Table 1-4. Associations with mortality in 132 HIV-associated TB patients from Jooste 
dataset. 
 
OR = odds ratio; CI = confidence interval 
The conclusion from this analysis would be that, although several variables, including blood 
culture status and uLAM, are associated with 90-day mortality in univariate analysis, none are 
independent predictors: all 95% confidence intervals on adjusted odds ratios comfortably cross 
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1. But this conclusion isn’t sensible. From a technical point of view, the variables included in 
the multivariate logistic regression are to a greater or lesser extent collinear. This inflates the 
standard errors around the coefficients for each variable, a major problem for significance 
testing.152 But note also that the multivariate effect sizes are also substantially reduced. This 
points to a more fundamental problem: all these variables are (presumably) connected in a 
network of causal relationships which relate fundamental disease processes to mortality. 
Whether adjusting one for the other is desirable depends on (a) what we think that causal 
structure looks like, and (b) what the purpose of the model is. If the purpose is to better 
‘describe’ or ‘explain’ the clinical phenotype of high-mortality HIV-associated tuberculosis, 
i.e. make inferential conclusions, the modelling approach is completely dependent on our 
domain knowledge / prior theory.153,154  
To illustrate, if we assume, as argued previously in this chapter, that uLAM and blood culture 
are both (imperfect) measures of an underlying latent variable (MTBBSI, or HIV-associated 
disseminated TB bacilli burden), then including both in the multivariate model isn’t very 
informative. Residual variation in one after adjusting for the other isn’t informative; instead we 
might be more interested in their co-variance as a combined measure of the underlying latent 
variable. The point is we need some prior beliefs about how the variables are related to make a 
useful inferential model. 
An alternative approach to “understanding” the Jooste dataset is to reduce the dimensions of 
clinical variables using principal components analysis (example shown in figure 6). About half 
the variation in ten clinical variables selected a priori [haemoglobin, mean corpuscular volume 
(MCV), red cell distribution width (RDW), serum sodium, C-reactive protein (CRP), albumin, 
HIV viral load, total lymphocyte count, CD4+ cell count, and a symptom score based on 
number of ‘TB symptoms’ present (cough, haemoptysis, night sweats, fever, weight loss)] can 
be captured in the first two principal components (PC1, PC2). PC1 mostly captures variation 
in CRP, albumin and markers of anaemia – for example CRP ‘loading’ on PC1 was +0.7 and 
haemoglobin loading was -0.7 (figure 6A): a high PC1 score represents high CRP and low 
haemoglobin. Using our prior (theoretical) knowledge about these clinical variables (e.g. the 
hepcidin work described above), we can infer that the covariance captured in PC1 represents 
inflammation. Similarly, PC2 seems to represent immunosuppression.   
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Figure 1-6. Reduced dimension representation of variables in Jooste dataset using PCA 
PCA constructed with 10 major clinical variables. PC1 and PC2 explain 26% and 18% of variation in these variables. Loadings 
(correlations) of each of these variables with PCs are shown by coordinates in panel A. Site of TB disease groupings clustered 
distinctively on these dimensions (panel B, each point is PC1 and PC2 coordinates of an individual patient). PC1 and PC2 varied 
significantly overall by TB site (Kruskal-Wallis p=0.003 and p<0.001 respectively). 90-day mortality was also strongly associated 
with both PCs (panel C). More positive tests out of the three assays from set [urine-LAM, urine-Xpert, M. tuberculosis blood 
culture] was associated with greater inflammation and immunosuppression (“disseminated TB score”, panel D). The loadings were 
used to reconstruct the same PCs in the KDHTB cohort, i.e. with PC1 and PC2 scores were calculated for KDHTB patients using 
the values derived from the Jooste dataset. This reproduced the same relationship with “disseminated TB score” suggesting this 
representation of the clinical variation has external validity. 
uXp = urine-Xpert / uLAM = urine-LAM / BC = M. tuberculosis blood culture; Suffix “-” = test negative / suffix “+” = test 
positive; PC = principal component; adj OR = adjusted odds ratio. 
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When the patients’ PC1 and PC2 scores are calculated and used to plot individuals in this (2-
dimensional) space, several strong patterns are seen. Firstly, although TB diagnostic tests were 
not used to construct the PCs, the results of these tests map in a non-random way on the PCA 
space. Patients with positive uLAM, uGXP and/or TB blood culture are more likely to localise 
in the upper right quadrant (representing advanced immunosuppression and severe 
inflammation). By contrast, compartmentalised extra-pulmonary TB in absence of 
dissemination (i.e. pleural TB or TB meningitis) had significantly lower PC1 and PC2 values 
(figure 6B). 90-day mortality also varied by PC1 and PC2 (figure 6C); a logistic regression 
model containing both as independent variables showed adjusted odds ratios for mortality of 
2.6 (95%CI 1.3-6.4, p=0.017) and 2.4 (95%CI 1.3-4.5, p=0.005) per one-unit (one standard 
deviation) increase in PC1 and PC2 respectively. If uLAM, uGXP and TB blood culture are 
combined in “disseminated TB score” (one point for each positive test, figure 6D), this 
correlates significantly with PCs (both p<0.001 by Spearman Rank test). This relationship is 
maintained when the PCs are reconstructed in the KDHTB dataset using the loadings from the 
Jooste analysis (figure 6E), so this is a robust representation of clinical variation in severe HIV-
associated TB (contrast this with the inconsistently shown in figure 2).  
I think this approach is more in keeping with clinical reasoning, where highly-dimensional data 
– generated by history taking, examination and investigations – is reduced, mapping individual 
patient findings to fit patterns, spectrums of severity, and diagnoses. The example analysis 
demonstrated above aims to formalises this approach and apply it to a cohort rather than an 
individual patient. 
Dimension reduction equivalent to PCA is also possible for categorical variables, like 
diagnostic test results, as illustrated next.  
1.4.2 Covariance in TB diagnostic test results 
In the preceding sections an argument was made that uLAM, uGXP and TB blood culture are 
theoretically all markers of blood stream dissemination. The empirical suggestion that these 
tests co-vary with respect to the major dimensions of clinical variation in severe HIV-
associated TB supports this argument, and will be made in more detail using the KDHTB 
dataset in the rest of the chapter.  First, though, I want to show that correspondence between 
these TB test results is – by itself – in keeping with them being mechanistically related.  
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In patients with proven TB, the level of agreement between TB blood culture and uLAM, and 
between TB blood culture and uGXP is substantial; by comparison agreement between TB 
blood culture and sputum based diagnostics doesn’t differ from chance (figure 7).  
 
Figure 1-7. Urine versus sputum TB diagnostics agreement with TB blood culture status in 
patients with proven HIV-associated TB. 
Cohen’s Kappa for 4 diagnostic tests compared to TB blood culture are shown for patients with proven 
TB in Jooste dataset (left, n=129) and KDHTB dataset (right, n= 482).  
uLAM = detected LAM (>0) on direct urine testing; uGXP = positive GeneXpert on concentrated urine 
sample; sptmMGIT = M. tuberculosis isolated from and sputum culture; sptmGXP = positive GeneXpert 
any sputum sample 
 
These Cohen’s Kappa results consider all the diagnostic tests on a single ‘axis’: variation in 
blood culture status. We might instead want to show correspondence across all 5 diagnostic 
tests. We could make a matrix of pairwise Cohen’s Kappa results and cluster the variables in 
this matrix based on the Kappa results as a measure of distance. These clusters would define a 
lower dimensional result of the test results. Such an approach would be equivalent to Multiple 
Correspondence Analysis (MCA) on the set of categorical variables.155 MCA can also be 
thought of as a PCA equivalent for categorical variables.†† An MCA on the five TB diagnostic 
test  in proven TB cases from the Jooste and KDHTB datasets is shown in figure 8.  
                                                             
†† In brief, distance between categories (e.g. diarrhoea_yes, fever_no, cough_yes etc.) are derived in i-
dimensional space, where i is the number of individuals in the data set. The coordinates of a category in 
that space are a vector length i of 1’s and 0’s defining if that category is present or absent in the i 
individuals. Distance between 2 categories is then dependent on how many individuals have co-
occurrence of these categories; a category is located at the barycentre of its individuals. Rarely occurring 
categories are given more weight and are further from the origin of the i-dimensional space after 
centering – unusual categories have greater variance. In an equivalent manner to PCA, this i-
dimensional space is reduced by defining orthogonal axes which capture maximum variance. Variance in 
a category, k, is defined as 𝑣𝑎𝑣(𝑘) =
1
𝑃𝑘
− 1 where Pk is the proportion of individuals in that category; 
dimension 1 is the eigenvector capturing maximal covariance in the categories. The categories can be 
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Figure 1-8. MCA TB diagnostics in proven TB cases from two independent datasets 
Major patterns of co-variance in diagnostic test categories are captured on the first two dimensions of an 
MCA.  Negative test category indicated by “_n” suffix and pink colour; positive test category indicated 
by “_y” suffix and blue colour. In both datasets sputum Xpert and culture show very high 
correspondence, but uLAM, uGXP and TB blood culture (MFLBC) also show similarly high 
correspondence. In addition, the two sets of diagnostic tests (sputum Xpert and culture; urine Xpert, 
LAM and TB blood culture) are shown to be essentially orthogonal – the manually added dashed lines 
are at right angles to help the reader visualise this. This relationship replicates in both independent 
datasets. 
 
This shows that uLAM, uGXP and TB blood culture are highly co-variant in “TB diagnostic 
test space”, in keeping with these tests being mechanistically related. This offers some 
empirical support for combining these variables to represent a single axis of variation in HIV-
associated TB patients, and this insight is used extensively in the subsequent analysis. 
While the Jooste study was an assessment of rapid diagnostics; the KDHTB study was 
specifically designed to describe severe HIV-associated tuberculosis, so presents a much richer 
clinical dataset. The rest of this chapter explores covariance in clinical variables in the 
KDHTB dataset, where possible using established clinical reasoning to ‘supervise’ dimension 
reduction and make inferences. 
                                                             
represented on this space. For example, two categories which frequently occur, and frequently occur 
together (in the same individuals), will be close to each other and close to the origin; two categories 
which are infrequent, and rarely occur together will be located far from the origin and far from each 
other, and so forth. The MCA thus gives a low-dimension summary of correspondence of multiple-
categories. 
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1.5 Patterns of covariance in categorical 
clinical variables & markers of MTBBSI 
Patterns of covariation of categorical variables (symptoms, signs, radiology findings) with both 
TB blood culture status and the “disseminated TB score” are shown in the following sections. 
In each case, patients with a confirmed or clinical diagnosis of HIV-associated TB from the 
KDHTB study are included in the analysis (referred to as KDHTB patients from here on); this 
means the comparison is between HIV-associated TB inpatients with or without MTBBSI.  
Two analyses are made. First, the univariate associations are characterised with proportions, 
Fisher exact test of those proportions, and summarised with the likelihood ratio for having a 
positive blood culture. Next, multivariate patterns are considered. Rather than adjusting one 
categorical variable for another, an attempt is made to demonstrate major patterns of 
covariance in the variables, and see if “disseminated TB score” [total positive tests out of TB 
blood culture, uLAM, uGXP] relates to those patterns. This is achieved using MCA (the same 
technique as described above). In addition to summarising major dimensions of co-variation 
between categories, ‘supplementary’ variables which were not used to construct the MCA can 
be ‘projected’ on the MCA space.155 This shows the strength of the relationship with the 
MCA dimensions (larger coordinates mean higher correlation of the supplementary variable 
with the MCA dimension – i.e. better representation, or more correspondence, with the MCA 
categories); the direction of the projection also indicates what categories the supplementary 
variable corresponds well to. In the subsequent analyses disseminated TB score is used as the 
supplementary variable, to answer the question are there multivariate patterns of categorical 
variables to which MTBBSI relates?  
To reiterate, the aim is to see how MTBBSI relates to patterns of categorical variables, rather 
than individual symptoms or signs, to better capture and formalise the approach clinicians take 
to “multivariate data”. 
1.5.1 Presenting symptoms 
499 HIV-associated TB patients from the KDHTB dataset had complete data on 7 symptom 
variables; association with TB blood culture is shown in table 5. Symptoms were recorded 
from direct questioning (not necessarily volunteered). Most symptoms showed no ability to 
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discriminate bacteraemic from non-bacteraemic TB. Although not ‘significant’, gastro-
intestinal symptoms were associated with positive likelihood ratios.  
Table 1-5. Symptoms associated with blood culture status 
 BC negative 
(N=305) 
BC positive 
(N=194) 
Total 
(N=499) 
p 
value 
LR+ 
Cough 208 (68.2%) 138 (71.1%) 346 (69.3%) 0.552 1.04 
Loss of appetite 192 (63.0%) 137 (70.6%) 329 (65.9%) 0.096 1.12 
Loss of weight 271 (88.9%) 178 (91.8%) 449 (90.0%) 0.369 1.03 
Night sweats 167 (54.8%) 109 (56.2%) 276 (55.3%) 0.825 1.03 
Nausea or vomiting 70 (23.0%) 54 (27.8%) 124 (24.8%) 0.261 1.21 
Diarrhoea 102 (33.4%) 75 (38.7%) 177 (35.5%) 0.275 1.16 
Headache 67 (22.0%) 24 (12.4%) 91 (18.2%) 0.010 0.56 
BC = Myco/F lytic TB blood culture; LR+ = positive likelihood ratio; p value from Fisher’s 
exact test. 
 
The MCA analysis (figure 7) suggests: 
• The major dimension of variation in symptoms (dimension 1) is simply presence or 
absence of symptoms – broadly, some patients report multiple symptoms and others report 
few – and that this, in itself, has very little bearing on whether a patient has MTBBSI (here 
defined by disseminated TB score, which correlates poorly with dimension 1).  
• Presence of diarrhoea, and nausea or vomiting, show some correspondence with each 
other, but less so with other symptoms. 
• When patients are clustered based on their MCA dimensions (figure 7B), this clustering 
does predict DTB-score. This implies that, although individual symptoms are not strongly 
related to MTBBSI, there are patterns of covariation – constellations of symptoms – which 
are more specific to MTBBSI.  
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Figure 1-9. MCA and clustering on presenting symptoms 
A. Major patterns of co-variance in recorded symptoms are captured on the first two dimensions of an 
MCA.  Absence of symptom category indicated by “_n” suffix and pink colour; presence of symptom 
category indicated by “_y” suffix and blue colour. Projection of disseminated TB score (DTBscore, 
total of tests positive from TB blood culture, uLAM, uGXP) on this MCA space is shown with red 
arrow, coordinates of which indicate correlation with the dimensions. NandV = nausea and vomiting; 
diar = diarrhoea; LoA = loss of appetite; LoW = loss of weight; hdache = headache; NgtSw = drenching 
night sweats. B. The first 3 dimensions of the symptoms MCA were used categorise patients into 4 
clusters using K-means clustering. The number of clusters was selected algorithmically by comparing 
the quality of the clustering solution for different numbers of clusters using NbClust package in R. 
Unlike individual symptoms, cluster was significantly associated with DTBscore (mosaic plot C.). 
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1.5.2 Imaging categories 
470 (98%) patients had chest x-ray results and 278 (58%) had an abdominal ultrasound scan 
recorded during their admission. Several individual variables were significantly associated with 
positive blood culture: adenopathy (mediastinal or abdominal) and splenic micro-abscesses 
(table 6). Use of the word ‘miliary’ in free text descriptions of chest radiology was also 
associated with a positive blood culture, although only weakly, and the majority (41/190, 78%) 
of blood culture positive patients did not have a miliary x-ray by this measure. A miliary chest 
x-ray was also weakly associated with splenic micro-abscesses (OR 2.1; 95%CI 0.95 to 5.3). 
Infiltrate in all 5 lobes was associated with positive blood culture (also weakly), while pleural 
effusion or fibrotic changes reduced likelihood of positive blood culture (table 6). 
An MCA including all systematically recorded radiology findings in patients that had both 
chest x-ray and abdominal ultrasound is shown in figure 10. Diffuse pulmonary pathology 
involving all 5 lobes, mediastinal adenopathy, splenic micro-abscesses and abdominal 
adenopathy broadly co-localise (lower left quadrant). Patients with pleural effusion are much 
less likely to have these pathologies noted (in keeping with more localised pauci-bacillary 
disease of the pleura). Ascities is probably associated with other abdominal disease, but not 
with more diffuse disease represented by chest x-ray findings. In sum, localised extra-
pulmonary or pulmonary disease can be distinguished from a more disseminated phenotype. 
As would be expected, DTB score correlates with the more diffuse phenotype. The major axis 
of variation is not pulmonary versus extra-pulmonary, but whether blood stream dissemination 
is active or contained. 
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Table 1-6. Radiology associations with TB blood culture. 
Chest X-ray finding 
BC negative 
(N=280) 
BC positive 
(N=190) 
Total 
(N=470) 
p value LR+ 
Pleural effusion 103 (36.8%) 52 (27.4%) 155 (33.0%) 0.042 0.74 
Increased cardio-thoracic ratio 60 (21.4%) 46 (24.2%) 106 (22.6%) 0.551 1.13 
Mediastinal adenopathy 110 (39.3%) 105 (55.3%) 215 (45.7%) < 0.001 1.41 
Nodular* 169 (60.4%) 104 (54.7%) 273 (58.1%) 0.264 0.91 
Miliary* 37 (13.2%) 41 (21.6%) 78 (16.6%) 0.023 1.64 
Cavitation* 31 (11.1%) 16 (8.4%) 47 (10.0%) 0.433 0.76 
Reticular* 24 (8.6%) 26 (13.7%) 50 (10.6%) 0.107 1.59 
Fibrotic* 26 (9.3%) 6 (3.2%) 32 (6.8%) 0.016 0.34 
Consolidation* 43 (15.4%) 22 (11.6%) 65 (13.8%) 0.304 0.75 
Infiltrate in all 5 lobes  99 (35.4%) 86 (45.3%) 185 (39.4%) 0.039 1.28 
Abdominal ultrasound finding 
BC negative 
(N=147) 
BC positive 
(N=131) 
Total 
(N=278) 
p value LR+ 
Abdominal adenopathy 72 (49.0%) 84 (64.1%) 156 (56.1%) 0.016 1.31 
Splenic micro-abscesses 77 (52.4%) 96 (73.3%) 173 (62.2%) < 0.001 1.39 
Ascities 45 (30.6%) 34 (26.0%) 79 (28.4%) 0.468 0.85 
Pericardial effusion* 30 (20.4%) 31 (23.7%) 61 (21.9%) 0.610 1.16 
Kidney abnormality* 19 (12.9%) 21 (16.0%) 40 (14.4%) 0.572 1.24 
Liver enlarged and/or echo-bright* 32 (21.8%) 29 (22.1%) 61 (21.9%) 1.000 1.01 
BC = Myco/F lytic TB blood culture; LR+ = positive likelihood ratio; p value Fisher’s exact test. 
* These variables were extracted by word search of free text variables so were not collected 
systematically.  
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Figure 1-10. MCA and clustering on radiology findings 
A. For 275 patients with chest x-ray and abdominal ultrasound results, major patterns of co-variance in 
radiology findings are shown on the first two dimensions of an MCA.  Absence of finding indicated by 
“_n” suffix and pink colour; presence of finding by “_y” suffix and blue colour. Projection of 
disseminated TB score is shown with red arrow, coordinates of which indicate correlation with the 
dimensions. Pleuralef = pleural effusion; medstnLN = mediastinal adenopathy; abdoLN = abdominal 
adenopathy; splnMcAbcs = splenic micro-abscesses; lobes5 = infiltrate on all 5 lung lobes.  
B. The first 3 dimensions of the symptoms MCA were used categorise patients into 4 clusters using K-
means clustering. The number of clusters was selected algorithmically by comparing the quality of the 
clustering solution for different numbers of clusters using NbClust package in R. Cluster was 
significantly associated with DTBscore (mosaic plot C.). 
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1.6 Overall covariance in continuous 
clinical variables & markers of MTBBSI 
 
1.6.1 A priori selection and transformation of quantitative clinical 
variables 
46 clinical variables were selected a priori. Attempted transformation to univariate normal 
using power transformations – log and power -1, -0.5, and 0.5 (reciprocal, reciprocal square-
root, and square root transformations respectively) – was assessed. Some variables could not 
be transformed to normal because of severe range restriction problems (eg O2 saturation), 
including limit of detection floors (time to positivity and cycle threshold values), because they 
are count data with a high proportion of zero values (e.g. CMV viral load), or because they are 
pseudo-numeric data (ECOG score, GCS, uLAM). Adequacy of conversions were assessed by 
QQplots (not shown) and density plots (figure 11). Final representations of quantitative 
variables are listed in table 7.  
Missing observations other than time to positivity of cultures and cycle thresholds from 
GeneXpert tests (figure 12) were imputed using Gibb’s sampling to minimise bias from data 
missing non-randomly (Multivariate Imputation by Chained Equations package in R).  
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Figure 1-11. Univariate distributions of transformed numerical variables. 
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Table 1-7. Quantitative clinical variables used in subsequent analysis. 
Variable Description 
age_log2 Age in years on log2 scale 
ECOG.Score  Eastern Cooperative Oncology Group (ECOG) performance score 
HR_sqrt Hear rate per minute ^0.5 power transformed 
BPSystolic Systolic blood pressure mm/Hg 
BPDiastolic Diastolic blood pressure mm/Hg 
Temperature Composite variable: highest temperature recorded by study team (at recruitment) or 
in patient notes, oC 
Saturation Pulse oximeter reading at tme recruitment, % 
GCS Glasgow Coma Scale at time of recruitment 
RR_log2 Composite variable: Respiratory rate recorded at time of recruitment by study team 
or Emergency Department at tie of admission (higher value used); on log2 scale 
CD4_log2 CD4+ lymphocyte count cells/mm3 on log2 scale 
glucose_log2 Venous glucose mmol/L  on log2 scale 
Sodium Serum sodium mmol/L 
Potassium Serum potassium mmol/L 
pH Venous pH 
SHCO3 Venous bicarbonate mmol/L 
creatinine_log2 Serum creatinine mmol/L on log2 scale 
Urea_log2 Serum Urea mmol/L on log2 scale 
PCO2_log2 Venous PCO2 mm Hg on log2 scale 
procalc_log2 Serum ProCalcitonin ng/ml on log2 scale 
lactate_log2 Venous lactate mmol/L on log2 scale 
CRP_sqrt Serum C-reactive protein mmol/L 
TotalProtein Total serum protein g/L 
Albumin Serum albumin g/L 
AST_log2 Serum transaminase IU/L  on log2 scale 
ALT_log2 Serum transaminase IU/L  on log2 scale 
AST_ALT_ratio
_log2 Ratio of AST to ALT on log2 scale 
GGT_log2 Serum gamma-glutamyl transferase IU/L on log2 scale 
ALP_log2 Serum alkaline phosphatase  IU/L on log2 scale 
BRC_log2 Serum conjugated bilrubin IU/L on log2 scale 
BRU_log2 Serum unconjugated bilrubin IU/L (derived from total minus conjugated) on log2 
scale 
CXR.lobes Number of lobes with infiltrate on ches x-ray 
Hb_sqrt Venous haemoglobin g/dL  
MCV Mean corpuscular volume fL 
Platelets_sqrt Platelet count x 10^9 /L  
ddimer_sqrt Serum D-dimer. Variable was recorded on 2 different systems, so values normalised 
to lie between 1 and 0 by subtracting the minimum value and dividing by the 
difference between the maximum and minimum value. 
WCC_log2 count x 10^9 /L on log2 scale 
neutro_log2 count x 10^9 /L on log2 scale 
lympho_log2 count x 10^9 /L on log2 scale 
mono_log2 count x 10^9 /L on log2 scale 
L_M_ratio_log2 Ratio of lymphocte to monocyte count 
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HIV_VL_log Serum HIV viral load in copies per ml log scale 
ulam Mean urine - lipoarabinomannan measure on Alere lateral flow test on direct urine 
sample by two independent readers 
sputumTTP_log2 Time to positive culture of sputum in MGIT BACTEC system. If more than one 
sputum result was available this is mean value. 
bloodTTP_log2 Time to positive culture of blood in Myco/F lytic BACTEC system. If more than one 
result was available this is mean value. 
CMV_VL_log2 Serum CMV viral load in copies per ml log2 scale 
min.ct_sptmGXP Minimum cycle threshold value across M.tb probes for sputum sample 
min.ct_urineGXP Minimum cycle threshold value across M.tb probes for concentrated urine sample 
 
 
Figure 1-12. Matrix plot showing missing observations by patient (rows) and variable 
(columns). 
Higher values in distribution of column are darker greyscale. Missing observations are in red. These 
missing observations were imputed for subsequent analysis.  
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1.6.2 Association of quantitative variables with mortality 
Before looking at covariance in these variables, their individual associations with mortality are 
shown. Follow-up in KDHTB formally ended at 12-weeks. Over this period, mortality hazard 
varied substantially, with half of the deaths occurring before day 14 (figure 13).  Associations 
with mortality varied between early (before day 14 follow-up) and later (death between day 14 
and day 84 follow-up) – table 8, figure 14. Variables related to early and late deaths include 
those reporting tissue damage or organ dysfunction (liver tests, creatinine, D-dimer, platelets, 
haemoglobin) and CD4 count. Variables with marked association with early but not late deaths 
include acute inflammation markers (CRP, pro-calcitonin, monocytes), functional status 
(ECOG and GCS), age and hyponatraemia. The latter must represent more proximal acute 
processes related to mortality, while the former have acute and longer, sub-acute, causal 
‘reach’.  There is a mortality cost associated with tissue damage which, even in the context of 
short-term survival, can affect later mortality. 
 
Figure 1-13. Mortality hazard over 84days of follow up. 
Kaplan-Meier plot (A.) and daily death rate over time (B.) 
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Table 1-8. Univariate mortality associations 
  Earlier death (N=65)  Later death (N=73) Survived (N=458)  p value 
    Median IQR Median IQR Median IQR 
age_log2 5.38 5.13, 5.57 5.28 4.94, 5.52 5.14 4.92, 5.39 < 0.001 
ECOG.Score 4 3.00, 4.00 3 2.00, 4.00 3 2.00, 3.00 < 0.001 
HR_sqrt 10.39 9.90, 11.09 10.25 9.90, 10.95 10.2 9.71, 10.94 0.141 
BPSystolic 111 97.00, 128.00 104 97.00, 116.00 108 97.00, 118.00 0.176 
temperature 37.4 36.80, 38.30 38.1 37.00, 39.00 37.8 37.00, 38.90 0.028 
Saturation 98 96.00, 100.00 98 97.00, 100.00 99 97.00, 100.00 0.052 
GCS 15 14.00, 15.00 15 15.00, 15.00 15 15.00, 15.00 < 0.001 
RR_log2 4.46 4.17, 4.58 4.32 4.32, 4.58 4.46 4.32, 4.70 0.151 
CD4_log2 5.17 4.00, 6.54 5.36 4.00, 6.48 6.04 4.60, 7.11 0.001 
glucose_log2 2.43 2.32, 2.72 2.43 2.32, 2.70 2.38 2.23, 2.58 0.029 
Sodium 127 123.00, 130.00 129 126.00, 131.00 129 125.00, 132.00 0.037 
Potassium 4 3.60, 4.70 4 3.60, 4.60 4 3.50, 4.50 0.218 
SHCO3 19.5 16.10, 23.60 20.5 16.70, 23.10 21.8 19.20, 24.17 < 0.001 
creatinine_log2 6.66 5.88, 7.61 6.66 5.98, 7.51 6.27 5.88, 6.72 0.001 
PCO2_log2 2 1.68, 2.41 2 1.68, 2.29 2.17 1.89, 2.41 0.001 
procalc_log2 3.27 1.38, 5.75 1.84 -0.27, 4.12 0.72 -1.84, 2.57 < 0.001 
lactate_log2 1.26 0.68, 1.68 0.93 0.58, 1.49 0.77 0.38, 1.26 < 0.001 
CRP_sqrt 14.71 12.01, 16.43 12.72 9.49, 15.05 12.13 9.29, 15.01 < 0.001 
TotalProtein 73 62.00, 80.00 73 66.00, 80.00 76 69.00, 85.00 < 0.001 
Albumin 21 16.00, 25.00 23 20.00, 28.00 25 22.00, 29.00 < 0.001 
AST_log2 5.98 5.17, 6.86 6.02 5.13, 6.55 5.73 5.04, 6.66 0.353 
ALT_log2 4.64 3.91, 5.29 4.58 3.91, 5.43 4.81 4.00, 5.58 0.481 
GGT_log2 6.07 5.49, 7.33 6.52 5.29, 7.75 6.17 5.22, 7.12 0.202 
ALP_log2 6.98 6.57, 7.69 7.12 6.43, 7.73 6.72 6.25, 7.36 0.001 
BRC_log2 2.32 1.00, 3.32 2.58 1.58, 3.17 2 1.00, 2.58 0.004 
CXR.lobes 5 2.00, 5.00 3 1.00, 5.00 3 1.00, 5.00 0.004 
Hb_sqrt 2.81 2.59, 3.16 2.85 2.59, 3.16 2.98 2.72, 3.25 0.012 
MCV 80.1 76.60, 86.30 83.3 78.00, 86.70 82.35 77.50, 87.18 0.755 
Platelets_sqrt 15.17 11.18, 17.46 15.43 12.21, 18.14 16.52 13.83, 19.02 < 0.001 
ddimer_sqrt 0.51 0.34, 0.70 0.51 0.37, 0.69 0.39 0.33, 0.59 0.002 
WCC_log2 2.79 2.00, 3.38 2.86 2.22, 3.43 2.85 2.21, 3.37 0.581 
neutro_log2 2.43 1.50, 3.13 2.43 1.68, 3.15 2.45 1.69, 3.08 0.958 
lympho_log2 -1.4 -2.12, -0.92 -1.09 -1.60, -0.38 -0.52 -1.46, 0.12 < 0.001 
mono_log2 -2.4 -3.32, -1.79 -1.69 -2.94, -0.94 -1.43 -2.47, -0.71 < 0.001 
L_M_ratio_log2 1.1 0.33, 1.69 0.93 0.06, 1.51 0.94 0.31, 1.54 0.313 
HIV_VL_log 5.2 3.61, 5.69 5.17 3.55, 5.77 5.11 3.73, 5.69 0.97 
CMV_VL_log2 5.61 5.61, 8.75 6.14 5.61, 9.46 5.61 5.61, 8.43 0.06 
Earlier deaths occurred before day 14, later deaths on or after day 14 (approximate median survival time in those that 
died before day 84 follow-up). IQR = interquartile range; variables are defined in table 7; p-values from Kruskal Wallis 
test across 3 groups. 
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Figure 1-14. Variables as predictors of early versus late deaths during 84-day follow-up 
y-axes show logged odds ratio for death (early, <14days; late≥14days) compared to those that survived to day 84. No effect is therefore y=0 [log(OR of 1) = 0] and 
larger effect is further from 0; 0 is indicated with back horizontal line. Significance test based on univariate logistic regression is indicated by colour (see key at bottom 
right for p-value bin). 
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1.6.3 Associations of quantitative variables with positive TB blood 
culture 
Of the 25 variables in table 8 which were associated with mortality outcome, 23 are also 
associated with positive blood culture (table 9). Variables significantly associated with TB 
blood culture but not with mortality include some of the liver enzymes, MCV and HIV viral 
load. Age and O2 saturation are associated with mortality but not blood culture status.  
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Table 1-9. Univariate associations with positive TB blood culture 
  
  
TB blood culture 
negative (N=352)  
TB blood culture  
positive (N=220)  
Total (N=572) 
  p value 
Median IQR Median IQR Median IQR 
age_log2 5.2 5.0, 5.5 5.2 4.9, 5.4 5.2 4.9, 5.4 0.509 
ECOG.Score 3 2.0, 3.0 3 2.0, 4.0 3 2.0, 4.0 < 0.001 
HR_sqrt 10.1 9.6, 10.8 10.5 9.9, 11.1 10.2 9.8, 11.0 < 0.001 
BPSystolic 107 97.0, 118.0 109.5 97.8, 119.0 108 97.0, 118.0 0.437 
Temperature 37.5 36.9, 38.6 38.2 37.1, 39.0 37.8 37.0, 38.9 < 0.001 
Saturation 99 97.0, 100.0 98 97.0, 100.0 99 97.0, 100.0 0.746 
GCS 15 15.0, 15.0 15 15.0, 15.0 15 15.0, 15.0 0.001 
RR_log2 4.5 4.3, 4.6 4.5 4.3, 4.7 4.5 4.3, 4.7 0.24 
CD4_log2 6.5 5.2, 7.3 4.9 3.3, 5.9 5.8 4.5, 6.9 < 0.001 
glucose_log2 2.4 2.2, 2.6 2.4 2.3, 2.7 2.4 2.2, 2.6 < 0.001 
Sodium 129 126.0, 132.0 127 124.0, 130.2 129 125.0, 131.2 < 0.001 
Potassium 4 3.5, 4.5 4 3.4, 4.6 4 3.5, 4.6 0.748 
SHCO3 22.5 19.7, 24.5 20.4 17.2, 23.0 21.5 18.7, 24.0 < 0.001 
creatinine_log2 6.2 5.9, 6.6 6.6 6.1, 7.4 6.3 5.9, 7.0 < 0.001 
PCO2_log2 2.2 2.0, 2.4 2 1.7, 2.2 2.1 1.8, 2.4 < 0.001 
procalc_log2 -0.2 -2.3, 2.1 2.5 1.1, 4.5 1.2 -1.3, 3.3 < 0.001 
lactate_log2 0.8 0.4, 1.2 1 0.6, 1.6 0.8 0.4, 1.4 < 0.001 
CRP_sqrt 11.5 8.6, 14.6 13.9 11.6, 15.9 12.5 9.5, 15.2 < 0.001 
TotalProtein 78 69.0, 86.0 72 65.0, 80.0 75.5 67.0, 84.0 < 0.001 
Albumin 25.5 22.0, 30.0 23 20.0, 27.0 25 21.0, 29.0 < 0.001 
AST_log2 5.6 4.9, 6.3 6.3 5.6, 7.1 5.8 5.1, 6.7 < 0.001 
ALT_log2 4.6 3.9, 5.4 5 4.3, 5.8 4.8 4.0, 5.6 < 0.001 
GGT_log2 6.1 5.2, 7.0 6.4 5.7, 7.5 6.2 5.3, 7.3 < 0.001 
ALP_log2 6.8 6.3, 7.4 7 6.3, 7.6 6.8 6.3, 7.5 0.01 
BRC_log2 1.6 1.0, 2.6 2.6 1.6, 3.0 2 1.6, 2.8 < 0.001 
CXR.lobes 3 1.0, 5.0 4 1.0, 5.0 3 1.0, 5.0 0.068 
Hb_sqrt 3 2.8, 3.3 2.8 2.6, 3.1 2.9 2.7, 3.2 < 0.001 
MCV 82.5 77.7, 87.5 81.5 76.1, 85.8 82.3 77.3, 86.9 0.018 
Platelets_sqrt 17 14.3, 19.4 15.1 11.6, 17.1 16.2 13.3, 18.5 < 0.001 
ddimer_sqrt 0.4 0.3, 0.5 0.5 0.4, 0.7 0.4 0.3, 0.6 < 0.001 
WCC_log2 2.8 2.2, 3.4 2.9 2.1, 3.3 2.8 2.2, 3.4 0.857 
neutro_log2 2.4 1.6, 3.1 2.6 1.7, 3.1 2.4 1.7, 3.1 0.104 
lympho_log2 -0.4 -1.2, 0.3 -1.4 -2.0, -0.7 -0.8 -1.6, -0.0 < 0.001 
mono_log2 -1.4 -2.2, -0.7 -2.3 -3.2, -1.2 -1.6 -2.6, -0.8 < 0.001 
L_M_ratio_log2 1 0.4, 1.5 0.9 0.2, 1.6 1 0.3, 1.5 0.337 
HIV_VL_log 4.9 3.3, 5.5 5.5 4.6, 6.0 5.1 3.7, 5.7 < 0.001 
CMV_VL_log2 5.6 5.6, 8.2 5.6 5.6, 8.8 5.6 5.6, 8.6 0.008 
IQR = interquartile range; variables are defined in table 7; p-values from Wilcox rank test across 2 groups. 
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1.6.4 Algorithmic dimension reduction in quantitative clinical variables 
A correlation matrix of the transformed quantitative clinical variables is shown in figure 15. 
Variables are ordered by a complete-linkage hierarchical clustering algorithm. An alternative 
clustering of variables is shown in figure 16 showing that the clustering is robust to algorithm 
used.  Substantial multi-collinearity exists for almost all variables. 
 
Figure 1-15. Pairwise correlation matrix major quantitative clinical variables 
Absolute values of pairwise Pearson’s r correlation coefficients are indicated by darker green colour and 
were used to define distance between variables. Variables are ordered based on a hierarchical clustering 
algorithm (complete linkage used to define distance between clusters).  
 
51 
 
 
Figure 1-16. Dendrogram by alternative hierarchical clustering method (average linkage) 
 
The 39 dimensions of the correlation matrix can be radically reduced using PCA. The first two 
dimension of this PCA (figure 17) are similar to those developed for the Jooste dataset (figure 
6) but show that many of the other variables now considered also load on the first two principal 
components.  
 
Figure 1-17. Previous correlation matrix reduced to 2 dimensions of covariance using 
PCA. 
PCA performed on 39 variable correlation matrix shown in previous figure (using raw not absolute 
correlation coefficient values) with varimax rotation. Variables which ‘load’ on the first 2 dimension 
with correlation coefficient > 0.4 are shown. 
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Cumulatively, 24% of variance in the quantitative clinical variables is captured by the first two 
PCs (a substantial amount given the number of recorded variables – a quarter of the variance in 
39 variables is ‘explained’ by just two axes). More importantly, although not used in their 
construction, PC1 and PC2 have a strong relationship to both mortality (figure 18 A & B) and 
dissemination of TB observed by diagnostic tests (figure 18 C & D). A one standard deviation 
increase in PC1 increases odds of death before 84 days more than 2-fold (OR 2.1; 95%CI 1.7 to 
2.7; p=5.6e-11), and increase in PC2 by one standard deviation decreases odds of death by 40% 
(OR 0.6; 95%CI 0.5 to 0.7; p=2.4e-6).  
 
Figure 1-18. Mapping outcome and disseminated TB score to PCA 
PCA performed on 39 variable correlation matrix shown in previous figure. Patients are plotted by their 
coordinates in PCA space based on first two components. A. Data points coloured by day 84 mortality 
outcome, with percentages of patients who died (solid black circle, black text) and survived (light blue 
fill circles, light blue text) by quadrant. B. Data points coloured by early death (before 14 days follow up, 
magenta), later death (between day 14 and 84, yellow-green) or survived to end of study (grey). 
Barycentre (centre of gravity) for each grouping shown by coloured text position. C. Data points 
coloured by disseminated TB score value. D. Proportions of patients by disseminated TB score and PCA 
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quadrant are highly dependent as shown in mosaic plot with Chi-squared testing of the equivalent 
frequency table. ULQ = upper left quadrant; LRQ = lower right quadrant etc. 
 
The patients can be more formally clustered in the 39-dimensional space defined by the 
quantitative clinical variables using K-means clustering. This approach is complementary to 
PCA but allows an unsupervised classification of patients based on their similarity on all 
variables, rather than arbitrary cut-offs like the quadrants of the two-dimensional PCA space 
used in figure 18. The optimal number of clusters can be empirically derived using a variety of 
metrics mostly based on the magnitude of reduction in sum-of-squares versus a penalty for 
increasing number of clusters.156 Using this approach for the 39 variable dataset, i.e. variables 
other than outcome and TB diagnostics, most metrics indicate 2 clusters are optimal. Again, 
this radically parsimonious representation of co-variance in clinical variables captures 
substantial variation in mortality outcome (figure 19) and TB diagnostic test results (figure 20, 
table 10).  
In short, covariance in the large number of clinical variables measured by the KDHTB study 
provides a more compelling summary of this cohort (rather than considering individual 
variables as “independent predictors”), not least because it successfully separates signal from 
noise. When dimensions of the quantitative clinical variables are reduced by PCA or direct 
unsupervised clustering of patients, they are overwhelmingly related to blood stream 
dissemination of tuberculosis (measured by blood culture, uGXP and uLAM) and to mortality 
outcome. This is in keeping with a single major axis of clinical variation in these patients 
(rather than many different ‘types’ of HIV-associated TB).  
This unsupervised analysis shows that substantial meaningful clinical variation is captured by 
the KDHTB study. Next, I want to flesh out the description of this clinical variation in a more 
theory-driven way, i.e. relating the variation to prior clinical domain knowledge.  
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Figure 1-19. K-means cluster association with mortality. 
Patients allocated to 2 clusters based on K-means algorithm which determines cluster 
membership that minimises sum-of-squares ‘error’ across all included variables (39 in this 
case). Cluster 2 is associated with substantially higher mortality risk. 
 
 
Figure 1-20. K-means cluster association with TB diagnostic results. 
Although not used to construct clustering, dependence of cluster by TB diagnostic test (mosaic plot 1 to 
4) and DTB score (5th plot) is seen. Positive TB blood culture (BC+) was the TB diagnostic most 
associated with membership of cluster 2, the high mortality cluster. DTB score has higher predictive 
accuracy of cluster membership than any individual test. 
 
Table 1-10. TB diagnostic results as predictors of cluster 2 membership. 
  OR 95%CI p value pseudoR2 
DTB score (per 1-point increase) 3.39 2.77 to 4.21 1.00e-30 0.35 
TB blood culture positive 8.62 5.81 to 13.03 1.10e-25 0.27 
uGXP positive 7.35 4.99 to 10.95 2.10e-23 0.26 
uLAM positive 4.39 3.06 to 6.38 3.00e-15 0.14 
Sputum culture positive 3.76 2.33 to 6.23 1.10e-07 0.10 
OR = odds ratio; 95%CI = 95% confidence interval; pseudoR2 = Nagelkerke’s pseudo-R-
squared measure for binary outcome models (0 if model is no better at predicting outcome 
than the intercept; 1 if predicts all outcomes correctly). 
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1.7 A more supervised approach to 
dimension reduction in continuous 
clinical variables 
In figure 15 liver enzymes were seen to be highly collinear and clustered together in figure 16. 
To say that liver function tests (LFTs) tend to covary is somewhat trivial from a clinical 
perspective; when assessing LFTs clinicians are interested in patterns of abnormalities based 
on prior theoretical understandings of how these patterns relate to pathology. The same is true 
of several other subsets of these variables. We can use ‘clinical theory’ – i.e. prior domain 
knowledge – to inform dimension reduction on these subsets of variables, and better explore 
their relationship to mortality and MTBBSI.  Several examples are given, starting with 
covariance in LFTs. 
1.7.1 Patterns of covariance in liver enzymes 
A raised ALT is regarded is more sensitive and specific to hepaocellular injury than 
disturbance in AST.157 By extension, elevated AST:ALT ratio is associated with extra-hepatic 
pathologies: myositis, haemolysis, critical ischaemia, tumour lysis syndrome, DIC, 
haemophagocytic syndrome;158-162 and, importantly, disseminated/systemic infections 
(disseminated histoplasmosis, late leptospirosis, severe Rickettsia infections, Ebola virus 
disease and virtually all other viral haemorrhagic fevers)163-167 in which it generally carries 
prognostic significance.  
As shown in table 8 and 9 above, in the current cohort both AST and ALT are associated with 
blood culture positive TB but neither is significantly associated with mortality. Residual 
variation in AST after adjusting for ALT is also associated with TB blood culture, but ALT 
adjusted for AST is not (figure 21 A & B). Interestingly, elevated residual variation in AST 
after adjustment for ALT is strongly associated with mortality, while elevated adjusted ALT is 
(weakly) associated with lower mortality (figure 21 C & D). AST seems to be a measure of 
some process independent of hepatitis related to both dissemination of TB and mortality. 
Unlike unadjusted ALT, residual variation in AST after adjusting for ALT correlates with 
major markers of systemic inflammation (figure 22), and it seems most likely that this relates to 
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tissue damage (specifically, mitochondrial damage in organs with high mitochondrial AST 
such as the reticuloendothelial system)168.  
 
 
Figure 1-21. Transaminases relationship to MTBBSI and mortality 
A. Scatterplot ALT versus AST (both on log2 scale) by positive TB blood culture (MFLpositive) 
category. B. Distribution density plots of ALT, ALT after adjusting for AST (ALTresid), AST, and 
AST after adjusting for ALT (ASTresid); disaggregated by TB blood culture. C.  Scatterplot ALT 
versus AST (both on log2 scale) by day 84 mortality outcome. D. Distribution density plots of ALT, 
ALT after adjusting for AST (ALTresid), AST, and AST after adjusting for ALT (ASTresid); 
disaggregated by TB blood culture. ** = p<0.0001; * p < 0.01; NS = p>0.05 all by t-test. 
 
 
Figure 1-22. Adjusting AST for ALT changes its relationship to other variables 
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ASTresid = residual variation in AST after adjusting for ALT. 
Classically, liver enzymes are grouped by site of predominant pathology, with hepatocellular 
damage associated with the transaminases and cholestasis associated with the bile canalicular 
enzymes (alkaline phosphatase and gamma-glutamyl transferase – ALP and GGT), while 
raised bilirubin can be caused by pathology at either site, or be ‘pre-hepatic’ from red blood 
cell lysis where it is then predominantly unconjugated.157 A PCA representation of LFT 
covariance in the current cohort follows this classification well, with ALT and AST loading 
PC1; (predominantly unconjugated) bilirubin and to a lesser extent AST load on PC2; ALP, 
GGT and to a lesser degree conjugated bilirubin load on PC3 (figure 23). We can tentatively 
label these PCs hepatitic, extra-hepatic, and canalicular respectively. All three are associated 
with disseminated TB score (PC1, hepatitis, Rho = 0.23, p=2.4e-08; PC2, extra-hepatic, 
Rho=0.13, p=0.001; PC3, canalicular, Rho=0.16, p=5.7e-05), but it is the canalicular 
component that has the strongest relationship with mortality (figure 24). ALP and GGT rises 
are regarded as most typical of “infiltrative” hepatic tuberculosis,169 irrespective of CD4 
count.170 In this cohort, ALT has significant positive correlation with CD4 count after adjusting 
for AST (Pearson’s r = 0.12, p=0.004) so it may be that a hepatitic response to liver TB is 
immune-mediated (e.g. type IV hypersensitivity). 
 
 
Figure 1-23. Correlation of individual liver enzymes with their first 3 principal 
components 
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Figure 1-24. Liver enzyme principal component 3 relationship with DTB score and 
mortality 
Patients who died shown with pink dots, survivors in grey.  
 
1.7.2 Acid-base balance and renal impairment 
Most HIV-associated TB patients in the KDHTB dataset have a metabolic acidosis (figure 25 
A & B): 330/596 (55%) venous bicarbonate < 22mmol/L, of which 114/330 (35%) are 
decompensated with pH < 7.35. Raised venous lactate was also common (221/596, 37%, 
venous lactate > 2.2mmol/L), but unrelated to venous pH (raised lactate: OR for pH<7.35 = 
0.98, 95%CI 0.64 to 1.50; OR for bicarbonate < 22 = 1.35, 95%CI 0.96 to 1.95; figure 25 C). 
Metabolic acidosis was also largely independent of levels of buffers like haemoglobin (figure 25 
E). By contrast, renal dysfunction explained about 35% of variation in venous bicarbonate 
(figure 25 D and table 11), suggesting that renal dysfunction (+/- gastro-intestinal loss of 
bicarbonate, which was unobserved) was the major driver of metabolic acidosis in this cohort. 
In addition, DTB score was negatively correlated with venous bicarbonate (Rho = -0.19, 
p=2.6e-06, figure 25 F). 
Table 1-11. Predictors of metabolic acidosis 
Sequential addition of predictors to model predicting SHCO3: 
Predictor variable added Adjusted R2 LRT p value 
creatinine_log2 0.344 -- 
urea_log2 0.353 0.00170 
lactate_log2 0.364 0.00079 
Hb_sqrt 0.375 0.00076 
Potassium 0.385 0.00109 
Variables in first column were sequentially added to a linear model predicting 
venous bicarbonate. Each (nested) model was compared for improved data fit 
to the previous model using Likelihood ratio test (LRT) 
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Figure 1-25. Acid-base balance overview 
A. Davenport diagram showing venous pH by bicarbonate level for each patient coloured by pCO2 
(distribution divided into 6 equal width intervals). B. Acid-base status of each patient is categorised by 
Boolean operators on pH, bicarbonate and pCO2. C. Patient data points coloured by venous lactate 
(>2.5mmol/L = blue; ≤2.5mmol/L = red). D. Patient data points coloured by creatinine (distribution 
divided into 5 equal width intervals). E. Patient data points coloured by haemoglobin (distribution 
divided into 4 equal width intervals). F. Patient data points coloured by DTB score. 
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Because acid-base balance is a completely understood homeostatic system, it provides a good 
example to test the specific hypothesis that limited physiological reserves are the mechanism 
by which increased age is associated with mortality in KDHTB. In summary, pH is determined 
by magnitude of metabolic acidosis (sHCO3) plus degree of respiratory compensation (pCO2) 
and secondary buffers. Upstream disease processes (D in figure 26) determine renal and 
lactate sources of the acidosis. There is correlation between renal dysfunction and age. We can 
hypothesise that age is a determinant of adequacy of respiratory compensation in metabolic 
acidosis (supported by the correlation between age and pCO2 in the correlation matrix 
presented earlier).   
 
Figure 1-26. Directed acyclic graph: age and acid-base balance 
This implies that, after adjusting for relevant confounders presented in figure 26 (markers of 
renal function and metabolic acidosis, i.e. creatinine, urea, and bicarbonate) age should 
‘explain’ some residual variation in pCO2. In other words, for a given level of metabolic 
acidosis, is age associated with an ‘inappropriately’ high pCO2? In a linear model testing this 
hypothesis, age was indeed associated with a higher pCO2 (p=0.02, figure 27). Although the 
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effect size was small (increasing age from 18 to 36 years, with all other variables held constant 
at their mean value, was on average associated with a 0.2mmHg increase in pCO2) this is only 
one example of potential physiological reserve limitation associated with increasing age.  
 
 
Figure 1-27. Age - adjusted pCO2 from model based on DAG in preceding figure. 
A linear model of form PCO2_log2 ~ SHCO3 + age_log2+ creatinine_log2 + Urea_log2 was fitted to the 
KDHTB data. SHCO3 is the major driver of pCO2 in this cohort because it is dominated by metabolic 
acidosis secondary to renal dysfunction. After adjusting for renal dysfunction and bicarbonate, age was 
associated with significantly higher pCO2 (p=0.02). Predicted pCO2 values from the model are shown 
for a range of SHCO3 values and 7 ages at 6- year intervals. 
 
A PCA on acid-base and renal variables gives an intuitive representation of these variables on 
just 2 dimensions (figure 28). PC1 captures metabolic acidosis related to renal dysfunction 
(figure 28 A). PC2 captures about half of the remaining variance in acid-base status, including 
variation in pCO2 which is not directly correlated with renal driven metabolic acidosis – for 
example separating respiratory acidosis and alkalosis, and degree of respiratory compensation 
for metabolic acidosis.‡‡ The 2-dimensional PCA therefore replicates the standard clustering 
of patients based on the Davenport diagram (figure 28 B). And, in this cohort, it is PC1 that 
relates strongly to disseminated TB (figure 28 C) and mortality (figure 28 D). This puts renal 
                                                             
‡‡ Note that potassium is surprisingly strongly related to PC2; hyperkalaemia is uncommon in this 
cohort (11% have K+ >5.0), while one in four patients had hypokalaemia. The variance in potassium 
captured on PC2 may (in part) be related to respiratory alkalosis – patients with acute respiratory 
alkalosis do have a mean potassium 0.5mmol/L lower than the overall cohort. There isn’t much 
evidence here of a metabolic acidosis caused by gastro-intestinal bicarb loss associated with 
hypokalaemia, but it could be masked by associated pre-renal acute kidney injury. 
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dysfunction centre-stage in the pathophysiology of advanced HIV-associated TB at least in this 
cohort.  
 
Figure 1-28. PCA of renal/acid-base variables. 
A. Correlation of renal and acid-base variables with their first two principal components. B. Patients 
plotted in 2-dimension PCA space coloured by standard acid-base clustering. The colour scheme is the 
same as figure 25B for comparison. C. DTB score correlation with the first two acid-base principal 
components (patients who died by day 84 are coloured pink in these plots, survivors in grey). D. Density 
distributions of acid-base PCs disaggregated by TB blood culture status (MFLpositive TRUE = positive 
TB blood culture) and by day 84 death outcome. P-values from t-tests; NS= non-significant (both 
p>0.2). 
 
 
What, in turn, is driving this acute kidney injury (AKI)? Historically, infection-associated AKI 
was described as resulting from systemic hypotension, renal vasoconstriction, and ischaemia-
reperfusion damage.171,172 AKI is unrelated to blood pressure in the present cohort (metab_pc1 
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correlation with systolic blood pressure = 0.03, 95%CI -0.05 to 0.11, p=0.4). This is in keeping 
with the growing evidence that sepsis-AKI most often occurs in the absence of overt hypo-
perfusion. For example, AKI is commonly un-associated with haemodynamic instability in 
patients with pneumonia,173 and animal-models of sepsis show AKI in the context of increased 
renal blood flow.174 Consequently, focus has shifted to other mechanisms, of which a large 
number have been found:175  
• direct effects of DAMPs and PAMPs on renal tubular cells causing microcirculatory flow 
changes (presumably of particular importance in BSI); 
• endothelial activation, coagulation abnormalities, causing tissue damage; 
• mitochondrial damage and/or adaptation in the face of reduced energy availability (as 
sources of ATP are redirected to inflammatory responses); 
• circulating microparticles (intact vesicles of plasma membrane resulting from apoptosis, 
increased production in inflammation). 
These mechanisms are “inflammation” and clearly inter-related and potentially concurrent. In 
the KDHTB cohort, AKI correlates strongly with markers of systemic inflammation (for 
example, metab_pc1 correlation with pro-calcitonin = 0.51, 95%CI 0.45 to 0.57, p<2.2e-16). 
An important point, though, is that the kidneys are not just passive subjects of inflammation, 
and all elevations in creatinine are not strictly pathological. The renal response to reduced 
extracellular fluid volume§§ is to conserve water and sodium at the expense of (transient) 
decrease in filtration: elevated creatinine in this context has been referred to as “functional 
pre-renal AKI or even acute renal success”.176 The transcript signature associated with this 
response (osmoregulation and metabolic pathways) is completely distinct from that seen in 
ischaemic injury (inflammation, cell death).177 Some authors have conceptualised sepsis-AKI 
as a ‘second-hit’ phenomenon where the protective mechanisms of functional AKI are 
overwhelmed by non-resolving inflammation.176 Importantly, it should be possible to separate 
AKI caused by the protective response to reduced ECFV and intrinsic nephron damage using 
urine biomarkers.178 
  
                                                             
§§ ECFV in KDHTB is discussed more in the section on hyponatraemia. 
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1.7.3 Hyponatraemia 
Nine in ten TB patients in KDHTB have serum sodium < 135 mmol/L. Hyponatraemia is 
associated with a long list of infections, almost invariably as a marker of disease severity and 
mortality.179-185 This ubiquity masks an assortment of underlying disease processes, from 
diarrhoea to syndrome of inappropriate anti-diuretic hormone secretion (SIADH),186 so the 
meaning of hyponatraemia will differ between one infection and another and one patient 
population and another.   
The volume of literature discussing hyponatraemia in HIV 187-194 suggests it is commonly 
multifactorial. By contrast, reference textbooks unequivocally link hyponatraemia of TB to 
SIADH.165,195 Hill et al.’s classic study of 20 hyponatraemic HIV negative pulmonary TB 
patients demonstrated detectable ADH in blood, with some response to water loading, which 
they attributed to down regulation of osmoregulation by active TB ("reset osmostat", 
essentially, a subtype of SIADH).196 The mechanism remains unknown, but the phenomenon 
is probably not completely TB specific.184 More generally, IL-6, nausea & vomiting, and 
physiological stress (such as hypoglycaemia) are stimulants of ADH release (independent of 
serum osmolarity).186 
Other hyponatraemia mechanisms potentially relevant to KDHTB patients include gastro-
intestinal losses (associated with appropriate ADH secretion if low extracellular circulating 
volume, ECFV), or adrenal insufficiency.*** Two small South African studies have looked for 
adrenal insufficiency in hospitalised TB patients. Venter et al.197 measured cortisol in 20 
inpatients with TB, randomised to rifampicin versus fluroquinolone based TB treatment. 18 
patients were known HIV co-infected; 7 of these patients had hyponatraemia, none had 
adrenal insufficiency, all 7 had "features of SIADH", although volume status wasn't 
specifically commented on and mean urine sodium was only 31 mmol/L. Kaplan et al.198 
determined cortisol response to ACTH in 40 pulmonary TB inpatients (18 HIV co-infected). 
None of the 4/40 patients with hyponatraemia had adrenal insufficiency, or clinical evidence of 
volume depletion, but all 4 had "features of SIADH". This included low serum osmolarity (261 
- 279 mOsm/Kg) and relatively high urine osmolarity (642 - 861 mOsm/Kg), although no 
                                                             
*** Rates of TB meningitis were low so intra-cranial causes of hyponatraemia are unlikely. Few patients 
have markedly raised blood glucose suggestive of pseudo-hyponatraemia. 
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"inappropriate natriuresis" was noted. In both studies, patients were all sputum smear positive 
with mean CD4 count around 190 cells/ml, so MTBBSI was unlikely.   
Following the method of both the Venter and the Kaplan studies mentioned above, serum 
osmolarity for the KDHTB cohort can be calculated using 2*(sodium + potassium) + urea + 
glucose. Based on this, a large proportion of hyponatraemic patients appear to have normal or 
raised serum osmolarity (> 280, to the right of the vertical axis figure 29 A) but this is spurious, 
due to raised urea levels – indicated by green, yellow and red points in figure 29A (serum urea 
does not signal osmoreceptors in the posterior pituitary to effect ADH release199). In sum, the 
Venter and Kaplan studies could show (or assume) euvolaemia in their HIV-associated TB 
patients, and conclude that hypotonic hyponatraemia was due to SIADH, but such an 
assumption isn’t valid here.  
 
Figure 1-29. Hyponatraemia, calculated osmolarity, and urea. 
A. Calculated osmolarity versus sodium. Data points are coloured by urea level (distribution divided 
into 5 equal width intervals). Vertical line is upper limit of normal for serum osmolarity; horizontal line 
is lower limit of normal for serum sodium. B. Boxplot urea distribution by sodium interval (median, 
IQR, range, outliers indicated by line, box, whiskers and dots respectively). Upper limit of normal for 
urea shown with dashed red line [log2(7.1) = 2.82]. 
 
Indeed, although the relationship isn’t entirely linear (figure 29B), overall urea_log2 has 
significant negative correlation with sodium (r = -0.11, p=0.008), as does creatinine_log2 (r = -
0.11, p=0.009). This might be in keeping with hyponatraemia due to sodium and water loss, 
with reduced extracellular circulating fluid volume (ECFV), and reduced glomerular filtration. 
This interpretation is complicated by the fact that urea and creatinine have a weak relationship 
with fluid volume status (being confounded by multiple factors like underlying renal function, 
muscle mass etc.), and secondly, because correlation between hyponatraemia and renal 
function could also be because they are both related to some other underlying variable (e.g. 
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inflammation, TB dissemination). Temporal trends in renal markers and sodium after 
admission help test this association. In a random subset of 50 KDHTB patients, any serial 
electrolyte results found on the laboratory system sent as part of their routine care were 
extracted; 39/50 had ≥2 measures of creatinine and 34/50 had ≥2 measures of sodium 
available, allowing trends to be plotted (figure 30 A & B). In addition, Emergency department 
records were reviewed showing that intra-venous normal saline was prescribed on admission in 
all patients. 32/40 patients had an increasing sodium trend (positive gradient), and 30/39 had 
a decreasing creatinine trend (negative gradient) observed during their admission. Further, 
magnitude of sodium and creatinine gradients were strongly correlated (figure 30 C). 
Potassium levels also fell in parallel, in keeping with return of GFR but lingering tubule 
dysfunction (data not shown). Despite the risk of bias associated with non-systematic 
ascertainment of serial measures, this is evidence that these patients’ hyponatraemia was 
(substantially) due to sodium / ECFV depletion. By the same token, full resolution of 
hyponatraemia was observed in only 2 patients, and a substantial minority had worsening 
hyponatraemia after IV fluids, so it is very plausible that multiple mechanisms of 
hyponatraemia are present both within and between patients.  
 
Figure 1-30. Serial measurement of sodium and creatinine during admission. 
50 KDHTB patients selected at random had electrolyte results from blood tests carried out as part of 
their routine care (non-study samples) extracted from the National Health Laboratory Service results 
portal. 39 had ≥2 measures of creatinine and sodium during admission. Trends in both these electrolytes 
are shown (left and middle plot; coloured trend lines are lines of best fit by patient, overall line of best fit 
ignoring dependence by patient is shown in black with 95%CI). The gradients of these trend lines were 
extracted (lmList() function of lme4 package in R) and pairwise correlation between sodium and 
creatine gradients assessed (right plot). 
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1.7.4 Covariance in Leukocytes 
White cells are highly collinear; total white cell count correlates to a greater or lesser extent 
with all subsets but is mostly related to absolute neutrophil count; lymphocyte count correlates 
strongly with CD4 subset and with monocytes; platelets correlate with total white cell count 
and monocytes; percentage neutrophil count is only moderately related to absolute neutrophil 
count, and has different covariance pattern with other cells (figure 31).  
It is well established that HIV infection progressively diminishes CD4+ lymphocytes and 
monocytes,200,201 as well as platelet and neutrophil counts.202,203 Lymphocytopenia is also 
classically associated with specific infections including influenza, dengue, malaria and 
tuberculosis,204 but is more commonly a general response to stress and inflammation (e.g. 
bacterial sepsis) in hospitalised patients.205 Intercurrent infections cause reversible drops in 
total and CD4+ lymphocyte counts in HIV infected patients including tuberculosis.206 
Neutrophilia is the hallmark response to acute inflammation caused by infections (classically, 
more marked in pneumococci, staphylococci and clostridia infections) and/or tissue 
damage.††† In sum, variation in white blood cells (WBCs) in the KDHTB cohort will represent 
the net effects of at least two different (and interacting) processes: immunosuppression and 
inflammation. 
Can these be disaggregated? Covariance of WBCs with strong markers of acute inflammatory 
response (CRP and procalcitonin) can be assessed, again using PCA (figure 32). The first two 
PCs separate variance in WBCs into axes which seem to correspond well to immune status 
(PC1, strong positive correlation with CD4 count, total lymphocytes, monocytes, and weak 
negative correlation with pro-calcitonin/CRP), and inflammation (PC2 strong positive 
correlation with pro-calcitonin/CRP, moderate correlation with higher neutrophils, and weak 
correlation with lower agranulocyte counts). In turn, WBC PC1 and PC2 both relate strongly 
to MTBBSI and mortality outcomes exactly as we would expect (figure 33).  
  
                                                             
††† The role of neutrophils in TB is discussed below. 
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Figure 1-31. Pairwise relationships in blood cells. 
Corr = Pearson’s correlation coefficient; neut_perc = percentage neutrophils (absolute neutrophil count 
on original scale divided by total white cell count on original scale); other variables as defined in table 7. 
Univariate densirt distributions shown on diagonal. Bivariate distributions with line of best fit below 
diagonal. 
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Figure 1-32. Correlation of WBC and inflammatory markers with their first 3 PCs 
(varimax rotation). 
 
 
Figure 1-33. WBC principal components relationship with TB blood culture, DTBs core, 
and mortality outcome. 
A. Density distributions of the first 3 WBC principal components disaggregated by TB blood culture 
status (MFLpositive, top) and day 84 outcome status (day84death, bottom). P values are from t-tests, 
NS = non-significant (p>0.1). B. Individual data points are patients plotted by their coordinates on the 
first two WBC principal components, coloured by DTB score. 
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The third WBC principal component – positively correlated with neutrophils and to a lesser 
extent lymphocytes and monocytes – is harder to interpret. Based on a Scree plot (eigen values 
of the components versus number of components, not shown) the third component probably 
contains signal rather than noise.207 WBC PC3 is highly correlated with total white cell count (r 
= 0.86; 95%CI 0.84 to 0.86, p<2.2e-16). It has no correlation with TB blood culture status 
(figure 33 A) or DTB score (r = 0.00, 95%CI -0.07 to 0.09, p=0.45), but does have some 
relationship to mortality outcome such that a higher value is weakly associated with survival 
(figure 33 A).  This means higher neutrophils are associated with lower mortality on PC3, but 
associated with higher mortality on PC1. Neutrophil variance which is collinear with 
inflammatory markers is harmful (and closely related to MTBBSI), but neutrophil variance 
correlating with total white cell count is protective (and independent of MTBBSI). This 
relationship can also be seen on the original variables, where percentage neutrophils are 
(tautologically) related to total white cell count and absolute neutrophil count; percentage 
neutrophils are moderately correlated with DTB score; and DTB score has no relationship to 
total white cell count at all (figure 34) – a good example of noncommutative pairwise 
correlations: neutrophils are being influenced by (at least) two completely independent 
processes. 
 
Figure 1-34. Correlation between total white cells, neutrophil measures, and DTB score. 
R = Pearson’s. Nø = neutrophil; % percentage; abs = absolute count; WCC = white cell count. 
 
The role of neutrophils in tuberculosis pathology is not straight forward. Many potentially 
myco-bactericidal mechanisms have been found in vitro for neutrophils (e.g. NETs, cytokine 
signalling, cathcidin production) and their role in containing some stages of TB infection are 
thought to be important but incompletely understood.208 In a study of household contacts of 
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smear-positive pulmonary TB patients, risk of TB infection (positive IGRA) was inversely 
proportional to peripheral blood neutrophil count.209 Of note, in that study 95% of contacts had 
a neutrophil count within the normal range, but counts were higher than in healthy controls. 
Animal knock-out models focused on established TB disease (as opposed to early innate 
response to new infection) are spectacularly inconsistent.210  
In clinical studies of established disease, neutrophilia has often been associated with adverse 
outcomes (slow bacillary clearance,211,212 treatment failure,213 and death214-217) , though not 
consistently so.218,219 There is evidence of neutrophil count correlation with sputum bacilli 
load.220 Clearly, these findings relate neutrophils to severe disease, but can’t determine if they 
are a benefit, a liability, or a neutral marker in such disease. Studies from the pre-antibiotic era 
had an opportunity to observe the natural history of neutrophils in TB disease in a way not 
possible now. Peripheral blood neutrophilia was though to relate to abscess formation or 
cavitation in tubercles, but was also a non-specific marker of inflammation (“tuberculosis 
complications and superimposed infections influence the picture to a great extent… at times 
there is marked disagreement between the leukocytic picture and the impression gained from 
clinical observation”).45  In longitudinal follow-up of 107 patients with detailed blood 
examination during the 1930s, Houghton weighted neutrophil lobe count (left-shift in modern 
parlance, i.e. peripheral neutrophil maturity) more than absolute count as an indicator of poor 
prognosis.221‡‡‡ The same finding was published in Frontiers in Immunology last year: using a 
variety of multivariate and clustering approaches data from 50 HIV-seronegative pulmonary 
TB patients, disease severity (pulmonary destruction, bacilli load, radiological extent of TB 
disease, and other clinical indices) was most closely related to band neutrophils (as compared 
to absolute counts, other WBC subsets, or Th1 signalling).222 
Neutrophils are convincingly associated with TB-IRIS pathophysiology, specifically, an 
activated, early-cell-death, and impaired ability to kill M. tuberculosis ex vivo neutrophil 
phenotype.223 Importantly, dynamics of neutrophil activation markers and tissue-destruction 
effectors (like neutrophil elastase) are more predictive of TB-IRIS than neutrophil count 
dynamics (distribution of neutrophil count 2 weeks after HAART initiation may not be very 
different between IRIS and non-IRIS patients).224  
                                                             
‡‡‡ “Houghton’s Index – which included lobe counts, lymphocytes, monocytes and ESR – was in fact 
his heuristic attempt at dimension reduction to principal components, to separate signal from noise: “It 
is certainly necessary, in view of the fluctuations which occur in the component figures of haemograms, to have a 
method of summarizing the information derived from each source.”(ibid). 
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Finally, while the immunology literature tends to treat neutrophil count as a linear variable, it 
shouldn’t be overlooked that severe neutropenia is a rare but grave finding in tuberculosis.68,216  
In short, neutrophils can mediate tissue damage, with neutrophilia signalling inflammation and 
severe disease, but neutrophils could also have an advantageous, bactericidal role.210 The dual 
covariance of neutrophils – with adverse and protective components – is, then, well in keeping 
with previous literature. Further, thinking about neutrophils as representing 2 orthogonal axes 
of covariance could help better characterise their role in TB pathophysiology in future 
studies.§§§  
1.7.5 Fever and globulins 
These variables are discussed together here because they are both instructive examples of 
Simpson’s paradox in the KDHTB data set. Higher temperature is associated with MTBBSI 
(both TB blood culture positivity (t-test p = 1.6e-06) and DTB score (Rho = 0.20, p = 6.5e-07)) 
so might be expected to be a marker of adverse outcome. This would certainly be the case if the 
comparator group was (apyrexial) CD4 matched controls without tuberculosis, for example. 
But, in fact, higher temperature is weakly associated with decreased risk of death in KDHTB, 
specifically early mortality (figure 35 A). With earlier death as the outcome variable (so later 
death and survivors are the comparator group) a one-degree centigrade rise in temperature has 
odds ratio 0.80 (95%CI 0.64 to 1.00, p = 0.05). Adjusting for TB blood culture status reduces 
this OR to 0.72 (95%CI 0.57 to 0.90, p = 0.006). The mechanistic explanation consistent with 
this finding is that a blunted febrile response in MTBBSI is pathological (figure 35 B). 
Hyperglobulinaemia is strongly associated with tuberculosis infection, classically indexed by an 
abnormally low albumin/globulin (A/G) ratio, which has been related to severity of disease 
and prognosis.219,225-227  A/G ratio is a predictor of all-cause mortality in broadly defined 
cohorts (but in particular for pulmonary and malignancy diagnoses).228,229 While HIV infection 
is associated with polyclonal gammaglobulinaemia, HIV-associated TB results in a more 
deranged A/G ratio than HIV alone.169,230 Although rises in α2-globulin are perhaps “most 
consistent”, higher levels of all globulin subsets (α1, α2, β, and γ) are seen in active TB.226 
This makes sense, as TB infection can be associated with amyloid231 (a major α1 globulin), 
haptoglobin232-234 (a major α2 globulin), complement235 (the major β2 globulin), and specific 
IgGs.236,237 Even the acute phase reactants in this list (like haptoglobin) may have a special 
                                                             
§§§ For example, neutrophil transcriptomic signatures may be better related to clinical data using this 
approach. 
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association with tuberculosis, distinct from other infections.234 Rises in all these classes, and a 
fall in A/G ratio despite albumin and globulins being in the “normal range”, can be seen (in 
the absence of manifest systemic inflammation) after BCG immunisation.238  Globulins are a 
major determinant of ESR; ESR is often ‘disproportionately’ raised in tuberculosis (one of the 
classic causes of ESR > 100), with distinct dynamics compared to CRP.239,240  In sum, 
hyperglobulinaemia in tuberculosis isn’t simply another non-specific marker of inflammation, 
but encompasses multiple relatively specific host-responses to TB, some of which are likely to 
be adaptive rather than pathological.  
In keeping with above, and without exception, every patient in the KDHTB cohort has an 
abnormally high globulin level, and an abnormally low albumin-globulin ratio < 0.8 (figure 36 
A). However, within this group of TB patients, those with more disseminated disease tend to 
have a paradoxically lower globulin level (figure 36 A & B). While albumin correlates most 
strongly with inflammatory markers, globulins positively correlate with lymphocyte count (and 
even more with WBC principal component 1, i.e. variation in mononuclear leukocytes relating 
to immune status rather than inflammation) – figure 36 C & D.   
This is in keeping with globulin variation representing a host-response axis independent of 
systemic inflammation, with apparent decompensation in severe, disseminated, disease. 
However, curiously, only albumin and not globulin level is related to mortality (figure 36 B) so 
the mechanistic importance is unclear. Serum protein electrophoresis +/- longitudinal 
measurement might help unpick this finding. Irrespective, an important takeaway message is 
that pathophysiology can show non-linear relationships, with deviation from normal in mild-
moderate disease, but distributions closer to the normal range when infection is severe / 
decompensated. The apparent relationship of such a variable to mortality will depend heavily 
on inclusion criteria / selection of controls. These globulin findings resonate with patterns 
seen in some coagulation factors (another major class of plasma proteins) in a subset of the 
KDHTB cohort.141 **** 
  
                                                             
**** U-shaped patterns are seen in fibrinogen, factor IX, XI, V, II comparing HIV-infected outpatient 
controls, hospitalised survivors, and non-survivors. 
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Figure 1-35. Temperature (oC) relationship with mortality and MTBBSI 
A. Temperature distribution by outcome with overlaid box-plots (median, IQR, range, outliers indicated by line, box, 
whiskers and dots respectively). B. Temperature distribution by DTB score, with line of best fit by outcome status. Earlier 
death = death before day 14 follow-up; later death = death between days 14 and 84; survived = survived to end follow-up. 
 
 
Figure 1-36. Albumin and globulins by outcome and MTBBSI. 
A. Albumin versus globulin scatter plot with patient data points coloured by TB blood culture status (MFLpositive = 
positive TB blood culture). Lower limit of normal for albumin (35g/L) and upper limit of normal for globulins (35g/L) 
indicated by vertical and horizontal dashed lines respectively. The solid black line indicates albumin globulin ratio of 0.8 – 
all patients are to the left of this line i.e. ratio < 0.8. B. Albumin and globulin distributions by DTB score, with line of best 
fit by outcome status. Earlier death = death before day 14 follow-up; later death = death between days 14 and 84; survived 
= survived to end follow-up. C. Albumin and globulins linear relationship to procalcitonin. D. Albumin and globulins 
linear relationship to WBC principal component 1 (detailed in figure 33). 
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1.7.6 Physiological sepsis response 
494/596 (83%) patients had ≥2 SIRS criteria,241 114/596 (19%) had ≥1 qSOFA criteria,242,243 
and 196/596 (33%) had SOFA242,243 score ≥2 (when calculated without PaO2/FiO2 variable - 
which was not part of KDHTB protocol - and without data on inotropes/vasopressors, which 
were rarely used in this setting). Agreement between these “sepsis scores” is only marginally 
better than chance (figure 37). However, SIRS criteria were proposed to identify “sepsis 
syndrome” (a now defunct term), whereas qSOFA and SOFA are intended to identify organ 
dysfunction in high mortality risk patients. The lack of agreement between qSOFA and SOFA 
is largely the result of only the later including renal dysfunction, which is the most common 
observed organ dysfunction in this cohort. 
 
Figure 1-37. SIRS, qSOFA, SOFA Venn diagram 
Numbers indicate those with ‘positive’ scores (e.g. 58 are positive on all three Sepsis scores). 
 
Both SOFA and qSOFA score patients on mean arterial pressure (MAP, calculated here as 
[2*diastolic blood pressure + systolic pressure)/3]). 102/596 patients have MAP<70mmHg in 
this cohort, but as seen in table 8, blood pressure has no relationship with mortality. Systolic 
and diastolic pressure cluster remotely from all other clinical variables (figure 15 & 16); in 
particular they have no correlation with lactate (r = -0.03; 95%CI   -0.12 to 0.05; p=0.378). 
Again, covariance in physiological sepsis variables (MAP, lactate, heart rate, respiratory rate 
and temperature) can be parsimoniously represented with PCA (figure 39).  
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Figure 1-38. Correlation of variables traditionally associated with sepsis with their first 3 
PCs (varimax rotation). 
M_A_P = mean arterial pressure. 
 
 
Figure 1-39. 'Sepsis' variables PCs association with MTBBSI and mortality. 
A. Density distributions of the first 3 ‘sepsis’ PCs disaggregated by TB blood culture status (MFLpositive), B. 
day 84 outcome status, and C. DTB score. P values in A&B are from t-tests, NS = non-significant (p>0.1). 
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This shows 3 major axes of variation, with temperature (PC1), lactate (PC2) and MAP (PC3) 
being largely independent. Respiratory and heart rate have some covariance with all three 
components, but note that weak correlation between these variables and PC3 (ie MAP) is 
positive – there is no tachycardia /hypotension signal here. As would be expected from the 
univariate analyses, PC3 has no detectable relationship to MTBBSI or mortality (figure 39 B & 
C). PC2 – a febrile response capturing temperature, with associated raised heart and 
respiratory rate – is related to MTBBSI but not to higher mortality (reiterating the analysis in 
the preceding section on fever). By contrast, PC2 – raised lactate with associated raised heart 
and respiratory rate – is firmly related to MTBBSI and mortality. 
In short, there is no evidence that traditionally defined septic shock is an important feature in 
the KDHTB study, while raised venous lactate – independent of any strong indication of 
haemodynamic compromise – is strongly related to MTBBSI and mortality. It is possible that 
blood pressure was an insensitive measure of tissue hypo-perfusion in this cohort, or that frank 
hypotension only developed after recruitment in patients that died. However, irrespective of 
the time cut-off used to define early death, MAP remains unrelated to mortality (data not 
shown), and it is hard to square the complete absence of a signal at time of acute admission 
with a causal relationship between hypotension and adverse outcome, particularly when lactic 
acidosis was already manifest in so many patients.  Rather, it suggests at a minimum, that 
lactate and hypotension are largely on different causal pathways in this cohort. 
In recent years a range of data has called into question the traditional model of 
hyperlactataemia representing anaerobic respiration in hypoxic, hypoperfused tissues 
(“oxygen debt”). Endotoxin induces hyperlactataemia in healthy volunteers, with associated 
increased resting energy expenditure, and glucose and lactate production, in the absence of 
tissue hypoxia.244 Muscle and other tissue biopsies in patients with sepsis show supernormal 
tissue PO2, with highest levels seen in patients with more severe sepsis.245,246 Based on these 
and other findings, alternative or additional sources of hyperlactataemia in sepsis have been 
proposed, including accelerated aerobic glycolysis from sepsis-induced inflammation. The theory 
is that increased energy demand from inflammation exceeds the oxidative phosphorylation 
capacity of mitochondria, with consequent build-up of pyruvate, which drives lactate 
production by mass-effect.247 This metabolic effect is likely to be predominantly in cells of the 
immune system, which are highly energy dependent when activated: for example, M1 (but not 
M2) macrophages increase glucose consumption and release lactate.248 This metabolic shift 
78 
 
seems to be necessary for subsequent inflammatory cytokine response – an upstream metabolic 
step in the biochemistry of inflammation, not a downstream metabolic consequence of 
inflammation.249  In turn, at least in cell cultures, pro-inflammatory cytokines induce glucose 
uptake and glycolysis, but not oxidation of glucose by the Kreb’s cycle.250 In severe sepsis, 
isotope dilution studies show increased turnover of glucose and lactate.247 In short, aerobic 
glycolysis is an inefficient but rapid (and adaptive) means to meet exceptional need for ATP in 
inflammatory immune cells.251 
Further, recent data links this metabolic shift directly to the host-response to M. tuberculosis. 
Human alveolar and monocyte derived macrophages switch from oxidative phosphorylation to 
aerobic glycolysis when infected ex vivo with M. tuberculosis, increasing lactate production; 
inhibition of this shift decreases IL-1β and increases IL-10 production, and impairs killing of 
bacilli.252 This finding has been corroborated in vivo: glycolysis pathway gene expression is 
upregulated in human tuberculin skin test challenge model experiments, and in clinical 
samples from sites of TB disease.253  
The KDHTB results support upregulated aerobic glycolysis from sepsis-induced inflammation 
as the main driver of hyperlactataemia in severe HIV-associated tuberculosis. In addition to the 
absent association with MAP, lactate (and sepsis PC2) positively correlate with markers of 
inflammation and with glucose (figure 40). 
 
Figure 1-40. Lactate, and sepsis principal component 2, correlate with glucose and 
inflammation markers. 
Sepsis PC2 is a composite variable mostly representing lactate, but also some covariance of respiratory 
and heart rate. WBC PC2 is a composite variable combining several markers of inflammation. Black lines 
show linear model with 95%CI in shaded area. 
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Given that age is not strongly related to lactate (or inflammation) – see figure 15 – what is the 
relationship between age, lactate and glucose? The effect of age on glucose can be shown to be 
largely mediated via an interaction effect on the relationship between lactate and glucose – in a 
linear regression model the main effect of age is non-significant, but the interaction effect with 
lactate is strongly related to glucose, i.e. a cross-over effect (figure 41).  The parsimonious 
explanation is: inflammation / stress response induces metabolic shift to gluconeogenesis / 
oxidative glycolysis, causing increased lactate and glucose production. The extent to which 
increased glucose production results in venous hyperglycaemia then depends on degree of 
insulin resistance. Glucose tolerance / insulin sensitivity – in addition to being worsened by 
sepsis254,255 – is inversely and linearly related to age across the range 18 to 80 years, 
independent of BMI and VO2 max:  40-year olds have more insulin resistance than 30-year 
olds.256,257 
 
Figure 1-41. Regression model predicting venous glucose from independent variables 
lactate and age. 
The model form is log2(glucose) = intercept + β1*log2(lactate) + β2*log2(age) + β3*log2(lactate) *log2(age) + 
ε. Predicted values for glucose are shown across the empirical range of lactate and for 5 representative 
ages, converted to original scale for ease of interpretation (A). β estimates and their precision, with 
indices of model fit are shown in B. Addition of inflammatory markers (e.g. WBC PC2) to the model did 
not improve fit (p0.158 by nested model Likelihood Ratio Test), and residuals from the model 
(unexplained variance in glucose, ε) were not strongly related with any other variables in the dataset. 
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1.7.7 Thrombocytopenia  
Platelet count is a complex variable, related to multiple pathogenesis mechanisms in both HIV 
and tuberculosis.258 For example, in PLWHIV suffering from immune thrombocytopenia 
(ITP), a high proportion may additionally have a low immature platelet fraction, suggesting 
inappropriately suppressed megakaryocyte activity.259 Tuberculosis is classically associated 
with a reactive thrombocytosis, reduced platelet survival time, and increased platelet 
clumping.260 TB thrombocytosis correlates with ESR,260 and bacilli burden in sputum261 and 
within granulomas.262 Conversely, thrombocytopenia can result from ITP caused by 
tuberculosis,69,263 pancytopenia associated with bone marrow TB,264 adverse reaction to 
rifampicin,265 and disseminated intravascular coagulation,266 especially in HIV-associated 
TB.267 In the KDTH dataset, platelet count is higher with more preserved immune-status (r = 
0.27, p=1.1e-11, for WBC PC1), lower with advanced inflammation (r = -0.14, p=2.5e-04, for 
WBC PC 2), and correlates with total white cell count independently of CD4 count (r = 0.42, 
p<2.2e-16, for WBC PC3). Since all these axes are largely independent, platelet count should 
be considered a net effect of multiple concomitant processes. HIV viral load also relates to 
platelet count independently of CD4 count (table 12). 
Table 1-12. Multivariate linear regression predicting platelets_sqrt. 
Variable Estimate 95%CI p-value 
WBC PC1, per 1 s.d. 
(immune-status composite) 
1.06   0.76 to 1.36 1.2e-11 
WBC PC2, per 1 s.d. 
(inflammation composite) 
-0.63   -0.93 to -0.34 2.8e-05 
WBC PC3, per 1 s.d. 
(total white cell count surrogate) 
1.84   1.55 to 2.14 <2e-16 
HIV viral load, per log -0.47   -0.66 to -0.27 2.9e-06 
Model fit: F-statistic: 63.32 on 4 & 591 DF,  p < 2.2e-16 
  Adjusted R2 = 0.30   
Model form: √platelets = WBC_PC1 + WBC_PC2 + WBC_PC3 + log(HIV viral load), so 
estimates relate to a one unit increase in platelets after 0.5 power transformation.  
s.d. = standard deviation.  
 
This complicates interpretation of the association between MTBBSI and thrombocytopenia 
(Rho = -0.28, p= 7.7e-12, for DTB score) – is it causal, or from confounding by worse immune 
status? To help attribute causality, any serial measures of platelets during admission 
(performed as part of routine care, i.e. non-systematically) were extracted for 50 patients 
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selected at random from the KDHTB cohort.†††† 12/50 had platelet count < 150 on day of 
study recruitment; 43/50 had platelet counts from more than one time-point. 30/43 had an 
average downward trend in platelet count during admission (based on line of best fit), and 
probability and magnitude of a downward trend was correlated with MTBBSI (figure 42). 
Again with a caveat from non-systematic ascertainment of serial measures, this supports a 
mechanistic link between MTBBSI and thrombocytopenia, within the complex causal web 
determining net platelet count. 
We can hypothesise that the covariance of platelets with d-dimer might capture underlying 
pathophysiology relating to disseminated intravascular coagulation. A single principal 
component PCA (varimax rotation) captures 60% of variation in both variables. In turn this PC 
is associated with day 84 death (mean value in survivors = 0.11; mean value in those that died -
0.40; p = 8.6e-07 by t-test) and with DTB score (Rho -0.39; p<2.2e-16). 
 
 
Figure 1-42. Trend in platelet count during admission in 43 patients from KDHTB cohort. 
A. Line of best fit showing average trend in platelet count for patients with more than one full blood 
count performed during admission when study recruitment took place. Each line represents a single 
patient, and colour indicates DTB count of this patient on day 0 (day of recruitment). B. Gradient 
(slope) of line of best fit is extracted (using lmList() function in lme4 package of R) and plotted against 
DTB score. Overlaid boxplots show median, IQR, range, indicated by line, box, whiskers respectively). 
 
                                                             
†††† The same 50 patients referred to in the serial sodium measure analysis above. 
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1.8 Structural equation model of core 
variables relationship to disseminated 
TB and mortality. 
 
After the preceding supervised dimension reduction, there is a core set of (mostly constructed) 
variables which relate to both MTBBSI and mortality. A reminder of these variables and their 
proposed description is given in table 14. Covariance in these variables is shown in figure 43; a 
summary of their relationship to mortality and DTB score is shown in table 15.  
A hypothesised structural relationship underlying these covariances is shown in figure 44. This 
structural equation model (SEM) attempts to reproduce the covariance matrix in figure 43A 
and table 15, i.e. to provide a simple explanation of the phenomena consistent with these 
observations. It models disseminated TB (DTB) as an unobserved latent variable which in turn 
determines variation in the observed (‘manifest’) variables TB blood culture (MFL), uGXP 
and uLAM – i.e. that these markers are conditionally independent given the latent variable 
DTB. This deals with the measurement error related to each of these manifest variables: i.e. 
the correlation between manifest variables is assumed to be an under-estimate of the true 
correlation between the latent variable and other variables in the model.  
What does the SEM show? It implies that the effect of immunosuppression (wbc_pc1) on 
mortality in KDHTB is mediated through DTB, which in turn mediates its effects through 
physiological effects (sepsis_pc2 – hyperlactataemia), inflammation (wbc_pc2), and metabolic 
disturbance associated with renal dysfunction (metab_pc1). This is shown by the lack of 
significant direct effects of these upstream variables (arrows not passing through the mediating 
variables). Age and wbc_pc3 (the WBC PC dominated by total white cell count) by contrast 
have direct effects, independent of these other variables. Substantial collinearity remains 
between the mediating variables (sepsis_pc2, wbc_pc2, metab_pc1) suggesting they are not 
truly independent mechanisms.  
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A variety of metrics of model fit suggest this SEM is reasonably consistent with the data.‡‡‡‡ 
But this model also has a number of profound limitations. Firstly, the choice of mediating 
variables is fairly arbitrary; replacing them with other markers (for example, haemoglobin, D-
dimer-platelets covariance, albumin) makes very little difference to the model fit. Combining 
all these mediators inflates the standard errors in the regression rendering most non-
significant. We don’t really know enough about the pathways connecting these mediators to 
each other, and don’t have unique enough assays of the pathophysiology they represent, to 
resolve this further. At some level, all this model says is that sick patients have worse 
outcomes. Secondly, the SEM assumes a static system (e.g. without feedback loops); this is 
theoretically implausible. Third, although the individual pathways are found to be highly 
significant (i.e. the z-scores of individual parameters are strong), when the total variance in 
mortality explained is estimated by adding up the products of all the partial correlations on 
each pathway, the total is only ~24%.§§§§  In sum, there are several important associations 
summarised in this model, but we are far from a complete understanding of the 
pathophysiology of HIV-associated MTBBSI. 
Table 1-13. Core variables relating MTBBSI & mortality after supervised dimension 
reduction. 
Variable Description 
wbc_pc1 Immune status. Greater immunosuppression = lower value. 
wbc_pc2 Inflammation. Greater inflammation = higher value. 
wbc_pc3 
Covariance in WBC relating to total white cell count, independent of 
immunosuppression and inflammation. 
LFTs_canalicular 
Predominantly gamma-GT and alkaline phosphatase elevation in abnormal 
LFTs 
metab_PC1 Metabolic acidosis predominantly associated with worse renal function 
sepsis_pc2 Predominantly variance relating to hyperlactataemia 
ddm_plt_pc Covariance in platelet count and D-dimer 
Sodium Serum sodium on original measured scale  
glucose_log2 Log2 transformed venous glucose 
Albumin Serum albumin as measured on original scale 
Hb_sqrt power 0.5 transformed haemoglobin level 
age_log2 Log2 transformed age in years 
 
                                                             
‡‡‡‡ There are over 60 metrics of SEM fit available in lavaan package alone, and no consensus in the 
literature about which to use. As an example, Goodness of Fit index (GFI) compares the model of 
interest to a model which allows all included variables to covary (no a priori structure), and therefore 
gives some indication of how much covariance is explained by the structure. GFI ranges between 0 and 
1, with higher values indicating better fit. GFI for the model described here is 0.96.  
§§§§ For comparison, this is similar to pseudo-R2 values for logistic regression model using all the core 
variables and DTB score as predictors of day 84 death. 
84 
 
As another example, a SEM of acute kidney injury is presented in figure 45. The hypothesis 
that MTBBSI effect on AKI is mediated via more than one causal pathway is consistent with 
the covariance structure of the data. Several other variables independently relate to AKI, 
including age and sodium. Mean arterial pressure has a weak association with AKI, but the 
direction of partial correlation is positive, again emphasising that hypotension is not a major 
driver of AKI in this cohort. This model would likely be substantially improved by variables 
specific to ECFV and cytotoxic renal cell injury (such as urine biomarkers).  
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Table 1-14. Summary of core variable association with DTB score and mortality outcome; medians by grouping variables and test of 
significance. 
 
Values are median for grouping level. Variables are described in previous sections and briefly again in table 14. P-values are from Kruskal-Wallis test 
across categories shown. 
 
0 
(N=144)
1 
(N=196)
2 
(N=129)
3 
(N=127)
p value
No 
(N=469)
Yes 
(N=127)
p value
early 
(N=65)
later 
(N=73)
survived 
(N=458)
p value
wbc_pc1 0.66 0.19 -0.29 -0.46 < 0.001 0.14 -0.22 < 0.001 -0.23 -0.17 0.17 < 0.001
wbc_pc2 -0.42 -0.18 0.21 0.54 < 0.001 -0.04 0.51 < 0.001 0.9 0.21 -0.05 < 0.001
wbc_pc3 -0.04 0.06 -0.06 0.08 0.871 0.08 -0.19 0.009 -0.31 -0.04 0.08 < 0.001
LFTs_canalicular -0.36 -0.1 0.04 0.16 < 0.001 -0.14 0.24 < 0.001 0.25 0.28 -0.16 < 0.001
metab_PC1 -0.48 -0.32 0.07 0.26 < 0.001 -0.24 0.22 < 0.001 0.21 0.26 -0.25 < 0.001
sepsis_pc2 -0.52 -0.22 0.15 0.22 < 0.001 -0.21 0.32 < 0.001 0.43 0.03 -0.2 < 0.001
ddm_plt_pc 0.5 0.37 -0.22 -0.48 < 0.001 0.21 -0.43 < 0.001 -0.24 -0.42 0.22 < 0.001
Sodium 130 129 127 128 < 0.001 129 128 0.124 127 129 129 0.062
glucose_log2 2.35 2.35 2.43 2.43 0.003 2.38 2.46 0.006 2.43 2.43 2.38 0.013
Albumin 27 26 23 23 < 0.001 25 22 < 0.001 21 23 25 < 0.001
Hb_sqrt 3.1 2.98 2.85 2.81 < 0.001 2.97 2.83 0.007 2.81 2.85 2.98 0.021
age_log2 5.25 5.14 5.18 5.14 0.099 5.14 5.31 < 0.001 5.38 5.28 5.14 < 0.001
DTB score Day 84 death Death early v later v survived
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Figure 1-43. Covariance in core variables related to MTBBSI and mortality. 
A. Correlation matrix in 13 core variables known to relate to mortality and MTBBSI. These variables are mostly constructed from supervised or semi-supervised 
dimension reduction described in preceding sections, and a brief description of each is given in table 14. Depth of green colour indicates magnitude of absolute value of 
Pearson’s correlation coefficient. Variables are ordered based on a hierarchical clustering algorithm (complete linkage used to define distance between clusters). B. A 
complimentary clustering of the variables using average linking to test stability of the clustering solution to method. 
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Figure 1-44. Structural equation model relating selected core variables to disseminated TB and mortality outcome. 
The model was generated in lavaan package of R. DTB is modelled as a latent, unobserved, variable which causes observed variance in TB blood culture positivity 
(MFL), uGXP and uLAM value. Single headed arrows represent regressions; double ended curved arrows represent covariance out with the regression structure.  
Numbers in red/green boxes on arrow represent partial correlations – i.e. strength and direction of linear relationship between two variables after controlling for the 
effects of other variables in the regression structure – equivalent to a standardised regression coefficient. For example, residual variation in sepsis_pc2 after adjusting 
for wbc_pc1, wbc_pc2, wbc_pc3, metab_pc1, Age_log2, and DTB, has correlation coefficient 0.15 with day 84 death. Because death is a binary variable, these 
correlation coefficients are not Pearson’s r (they are Maximum Likelihood estimates of correlations to normal distribution modelled to underlie the binary variable) but 
can be interpreted in the same way.  Therefore, variance in death outcome explained by an individual variable in the model can be calculated by the product of all the 
coefficients in every path linking it to the outcome (including covariance arrows).  Total variance explained is 24%.  
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Figure 1-45. Acute Kidney Injury SEM. 
DIC = latent variable represented by variance in manifest variables Ddimer and platelet count. DTB = latent variable represented by manifest variables MFL (TB blood 
culture), uLAM and uGXP. Systm inflm = latent variable represented by manifest variables procalcitonin and CRP. AKI = latent variable represented by manifest 
variables creatinine, urea, bicarbonate and potassium.  HIV_VL = HIV viral load; MAP = mean arterial pressure. Overall SEMM fit is reasonable (GFI = 0.94) and 40% 
of variation in AK is explained by the regression pathways, indicated by partial correlations (standardised regression coefficients) in boxes. 
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1.9 Concluding discussion 
 
This chapter began by showing that ‘disseminated TB’ is regarded as a vague 
diagnosis, while MTBBSI is largely ignored by HIV-associated TB guidelines and 
normative international classifications of tuberculosis. A different 
conceptualisation was offered. Active, ongoing blood stream and lymphatic 
dissemination is in fact the mode of severe HIV-associated TB. So-called 
“disseminated TB” in HIV is fundamentally a BSI; semantically, I would argue 
MTBBSI is a better description than disseminated TB, because all tuberculosis is 
disseminated to a greater-or-lesser extent. Blood culture is just one window on 
this process, but is bolstered by novel rapid diagnostics (uGXP and uLAM) to 
give a more complete picture of MTBBSI.  
MTBBSI is not clinically vague. Gastro-intestinal symptoms combined with 
‘classic’ TB presenting complaints, inability to walk unaided (high ECOG score), 
diffuse adenopathy, generalised infiltrate on chest x-ray, and splenic 
microabscesses all have positive likelihood ratios, while localised serositis and 
fibrotic changes have negative likelihood ratios for MTBBSI versus non-BSI HIV-
associated TB. Immunosuppression, hyponatraemia, thrombocytopenia, anaemia, 
hyperlactataemia, acute kidney injury with metabolic acidosis, ‘infiltrative’ LFT 
derangement, disproportionate rise in AST, and systemic inflammation all 
correlate strongly with MTBBSI, but classical septic shock (hypotension, hyper-
pyrexia) does not. These signs suggest MTBBSI is pathophysiologically distinct, 
and that the term has convergent and discriminant validity. It also makes it a well-
defined target for interventional trials. 
All these features can be related to (semi) quantitative measures of MTBBSI 
(blood culture positivity and DTB score), which in turn can be related to 
immunosuppression, suggesting a single major axis of clinical variation in these 
patients. Many of the features may be adaptive (for example, pre-renal acute 
kidney injury, hyperlactatemia as a bioenergetic response, or anaemia if hepcidin 
is protective in the context of a massive and largely extracellular bacilli burden) in 
the face of non-resolving infection. The strong independent effect of age on 
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mortality may in fact be an interaction with this axis: less physiological reserve to 
accommodate the host-response to severe disease.  
This might imply that the most obvious place to target interventions is on faster 
bacilli-killing and restoration of adaptive immunity, because downstream (host-
response) effects of these abnormalities are complex and incompletely 
understood. For example, what fluid resuscitation should be recommended for 
these patients? Although AKI and hyperlactaemia are prevalent, hypotension is 
not. Sodium and water status is far from normal. But what effect would rapid fluid 
resuscitation have in patients who have sub-acute ECFV depletion? What if there 
is concurrent SIADH? Consumptive coagulopathy may be present in many of 
these patients – what effect would fluid dilution of clotting factors have? A recent 
RCT testing a ‘bundle of care’ intervention, including aggressive fluid 
resuscitation, in adult inpatients with hypotensive sepsis from Lusaka reported a 
22% absolute increase in 28-day mortality in the intervention arm.268  The trial 
population was predominantly patients with HIV-associated MTBBSI (21% TB 
blood culture positive, 11% other bacterial pathogen on blood culture; 90% HIV 
prevalence, median CD4 66 cells/ml, 63% clinical diagnosis of tuberculosis), 
median creatinine above normal range and near universal anaemia. The current 
analysis suggests several pathways by which fluid boluses could cause harm and 
suggests that any fluid administration should be cautious and individualised. 
Better characterisation is indicated before further interventional trials. 
Sepsis is currently defined as organ dysfunction caused by an “aberrant or 
dysregulated host-response” to infection.243 I would argue that to the extent that 
host-responses such as inflammation are proportionate to infection burden (like 
DTB score) it is anomalous to see them as aberrant or dysregulated. In this 
cohort, bacilli burden (as far as we can accurately measure it) doesn’t explain all 
variance in, for example, inflammation (as measured by markers like pro-
calcitonin), but the covariance is substantial, and improved by measurement error 
minimising techniques like PCA and SEM. A constructive takeaway conclusion 
would be that measures of pathogen burden could improve interpretability of 
sepsis studies more widely than MTBBSI. 
Detection and quantification of mycobacteria are a major theme of the rest of this 
thesis, starting with prediction of TB blood culture status using ‘baseline’ clinical 
variables in the next chapter.  
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2 Predicting TB blood culture 
results  
 
2.1 Introduction 
The previous chapter described multiple clinical variables associated with 
MTBBSI, and made the inference that MTBBSI defined the major underlying 
axes of variation in severe HIV-associated tuberculosis. In short, plotting 
KDHTB patients on a spectrum of MTBBSI – represented by a ‘disseminated TB 
score’ – could explain a large amount of variation in clinical variables such as 
inflammation markers and mortality outcome. Such explanations are a way to 
grapple with complexity; a  useful framework to generate, attach, and test 
knowledge.269 But often of more interest in the real world is the use of data to 
predict future events. If it is true that MTBBSI is strongly related to clinical 
variance in HIV-associated TB patients, and – as argued previously – MTBBSI is 
ripe for positive empirical diagnosis, then it should be possible to predict which 
patients have MTBBSI using surrogate clinical variables. The prediction 
approach is complimentary, but different, to the preceding analysis. Inferences 
require prior theory about causal structure; predictions can be completely 
agnostic about mechanism.  
This chapter is about development and validation of algorithms to predict TB 
blood culture status using clinical variables available on day of admission to 
hospital. Data from the first half of the KDHTB study were subjected to a variety 
of machine learning methods, and selected models were wrapped into a web-
based ‘app’ for use at patients’ bedside via smart ‘phone. This allowed 
prospective validations to be carried out during the second half of KDHTB 
recruitment. 
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In addition to showing that MTBBSI (here defined as blood culture positivity) can 
be accurately predicted in hospitalised PLWHIV using basic clinical observations, 
this work had the practical application of enriching recruitment to sub-studies 
described here and in subsequent chapters.  
2.2 Predictions & clinical decision 
rules in medicine 
Prediction is central to clinical practice. Diagnosis, prognosis, and treatment 
decisions are all predictions. Use of algorithms to support practice is as old as 
clinical medicine, but the last 50 years has seen the rise of “clinical decision 
rules” (CDRs, also called clinical prediction rules, risk scores etc.).270 Over time 
the methods used in development of CDRs has evolved. Early examples relied on 
expert opinion (e.g. SIRS criteria,271 Glasgow Coma Scale272, APACHE-II273) or 
combinations of risk-factors identified through strength of univariate associations 
(e.g. the Glasgow-Imrie Pancreatitis score274).  
Two decades ago multivariate logistic regression became the norm for developing 
CDRs, archetypal examples including the Framingham cardiovascular risk 
calculator,275 CURB-65 score for pneumonia,276 FRAX osteoporotic fracture risk 
score,277 and the Model for End-Stage Liver Disease278. To avoid the requirement 
for clinicians doing matrix algebra at the bedside, multivariate models are 
represented by normographs, converted to scores (variable reference ranges are 
categorised and category midpoints mapped to a points score based on non-
arbitrary weights derived from the regression model parameters279), or accessed 
via the web.  
More recently, a plethora of computationally intensive methods have been 
brought to CDR development – such as decision trees and neural networks.280,281 
Rather than resting on sophisticated ‘parametric’ statistical theory, these 
‘machine learning’ methods use the brute-force of iteration made possible by the 
greater availability of high-speed computer processing. Typically, these ‘black-
box’ methods don’t offer easy summaries of how variables are being translated 
into predictions – there is no normograph or score to tot-up, so they can only be 
used with access to a computer (e.g. online). Despite an explosion of publications 
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reporting machine learning in medicine, it is still hard to find any examples that 
have been broadly applied in routine practice.  
It is often stated that multivariate approaches are an advance on expert opinion or 
univariate methods, because, in the former, dependence between predictors is 
accounted for, and weighting for scores is non-arbitrary.282 Similarly, the 
purported advantage of iterative models over logistic regression is they can 
include complex, non-linear relationships between variables.281,282 This somewhat 
misses the point. Consider, for example, that scores based on expert opinion can – 
and do – include non-linearity (for instance, abnormally high or low temperature 
and white cell count score in SIRS criteria). Fundamentally, all that matters is 
predictive accuracy.  
It is useful to think of predictive accuracy in terms of bias versus variance trade-
off.283-285 Any model can be made more complicated. Variance error is the extent 
to which the parameters of a model would change if we estimated them with a 
different data set.283 Bias error is the extent to which the form of the model fails to 
capture the complexity of real life.283 In general, a more flexible model will reduce 
bias but increase variance.284,285 For example, fitting a linear function to a non-
linear relationship will cause bias in predictions, but the slope and intercept of the 
model are unlikely to vary if re-estimated with a different data set. By contrast, if 
the ‘real’ relationship is substantively linear, a more flexible non-linear model is 
likely to be overfitted; its parameters would vary if re-estimated with another data 
set containing randomly different noise. Increasing model flexibility will have 
diminishing returns for reducing bias, while decreasing model flexibility will have 
diminishing returns for reducing variance. The optimal trade-off in appeasing 
these two error sources depends on what the true relationship between variables 
is in the real world (which we don’t know), and on the quality and quantity of data 
available to the modelling exercise (a small number of noisy observations equates 
to greater variance so a less flexible model will perform better, even if this model 
is highly biased).  
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Figure 2-1. Sources of error in prediction schematic. 
Total error is the sum of severally logically distinct errors. Variance – bias trade-off is 
described in main text. Irreducible error is unmeasured or unmeasurable factors which 
impact on outcome. 
 
While novel modelling techniques allow examination of a much wider range of 
variance-bias trade-off points, the real power of machine learning comes from 
better ability to observe where that trade-off is best and ‘tune’ models using 
‘training’ data to this optimum. Historical CDR development has relied on 
validation in new cohorts, which is expensive and inefficient: it requires a lot of 
data. The more data that is “spent” on validation cohorts, the less available for 
model development. Recall that small samples, with less power to distinguish 
signal from noise i.e. more variance, will select for a less flexible model, pushing 
the optimal trade-off towards more bias. Over-reliance on validation sets, at the 
expense of the sample size of the derivation cohort,  might therefore increase 
bias.283,286 
 Resampling methods can make much more efficient use of data available at time of 
model development, and are the engine that runs most machine learning 
approaches.  
2.3 Resampling methods & model 
tuning 
Re-fitting a model from repeated subsets of available data (resampling) can 
generate information about the model. Resampling gives an estimate (and 
confidence interval) for out-of-sample model performance. In addition, the effect 
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of increasing or decreasing model complexity can be assessed (model ‘tuning’ and 
selection) to optimise variance-bias trade-off. 283,285,286 
k-fold cross validation is the resampling method used in the analysis described in 
this chapter. Observations in the dataset are divided into k subsets (folds) with 
approximately equal numbers of patients. Each fold is treated as the validation set 
in k repeated fittings of a model, giving k estimates of model predictive error, for 
which the mean and standard deviation can be calculated. 287 
The degree of flexibility in any model can be controlled, often by adjusting a single 
parameter. An example for linear regression would be increasing the number of 
function terms, from a simple linear regression to a polynomial regression. By 
comparing the k-fold cross-validation estimate of model performance across a 
range of values of this parameter (e.g. different degrees of polynomial in a linear 
regression) the optimal model flexibility can be learned, and the model flexibility 
parameter ‘tuned’.288 
 
2.4 Published MTBBSI prediction 
models  
In the previous chapter associations with TB blood culture status from previous 
studies were reviewed. Several of these studies refer to prediction of MTBBSI in 
reported study objectives. 
Patients recruited to the Zambian Simplified Severe Sepsis Protocol (SSSP) trials 
1 & 2 had routine TB blood culture performed as part of these trials.268,289 
Muchemwa et al. present an analysis of 201 patients from these trials who were 
HIV-infected, examining predictors of a positive TB blood culture.124 Variables 
collected as part of the original trials were assessed for univariate association, 
those with p<0.2 were then entered into a multivariate logistic regression, and 
stepwise deselected. Odds ratios from a final model are presented, but no measure 
of predictive performance is reported, and no validation of results is shown.  
This is true of the other ‘predictor’ studies as well,57,125,126 with one exception. 
Jacob et al. developed a clinical score for prediction of M. tuberculosis bacteraemia 
in an n=368 cohort of HIV-infected adult in-patients with severe sepsis recruited 
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in Uganda.127 Variables were chosen by univariate association at p<0.2 with 
positive TB blood culture, and further deselected in a backwards stepwise logistic 
regression model. Unlike the other studies, area under the receiver operating 
curve (ROC AUC) was reported for the final model. In addition, a prediction 
score was derived using the Framingham method.279 The ROC AUC value was 
determined using 10 iterations of 10-fold cross validation (AUC = 0.82, range 
0.61 to 0.91 in the resamples), although it does not appear that cross-validation 
was used to tune the logistic regression model. Variables included in the final 
model were sex, heart rate, CD4 count, current HAART use, fever symptom as 
chief complaint, haemoglobin, and sodium. This represents the best previous 
literature on MTBBSI prediction so was used to inform some of the current 
analysis as described below. The performance of the Jacob score was assessed in 
both the whole KDHTB cohort (i.e. including patients who were suspected of 
having TB but did not have a final diagnosis of TB) and the Jooste rapid TB 
diagnostics study (all HIV-infected patients admitted to medical wards 
irrespective of suspected or final diagnosis). The Jacob score had ROC AUC 0.76 
(bootstrapped 95% CI 0.72 to 0.79) and 0.78 (bootstrapped 95% CI 0.70 to 0.86) 
in KDHTB and Jooste data, respectively. 
 
2.5 Summary of predictive modelling 
strategy used in this chapter 
2.5.1 Included data 
Initial predictive modelling was performed in May 2016 when 348 patients had 
been recruited to KDHTB and captured on the study data base. Patients were 
included in the analysis if they met KDHTB inclusion criteria (CD4 count < 350 
cells/mm3) and if they had a valid baseline Myco/F lytic (MFL) tuberculosis 
blood culture result (defined as a positive or negative MFL on day of recruitment 
+/- 1 day, excluding contaminated samples). Patients who had a negative baseline 
MFL but were TB blood culture positive at another time point were excluded. 
75% of the available data was selected for a training set by random stratified 
allocation so that an equal proportion of patients were MFL positive in training 
and test sets.  
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Figure 2-2. Consort diagram for May 2016 predictive modelling analysis. 
MFL = Myco/F lytic TB blood culture. 
2.5.2 Model types 
Five model types were used, briefly described below.  
2.5.2.1 Logistic regression 
Generalised linear models based on the binomial probability distribution were 
constructed using the glm() function in R. Method summary: the conditional mean of 
the log odds ratio of the bacteraemia outcome (logit) is modelled as a linear function 
of the predictor variables weighted by parameters derived from maximum likelihood 
estimation. 
2.5.2.2 Decision tree 
Decision tree models were constructed using the recursive partitioning (rpart) 
package in R. Method summary: the rpart algorithm searches for a predictor variable 
which splits the individuals of the data set into two groups such that the homogenity 
(purity) of the outcome in the two groups is maximised. This is serially repeated in 
the ‘daughter’ groups until purity is not increased by further splits, or a maximum 
number of branches has been reached. To avoid over-fitting a ‘complexity 
parameter’, cp, is specified which penalises larger trees; cp can be optimised (‘tuned’) 
using cross-validation. 
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2.5.2.3 Random forest 
Random forest models were produced using the randomForest package in 
R. Method summary: For a data set with N individuals (rows) and V predictor 
variables, a large number, K, of decision tree models are constructed as follows. 
To create tree k, a random sample of n < N individuals is made (with 
replacement), with approximately 1/3 individuals held in reserve. At each node of 
tree k, v < V predictors are randomly chosen for consideration as potential 
splitting variables. Predictions for new cases can be made by applying all K 
decision trees to the new case and counting the predicted outcomes (‘votes’) 
across all the trees. In addition, the accuracy of each tree is tracked by running the 
reserved cases down each decision tree to give an estimate of ‘out-of-sample’ error 
rate. The main parameter affecting random forest flexibility is the size of v, which can 
be ‘tuned’ using cross-validation. 
2.5.2.4 Boosted tree 
Boosted tree models were made using the gbm package in R. Method summary: Similar 
to random forest models, the boosted tree algorithm builds multiple decision trees 
and combines their predictions. However, unlike in the random forest method, each 
new tree is constructed using information from the previously constructed trees and 
is weighted to return more accurate predictions for cases misclassified in the previous 
trees. A modified version of the data set is used for each new tree. This is equivalent 
to running a new model to ‘explain’ the residuals from the previous model. The 
amount of ‘explanation’ that the new model is permitted to provide is an adjustable 
parameter (lamda, the ‘shrinkage’ or ‘learning rate’). Other parameters include 
number of branches per tree, total number of trees, and maximum number of 
observations in each node of the tree; all can be optimised through cross validation. 
2.5.2.5 Support vector machine 
SVM models were implemented in R using the svmLinear2 function of the e1071 
package. Method summary: For V predictor variables, individuals are located 
in (V−1)-dimensional space. The SVM algorithm finds the optimal separating 
hyperplane between the two classes by maximizing the margin between the 
classes’ closest points using quadratic algebra. A cost parameter for misclassifying 
an individual, and a flexibility parameter determining the ‘smoothing’ in the 
hyperplane can be tuned using cross validation to reduce over-fitting. 
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2.5.3 Variable selection and dimension reduction 
Feature selection for predictive modelling can, at one extreme, be completely 
based on domain knowledge (for example in development of CDRs based on 
expert opinion) or completely data driven and automated (such as in gene 
selection in microarray data)290 or somewhere in between (such as the univariate 
testing of a priori variables and inclusion in final model based on an arbitrary p-
value cut-off).  
Selection of variables is important not just because it makes analysis more 
manageable and interpretable. Having a large number of variables reduces the 
effective sample size – as variables (or dimensions) are added the density of 
observations decreases quadratically in the space defined by those variables, 
increasing risk of overfitting and adversely shifting the dynamics of variance-bias 
trade-off (called “the curse of dimensionality”).291 In the machine learning 
literature, a distinction is made between relevant predictors (which are strongly 
associated with the outcome, but may be redundant when included with other 
variables) and useful predictors (which add predictive value despite a weaker 
univariate association, because they capture non-redundant information). The 
implication is that selecting only the most relevant variables may be suboptimal.292 
Consequently a number of alternative approaches to variable selection have been 
developed, several of which are adopted here. 
All variables collected as part of the KDHTB study which were potentially 
available during the first 24 hours of admission were considered for use in the 
analysis. This included all clinical variables associated with TB blood culture 
status in previous literature. Variables with more than 20% missing observations 
(Body Mass Index) were excluded. Low information variables – those that showed 
near zero variation across the cohort, e.g. a categorical variable where nearly all 
observations were in one category – were identified using the nearZeroVar 
function of the Caret package in R and excluded (presence of central nervous 
system tuberculoma). This left 50 variables in the ‘full variable set’ (table 1). 
Variables were log transformed if this resulted in a more normal distribution 
(assessed with histograms and QQ plots). 
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Table 2-1. Full variable set considered for predictive modelling. 
Variable Description 
Sex   
Age   
PreviousTB History of previous (not current) TB diagnosis 
Cough Reported symptom present in study recruitment questionnaire 
LossOfAppetite Reported symptom present in study recruitment questionnaire 
LossOfWeight Reported symptom present in study recruitment questionnaire 
DrenchingNightSweats Reported symptom present in study recruitment questionnaire 
Nausea.and.vomiting Reported symptom present in study recruitment questionnaire 
Diarrhea Reported symptom present in study recruitment questionnaire 
Headache Reported symptom present in study recruitment questionnaire 
BMI Body mass index 
BPSystolic Systolic blood pressure 
ECOG.Score 
Eastern Cooperative Oncology Group functional performance 
score 
GCS Glasgow Coma Scale 
BPDiastolic Diastolic blood pressure 
TempDegreesC Recorded temperature  
RR Respiratory rate 
HR Heart rate 
Lactate Venous lactate 
pH Venous pH 
SHCO3 Venous bicarbonate 
BE Venous base excess 
Glucose Venous glucose 
Albumin Serum albumin 
AST Serum aspartate transaminase  
Sodium Serum sodium 
Potassium Serum potassium 
Haemoglobin   
MCV Mean corpuscular volume 
WhiteCellCount Peripheral white cell count 
Platelets Platelet count 
CD4Count CD4 lymphocyte count 
ART Antiretroviral status (current, previous, naïve) 
Any.signs.of.Tuberculosis..CXR 
Chest X-ray finding as prospectively recorded on KDHTB 
recruitment proforma 
Pulmonary.infiltrate 
Chest X-ray finding as prospectively recorded on KDHTB 
recruitment proforma 
Pleural.effusion 
Chest X-ray finding as prospectively recorded on KDHTB 
recruitment proforma 
Mediastinal.lymphnodes 
Chest X-ray finding as prospectively recorded on KDHTB 
recruitment proforma 
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miliary 
Chest X-ray finding mentioned in free text on KDHTB 
recruitment proforma 
cavitary 
Chest X-ray finding mentioned in free text on KDHTB 
recruitment proforma 
nodular 
Chest X-ray finding mentioned in free text on KDHTB 
recruitment proforma 
CXR.sites 
Number of lobes showing infiltrate on chest x-ray 
(prospectively recorded), range 0 – 5. 
Tuberculoma Central nervous system tuberculoma diagnosed 
Pericardial Pericardial effusion on chest x-ray or other imaging 
Peripheral_LN Peripheral adenopathy 
Abdominal_LN Abdominal adenopathy (on ultrasound scan) 
Hepatic Hepatic TB diagnosed 
Splenic Splenic TB diagnosed 
TBM TB meningitis diagnosed 
Creatinine Serum creatinine 
Splenic.microabscesses Splenic microabscesses reported on ultrasound 
 
Then 4 further variable subsets were defined a priori as follows.  
• Prior Literature set. All the variables from the full set which have 
previously been found to be significantly associated with MTB 
bacteraemia from literature review (reviewed in previous chapter): fever, 
logCD4, Haemoglobin, Sex, lymphadenopathy (defined as peripheral OR 
mediastinal OR abdominal), Cough, current HAART, Diarrhoea, Heart 
Rate, log Respiratory Rate, Sodium, Loss of weight. 
• Jacob et al. set: Variables from full set which were used in the model 
published by Jacob et al.: fever, log CD4, Haemoglobin, Sex, current 
HAART, Heart Rate, Sodium. 
• Univariate associations set: All variables from full set which were found 
to have significant associations with MTB bacteraemia at the alpha=0.05 
level on univariate testing in the training set: PreviousTB, Heart Rate, 
SHCO3, Albumin, Sodium, Haemoglobin, Platelets, Pleural Effusion, 
Mediastinal LN, miliary disease on CXR, Peripheral LN, Abdominal LN, 
Splenic TB diagnosis, Splenic microabscesses, log CD4, log Creatinine, log 
AST, fever. 
• Supervised dimension reduction set: Based on exploratory PCA and 
MCA analysis on the training set several new variables were created 
intended to capture variation relating to independent processes. These 
variables are combinations of primary variables: 
o Immunosupression = log(CD4count) 
o AdvancedTB1 = 0.3∗(Haemoglobin) + 0.1∗(Albumin) − 6 
o AdvancedTB2 =Sodium 
o Septic1 =0.03∗(HR) + 2∗(ln(RR)) − 0.005∗(ln(lactate)) + 
0.7∗(fever) − 0.5∗(SHCO3) − 10 
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o Disseminated1 = 0.05 + 1.3∗(spleen) + 1.1∗(microabscess) − 
0.13∗(no.USS.done) + 1.3∗(AbdoLN) + 0.9∗(liverTB) 
o Disseminated2 = 0.5+1.7∗(miliaryCXR) + 3.5∗(periphLN) − 
0.003∗(Platelets) 
• LASSO variable set. LASSO (Least Absolute Shrinkage and Selection 
Operator) fits a regression model using an adapted least squares function 
which forces some of the β coefficients to be zero, thus removing some 
predictor variables from the model. It can therefore be used as a variable 
selection procedure similar to stepwise regression. LASSO was applied to 
the full variable set using the glmnet package in R; this defined a variable 
sub-set with good multivariate predictive performance (BPSystolic, HR, 
SHCO3, Albumin, Sodium, MCV, Platelets, logCD4, 
Splenic.microabscesses, Haemoglobin, bacteraemia).  
In addition to these variable reduction methods applied prior to modelling, 
unsupervised PCA pre-processing of the full variable set and the univariate 
association set were applied in iterations of each model. This means that, instead 
of entry of primary variables into the model, principal components of these 
variables are used as predictor variables. This has the advantage of potentially 
separating signal from noise, since lower Eigen value components are more likely 
to represent random error, while the first few principal components capture major 
covariance which has unlikely to have occurred by chance. In addition, because 
the components are orthogonal, they will not be redundant. The number of 
components to include is a complexity or tuning parameter which can be 
optimised by cross-validation.  
Finally, model-type specific variable selection procedures were used: 
• Stepwise logistic regression. Forward stepwise regression with variable 
inclusion based on Akaike information criterion carried out with the 
glmStepAIC function of the MASS package in R, using the full and the 
univariate association variable sets as starting points. 
• Random forest variable importance. The RF method generates a measure 
of importance for variable v by comparing the out-of-sample accuracy of all 
trees with and without v included. Using this index, random forest models 
can be re-run using only variables above an arbitrary variable importance 
level. 
• Boosted tree variable importance. A variable importance measure can be 
obtained from the boosted-tree method by tabulating the reduction in 
classification error attributed to each variable at each tree split and summing 
over each boosting iteration. Using this index, the boosted tree model can be 
re-run using only variables above an arbitrary variable importance level. 
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• SVM variable importance. No built-in importance score is available for 
SVM classification models; instead the area under the ROC curve for each 
variable can be used.  
2.5.4 Total number of models assessed 
Total number of models assessed is therefore 45: 
• Six variable subsets (full, prior literature, Jacob et al., univariate association, 
supervised dimension reduction, and LASSO set) in 5 models = 30; plus 
• Full set and univariate association set with PCA pre-processing applied in 5 
models = 10; plus 
• Five models re-run with variables of most importance in the previous 
iteration of that model = 5. 
Models are named for convenience (table 2). 
2.5.5 Model training and assessment 
All models were built using the training data, with 5 iterations of 10-fold cross-
validation to optimise model parameters and assess out-of-sample model 
performance. The metric used to define model performance was ROC AUC; i.e. 
cross-validation was used to tune model complexity parameters to maximise 
estimated out-of-sample ROC AUC. This was carried-out with the train() 
wrapper function in the caret package (Classification And REgression Training) 
in R. 
Final models’ predictions in the test set were then assessed, also with ROC AUC 
(figure 3).  
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Table 2-2. List of 45 models assessed in May 2016 analysis 
Model Type Variable selection 
boost.comp Boosted tree Supervised dimension reduction composite variables 
boost.full Boosted tree Full set 
boost.jacob Boosted tree Jacob et. al set 
boost.lasso Boosted tree LASSO set 
boost.prLit Boosted tree Prior literature set 
boost.univar Boosted tree Univariate association set 
CART.comp Decision tree Supervised dimension reduction composite variables 
CART.full Decision tree Full set 
CART.jacob Decision tree Jacob et. al set 
CART.lasso Decision tree LASSO set 
CART.prLit Decision tree Prior literature set 
CART.univar Decision tree Univariate association set 
Logit.comp Logistic regression Supervised dimension reduction composite variables 
Logit.full Logistic regression Full set 
Logit.jacob Logistic regression Jacob et. al set 
Logit.lasso Logistic regression LASSO set 
Logit.prLit Logistic regression Prior literature set 
Logit.univar Logistic regression Univariate association set 
pcaboost.full Boosted tree Full set + PCA pre-processing 
pcaboost.univar Boosted tree Univariate association set + PCA pre-processing 
pcaCART.full Decision tree Full set + PCA pre-processing 
pcaCART.univar Decision tree Univariate association set + PCA pre-processing 
pcaLogit.full Logistic regression Full set + PCA pre-processing 
pcaLogit.univar Logistic regression Univariate association set + PCA pre-processing 
pcaRF.full Random Forest Full set + PCA pre-processing 
pcaRF.univar Random Forest Univariate association set + PCA pre-processing 
pcasvm.full Support Vector Machine Full set + PCA pre-processing 
pcasvm.univar Support Vector Machine Univariate association set + PCA pre-processing 
RF.comp Random Forest Supervised dimension reduction composite variables 
RF.full Random Forest Full set 
RF.jacob Random Forest Jacob et. al set 
RF.lasso Random Forest LASSO set 
RF.prLit Random Forest Prior literature set 
RF.univar Random Forest Univariate association set 
stepLogit.full Logistic regression Full set + stepwise selection in model 
stepLogit.univar Logistic regression Univariate set + stepwise selection in model 
svm.comp Support Vector Machine Supervised dimension reduction composite variables 
svm.full Support Vector Machine Full set 
svm.jacob Support Vector Machine Jacob et. al set 
svm.lasso Support Vector Machine LASSO set 
svm.prLit Support Vector Machine Prior literature set 
svm.univar Support Vector Machine Univariate association set 
vi.boost.full Boosted tree Full set + model specific variable importance in model 
vi.RF.full Random Forest Full set + model specific variable importance in model 
vi.svm.full Support Vector Machine Full set + univariate ROC AUC 
 
 
106 
 
 
 
 
Figure 2-3. Model performance measured by ROC AUC. 
For each of the 45 models the cross-validated AUC within the training data is shown with 
a grey point, and the AUC with 95% confidence interval for the test data is shown with 
coloured point and line range respectively. 
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Table 2-3. Cross-validated model ROC AUCs in training data. 
Model Mean SD IQR 
pcasvm.univar 0.831 0.10 0.760, 0.889 
svm.full 0.821 0.13 0.753, 0.905 
svm.lasso 0.817 0.10 0.766, 0.891 
pcaLogit.univar 0.815 0.12 0.760, 0.894 
Logit.lasso 0.815 0.09 0.758, 0.877 
boost.prLit 0.808 0.09 0.750, 0.864 
Logit.comp 0.807 0.11 0.758, 0.890 
svm.comp 0.805 0.11 0.744, 0.894 
boost.jacob 0.804 0.09 0.750, 0.870 
boost.comp 0.804 0.11 0.750, 0.886 
Logit.prLit 0.802 0.10 0.748, 0.876 
Logit.univar 0.801 0.13 0.737, 0.889 
RF.comp 0.801 0.12 0.727, 0.890 
vi.RF.full 0.800 0.13 0.690, 0.875 
RF.prLit 0.799 0.11 0.717, 0.883 
svm.jacob 0.799 0.09 0.734, 0.874 
vi.svm.full 0.799 0.14 0.714, 0.905 
svm.prLit 0.798 0.10 0.744, 0.867 
pcasvm.full 0.795 0.16 0.710, 0.905 
Logit.jacob 0.795 0.10 0.720, 0.868 
svm.univar 0.791 0.13 0.720, 0.889 
pcaboost.univar 0.791 0.16 0.713, 0.917 
vi.boost.full 0.789 0.14 0.715, 0.875 
RF.univar 0.788 0.13 0.734, 0.862 
RF.full 0.784 0.17 0.672, 0.905 
boost.lasso 0.777 0.11 0.716, 0.836 
pcaRF.univar 0.776 0.13 0.678, 0.900 
boost.univar 0.775 0.14 0.656, 0.875 
RF.lasso 0.773 0.14 0.691, 0.879 
RF.jacob 0.768 0.11 0.699, 0.852 
boost.full 0.767 0.16 0.667, 0.905 
pcaRF.full 0.767 0.18 0.670, 0.926 
stepLogit.univar 0.752 0.14 0.669, 0.824 
Logit.full 0.731 0.18 0.640, 0.881 
pcaboost.full 0.723 0.19 0.629, 0.857 
CART.jacob 0.721 0.12 0.640, 0.797 
pcaCART.univar 0.714 0.15 0.613, 0.819 
CART.prLit 0.700 0.12 0.638, 0.750 
CART.lasso 0.691 0.12 0.628, 0.758 
pcaLogit.full 0.689 0.18 0.595, 0.833 
CART.full 0.681 0.15 0.591, 0.778 
stepLogit.full 0.674 0.13 0.586, 0.750 
CART.univar 0.659 0.16 0.566, 0.796 
CART.comp 0.659 0.12 0.570, 0.773 
pcaCART.full 0.640 0.18 0.500, 0.766 
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2.6 Results of 45 MTBBSI predictive 
models 
Cross-validated training data ROC AUCs are shown in figure 3 and table 3; test 
set ROC AUCs are shown in figure 3. The best performing were generally 
Random Forest and Support Vector Machine models. Decision tree models were 
substantially worse than other models. Performance of logistic regression models 
was very dependent on variable selection method. Overall, ROC AUCs greater 
than 0.8 appeared achievable. Note also that the cross-validated estimates of 
model performance using training data are all within the 95% confidence interval 
for the ROC AUC from the test data. The difference in AUC by the two methods 
is approximately normally distributed around zero, and less than 0.05 in 35/45 
cases (figure 4). 
 
Figure 2-4. Training versus test data estimates of ROC AUC. 
CV = cross validated. 
 
 
2.7 Combining models for a final 
ensemble model 
Imprecision in AUC estimates mean it isn’t possible to confidently say which 
model is best in figure 3. Some of the models are more practical than others due to 
lower numbers of variables included. Several of the higher AUC models use the 
same or similar variable sets – all these models can therefore be run without the 
extra difficulty of entering more observations.  Based on this, 6 models [RF.lasso, 
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RF.univar, Logit.lasso, Logit.univar, SVM.lasso, SVM.univar] were combined by 
simply averaging their predicted probabilities to give a single ensemble model. 
The AUC of this ensemble model was marginally higher than any of the 6 models 
used to construct it, though not significantly so (p > 0.3 for all correlated pairwise 
comparisons by DeLong method). Nonetheless it provides a practical way of 
reducing the predictions to a single value so was accepted.  
 
Figure 2-5. ROC curve plots for ensemble model 
Curves for the 6 models used to construct the ensemble model are shown in grey for 
comparison. AUC for ensemble model is 0.863. 
 
 
Using this final model, a predicted probability cut-off can be selected to classify 
new patients. The ‘yield’ – i.e. positive and negative predictive value – depends 
on the model ROC AUC but also on the prior probabilities of TB bacteraemia in 
the cohort the model is applied to. In the test data, 25% of patients have an 
ensemble model predicted probability greater than 0.56 (figure 6A); 80% of these 
patients had a positive blood culture (figure 6B).  
110 
 
 
Figure 2-6. Predicted probability from ensemble model mapped to 
classification rule. 
One-in-four KDHTB patients had predicted probability of MTBBSI above the 0.56 cut-
off (A). Positive predictive value (PPV) of the model predicted probability steadily 
increased up to 0.56 cut-off, becoming unstable after this due to lower numbers of patients 
in the validation cohort (B). Note selecting all patients above a predicted probability of 
0.56 can have a positive predictive value of much greater than 0.56 (in this case 0.8) 
because the probability distribution above 0.56 is on average higher than 0.56 – the PPV 
therefore depends on the distribution of predicted probabilities in a given cohort (in other 
words, post-test probability depends on pre-test probability). 
 
2.8 Building an app’ to make 
predictions accessible at bedside 
The complexity of the ensemble model precludes derivation of a prediction score 
or normogram. Instead the model was built into an application (app) using the 
shiny package in RStudio. This app was uploaded to shared servers operated by 
RStudio via the shinyapps.io platform, so that it was accessible via the web (for 
example on a smart phone). At the user interface (URL 
https://davidadambarr.shinyapps.io/KDH_MTB_bacteraemia/ ) observed values 
for the variables [Systolic blood pressure, diastolic blood pressure, heart rate, 
bicarbonate, albumin, sodium, MCV, platelets, haemoglobin, CD4 count, 
creatinine, AST, presence of splenic micro-abscesses (no, yes, or no ultrasound 
performed), history of previous TB, pleural effusion, mediastinal adenopathy, 
peripheral adenopathy, and fever] can be input and a predicted probability of 
positive TB blood culture is output.  
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2.9 Prospective validation sub-study 
2.9.1 Method 
To test the predictive modelling, prospective validation was performed during the 
ongoing recruitment to KDHTB. Between 21 June 2016 and 18 August 2016 all 
patients recruited to KDHTB were additionally screened using the app. If a 
predicted probability of positive MFL was greater than 0.56, no anti-tuberculosis 
therapy had been taken in the last 4 weeks, and consent was given, patients were 
recruited to a sub-study. This sub-study aimed to: 
1. Assess the predictive performance of the model and cut-off value when used 
prospectively to classify patients as having MTBBSI. 
2. Estimate the increased yield from more than one MFL culture for diagnosing 
MTBBSI. 
To this end, recruited patients had two MFL blood cultures performed at up to 
four time-points, for a total of up to eight samples. Time points were: 
• Before commencing anti-tuberculosis therapy (0 hours); 
• Within 12 hours of first dose anti-tuberculosis therapy (4-12 hours); 
• Prior to second dose anti-tuberculosis therapy (24 hours); and 
• Prior to third dose anti-tuberculosis therapy (48 hours). 
One 3-5ml sample from each time-point pair was inoculated directly to a Myco/F 
lytic Bactec (BD, Sparks, MD) bottle. To minimise antimicrobial carry-over from 
plasma in the second sample from each time-point pair, 5 ml of blood was 
collected in a sterile sodium heparin tube and immediately centrifuged for 25 min 
at 3,000 × g, and the resulting cell pellet (red cells and buffy coat) inoculated into 
a Myco/F Lytic bottle. Both MFL bottles were then transported to the NHLS TB 
laboratory in Groote Schuur Hospital, Cape Town, for incubation the same day, 
where any subsequent growth was confirmed by secondary Löwenstein–Jensen 
slope culture, auramine acid-fast microscopy, and PCR/line probe assay. 
2.9.2 Results – prediction accuracy 
During the sub-study period, 46 patients were recruited to the main KDHTB 
study. A final microbiologically proven diagnosis of TB was made in 42/46 (91%) 
and 19/46 (41%) were MFL TB blood culture positive. This is higher than the 
overall KDHTB cohort (73% and 33% respectively for patients meeting inclusion 
criteria in the whole n=659 cohort), so prior probabilities were slightly higher than 
in the model development data.  
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Based on the app predicted probabilities, 16/46 (35%) patients were recruited to 
the sub-study – again slightly higher than the 25% anticipated in model 
development. Of these patients, 9/16 were positive on first MFL blood culture, 
while 14/16 had at least one positive out of any of the samples sent, giving 
positive predictive values of 0.56 or 0.88 for first or any blood culture respectively 
(table 4). 
Table 2-4. Performance of predictive model in prospective sub-study. 
Predicting result of first TB blood culture  
  1st MFL + 1st MFL - Total 
Predicted positive 
(recruited) 
9 7 16 
Predicted negative  
(not recruited) 
5 25 30 
Total 14 32 46 
Point estimates and 95% confidence intervals   
Apparent prevalence 0.35 0.21 to 0.50 
True prevalence 0.3 0.18 to 0.46 
Sensitivity 0.64 0.35 to 0.87 
Specificity 0.78 0.60 to 0.91 
Positive Predictive Value 0.56 0.30 to 0.80 
Negative predictive Value 0.83 0.65 to 0.94 
Positive Likelihood Ratio 2.94 1.37 to 6.30 
Negative Likelihood Ratio 0.46 0.22 to 0.95 
Predicting positive result from any TB blood culture  
  
Any 
MFL + 
All 
MFL - 
Total 
Predicted positive 
(recruited) 
14 2 16 
Predicted negative  
(not recruited) 
5 25 30 
Total 19 27 46 
Point estimates and 95% confidence intervals   
Apparent prevalence 0.35 0.21  to  0.50 
True prevalence 0.41 0.27  to   0.57 
Sensitivity 0.74 0.49  to  0.91 
Specificity 0.93 0.76  to  0.99 
Positive Predictive Value 0.88 0.62  to  0.98 
Negative predictive Value 0.83 0.65  to  0.94 
Positive Likelihood Ratio 9.95 2.55  to  38.7 
Negative Likelihood Ratio 0.28 0.13  to  0.61 
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2.9.3 Results – yield from additional MFL cultures 
In total, 111 MFL results were available from the 16 patients, with 17 results 
missing (3 contaminated, 4 missing due to patient declined further venesection, 
10 missing due to patient transfer or discharge precluding venesection).  Of these, 
34/111 (30.6%) were positive for M. tuberculosis. Pelleted samples were more 
likely to result in the recovery of M. tuberculosis (20/55 [36%]) than directly 
inoculated samples (14/56 [25%]), but the difference may have been due to 
chance (OR 1.7, 95% CI 0.7 to 4.2, p = 0.22 by Fisher's exact test). 
Nine patients were diagnosed with TB bacteraemia on the first blood culture, 
while 12 were positive if the first two cultures (i.e. both cultures from the first 
time-point pair) are considered (figure 7). This implies that only 2/3 of prevalent 
TB bacteraemia is diagnosed on a single blood culture. 
 
 
Figure 2-7. Increasing yield from additional MFL blood cultures. 
 
This finding was further corroborated using data from the overall KDHTB cohort 
and data from the Jooste rapid TB diagnostics study.***** In both these studies a 
single MFL blood culture was performed as part of the study protocol. In 
addition, because recruited patients were managed by non-study clinicians, who 
had access to mycobacterial blood culture investigations through the National 
Health Laboratory Service (NHLS), a subset of patients in both cohorts had 
                                                             
***** This study was described briefly in the previous chapter. Again, I acknowledge Dr 
Andrew Kerkhoff for making this data available for the current analysis. 
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further MFL blood cultures if requested by their admitting medical team. Local 
guidelines recommend TB blood culture if CD4 count is less than 100 
cells/mm3 in a patient with TB symptoms where there is difficulty obtaining 
sputum samples for TB testing or the sputum Xpert MTB/RIF assay is negative, 
and cultures are generally sent before the start of anti-TB therapy. By 
interrogating the NHLS electronic records system, the results of these additional 
MFL blood cultures were collected. 
A second (non-study) MFL result was found for 59 Jooste study patients and 169 
KDHTB patients, giving a total sample size of 228 for analysis. Of these patients, 
99/228 (43%) had at least one blood culture positive for M. tuberculosis (20/59 in 
JHTB and 79/169 in KHTB). Overall, 72/99 (0.73; 95% confidence interval [CI], 
0.64 to 0.82) of M. tuberculosis bacteraemia was identified on the first culture, 
while 27/99 (0.27; 95% CI, 0.18 to 0.36) had a negative first culture but grew M. 
tuberculosis on the second. This is a near identical result to the prospective sub-
study, where 0.75 of patients diagnosed on 2 cultures were identified on the first 
of the pair. 
 
2.10 Discussion 
Using a variety of modelling techniques, a positive TB blood culture can be 
predicted in hospitalised PLWHIV suspected of having tuberculosis, using only 
baseline clinical data available in the first 24 hours of admission.  The accuracy of 
this prediction, in the Khayelitsha Hospital setting, is above 0.8 for both negative 
and positive predictive value. This conclusion is supported by cross-validation, 
test set performance, and prospective validation. 
Is predicting TB blood culture status worthwhile? One short answer is yes, 
because blood cultures normally take several weeks to flag positive (the median is 
22 days in the KDHTB cohort). Another short answer is no, because this does not 
change management: the real goal is to predict a TB diagnosis and risk of death 
without empiric treatment, and knowing that TB is bacteraemic is superfluous.  
The longer answers are, however, more cogent. First, being able to predict this 
marker of MTBBSI facilitates research investigation. This was clearly 
demonstrated in the current chapter, where the predictive modelling was used to 
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enrich recruitment to a sub-study and show the yield of additional blood cultures 
for diagnosing prevalent MTBBSI. To have performed this analysis in the 
KDHTB cohort without predictive modelling (while achieving the same study 
power) would have required around 200 extra blood cultures to be performed (to 
recruit 14 MFL+ patients at the baseline KDHTB rate of 0.33 would require 
14/0.33 ~ 42 patients; 42 * 8 = 336 MFL bottles as compared to 16*8 = 128 
bottles). The predictive modelling to enrich recruitment approach was also 
employed in another sub-study described in chapter 5.  
Second, while currently management is the same for BSI versus non-BSI 
tuberculosis, this is – as discussed in the thesis introduction – because there is an 
absence of evidence to the contrary, not because there is evidence that this is best 
practice. Being able to predict the presence of MTBBSI would make a focussed 
trial feasible. Consider that other (non-tuberculosis) BSI intervention trials must 
either recruit after a delay (for example, most patients in the ARREST trial of S. 
aureus BSI had >60 hours of antimicrobial therapy before randomisation),293 or 
recruit based on empiric treatment and testing the intervention in a 
heterogeneous patient population including different infections and even non-
infectious conditions.294,295 Both these approaches could reduce power; recruiting 
patients at start of therapy with a >80% PPV of the target diagnosis is likely to 
make trial designs more efficient and affordable. 
Thirdly, and more speculatively, being able to predict the presence of MTBBSI 
might influence empiric management of inpatients with advanced HIV infection, 
or at least influence prior probability and predictive value of rapid diagnostic tests. 
Empiric treatment of TB in high HIV-burden, low-resource settings is 
common,296 but little is known about the basis on which clinicians make treatment 
decisions.297 Utility theory – where treatment decisions are modelled as a 
risk/benefit calculation – explains some clinician behaviour,298 but is an 
oversimplification. Perceived prior probability influences the sensitivity and 
specificity (rather than just the predictive values) with which clinicians interpret 
signs. For example the presence of a red dot on an x-ray, indicating that a 
radiographer thought there was high probability of an abnormality, increases 
doctors’ sensitivity, and decreases specificity, for identifying abnormalities on 
that x-ray, without changing diagnostic odds ratios – in effect shifting the 
clinicians’ interpretation along an implicit ROC curve.299 A predicted probability 
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of MTBBSI generated from laboratory results, and flagged on the webpage portal 
where those laboratory results are reviewed, could similarly influence clinicians’ 
diagnostic behaviour. More qualitatively, “mental representations” of diseases, 
or “illness scripts”, provide the basis for diagnostic reasoning.300 An empiric 
diagnosis of MTBBSI might be more compelling and urgent than “smear-negative 
tuberculosis”.  
The only validated prior attempt to predict TB blood culture status is the clinical 
prediction score by Jacob et al. discussed earlier in this chapter.127 This score was 
developed in a cohort of HIV-infected inpatients with severe sepsis, and had ROC 
AUC 0.82 estimated through k-fold cross-validation in the same dataset the score 
was developed from. It is tempting to compare this performance with that seen for 
the best models in the current analysis. In theory, because models’ variance-bias 
trade-off was optimised using machine learning techniques, the current models 
may be expected to perform better than the more traditional approach used by 
Jacob et al. However, a direct comparison isn’t prudent since the study 
populations are different, potentially leading to spectrum (i.e. case-mix) bias.  
That the prospective sub-study accurately predicted patients’ blood culture status 
is a major strength of this analysis. Correct classification of future events requires 
extra assumptions – that there are no temporal biases, and that the probability cut-
off remains optimal for classification – making this a more robust test of the 
ensemble model.301 However, in retrospect I think there are also some 
weaknesses. 
First, reserving a test set from the original data added little to the results. In fact, 
choice of models to take forward to the ensemble approach was, I think, overly 
influenced by test set performance. Using all the original data to train models and 
selecting based on cross-validated performance within this training data would 
have been more efficient and probably less biased (for reasons outlined in section 
2.2 above).  
Second, algorithmic variable selection prior to modelling – i.e. the univariate 
associations and LASSO selection – were performed outside of the cross-
validation procedure. While this approach is quite standard in clinical research it 
poses a high risk of over-fitting.  
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Finally, the point estimates of model performance in the prospective sub-study 
(table 4) are, arguably, over optimistic. Patients predicted to be blood culture 
negative were not recruited for serial blood cultures, so mostly had only a single 
MFL sent (5/30 had two, the second sent by non-study clinicians). We now know 
that this will have underestimated the true rate of TB bacteraemia in these 
patients, thus inflating negative predictive value of the model. Nonetheless, the 
use of different procedures in those predicted to be positive versus negative (8 
versus 1 blood culture) is a weakness of the comparison. Relatedly, the KDHTB 
training data included patients who may have received up to 2 days of 
antimicrobial therapy prior to MFL blood culture, adding noise (false negatives) 
to the dependent variable. Excluding such patients would, however, have 
substantially reduced sample size.   
This highlights a broader point. Measurement error in the dependent (outcome) 
variable equates to irreducible error – the red line in figure 1 – putting a ceiling on 
the accuracy gain from optimising variance-bias trade-off. The current analysis is 
the first reported attempt to assess this measurement error. Previous studies have 
compared yield from different TB blood culture methods, but not the yield from 
additional cultures.15,112,302-307 One previous study randomized patients to 6 blood 
cultures at a single time-point or 3 blood cultures at 2 time-points (i.e. the same 
total number of cultures) and found no difference in the recoveries of M. 
tuberculosis between these arms.308 The finding that a single blood culture will 
identify only 2/3 of culturable bacteraemia is therefore novel. It is also 
unsurprising given the established evidence for non-mycobacterial BSI, where a 
single 10-ml blood culture will detect 73% and four samples will detect 90 to 95% 
of patients with documented bacteraemia.309,310 
The implication of this finding is that the prevalence of MTBBSI has been 
systematically underestimated. Almost every prior cohort study examining 
prevalence and associations of MTBBSI has been based on a single blood culture. 
What would the estimated prevalence of MTBBSI have been in these studies if 
factors like number of blood cultures performed had been accounted for? This 
question is answered in the next chapter which reports an individual patient data 
meta-analysis of TB blood culture studies. 
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3 Individual Patient Data meta-
analysis of TB blood culture studies 
 
 
3.1 Introduction 
 
In the previous chapters it was claimed that MTBBSI is a central feature of severe 
HIV-associated tuberculosis, and likely causally related to mortality in this patient 
group. The specificity of MTBBSI was contrasted with the vague 
recommendations on ‘disseminated TB’ found in WHO guidelines on 
management of PLWHIV suspected of having tuberculosis.  
Several objections to these points could be made. First, the reported prevalence of 
MTBBSI in high burden settings is not consistently high, and there is marked 
heterogeneity in reported rates of positive blood cultures in HIV-positive 
adults.311 If MTBBSI is rare in some settings, how can it be of universal 
importance? Second, while some studies link bacteraemia to high risk of death in 
HIV-associated TB,15,59,127 others find no significant independent 
association.125,126,141 Might MTBBSI be simply an incidental feature of advanced 
immunosuppression? Third, while WHO guidelines on HIV-associated TB do not 
address MTB BSI directly,48,53 an algorithm is given for managing ‘seriously ill’ 
people living with HIV and suspected of having TB (figure 1 & table 1). Isn’t this 
algorithm sufficient for managing patients with MTBBSI? 
The analysis in this chapter uses individual patient data from 20 published and 
unpublished data sets to try to resolve these questions. First, it is shown that 
heterogeneity in reported rates of TB blood culture positivity (TBBC+) might be 
explained by differences in inclusion criteria, and individual level variation in 
clinical factors such as CD4 count, which are difficult to adjust for in aggregate 
meta-analysis. Failure to account for technical factors such as number and timing 
of blood cultures in relation to start of anti-TB treatment has underestimated 
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TBBC+ prevalence in some cohorts. Further, the WHO danger signs (table 1 and 
figure 1) positively select for inpatients with TBBC+.  
Second, rapid diagnostics – including sputum Xpert – have unreliable sensitivity 
to diagnose unwell patients with HIV-associated TBBC+ disease.  
Finally, bacteraemia is shown to be a robust predictor of mortality, independent of 
other factors like CD4 count. In addition, waiting 3-5 days to see if danger-sign 
positive patients improve before starting presumptive therapy (figure 1) is 
probably associated with increased mortality risk in TBBC+ patients.  
3.1.1 Statement on collaboration 
The work presented in this chapter is the result of a collaboration with Dr Joseph 
M. Lewis (JML) of the Liverpool School of Tropical Medicine. The conception of 
the study and analysis presented are the result of equal contributions from myself 
and Dr Lewis. 
 
Table 3-1. WHO algorithm: managing PLWHIV & suspected of having TB 
(seriously ill)48 
Summary points 
1 TB suspected if cough, fever, night sweats, or weight loss present. 
2 Seriously ill defined as presence of any danger signs: respiratory 
rate > 30 per minute, temperature > 39oC, heart rate > 120 beats per 
minute, and inability to walk unaided. 
3 Hospital admission and parenteral antibiotics for bacterial infections 
in all cases. 
4 Xpert MTB/RIF on sputum and extra-pulmonary samples if 
extrapulmonary TB is suspected. 
5 If Xpert MTB/RIF negative or not available, and no clinical 
improvement after 3-5 days, start presumptive TB therapy. 
6 In addition, urine lateral flow lipoarabinomannan (uLAM) “may be 
used… regardless of CD4 count”. 
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Figure 3-1. WHO algorithm: managing PLWHIV & suspected of having TB 
(seriously ill) 
Reproduced directly from WHO 2016.48 
 
3.2 Methods 
 
3.2.1 Meta-analysis questions 
1. What is the prevalence of TB blood culture positive disease amongst adult 
inpatients with HIV-associated TB and, in particular, those who are seriously 
unwell (having at least one WHO ‘danger sign’)? 
2. What is the sensitivity and diagnostic yield of sputum Xpert MTB/RIF, and 
urine LAM, for diagnosing TB in patients with positive TB blood culture? 
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3. What is the independent mortality hazard associated with having a positive 
TB blood culture, compared to blood culture negative HIV-associated TB, 
and what proportion of TBBC+ deaths occur within 3-5 days of presentation? 
4. Is there evidence of increased mortality risk from delaying treatment by 3-5 
days in patients with a positive TB blood culture? 
 
3.2.2 Literature search strategy and selection criteria  
A search was conducted for prospective cross-sectional, cohort, or interventional 
studies where routine (non-selective) blood culture for mycobacteria was 
performed in a study-defined population including people living with HIV aged 
13-years or more. Studies which didn’t collect CD4 cell count results were 
excluded.  
PubMed and Scopus were searched without language or publication period limits 
using [(Blood stream infection OR BSI OR bacter?emia OR septic?emia) AND 
(tuberculosis OR TB)] OR [mycobacter?emia]. Reference lists of identified articles 
and of review articles were also examined for relevant studies. Researchers known 
to have an interest in HIV associated tuberculosis were contacted in attempt to 
identify unpublished cohorts. 
Abstracts were reviewed independently by JML and DAB and, if potentially 
eligible according to either reviewer, full texts were obtained. Full texts were 
reviewed independently by JML and DAB with disagreements resolved by 
consensus or after clarification of method details with primary authors. 
 
3.2.3 Procedures 
A meta-analysis protocol was registered on the PROSPERO database 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=50022 ). 
Original investigators of identified studies were contacted and asked to provide 
primary data, and provide clarification and meta-data in the event of discrepancies 
or unclear data coding. Individual patient observations of a priori specified 
variables were extracted from the primary datasets and resolved to a standardised 
format using reproducible R scripts. Patients with more than three missing 
observations of danger signs were deemed to be missing the composite variable 
“presence of danger signs”.  
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3.2.4 Individual patient data inclusion criteria 
Harmonised inclusion criteria were applied to the individual patient data (IPD). 
Patients from the selected studies were included in the meta-analysis if they were 
aged >13 years, had confirmed HIV-infection, an available CD4 count, at least 
one valid TB blood culture result (excluding patents with missing data for the 
index test, for example due lost or contaminated samples), and had at least one 
WHO TB screening symptom present. All included patients therefore met WHO 
definitions for PLWHIV and were suspected of having TB, i.e. the target 
population for the WHO management algorithms.48  
3.2.5 Synthesis strategy and statistical analysis 
Primary studies were classified by inclusion criteria (into categories: all HIV-
infected patients; febrile HIV-infected patients; HIV-infected patients with 
suspected TB; HIV-infected patients with sepsis syndrome†††††) and by 
hospitalisation (inpatient; outpatient).  
3.2.6 Prevalence of positive TB blood culture analysis 
The starting point for this analysis was patients meeting the harmonised inclusion 
criteria, i.e. the target population for the WHO algorithms for managing 
PLWHIV and suspected of having TB.48 
Prevalence of TBBC+ was assessed using mixed-effects logistic regression ( 
glmer() function in R package lme4 )312 with random effects by primary study to 
account for random variation between studies, and fixed-effects to account for 
hypothesised systematic variation by a priori specified variables. These effects 
were added iteratively to the model in the following order: 
• Random intercept by primary study (null model). 
• Fixed effect of CD4 count. 
• Random effect of CD4 count by primary study (random slope). 
• Fixed effect of presence of the WHO danger signs. 
• Fixed effect by admission status (outpatient versus inpatient). 
• Fixed effect of already on TB treatment at time of blood culture (>1 dose 
prior to venesection). 
• Fixed effect of number of blood samples taken for TB culture. 
                                                             
††††† Sepsis syndrome defined as per original study definitions, which in all cases were 
based on Sepsis-2 criteria.  
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• Fixed effect of final TB diagnosis. Respective original study case definitions 
were used to classify patients as having a final TB diagnosis. Addition of this 
variable to the model allows estimation of TBBC+ prevalence in patients with 
HIV-associated TB, rather than those suspected of having TB.  
Continuous variables were standardised to have mean 0 and standard deviation 1. 
Each iterative model was compared to (i) a null model containing only a random 
effect by study on the intercept, and (ii) the preceding iteration model. Where 
incomplete data was available for the added variable, the comparison models were 
rebuilt using the same, reduced, dataset, such that the models were nested. This 
allowed assessment of each iterative model with the following statistics: 
• LRTnull: Likelihood-Ratio test p-value testing the hypothesis that the new 
model has no better fit than the null model. 
• LRTpreceding: Likelihood-Ratio test p-value testing the hypothesis that the 
new model has no better fit than the previous iteration model, i.e. that the 
added variable has not improved fit more than would be expected by chance 
alone. 
• Τ2: Measures variance in the random effects, i.e. it describes variance arising 
from systematic differences between the primary studies, after adjustment 
for fixed effect cofactors have been adjusted for.313,314 
• Variance Partition Co-efficient (VPC): Measures proportion of residual 
individual variation arising from systematic differences between primary 
studies after adjusting for fixed effect cofactors in the model. The ‘latent 
variable’ method was used, which assumes that the binary outcome results 
from a dichotomised underlying (latent) continuous variable, which follows a 
logistic probability distribution.313,315 
• R2marginal: Measures proportion of total variance explained by fixed-effects. 
Calculated using r.squaredGLMM() function of R package MuMIn.313,316-319 
• R2conditional: Measures variance explained by the complete model – i.e. by 
fixed and random effects. Calculated using r.squaredGLMM() function of R 
package MuMIn.313,316-319 
• ROC AUC: Area under the receiver operating characteristic curve capturing 
the within-sample prediction accuracy of the complete model (fixed and 
random effects). Calculated using the model predicted probabilities 
compared to the observed outcome. 
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• ΔAUC: Measures the importance of clustering by primary study after 
adjusting for fixed effect variables. A model containing only fixed-effects 
variables (no random effect by primary study), and a mixed-effect model 
containing the same as fixed-effects plus random effects by primary study, 
are made, and the difference in ROC-curve AUC between these two models 
is calculated.313 
As fixed-effect variables are iteratively added to the model, if they ‘explain’ 
heterogeneity between primary study estimates, Τ2, VPC, and ΔAUC will 
decrease; while R2marginal, R2conditional, and ROC AUC will increase. 
Having established model fit using the above statistics, estimated prevalence of 
TBBC+ in specific patient populations was defined using predicted probability of 
positive MTB blood culture for given levels of the relevant fixed-effects in the 
final models. Estimates of predicted probability of TBBC+ from the final models 
were generated both for each primary study included in the model, and an 
aggregate ‘grand mean’ predicted probability across all studies. These were 
presented in forest plots. To capture uncertainty in these estimates boot-
strapping and simulation methods were used. A 95% confidence interval for the 
predicted probability of TBBC+ in each primary study was generated using 
repeated estimates of the random- and fixed-effects parameters across 100 
parametric bootstrap-resampled versions of the dataset, stratified by primary 
study. A 95% confidence interval for the predicted probability ‘grand mean’ – the 
range within the mean predicted probability is expected to lie if we continue to 
add new studies – was generated by stratified bootstrap of the fixed-effect 
parameters. Finally, a 95% prediction interval for the grand mean – the range 
within which the mean for a new, unobserved, study is expected to lie – was 
estimated by 100 bootstrapping simulations based on the probability distributions 
in the fitted models.320 The boot() function in R package boot321 was used for the 
bootstrapped confidence intervals, and bootMer() in the R package lme4312 for the 
simulated prediction interval. 
3.2.7 Diagnostic performance of sputum Xpert and urine-LAM in 
TBBC+ disease 
 Studies which collected IPD on sputum Xpert and urinary-LAM were included in 
this analysis; diagnostic tests actively carried out as part of the original study 
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protocol, or passively recorded from routine care were accepted. Sputum MTB 
culture results were accepted as a surrogate of sputum Xpert results if Xpert was 
not performed. Information on use of sputum induction was collected where 
available. 
To assess diagnostic performance of the index test (sputum Xpert or urine-LAM) 
against the reference test (TB blood culture) two measures were applied: 
1. Sensitivity of index test. A bivariate meta-analysis excluding patients who had 
no recorded result for the index test was performed, and sensitivity estimates 
extracted. For sputum, heterogeneity by primary study was investigated 
using study level covariates in meta-regression. This analysis gives summary 
estimates of the test characteristics but ignores participants for whom 
sputum or urine was unavailable 
2. Diagnostic yield of index test. ‘Diagnostic yield’ was assessed by two-stage 
meta-analysis of the proportion of TBBC+ patients who were identified as having 
TB using the index test; this proportion was assumed to follow a binomial 
distribution, with a normally distributed random effect by primary study. 
Diagnostic yield considers the real-world performance of the test, as it 
includes patients for whom a sample could not be obtained.322 Heterogeneity 
in diagnostic yield by primary study was also investigated using study level 
co-variate meta-regression.  
3.2.8 Mortality association analysis 
This analysis was restricted to patients with a TB diagnosis, as per the respective 
original study case definitions. A naïve, aggregated Kaplan-Meier plot (ignoring 
dependence by primary study) was used to visualise mortality stratified by TB 
blood culture status amongst patients with HIV-associated TB. A mixed-effects 
logistic regression model was developed to quantify the independent odds ratio of 
positive TB blood culture for death by day 30 or inpatient death, using the glmer() 
function in R package lme4.312 A random intercept by primary study, and fixed-
effects for age, sex, CD4 count, presence of WHO danger signs, and positive TB 
blood culture (TBBC+) were specified a priori. Patients with missing observations 
on these variables were excluded. Confidence intervals on coefficients were 
calculated from 1000 bootstrap replicates. 
In addition to this core mortality analysis, two other exploratory analyses were 
performed. First, to assess the effect of urine-LAM positivity on mortality, the 
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TBBC+ result was replaced with urine-LAM result as an independent variable in 
the above mixed-effects logistic regression model.  
Second, an association between delaying TB treatment by 3-5 days – as 
recommended in the WHO algorithm when sputum Xpert is non-diagnostic (table 
1, figure 1) – and mortality in patients with TBBC+ was examined. The 
hypothesis was that any mortality association of treatment delay would be more 
pronounced in patients with bacteraemic infection. Therefore the a priori variable 
of interest was an interaction term between TBBC+ and treatment delay. 
Treatment delay was defined as a greater than 4-day time difference between 
blood culture being taken and anti-TB treatment being started. Patients without a 
final TB diagnosis, those with incomplete observations, and patients starting anti-
TB treatment more than 24-hours before blood culture was taken, were excluded 
from this analysis. Outcome was again 30-day death or non-survival to discharge 
(the most complete outcome variables across primary datasets).  
 
3.3 Results 
3.3.1 Identified studies and IPD description 
The literature database search strategy identified 18 primary studies reporting on 
19 datasets for inclusion. An additional 4 datasets were identified from other 
sources. Responses were obtained from all primary study authors; IPD had been 
lost for 2 datasets, and 1 further dataset was not received. The remaining 20/23 
datasets were contributed to the meta-analysis, representing 96.1% of the IPD 
identified for potential inclusion (figure 2). All received datasets were from 
studies published since the year 2000, all studies for which IPD was not received 
predated the HAART era. Of the received datasets, 16/20 were from sub Saharan 
Africa; 12/20 had recruited patients suspected of having TB; 15/20 had recruited 
exclusively inpatients, 2/20 exclusively outpatients, and 3/20 a mix (table 2). 
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Figure 3-2. Identification of primary datasets, flowchart. 
  
Application of the harmonised IPD level inclusion criteria left 5746 patients 
available for subsequent analyses. Characteristics of these patients are shown in 
table 2. Proportion of missing variables by study (which limits available data in 
subsequent analyses on a case-by-case basis) is shown in figure 3. 
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Table 3-2. Identified primary datasets. 
Dataset ID Source Data Site Design Dates 
Primary study 
population category 
MTB blood culture 
positive * 
n IPD 
available 
n meet 
inclusion 
Brazil_2004323 DS Received 3o care hosp cohort 2001 -02 Spct TB IP 29.5% 53 44 
Brazil_1997324 DS Not received 3 specialist ID 
centres 
cohort 1992-94 Spct TB 
38.0% NA NA 
SE.Asia_2010128 DS Received VCT OPCs cohort 2006-08 OP 1.8% 2009 1338 
India_2008325 DS Received 3o care hosp cohort 2005-06 Spct TB IP 30.8% 52 36 
Ivory Coast_1993326 DS No IPD 3o care hosp cohort 1991 Febrile IP? 4.0% NA NA 
Kenya_1995120 DS No IPD ?3o care hosp cohort 1992 Spct TB IP 22.9% NA NA 
Malawi_2012327 DS Received OP clinics cohort 2010 Spct TB OP 2.3% 469 411 
Malawi_201315 DS Received 2o care hosp  cohort NA Febrile IP 8.7% 104 90 
South Africa_201524 DS Received 2o care hosp  cohort 2012-13 IP 9.6% 427 338 
South Africa_2009144 DS Received 3o and 2o care hosps nested cohort NA Spct TB IP 8.6% 498 264 
South Africa_2001129 DS Received 3o care hosp cohort 1998 Spct TB IP 22.5% 45 44 
South Africa_2018328 PC Received 2o care hosp  cohort 2014-17 Spct TB IP NA 679 614 
South Africa_201721 PC Received 2o care hosps cohort 2011-14 Spct TB IP 23.6% 484 444 
South Africa_2006329 RS Received 2o care hosp  cohort 2002 Spct TB IP & OP 24.5% 147 141 
South Africa_2014330 DS Received 2o care hosps + OPCs cohort 2011 Spct TB IP & OP 9.5% 513 483 
Uganda_2014330 DS Received 2o care hosps + OPCs cohort 2011 Spct TB IP & OP 15.6% 524 479 
Tanzania_201259 DS Received 3o care hosps cohort 2006-10 Febrile IP / spct TB 
IP 
5.70% 411 145 
Tanzania_2011308 DS Received 2o care hosps RCT 2007-08 Spct TB IP 15.9% 258 226 
Vietnam_2004331 DS Received 3o care hosp cohort 2000 IP 12.3% 100 61 
Uganda_2009332 DS Received 3o care hosps cohort 2006 Sepsis IP 22.1% 150 98 
Uganda_2013127 DS Received 3o care hosps nested cohort 2008-09 Sepsis IP 23.4% 427 315 
Zambia_2014289 DS Received 3o care hosp RCT 2012 Sepsis IP 37.8% 88 58 
Zambia_2017268 PC Received 3o care hosp RCT 2012-13 Sepsis IP 20.6% 187 117 
DS = database search; PC = personal contact; RS = manual reference search; hosp = hospital; VCT = Voluntary Counselling and Testing; OPC = outpatient clinic; 1o = 
primary; 2o = secondary; 3o = tertiary; OP = outpatient; IP = inpatient; NA = not available; spct = suspected; ? = unclear from publication (and no IPD or meta-data received) 
*Disaggregated HIV-positive sample if available.
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Table 3-3. IPD characteristics by primary dataset in 5746 patients meeting harmonised inclusion criteria for meta-analysis. 
Primary dataset 
Female 
Median age 
(IQR) 
Inpatient 
Median 
CD4 (IQR) 
Danger sign 
present 
Final TB 
diagnosis rate$ 
MTB blood 
culture positive 
Sputum 
positive 
uLAM 
positive 
Early 
mortality* 
Brazil_2004 32% 34 (9) 100% 45 (80) -- 50% 30% -- -- -- 
India_2008 10% 32 (10) 0% 230 (92) -- 50% 33% 33% -- -- 
Malawi_2012 61% 35 (12) 0% 129 (172) -- 11% 3% 11% -- 6% 
Malawi_2013 31% 36 (13) 100% 94 (184) 81% 42% 10% 46% -- 9% 
S.E.Asia_2010 48% 32 (11) 3% 216 (304) 7% 25% 2% 17% -- -- 
SouthAfrica_2001 41% 36 (12) 100% 68 (98) 42% 59% 34% 64% -- 9%# 
SouthAfrica_2006 65% 32 (12) 25% 107 (182) 17% 89% 23% 64% -- 7% 
SouthAfrica_2009 70% 35 (13) 100% 82 (155) 89% 61% 13% 34% 35% 11%# 
SouthAfrica_2014 63% 35 (13) 42% 154 (160) 0% 42% 10% 36% 11% 2% 
SouthAfrica_2015 59% 35 (13) 100% 132 (225) -- 36% 12% 26% 16% 8% 
SouthAfrica_2017 66% 36 (12) 100% 88 (175) 100% 54% 25% 48% 40% 8% 
SouthAfrica_2018 51% 36 (13) 100% 60 (113) 45% 86% 34% 62% 24% 14% 
Tanzania_2011 65% 36 (12) 100% 74 (191) 12% 27% 15% 16% -- 40% 
Tanzania_2012 65% 39 (15) 100% 110 (199) 53% 8% 8% -- -- 17% 
Vietnam_2004 16% 30 (15) 100% 20 (89) 51% 49% 13% 50% -- 38%# 
Uganda_2009 66% 34 (15) 100% 34 (94) 96% --£ 13% -- -- 38% 
Uganda_2013 53% 35 (13) 100% 49 (118) 97% --£ 24% -- -- 32% 
Uganda_2014 64% 32 (11) 71% 97 (266) 0% 42% 11% 35% 14% 4% 
Zambia_2014 57% 34 (12) 100% 49 (83) 93% --£ 47% -- 50% 62% 
Zambia_2017 45% 34 (13) 100% 60 (120) 85% --£ 30% -- 28% 53% 
$ Number of patients with final TB diagnosis as per original study definitions divided by number with non-missing observation of this variable. Four data sets had high 
proportions of missing observation of final TB diagnosis and are redacted for this summary estimate (marked with £).  
Diagnostic test percentages are number positive for this test divided by number of patients who had a valid test result in the whole cohort (not sensitivity or yield within those 
that had a final TB diagnosis).  
Note that final Tb diagnosis and diagnostic test percentages are using different denominators so having a higher percentage test positive than diagnosis positive is not 
contradictory. 
* Early mortality defined as death by day 30 or inpatient death if primary study follow-up was less than 30 days or only inpatient death was ascertained (these studies marked 
with #). 
IQR = Magnitude of inter quartile range; uLAM = urine-LAM 
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Figure 3-3. Proportion data missing by variable and primary dataset. 
* Early mortality defined as death by day 30 or inpatient death if primary study follow-up 
was less than 30 days. 
 
3.3.2 Prevalence of TBBC+ disease 
Compared to the prevalence reported in the original publications (table 1; mean 
proportion 0.171, coefficient of variation 59.1%), the proportion of patients with 
positive TB blood culture (TBBC+) after application of harmonised IPD inclusion 
criteria was higher, but no less heterogeneous (table 3; mean proportion 0.195, 
coefficient of variation 62.4%).  
Heterogeneity in probability of TBBC+ between primary datasets was 
investigated using a logistic regression model containing random-effects by 
primary dataset. The following hypothesised explanatory variables were added as 
fixed-effects to this null model: 
• CD4 count 
• Presence of WHO danger signs 
• Hospitalisation (inpatient or outpatient) 
Primary dataset:
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Sex 0 0.17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Age 0 0.17 0.01 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.04 0 0
Danger signs 1 1 1 0 0 0.02 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Sputum result 1 0.17 0.07 0.12 0.01 0 0.1 0.22 0.01 0.59 0 0.18 0.15 1 0.28 1 1 0.04 1 1
ULAM result 1 1 1 1 1 1 1 0 0 0.02 0.33 0.12 1 1 1 1 1 0 0.79 0.73
Final TB diagnosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.87 0.36 0 0.62 0.56
Start date TB therapy 1 1 0.75 0.63 1 1 0.01 0.45 0.7 1 0.36 0.11 1 1 0 1 1 0.72 0.71 0.56
TB treatment prior to 
blood culture
0 0 0 0 0 0 0 0.45 0 0 0 0 1 0 0 0.01 0.03 0 0.71 0.56
Early death* 1 1 0.06 0.1 1 0 0.13 0.06 0.05 0 0 0.01 0.56 0.01 0.18 0 0 0.03 0 0
Follow up censor date 1 1 0.06 0.01 1 0.64 0.04 0.02 0 0.01 0 0 0.55 0.01 0 0 0 0 0 0
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• Whether anti-TB treatment was given before blood culture taken 
• Total number of blood cultures performed 
• If final diagnosis was TB or if an alternative diagnosis was made 
 
Each of these improved model fit (p<0.001 by Likelihood-Ratio test comparison 
to preceding model, table 4), and explained variance attributable to fixed-effects 
(R2marginal 0.66 for model containing all, table 4), increasing total variance 
explained by the full model (R2conditional 0.19 in null model, 0.72 in the final iteration 
model, table 4). Within-sample predictive accuracy also increased with the 
addition of each fixed-effect variable (ROC AUC 0.75 in null model, 0.91 in final 
iteration model, table 4), with reciprocal decline in importance of clustering by 
primary dataset for predictive accuracy (ΔAUC 0.02 in final iteration model, table 
4). 
The final iteration model (model 7, table 4) was used to estimate predicted 
probability of TBBC+ in patients with a diagnosis of HIV-associated TB made by 
the study. Estimates for patients suspected of having TB were taken from the 
previous iteration, which did not include final TB diagnosis as a variable (model 6, 
table 4). Estimates were generated for patient populations defined by specific 
levels of CD4 count, hospitalisation status, and presence of danger signs. In all 
estimates, it was assumed that 2 blood cultures were taken prior to anti-TB 
therapy.‡‡‡‡‡  
In all models, inpatients with danger signs had highest mean predicted probability 
of TBBC+, with probability rising rapidly at CD4 counts less than 100 cells/µL 
(figure 4A & B).  
Mean predicted probability and uncertainty estimates were generated for a 
hypothetical population of seriously unwell (danger sign positive) inpatients with 
CD4 count 50 cells/µL (figure 4C & D). Uncertainty in the location of this mean 
was captured with boot-strapped 95% confidence intervals, estimating uncertainty 
for the aggregate predicted probability (or in an ‘average’ dataset with random-
effects of zero). The random-effects, or residual heterogeneity between datasets, 
was used to simulate a 95% prediction interval. Assuming the datasets in this 
                                                             
‡‡‡‡‡ Across all studies, 457/5746 (8%) patients actually had more than 1 blood culture. 
Using data from these patients the effect of having 2 cultures versus 1 is being estimated 
and applied to the whole data set. 
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meta-analysis are a random sample of different settings, the prediction interval 
captures the expected probability of TBBC+ in 95% of settings (or where the mean 
probability would lie 95% of the time in a new, unobserved, dataset).  
Predicted probability of TBBC+ for danger sign positive inpatients with CD4 
count 50 cells/µL and suspected TB was 0.31 (95% confidence interval for overall 
mean, 0.27 to 0.42; 95% prediction interval for an unobserved dataset 0.13 to 
0.66; figure 4C). For danger sign positive inpatients with CD4 count 50 cells/µL 
and HIV-associated TB, the predicted probability of blood stream infection was 
0.58 (95% confidence interval, 0.50 to 0.68; 95% prediction interval, 0.29 to 0.85; 
figure 4D).  
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Table 3-4. Iterative mixed-effect models for logged-odds of TBBC+. 
Iteration 
N  N  LRT LRT 
Τ2 VPC 
R2 R2 ROC  
ΔAUC obsᶧ datasetsᶧ null  preceding marginal conditional AUC 
     p value p value       
Model 0 Null model (RE by primary dataset) 5746 20 NA NA 0.79 0.194 0 0.194 0.752 NA 
Model 1 Null model + CD4 count# FE 5746 20 1.26E-67 1.26E-67 0.81 0.198 0.113 0.289 0.804 0.071 
Model 2 Model 1 + CD4 count# RE by primary study 5746 20 2.71E-71 6.77E-07 0.76 0.188 0.089 0.278 0.814 0.081 
Model 3 Model 2 + presence of danger signs FE 4916 16 5.15E-71 7.57E-06 0.538 0.141 0.13 0.274 0.816 0.059 
Model 4 Model 3 + hospitalisation (inpatient v outpatient) FE 4916 16 2.42E-78 5.14E-10 0.404 0.109 0.257 0.363 0.821 0.041 
Model 5 Model 4 + TB treatment prior* to blood culture FE 4453 15 6.70E-82 9.84E-07 0.422 0.114 0.283 0.386 0.837 0.035 
Model 6 Model 5 + number of blood cultures performed FE 4453 15 1.75E-83 0.00062 0.433 0.116 0.288 0.392 0.839 0.032 
Model 7 Model 6 + final diagnosis was TB$ FE 4223 15 1.93E-190 4.06E-113 0.399 0.108 0.66 0.716 0.913 0.02 
 
RE = Random-effect; FE = Fixed-effect 
LRTnull = p-value testing the hypothesis that the new model has no better fit than the null model. 
LRTpreceding = p-value testing the hypothesis that the new model has no better fit than the previous iteration model. 
Τ2 = Variance in random effects; describes magnitude of systematic differences between the primary datasets, after adjustment for fixed-effects in model.313,314 
VPC = Variance Partition Co-efficient; proportion of residual individual variation arising from random effects. 313,315 
R2marginal = Measures proportion of total variance explained by fixed-effects.313,316-319 
R2conditional = Measures variance explained by the complete model.313,316-319 
ROC AUC = Area under the receiver operating characteristic curve for within-sample prediction by the complete model (fixed and random effects).  
ΔAUC = Measures the difference in ROC AUC if model includes random effects (compared to fixed-effects only model).313 
# CD4 count log converted and standardised to have mean 0 and standard deviation 1. 
* Defined as any dose of anti-TB treatment more than 24 hours prior to blood culture being taken 
$ As per primary study case definitions. 
ᶧ Describes data available for this iteration, after missing observations on added variable are excluded. At each iteration, Null and preceding model were re-built with this 
reduced dataset, and these nested models used for LRT comparisons.  
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Figure 3-4.  Predicted probability of TBBC+ by CD4 count, danger sign, and 
hospitalisation status. 
Predicted probabilities from the mixed-effects models 6 and 7 (described in table 4) were used 
to estimate prevalence of positive TBBC in patients with suspected TB, and those with a final 
TB diagnosis, respectively. For all predictions, ‘TB treatment prior to blood culture’ was set to 
nil, and ‘number of blood cultures’ set at 2. The mean population predictions (zero random-
effects) are shown for CD4 count 0 to 200 cells/µL, danger sign and hospitalisation status in A 
& B. 
Estimates accounting for random-effects by primary dataset are shown in forest plots C & D for 
inpatients with danger signs and a CD4 count of 50 cells/µL. Fixed-effects parameters were re-
estimated in 1000 bootstrap replicates (stratified by primary dataset) and used to generate a 
95% confidence interval around the overall population mean predicted probability (black box 
around red dot). Fixed and dataset specific random-effects were similarly re-estimated for 95% 
confidence intervals around each dataset prediction. The distribution of random effects around 
the overall population mean was also re-estimated by bootstrap resampling, and used to 
simulate a 95% ‘prediction interval’ within which the mean predicted probability of TBBC+ in a 
new, unobserved or random, dataset is expected to lie (whiskers around ‘overall’ box). 
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3.3.3 Diagnosis of TB in patients with TBBC+ 
Fifteen primary studies had available sputum Xpert or culture data, which included 
5750 patients with 410 TBBC+. Eight studies had sputum induction available as part 
of the study protocol. Urine-LAM was available in 8 studies, totalling 2797 patients 
with 554 TBBC+. Patients with available urine-LAM data were predominantly 
recruited in South Africa (79%). Availability and results of index tests in patients with 
TBBC+ varied substantially by primary dataset (figure 5). 
Diagnostic utility of sputum Xpert/culture and urine-LAM were assessed in patients 
with a positive TB blood culture. Sensitivity of index tests was defined as number of 
patients with a positive result divided by number of patients with an available result. 
Diagnostic yield was defined as number of patients with a positive result divided by 
total number of patients (including those with an unavailable test result, e.g. unable to 
produce sputum). 
For sputum, the combined estimate of sensitivity from a bivariate random-effects 
model was 0.83 (95%CI 0.76 to 0.88), with significant heterogeneity between datasets 
(I2 45%, 95%CI 0 – 70%; test for heterogeneity on Cochrane’s Q, p=0.0336; Figure 5A). 
Addition of study level co-variates – including median number of sputa obtained, 
availability of sputum induction, proportion of patients with danger signs – did not 
improve model fit (data not shown). Because of substantial variation in sputum 
availability, diagnostic yield of sputum showed even greater heterogeneity between 
datasets (mean 0.69, 95%CI 0.55 to 0.83; figure 5B).  
Compared to sputum, urine-LAM had lower overall sensitivity in TBBC+ patients 
(0.70, 95%CI 0.58 to 0.80 in bivariate mixed-effects model), and comparable 
heterogeneity between datasets (I2 79%, 95%CI 59 – 89%; test for heterogeneity on 
Cochrane’s Q, p<0.001; Figure 5C). Diagnostic yield was similar to sputum, also with 
substantial heterogeneity driven by sample availability, rather than sensitivity of the 
test (mean 0.51, 95%CI 0.31 to 0.71, figure 5D).  
A post-hoc exploration of individual patient factors associated with missing index test 
results was performed. Inability to walk unaided, reduced consciousness, severe sepsis, 
presence of danger signs, TBBC+, lactic acidosis, and early mortality were all 
associated with both no sputum, and with no urine, being obtained (tables 5 & 6). 
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Figure 3-5. Availability and results of sputum Xpert or culture, and urine-LAM in 
patients with TBBC+. 
Sputum results and urine-LAM are summarized by primary dataset (A & B respectively). 
C. Aggregate results of both index tests for datasets shown in B. This is a graphical 
representation of a contingency table. Marginal frequencies of the individual categories 
(sputum positive, sputum negative, no sputum available; uLAM positive, uLAM negative, no 
uLAM available) are shown by size of the radial segment. Cross-tabulations are shown by 
‘chords’ connecting these segments; for example, the red chords show the number of sputum 
negative patients who were uLAM positive, uLAM negative, or had no uLAM available. 
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Figure 3-6. Sensitivity and diagnostic yield of sputum Xpert/culture and urine-
LAM in patients with TBBC+. 
A & C: forest plots of sensitivity (non-available tests excluded from denominator) of sputum 
testing and urine-LAM testing in patients with TBBC+. Where a sputum Xpert result was not 
available, sputum culture result was accepted as a surrogate. B & D: diagnostic yield – which 
accounts for non-diagnosis when test result is unavailable – of sputum testing and urine-LAM 
testing in patients with TBBC+, versus test availability. Red diagonal identity line represents 
maximum possible yield for given test availability (diagnostic yield = proportion with test sent 
who were positive). Each dot represents a dataset. Black curve shows predicted diagnostic yield 
for given proportion with test available, from a mixed-effects model with random effect by 
study and fixed effect of proportion of available test, with shaded 95% confidence interval 
generated from 1000-bootstrap replicates. 
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Table 3-5.  IPD associations with probability of no sputum obtained. 
 
N 
obs 
Unadjusted  N  
datasets 
Adjusted for clustering by dataset 
OR 95%CI pvalue OR 95%CI p-value 
Walks unaided 1859 0.41 0.29 to 0.57 0.00000 9 0.52 0.35 to 0.77 0.00100 
Encephalopathic 977 2.63 1.67 to 4.09 0.00002 5 4.17 2.53 to 6.88 0.00000 
Sepsis 1483 1.03 0.73 to 1.45 0.87107 10 0.91 0.62 to 1.35 0.65118 
Severe sepsis 1350 1.23 0.84 to 1.78 0.27693 7 1.68 1.12 to 2.53 0.01266 
Danger signs 1945 1.96 1.43 to 2.68 0.00003 11 1.62 1.11 to 2.37 0.01212 
TBBC+ 2131 1.82 1.39 to 2.38 0.00001 14 1.69 1.25 to 2.31 0.00080 
Early mortality 1687 2.74 1.90 to 3.91 0.00000 12 2.71 1.78 to 4.11 0.00000 
log CD4 count 2131 0.87 0.79 to 0.96 0.00663 14 0.93 0.83 to 1.04 0.20357 
Age, per 10 years 2124 1.04 0.90 to 1.20 0.57781 14 1.04 0.88 to 1.22 0.65606 
Tachypnoeic 1742 0.95 0.57 to 1.51 0.83815 9 1.44 0.82 to 2.53 0.20939 
Pulse, per 10bpm 1318 1.01 0.94 to 1.09 0.75512 6 1.03 0.95 to 1.12 0.44950 
Hypotensive 1017 0.76 0.50 to 1.14 0.19013 6 0.70 0.46 to 1.06 0.09467 
log blood lactate 528 2.11 1.34 to 3.35 0.00133 1  -     -     -  
 
Table 3-6.  IPD associations with probability of no uLAM obtained. 
 
N  
obs 
Unadjusted n  
datasets 
Adjusted for clustering by dataset 
OR 95%CI pvalue OR 95%CI ppvalue 
Walks unaided 1334 0.20 0.14 to 0.29 0.00000 7 0.39 0.25 to 0.60 0.00002 
Encephalopathic 949 4.17 2.79 to 6.22 0.00000 5 2.63 1.63 to 4.25 0.00007 
Sepsis 950 1.63 1.05 to 2.63 0.03708 5 0.89 0.53 to 1.49 0.65336 
Severe sepsis 950 3.51 2.44 to 5.10 0.00000 5 1.87 1.15 to 3.03 0.01195 
Danger signs 1350 5.64 3.73 to 8.80 0.00000 7 2.38 1.43 to 3.96 0.00087 
TBBC+ 1473 1.76 1.24 to 2.47 0.00135 8 2.18 1.44 to 3.31 0.00026 
Early mortality 1449 5.22 3.54 to 7.66 0.00000 8 2.18 1.33 to 3.58 0.00203 
log CD4 count 1473 0.86 0.76 to 0.98 0.02158 8 0.88 0.75 to 1.03 0.11321 
Age, per 10 years 1468 1.15 0.96 to 1.37 0.12704 8 1.09 0.88 to 1.33 0.43182 
Tachypnoeic 1346 3.67 2.53 to 5.31 0.00000 7 1.47 0.85 to 2.53 0.16406 
Pulse, per 10bpm 947 1.16 1.08 to 1.26 0.00014 5 1.14 1.03 to 1.27 0.01157 
Hypotensive 945 1.94 1.35 to 2.78 0.00029 5 0.72 0.44 to 1.18 0.19769 
log blood lactate 576 3.60 2.44 to 5.40 0.00000 2 1.93 1.20 to 3.09 0.00627 
 
Encephalopathic = GCS<15 or AVPU < 4; sepsis & severe sepsis by Sepsis-2 definitions; early 
mortality = death in hospital or by 30-days follow-up; tachypnoeic = respiratory rate > 30 per 
minute; hypotensive = systolic BP < 100 mmHg.  
Unadjusted estimates from univariate logistic regression; adjusted estimates are fixed-effects 
from mixed-effects logistic regression including random-intercept by primary dataset. OR = 
odds ratio of no available index test (sputum or urine); 95%CI estimated from fixed-effect 
standard errors (* +/- 1.96). 
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3.3.4 Mortality associated with TBBC+ 
Including only patients with a final TB diagnosis, and excluding those with missing 
observations on pre-specified variables, 2454 patients’ IPD was available for mortality 
analysis. TBBC+ compared to blood-culture negative TB had a strong unadjusted 
hazard of mortality, which was most pronounced in the first 30 days of follow up 
(figure 6). Across all datasets, 10% (55/539) of patients with TBBC+ had died by day 
5. 
This association was adjusted for pre-specified dependent variables (age, sex, presence 
of WHO danger signs, CD4 count), and clustering by primary dataset, using mixed-
effects logistic regression modelling. All variables were independently significant at 
p<0.05 except sex (table 7), and TBBC+ had the strongest association with OR 2.54 
(95% 1.85 to 3.48).  
On univariate, testing urine-LAM positivity was associated with death (OR 2.15, 
95%CI 1.55 to 2.98, p=4.4e-06). This effect varied substantially by study, but a fixed 
effect of urine-LAM remains after accounting for random-effect by study (fixed-effect 
OR 1.67, 95%CI 1.13 to 2.46, p=0.0101). However, the effect is not independent of 
other variables in the model from the previous paragraph / table 7. This same model 
was reconstructed including only patients with available urine-LAM results. In this 
model, inclusion of TBBC+ significantly improved fit (p<0.001, comparing model with 
and without blood culture result by likelihood ratio test). By contrast, there was no 
evidence that urine-LAM improved model fit, either when included in addition to 
blood culture result (p = 0.952), or when added in place of blood culture result as a 
surrogate variable (p=0.264).  
Finally, the association between time-to-TB-treatment (number of days from blood 
culture being taken to start of anti-TB therapy) and early mortality (dying before 
discharge or 30-days follow-up) was examined. In patients with TBBC+, early 
mortality varied in a ‘U-shape’: highest proportion of deaths was seen in patients with 
longest, or shortest, time-to-TB-treatment (figure 8). To reflect the WHO algorithm, 
‘treatment delay’ was defined as time-to-TB-treatment greater than 4 days. 
Association of treatment delay with early mortality was adjusted for potential 
confounders in a logistic regression model (figure 9B). The strongest evidence for an 
141 
 
association between treatment delay and higher mortality was in patients with TBBC+, 
and the highest predicted probability of early death was in seriously unwell (danger 
sign positive) TBBC+ patients who had a delayed start to anti-TB treatment (figure 9A).  
 
 
Figure 3-7. Naive Kaplan-Meier plot showing mortality over time by TBBC status. 
Plots are unadjusted for dependence on primary dataset or other dependent variables. Mortality 
association with TBBC is maintained out to 100 days follow up (A), but occurs mostly in the 
first 30-days (B). Time in days since recruitment. 
 
 
Table 3-7. Fixed effect associations with 30-day or inpatient mortality. 
  
Fixed 
effect OR 
95%CI p-value 
Age, per 1 standard deviation increase 1.35 1.17 to 1.55 3.50E-05 
Female sex 0.78 0.58 to 1.05 0.0981 
Danger sign positive 1.87 1.23 to 2.84 3.20E-03 
CD4 count, per 1 standard deviation increase 0.84 0.72 to 0.98 2.35E-02 
TBBC+ 2.54 1.85 to 3.48 7.24E-09 
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Figure 3-8. Mosaic plots of early mortality by time-to-TB-treatment in different 
patient strata. 
Plots are proportional representations of contingency tables made from all IPD aggregated 
across primary datasets with available data. Time-to-TB-treatment was categorised into bins <0 
(treatment started at least one day before blood culture), 0 (same day as blood culture), 2-4, or 
>4 days after blood culture. All patients with a final TB diagnosis (A), patients with a positive 
TB blood culture (B), and patients with a positive blood culture and at least one WHO danger 
sign recorded (C) are shown. 
 
 
Figure 3-9. Predicted probability of early mortality in TB patients by CD4 count, 
danger signs, TBBC+, and TB treatment delay. 
Adjusted odds ratios (B) for early mortality (death before discharge or before day 30 follow-up) in a 
logistic regression model including all patients with a final diagnosis of TB. Patients starting anti-TB 
treatment more than 24-hours before blood culture was taken were excluded due to concerns about 
confounding bias (patients who blood culture positive despite antimicrobial carry-over in plasma may have 
atypically high-burden or drug resistant disease). Available data did not permit inclusion of random-effects 
by primary dataset. An interaction term between TBBC+ and treatment delay (TBBC+ * treatment delay 
in B) was pre-specified. Age and log CD4 count were standardised (to have mean=0 and s.d.=1) for 
modelling. 
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The predicted probabilities of early mortality for different levels of independent variables (A) 
are for patients aged 36-years-old, the mean age observed in all included IPD. 
 
3.4 Discussion 
This analysis shows that blood culture positive tuberculosis is more common in HIV-
infected inpatients than previously appreciated. A substantial amount of apparent 
heterogeneity between studies and settings can be explained by technical and clinical 
co-factors. Previous reports of TBBC+ prevalence are under-estimates because most 
studies have relied on a single blood culture, have not accounted for false negative 
results from antimicrobial carry-over in plasma, and have included patients with 
unobserved blood culture status (e.g. due to contamination) in the study denominator.  
After adjusting for these co-factors, heterogeneity was reduced but not eliminated: 
estimated prevalence of positive TBBC amongst seriously unwell HIV-infected 
inpatients suspected of having TB still showed pronounced variation between primary 
study populations. This likely reflects differences in settings or inclusion criteria in the 
original studies resulting in different prior probabilities of tuberculosis. This 
interpretation is supported by the marked reduction in heterogeneity when only 
patients with a final TB diagnosis are considered.   
Whatever the prior probability of TB in a given setting, presence of WHO danger signs 
and being unwell enough to be admitted to hospital both substantially and 
independently increase the posterior probability of a patient being TBBC+. In the final 
prevalence estimation model (model 7, table 4) adjusted fixed-effect ORs were 1.74 
(95%CI 1.28 to 2.36) and 3.26 (95%CI 2.09 to 5.07), respectively, for presence of a 
danger sign and hospitalisation. In other words, the ‘WHO algorithm for managing 
seriously unwell PLWHIV and suspected of having TB’ is selecting for TBBC+ 
disease. The recommendations contained in the algorithm therefore need to be valid 
for patients with bacteraemic tuberculosis.  
Sputum testing with Xpert is the central rapid-diagnostic step recommended in the 
WHO algorithm. We found a reasonable summary estimate of sensitivity for sputum 
testing (0.83; 95%CI 0.76 to 0.88), but with variation between datasets. Performance of 
sputum tests for diagnosis of TB in people living with HIV consistently show 
substantial unexplained heterogeneity on meta-analysis.333-336 By limiting the case-mix 
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to patients with TBBC+ (lessening “spectrum-bias”337), heterogeneity was certainly 
reduced, but not eliminated.  Variation in study design and conduct may have 
contributed to residual variance. Two studies had explicit biases – exclusion of patients 
unable to produce sputum despite induction,21 and exclusion of smear-positive 
patients.327 Datasets where the primary study aim was testing performance of 
diagnostics had highest observed sensitivity,15,129,329,330 while cohorts recruited to 
define and explore mortality associations had lower sensitivity.24,328 Arguably, the later 
better represent real-world conditions.  
Further, use of sputum culture as a surrogate for Xpert result in this analysis will have 
overestimated sensitivity of rapid sputum diagnosis (sensitivity of Xpert is 0.89 overall, 
0.67 in smear-negative cases, compared to culture, in meta-analysis),335 but the newer 
Xpert-ultra platform (currently being rolled-out in South Africa) has improved 
performance (sensitivity 0.63 versus 0.43 for smear negative culture positive cases in 
the largest validation to date).338  
A greater concern may be the even larger between-study differences in diagnostic 
yield, resulting from marked variation in sputum and urine availability. In post-hoc 
exploratory analysis, probability of obtaining sputum and urine was reduced in the 
sickest patients, a significant concern for the seriously ill patient algorithm, as reliance 
on these rapid diagnostics may be delaying diagnosis and treatment in patients at 
greatest risk of death.  
An ideal rapid diagnostic test in patients with MTBBSI would be easily obtainable in 
critically unwell patients, and not show evidence of marked heterogeneity in diagnostic 
yield in different settings.  This is emphasised by the finding that TBBC+ is strongly 
associated with early mortality (adjusted OR 2.54, 95%CI 1.85 to 3.48), with 10% of 
TBBC+ patients dying within 5 days of presentation in the pooled IPD.  
The WHO seriously unwell patient algorithm recommends delaying presumptive 
treatment for 3-5 days when rapid tests are non-diagnostic. Evidence was presented 
suggesting that such a treatment delay is associated with a higher risk of mortality, 
specifically in TBBC+ patients. This analysis was complicated by confounding. In the 
unadjusted data, the highest risk of death was seen in patients with treatment delay of 
long or short duration. A plausible interpretation is that clinicians in these datasets 
were often prioritising early treatment in the most moribund patients. After adjusting 
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for factors like presence of TBBC+ and danger signs, the highest risk of death was in 
patients experiencing treatment delay. Time-to-antibiotic benchmarks are an accepted 
standard of care in severe bacterial and (non-tuberculosis) sepsis guidelines;339-341 
several of the cohort studies which underlie these recommendations have also shown a 
‘U-shaped’ relationship between time-to-antibiotic and risk of death. 342-344 Studies 
which don’t report an association between treatment delay and mortality in sepsis 
generally present the data in a way that such a U-shaped relationship would be 
obscured if present, and model the effect of treatment delay as linear. In the best-
reported sepsis cohorts, a higher risk of death at shortest time-to-antibiotics is seen in 
the crude data, but shown to disappear in disease severity adjusted analysis, which 
instead affirm a mortality risk with treatment delay.345,346 The current analysis is 
therefore consistent with the bacterial sepsis literature, and supports a similar 
emphasis on avoiding treatment delay in seriously unwell patients with HIV-associated 
TB. Nonetheless the confounding, and small sample size precluding modelling of 
random-effect by study, are weaknesses of this analysis. 
While TBBC+ was strongly and independently associated with early mortality, positive 
urine-LAM was not. This is a surprising finding. Urine-LAM has been associated with 
mortality in previous studies, including several which contributed IPD to this meta-
analysis. As shown here and elsewhere,125,144 positive urine-LAM is strongly correlated 
with TBBC+. Even more importantly, two RCTs have shown large absolute mortality 
benefit from access to urine-LAM testing, specifically in patients with low CD4 count 
and anaemia who were very likely to have MTBBSI.22,347  
Two factors can explain the weak association of urine-LAM with mortality in this 
meta-analysis. First, there was a strong association between non-availability of a urine-
LAM result and death, suggesting missing-data bias reduced the mortality effect-size 
for urine-LAM. Secondly, heterogeneity in this effect size between primary studies 
was marked. Four studies have an above average mortality effect size for urine-LAM 
(SouthAfrica_2009, SouthAfrica_2014, SouthAfrica_2015, Uganda_2014), while the 
other four studies (SouthAfrica_2017, SouthAfrica_2018, Zambia_2014, 
Zambia_2017) have a below average effect size. These lower urine-LAM effect studies 
have higher mortality rates, more patients with profound CD4 count suppression, and 
higher rates of TBBC+ (table 3). In short, these studies recruited a different patient 
stratum. The consequence of stratifying analysis by a variable is the same as adjusting 
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for that variable. The effect size of urine-LAM is reduced when more urine-LAM 
negative, low-risk of death patients are excluded from a study: a Simpson’s 
paradox.130,131 This is illustrated with simulated data in figure 10. The TBBC+ 
mortality effect is robust to this adjustment, i.e. it is more independent of the 
stratification resulting from different recruitment criteria and settings. 
 
Figure 3-10. Simulating Simpson's paradox in relationship between urine-LAM 
and death. 
A. Assumed causal structure in simulated data. Probability of urine-LAM positivity and 
probability of death are modelled as sigmoidal functions (plus random noise) of an underlying 
latent (unobserved) variable: “bacilli burden”, which is itself a random normal variate amongst 
TB patients. A positive urine-LAM event and mortality event are in turn modelled as binomial 
trials of their respective probabilities. Urine-LAM positivity and mortality are therefore 
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correlated (r), but dependent on the underlying latent variable bacilli burden (which could be 
replaced by a proxy such as CD4 count or “MTBBSI” etc.). Adjusting for bacilli burden will 
render urine-LAM and death independent. 
B. Example simulation based on the causal structure defined in A. 1000 patients were simulated 
with mean bacilli burden = 0, s.d. = 4, and dependent variables (urine-LAM and death) derived 
based on this variable. In this simulated data set there is an overall odds ratio for death from 
positive urine-LAM of ~ 2.5. If the data set is stratified by bacilli burden, such that only patients 
with more severe disease are included, with bacilli burden > 0, this reduces the odds ratio to 
~1.4. 
C.  100 repeated simulations of 1000-patients as per A&B were run. The mortality odds ratio 
for death from positive urine-LAM were recalculated for strata defined by a range of bacilli 
burden cut-offs in each simulation. As a higher cut-off is used, defining increasingly high bacilli 
burden strata, on average the odds ratio progressively falls. This is equivalent to adjusting the 
odds ratio by bacilli burden, by stratified analysis. The apparent effect-size of urine-LAM will 
depend on how inclusion criteria of a study sample across the range of patients’ bacilli burden. 
 
 
3.4.1 Implications & conclusions 
Taken together, the above results argue that there are weaknesses in the WHO 
algorithm for managing seriously ill PLWHIV suspected of having TB. The algorithm 
selects for patients with TBBC+ disease; a significant proportion of these patients may 
be undiagnosed by sputum Xpert testing, and a significant proportion will die 
untreated if presumptive therapy is deferred for 3-5 days observation. PLWHIV with 
bacteraemic TB warrant specific research and guidance on diagnosis and empiric 
treatment.  
To illustrate this point, consider the three randomised trials of presumptive TB 
therapy in PLWHIV reported to date.§§§§§ None of these trials have shown a mortality 
benefit, but all have used inclusion criteria likely to have selected against TBBC+ 
disease. The REMEMBER study randomised patients with CD4 count < 50 cells/mm3 
to receive HAART plus pre-emptive TB therapy, or HAART plus isoniazid preventive 
therapy (IPT), with identical 24-week mortality in both arms.349 However, despite the 
low CD4 count, exclusion criteria included need for hospital admission (Karnofsky < 
30), creatinine clearance < 30mL/min, and LFTs>2.5x upper limit of normal. In 
addition, participants suspected of having TB by their (non-study) clinician were 
                                                             
§§§§§ A fourth, the PrOMPT study was stopped early due to poor recruitment and has no useful 
results.348. Manabe YC, Worodria W, van Leth F, et al. Prevention of Early Mortality by 
Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. Am 
J Trop Med Hyg 2016; 95(6): 1265-71. 
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excluded. As a result, only 5% of participants had haemoglobin < 8g/dL, 6% had a 
temperature ≥38.0oC, and 24-week mortality was only 5.2%.349  
The TB FAST TRACK study was a cluster randomised trial in 24 antiretroviral 
outpatient clinics in South Africa.350 In the intervention arm, HIV-infected patients 
with CD4 count < 150cells/mm3 at high risk of TB (urine-LAM positive, 
haemoglobin<10g/dL, or BMI<18.5) had immediate initiation of TB treatment; 
medium risk patients (symptom screen positive but no high-risk criteria) had further 
TB investigations and review in a week; and in low-risk patients (not meeting criteria 
for medium or high risk) HAART was initiated immediately. Two-month TB 
treatment initiation rates were 62% versus 11%, and six-month mortality was 19 and 21 
per 100 person-years, in the intervention and control arms respectively (adjusted 
mortality rate ratio 0.87, 95% CI 0.61 to 1.24). The trial has not yet been fully reported 
so sub-group analyses are not available, but it should be noted that only ambulant 
outpatients were recruited, and presence of danger signs was an exclusion criterion.  
The third trial, STATIS, compared automatic TB treatment initiation in HIV-infected 
adults with CD4 count < 100 cells/mm3, versus treatment based on extensive 
screening including chest x-ray, sputum Xpert and urine-LAM, with no difference in 
24-week mortality between the arms (6.3% and 6.9% respectively).351 Only ambulant 
outpatients with creatinine clearance > 50 mL/min and “no overt evidence that TB 
treatment should be started immediately” were included, and the final study 
population had relatively favourable characteristics (median haemoglobin 11.5g/dL, 
95% with Karnofsky score > 80%).   
Therefore, all three trials have – to a greater or lesser extent – recruited patient 
populations unlikely to have TBBC+ disease. No trial to date has adequately assessed 
for mortality benefit of empirical therapy in patients at high risk of MTBBSI.****** Each 
of the three trials is also confounded by the ability of local clinicians to identify high-
risk TB patients, who were excluded, or treated empirically in the control arms. The 
                                                             
****** If this seems obvious, note that summaries of these trials often gloss over the highly 
selective inclusion criteria: “The STATIS study confirms and extends the findings of [the 
REMEMBER trial] that failed to demonstrate mortality-related benefits of empiric TB 
[therapy] among individuals with low CD4+ cell counts.”352. Currier JS, Havlir DV. CROI 
2018: Complications of HIV Infection and Antiretroviral Therapy. Top Antivir Med 2018; 
26(1): 22-9. 
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greater the ability of these clinicians to identify high-risk TB disease, the lower the 
effect size of presumptive therapy. Alternative designs would likely have been 
unethical, but this means these trials in fact tell us little about who should be treated 
empirically. The current meta-analysis suggests risk from delayed treatment would be 
most marked in danger sign positive TBBC+ patients. Hospitalised PLWHIV, who 
have danger signs and low CD4 count, and are suspected of having TB, should be 
treated without delay. This is particularly true if sputum is unobtainable and/or urine-
LAM is not available. Patients with TBBC+ disease would be a rational pre-specified 
subgroup for analysis in any future empirical therapy trials. Proportion of TBBC+ 
patients treated as part of a presumptive therapy algorithm would also be a rational 
secondary outcome, more likely to be adequately powered than a hard mortality 
endpoint.  
In contrast to the three empirical therapy trials, the STAMP study22 recruited patients 
at much higher risk of TBBC+ disease: hospitalised patients with no exclusions based 
on danger signs, performance score or organ dysfunction. This study compared 
standard of care (sputum Xpert screening) to additional urine Xpert and urine-LAM 
testing in all HIV-infected adult inpatients in two hospitals in Southern Africa with 
severe burden of disease. Rates of empirical TB diagnosis were 8.3% versus 5.6%, and 
overall rates of inpatient TB treatment were 21% versus 14%, in the intervention and 
control arms respectively. Substantial absolute reductions in 56-day mortality were 
seen, but only in the pre-specified subgroups: CD4 count <100cells/mm3 (-7.1%, 
95%CI -0.4 to -13.7%), and haemoglobin < 8g/dL (-9.0%, 95%CI -1.3 to -16.6%). These 
are sub-groups at increased risk of TBBC+ disease. This implies empirical treatment 
coupled with sputum Xpert screening misses fatal TB cases in these hospitals, and that 
these missed cases are predominantly in high-TBBC risk patients. The question is, are 
all of these cases detected by urine-LAM and urine-Xpert? Might a rapid blood 
diagnostic detect more cases, or detect MTBBSI cases more expediently? There have 
been calls for novel rapid diagnostic tests to be specifically validated in MTB BSI.353 
Chapter 5 of this thesis discusses development of novel same-day tests for identifying 
TB in blood.  
Finally, the current meta-analysis supports the idea that, rather than being a rare 
event, MTBBSI is the mode of HIV-associated TB infection in hospitalised patients 
with severe disease. In the final prevalence estimation model (model 7, table 4) 
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adjusted fixed-effect OR for increasing from one to two TB blood cultures was 1.8 
(95%CI 1.3 to 2.6). More than two blood cultures might increase the prevalence 
estimate for TBBC+ further still, but was not estimated because this would have 
extrapolated beyond the observed data. It was argued in chapter 1 that TBBC+ was 
just one window on MTBBSI. As discussed in the next chapter, culture may have 
limited sensitivity for detecting TB, both in vitro and in clinical samples. In chapter 5, 
the sensitivity of culture is compared to novel MTBBSI diagnostics, with the 
suggestion that, even with multiple cultures performed, TBBC+ patients are just a 
subset of patients with detectable TB in the blood stream.  
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4 Counting mycobacteria in vitro  
 
 
4.1 Introduction 
 
The idea that tuberculosis is best characterised as a continuous spectrum of infection – 
a spectrum chiefly established by the total number of bacilli in the body – is as old as 
the discovery that tuberculosis is caused by a bacillus.47 As reviewed earlier, classical 
descriptions of tuberculosis held that “the number of bacilli reaching the blood stream 
and multiplying in the tissues is the main concern” for understanding post-primary 
disease.106,107 It was further postulated in chapter 1 that HIV-associated MTBBSI was 
an extreme form of this haematogenous post-primary tuberculosis, and that TB blood 
culture, urine-LAM and urine-Xpert gave non-redundant, systematic measurements of 
this process. For diagnostics, clinical phenotyping, and assessing response to 
treatment, quantifying mycobacteria is of basic importance in clinical TB science. 
Counting bacilli is also a fundamental task for basic TB research. Molecular 
mycobacteriology experiments, drug discovery assays, immune-cell multiplicity-of-
infection protocols, and animal models in TB vaccine research, all rely on accurate, 
reproducible quantification of bacilli. How we count bacilli is a methodological issue 
underlying much of our current knowledge of tuberculosis.  
Measuring mycobacteria is, however, not straightforward, in either research laboratory 
or clinical settings. And, while a multitude of methods have been described, direct 
comparisons and cross-validation between these methods are partial. In this chapter, 
established laboratory methods for quantifying mycobacteria are reviewed, with 
emphasis on inter-method comparisons and M. tuberculosis where data are available. 
The potential and technical difficulties of flow cytometry for counting and live/dead 
discrimination of bacteria are discussed. A novel in vitro method for flow cytometry 
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based absolute counting of mycobacteria is then described. This method is compared 
to gold-standards like colony forming unit (CFU) counting, exposing some major 
limitations of established approaches. Finally, in vitro antimicrobial killing of M. bovis 
BCG cultures is explored using the flow cytometry method, and it is concluded that 
additional pharmacodynamic information can be gleaned using this tool. 
 
4.2 Established methods for counting 
mycobacteria 
For convenience, methods have been grouped under the following sub-headings for 
review: 
• bulk or batch measures;  
• microscopy methods;  
• secondary culture methods;  
• molecular methods. 
These distinctions are not absolute (e.g. several secondary culture methods could also 
be described as bulk or batch measures). 
4.2.1 Bulk or batch measures 
These are methods which quantify growth of a culture by directly or indirectly 
measuring cumulative mass or metabolic activity across the whole population of cells. 
These measures are, therefore, not count data, but are often – explicitly or implicitly – 
used to estimate bacterial number.  
The classic bulk measure of broth cultures is turbidity (light scatter; assessed visually 
as degree of ‘cloudiness’) or optical density (attenuation of a transmitted light beam 
caused by absorption, reflection, scatter, and other physical processes; assessed with a 
nephelometer or spectrophotometer). These techniques are commonly used as 
methodological steps in mycobacterial research,354-358 often to standardise an inoculum 
size. The assumption that optical density (OD) has a linear relationship with bacilli 
density is often implicit, and sometimes extrapolates from turbidity data for E. coli 
cultures (using ‘McFarland standards’) without further justification.356,357  Only a few 
studies359-361 have tried to empirically assess the relationship between turbidity / 
optical density and genuine count measures of M. tuberculosis, with conflicting 
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conclusions. Peñuelas-Urquides et al.359 report R2 values of 0.89 and 0.93 between 
CFU count and OD600 or McFarland units respectively. However, the figures in this 
paper suggest a non-linear relationship, over only 7 data points, with clear dependence 
of the residuals on culture growth phase – strongly suggesting the R2 values are based 
on a mis-specified model. By contrast, Martin-Casabona et al.361 show data with similar 
dependence of correlation between M. tuberculosis CFU/ml and OD on growth phase, 
but conclude that, overall, there is “no significant correlation” between these metrics.  
Much more data is published for other mycobacterial species, but does little to resolve 
the confusion. For example, for M. avium subsp. paratuberculosis (MAP, a focus of 
bovine microbiology research) CFU/ml has been equated linearly to OD measures by 
several groups, including as follows: 
• OD600 of 0.3  ≡ 109 CFU/ml;362 
• OD540 of 0.65  ≡ 4 x 108 CFU/ml;363 
• OD550 of 1.0  ≡ 2.8 x 106 to 107 CFU/ml.364 
Note that, across studies, this would suggest that higher CFU/ml are associated with 
lower OD, which is nonsensical, beyond the conclusion that there is substantial, 
unexplained, between-study heterogeneity for the relationship between mycobacterial 
CFU and OD measures. 
Alternative batch measures used for mycobacteria include those based on metabolic 
activity rather than cell mass. Examples include the “Alamar-Blue®” assay, in which 
non-fluorescent, blue oxidised resazurin is irreversibly reduced to fluorescent, pink 
resorufin when aerobically active cells consume available oxygen. This colour change 
can be detected giving a bulk-measure of cumulative metabolic activity of a broth 
culture. Resazurin assays are frequently used for qualitative or semi-quantitative read-
outs in drug sensitivity testing of mycobacteria,365-373 with only limited attempts to 
relate colorimetric values to cell counts such as CFU/ml.371  
4.2.2 Microscopy methods 
Semi-quantitative assessments of bacilli load are routinely made on clinical specimens 
using acid-fast staining and microscopy.374 It is commonly asserted that the limit of 
detection for M. tuberculosis in sputum is 5000-10000 CFU/ml.375-378 This seems to be 
based on a handful of small studies from the mid-20th century.379-381 Only one of these 
studies reports crucial methodological details such as sputum volume processed or 
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number of microscopic fields examined. In that study (Hobby et al., 1973),381 
microscopy limit of detection was estimated 7.8 x 103 CFU/ml when 0.04 ml of 
sputum was examined on a 1cm2 area using a 97x objective. Importantly, this detailed 
study also reported that the ratio of microscopy bacilli count to CFU count was highly 
dependent on the patient that sputum was obtained from, and time on treatment: 
patients with extensive cavitation at baseline often had higher microscopy counts than 
CFU counts, and the difference increased with time on treatment (figure 1).381 
 
 
Figure 4-1. Hobby et al. comparison of CFU & Ziehl-Neelsen microscopy counts 
in sputum during first 150 days pulmonary TB treatment. 
Raw data was extracted from the tables presented in Hobby et al. 1973381 and plotted. Patients 
(pts) 1-19 had extensive chest X-ray (CXR) pathology; patients 20-28 had limited CXR 
pathology. AFB = microscopy. 
 
 
 Hobby et al. speculated that microscopy count may be more useful than CFU 
counting for assessing treatment effect in some patients. This line of enquiry has not 
been pursued. Instead development of mycobacterial microscopy has focused on 
improving qualitative, diagnostic sensitivity, with improvements in sample processing 
and use of alternative acid-fast staining techniques such as auramine-O.382 
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Quantitative microscopy of mycobacteria is seldom reported for in vitro samples. One 
protocol using acid-fast staining (Kinyoun method) and a Hausser counting chamber 
(haemocytometer) has been published.383 The authors found microscopy counts and 
CFU counts to be the same (or within 1 standard deviation on technical replicates) for 
M. bovis, M. marinum and M. smegmatis, but found CFU counts to be over 3-times 
higher than microscopy counts in an M. tuberculosis multiplicity-of-infection assay – no 
explanation for this difference is suggested.383  
Despite widespread use, standard acid-fast staining methods (auramine, Ziehl-
Neelsen, Kinyoun) are surprisingly insensitive for mycobacteria. Compared to a gold 
standard of phase contrast microscopy, the novel fluorescent stain SYBR-gold 
identifies 99% of M. tuberculosis bacilli in log phase and non-replicating hypoxic broth 
cultures; transmission light microscopy with Ziehl-Neelsen stain, or ﬂuorescence 
microscopy with auramine-O or auramine-rhodamine reveals only 54% to 86%, with 
particularly poor sensitivity for non-replicating cultures.384 In addition, a wealth of 
evidence suggests that TB bacilli often lose acid-fastness; in some growth conditions, 
acid-fast bacilli may be the exception not the rule.385-390  
4.2.3 Secondary culture methods: CFU counting, TTD, and MPN. 
Following extensive optimisation work in the first half of the 20th century, CFU 
counting has remained the gold standard for mycobacteria quantification, for in vitro 
and clinical samples. CFU counting has the major advantage of giving a read-out for 
cells which are unequivocally alive, as proven by their ability to undergo binary fission 
and form colonies. However, CFU counting has notable limitations. From a practical 
perspective, CFU counting is slow, resource intensive, and requires extensive bio-
safety level 3 (BSL3) precautions. It also has intrinsic accuracy constraints,391 and – at 
least in clinical specimens – may show significant within and between lab 
variability.392,393  
It is, however, possible that the major limitation of CFU counting is strategic rather 
than practical, and relates to the status of cells which do not grow on agar. Colony 
formation is unequivocal evidence of the existence of a living progenitor cell(s), but the 
converse is not true. Several lines of evidence point to the existence of a substantial 
viable but non-culturable (or at least ‘differentially culturable’) numbers of cells in a 
given M. tuberculosis population. First, clinical samples which are culture negative on 
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solid media can be culture positive when inoculated into parallel liquid broth 
cultures.394-396 Serial dilution experiments suggest numbers of bacilli recoverable from 
sputum in liquid culture may be 10-fold higher than CFU counts from the same 
sputum.397  
Bacilli growth is also dependent on presence of secreted enzymes, including 
resuscitation-promotion factors (Rpfs) and/or other molecules found in mycobacterial 
culture filtrate (CF).398-400 These factors are not required for standard in vitro log-
phase growth, but may be essential for recovery from a ‘dormant’ state and for survival 
in animal models.400-404 Consequently, apparent numbers of viable bacilli may be up to 
2 logarithms higher than CFU count, both in animal models, and in vitro depending on 
growth conditions.405 Two groups have assessed Rpf-dependency of bacilli in patient 
sputum. Mukamolova et al. found that in 20/25 patients, 80 to 99.9% of bacilli in pre-
treatment sputum were only detectable in presence of Rpf, that this dependence was 
lost in secondary cultures, and that the proportion increased in sputum samples 
obtained after start of anti-TB chemotherapy.406 In a larger study, Chengalroyen et 
al.407 found that 95/110 PTB patients had Rpf and/or CF dependent bacilli in spot 
sputums (some of which were probably from after start of treatment). In these 95 
patients, the log ratio of CFU count to Rpf/CF dependent most-probable number 
seems to have ranged from ~0.2 to ~7.8;†††††† this equates to 18 to 99.96% of bacilli 
being resuscitation dependent. 
Returning to the practical limitations of CFU counting, other more convenient 
secondary culture methods have been developed to quantify bacilli. Several 
commercial liquid culture systems have been developed based on radiometric or 
colorimetric detection of metabolic activity (a bulk measure of bacterial growth), and 
are more standardised than, for example, the resazurin assay described previously. In 
spiking experiments, time to detection (TTD) of growth in these systems correlates 
with the number of CFU in the inoculum.408 Although there may be other confounding 
attributes of the inoculum which influence TTD independent of bacilli number,409,410 
this correlation appears to be log-linear for clinical samples, at least over some 
range.410-417  
                                                             
†††††† Reading from figure 2 in ref 407. Chengalroyen MD, Beukes GM, Gordhan BG, et 
al. Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from 
Patients with Tuberculosis. Am J Respir Crit Care Med 2016; 194(12): 1532-40. 
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A second liquid culture quantification technique – most probable number (MPN) – has 
recently become prominent.418 This method, used in the Rpf studies referenced 
above,406,407 extrapolates results of a limiting dilution series to a bacilli count using a 
Poisson probability distribution. As well as greater speed, this method may have the 
advantage over CFU counting for detecting a greater proportion of the bacterial 
population – specifically bacilli which are culturable in liquid but not solid media. What 
proportion of “viable non-culturable” cells this represents in unknown. 
4.2.4 Molecular techniques 
Detection of nucleic acid has become a mainstream approach for M. tuberculosis 
diagnosis with the roll-out of the Xpert MTB/RIF platform. Xpert modules use real-
time polymerase chain reactions (RT-PCR) and can therefore report cycle threshold 
(CT) values which should reflect number of genomic copies in the original sample. 
Xpert CT values have been shown to have log-linear correlation with CFU count in 
spiking experiments across range 2 to 7 log10 per ml.419,420  In a multisite comparison 
study of clinical sputum samples, Xpert CT correlated with AFB smear grade 
(Spearman’s rho, -0.63), TTD in liquid culture (rho, 0.67), and CFU count (rho = -
0.53).421 All these correlations were strengthened by excluding samples with high 
internal control CT values (an indication of PCR inhibition), and all were noted to vary 
substantially between different sites. Xpert CT values have been largely dismissed as a 
measure for pharmacodynamic studies, due to comparatively low (compared to TTD 
and CFU counts) ratio of between-group to within-group variance when comparing 
groups of patients on different antimicrobial regimens in an EBA study.422 Given how 
poorly CFU and TTD dynamics predict phase 3 trial end-points the logic of this is 
unclear to me: the real question is whether the between-group variance (whatever its 
magnitude) correlates with relevant clinical endpoints, and this remains untested to 
my knowledge. Nonetheless, one theoretical concern is that, although Xpert only 
processes intact bacilli, the viability of these bacilli is unknown. In qPCR systems 
where genomic copies are related to CT values by an empirically derived standard 
curve a 10 to 100-fold excess of genomic copies is reported compared to CFU in 
animal or cell-culture derived bacilli.423 The use of 16S rRNA instead of DNA for 
qPCR is the basis of the molecular bacterial load assay (MBLA) based on the tenet that 
rRNA levels will decline more rapidly with cell death.424 Normalised against CT values 
from an in vitro M. tuberculosis culture, the MBLA measure correlates with CFU count 
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in clinical samples.425 This would imply MBLA does not ‘observe’ the differentially 
culturable bacilli described by Chengalroyen et al. and Mukamolova et al. Conversely, 
MBLA showed a different pharmacodynamic profile compared to CFU or TTD in a 
mouse model of tuberculosis, implying that it does measure a different subpopulation 
of bacilli.426 In that study, MBLA predicted numbers of bacilli were lower than CFU 
count at baseline, becoming higher than CFU count after ~4 weeks of treatment. This 
is unsurprising given that the MBLA assay is normalised against in vitro M. tuberculosis 
cultures, and highlights that the relationship between number of bacilli and RNA 
production is likely to be highly non-linear and dependent on conditions. Of note, 
mRNA can be detected in (culture-negative) broncho-alveolar lavage samples at end of 
treatment in pulmonary TB patients with stable cure.427 
CT values may not be directly comparable across different sites / instruments, due to 
differences in amplification curve performance and background fluorescence. Digital 
PCR (dPCR) overcomes this problem by providing true count data. By running 
individual well PCRs in limiting dilution series, the most probable number of genome 
copies can be determined with reference to an essential Poisson probability distribution 
rather than an empirically derived reference curve. Consequently, dPCR has 
substantially lower between lab variance, and has been suggested as an appropriate QA 
reference for TB laboratories running other PCR techniques like Xpert, avoiding the 
uncertainties about CFU counts.428 Number of genomic copies found by dPCR in a 
broth culture of M. tuberculosis are approximately 2-fold in excess of CFU counts, 
although this estimate is based on a single culture preparation without any published 
details of culture conditions.428 
Of note all the above molecular methods are subject to the efficiency of nucleic acid 
extraction methods. Comparisons of methods in mycobacteria suggest efficiency 
differs by orders of magnitude, without obvious consensus as to the best method.429-434  
In summary, CFU counting remains the gold standard for enumeration of 
mycobacteria. Other methods are generally normalised against this standard, but also 
indicate that a proportion of bacilli do not form CFU, and this proportion differs by 
growth conditions. Alternate methods which aim to capture viability, such as those 
based on oxygen consumption or RNA production, do not provide direct count data. 
The only alternative direct-count viability read-out method is MPN, which has been 
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used to show that CFU forming bacilli are a minority population of viable bacilli in 
sputum samples from most, but not all, patients. Counting bacilli may be fundamental 
to clinical and basic TB science, but there is much uncertainty about established 
techniques. 
New methods able to give direct cell counts, with single-cell level viability assessment, 
and an absolute cell count ‘denominator’, would help resolve some of these 
uncertainties.  
 
4.3 Flow cytometry & the live/dead 
discrimination of microbes 
The potential of flow cytometry (FCM) to advance microbiology has been heralded by 
many, largely for two reasons. First, FCM characterises individual cells, and therefore 
may reveal phenotypic heterogeneity across microbial populations. Second, this single-
cell analysis can occur without prior culture amplification, potentially avoiding biases 
introduced by this manipulation of the microbes under study. However, despite this 
anticipation, FCM has not yet been widely adopted in microbiology, and there are 
several difficulties associated with flow cytometry of prokaryotes.  
4.3.1 Technical challenges of bacterial FCM 
4.3.1.1 Size, sensitivity and specificity 
Mammalian cells typically examined by FCM are about 1000-fold larger than typical 
bacterial cells,‡‡‡‡‡‡ and flow cytometer hardware parameters (such as acceptable 
levels of stray light, and size of sheath fluid core) are calibrated to measure eukaryotes, 
not prokaryotes.435 Therefore, FCM detection of bacteria is relatively insensitive. It 
also means FCM signals from bacterial cells, e.g. light scatter, readily overlap with 
‘background’ signals such as electronic noise and/or physical artefacts such as bubbles 
and micelles found even in 0.22µm filtered media and buffers.436  
                                                             
‡‡‡‡‡‡ Assuming E. coli width and height 0.5 and 2 µm and approximately cylindrical shape, 
gives volume, V = π(0.5/2)2*2 = 0.4 µm3; assuming diameter 12µm and approximately 
spherical shape for a large human lymphocyte, gives volume, V = 4/3 π(12/2)3 =  900 µm3 
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This sensitivity and specificity problem is the primary challenge in bacterial FCM, and 
several strategies have been suggested to overcome it. Firstly, dual-thresholding – 
using two FCM signals, e.g. forward and side scatter, as a composite threshold / 
trigger-channel for recording events§§§§§§ – is recommended, along with extensive 
empirical determination of cut-off values for a specific experiment’s conditions.437,438 
Second, it is preferable that a fluorescence signal from a nucleic acid stain be used as 
one of the dual threshold signals, instead of the two light scatter signals.436,438 Third, 
given the smaller volume, surface area, protein or nucleic acid content of prokaryotes, 
very bright dyes are required.438,439 Fourth, because saturation of data acquisition 
capacity can occur, and duration of laser excitation can increase fluorescence or 
decrease it through bleaching, the flow rate and cell density of the FCM sample must 
be optimised to the specific experiment.435,437,438,440  
4.3.1.2 Cell clumping 
Many bacteria clump during liquid culture in suspended biofilms or microcolonies,441 a 
specific problem for single-cell FCM analysis, but also a general problem for any 
bacterial quantification method. Bacteria can also form exopolysaccharides in response 
to common fixation procedures which results in further agglutination.436 
Disaggregation strategies include chemical and physical processes. For mycobacteria, 
high concentrations of the detergent Tween80 have been used in media along with 
continuous agitation during culture.442,443 Vortexing, sonication or repeated needle 
passage (e.g. through a micro-emulsifying needle) have also been used.444-447 
4.3.1.3 Unpredictable response to fluorescent staining 
Bacterial species have greater physiological and genomic diversity than mammalian 
cells, and dyes which reliably stain one bacteria may show different and unpredictable 
uptake or efflux. Early proponents of bacterial flow cytometry were surprised to find 
that DNA staining by a given dye varied between closely related species, and that 
chemically similar dyes gave unpredictable results within the same species.435,448 More 
recently, it was shown that membrane integrity, as measured by ‘cell impermeant’ 
nucleic acid stains (described in detail below), could vary depending on growth stage of 
a batch culture, with this variability in turn being species dependent.449 Therefore, 
                                                             
§§§§§§ The concept of thresholding is described in more detail in section 4.8 for readers 
unfamiliar with flow cytometry jargon. 
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while commercial staining kits for bacterial FCM exist, testing and calibration to 
specific species and experimental conditions is required.  
4.3.2 Live/Dead discrimination of bacteria by fluorescence staining 
For some dyes the degree to which their fluorescence associates with a cell depends on 
a specific structural or physiological attribute of that cell. Functional status can 
therefore be probed by these fluorescent stains, and this information used to define 
bacteria as alive or dead. Examples of functional parameters probed by these dyes are 
described below. 
4.3.2.1 Membrane integrity 
It is argued that an intact cell membrane is necessary condition for a bacterium to be 
considered living. An incompetent membrane can be detected when a cell exhibits 
fluorescence from a dye normally excluded by an intact membrane. These ‘dye 
exclusion tests’ often use a molecule which increases fluorescence when bound to an 
intracellular component such as nucleic acid; this improves signal to noise ratio, and 
can remove the need for a wash step to remove extracellular dye. Accuracy of the 
membrane integrity signal can be further improved with normalisation against a second 
concomitant dye which stains cells irrespective of membrane integrity.  
This is the basis for several commercially available bacterial FCM staining kits, such as 
BD Biosciences’ Cell Viability Kit450 and ThermoFisher’s LIVE/DEAD® BacLight™ 
Bacterial Viability Kit,451 both of which use the cell impermeant red nucleic acid stain 
propidium iodide (PI) to detect membrane incompetence, and a secondary cell 
permeant green fluorescence stain (thiazole orange or SYTO-green  respectively): 
dead bacteria are purported to have a high red to green fluorescence ratio – revealed as 
a discrete population on a red against green fluorescence scatter plot.  
Despite the commercial kits’ resounding names, there are multiple warnings in the 
literature against a simplistic live/dead inference based on PI staining of bacteria.  As 
mentioned above, some species show high PI uptake during early exponential growth, 
and are still able to form colonies despite PI positivity during cell sorting.449 Other 
conditions – including sonication – have also been found to cause temporary PI 
permeability.452 Micrococcus luteus cultures rendered PI positive and unable to form 
colonies by prolonged starvation may be resuscitated under specific conditions.453 
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Even if a (PI impermeable) intact cell membrane is a necessary condition for a bacterial 
viability, it may not be a sufficient one, if dead cells can still have intact membranes. 
Bacteria inactivated by ultraviolet radiation provide a model example of cells with 
intact membranes which are found to be non-viable by any other measure.454  
Further, it has been pointed out that any bacterial killing which aggressively damages 
nucleic acids may give a weak fluorescent signal as the dye target site is degraded along 
with the membrane.455,456 Generalising this observation, the temporal mechanisms of 
cell death will likely influence dye exclusion tests such as PI positivity. For example, 
from the point of view of a dye exclusion test, bacterial killing via non-membrane 
targets ultimately leading to rapid lysis and disappearance of the cell would look very 
different to bacterial killing through progressive cell membrane damage, even when 
both killing mechanisms were equally effective. This implies that serial observations 
and absolute cell counts (i.e. a total cell denominator) could be useful for unbiased 
assessment of bacterial killing by fluorescent staining methods. 
The secondary dye common to commercial bacterial viability staining kits, intended to 
stain both live and dead cells, could facilitate absolute counts. This hinges on the 
ability of the secondary dye to reliably penetrate intact membranes, and again this is 
shown to be dependent on species and conditions. Langsrud & Sundheim found that 
SYTO-9 reliably penetrated Staphylococcus Aureus but not ~30% of pseudomonas 
species tested, resulting in poor correlation between live/dead counts and CFU 
counts, but also found that the alternative dye SYTOX-green reliably penetrated all 
the pseudomonas species tested.457 Again the emphasis here is that dyes behave 
differently in different species of bacteria. 
Finally, while PI is the most common fluorescent dye for bacterial dye exclusion 
testing, several others exist. Predictably this adds a further dynamic to the 
interpretation of membrane function as a viability indicator: in head-to-head 
comparisons different membrane exclusion probes are taken up by different 
proportions of bacteria under the same controlled conditions.458 Some authors have 
suggested that “the magnitude of membrane damage can be measured with the use of 
different [membrane integrity probe] dyes, but conclusive information in this regard is 
still required”.459  
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4.3.2.2 Enzyme activity 
Esterases with broad substrate activity are ubiquitous in the cytoplasm of bacteria.460 
Esters which are lipophilic, non-polar, and non-fluorescent, but become charged and 
fluorescent on hydrolysis by these bacterial ‘house-keeping’ esterases, can function as 
fluorescent probes of enzyme activity or metabolic competence. Examples of such dyes 
include fluorescein diacetate (FDA) and calcein-AM. 
While esterase activity may correlate with concentration of ATP in microbial 
samples,461 the actual hydrolysis reaction is not energy dependent, so is not a direct 
assessment of vitality.462 Cells with damaged membranes may even display higher 
ester-dye cleavage, presumably because of better transport of the dye into the cell 
which still has intact enzymes.463 Conversely, ‘dormant’ cells may have low esterase 
activity but still be culturable.464 Therefore, interpretation of FDA or calcein-AM 
fluorescence probably requires a trend rather than a single time point. 
4.3.2.3 Other methods 
Maintenance of membrane potential, which drives ATP synthesis, active transport of 
ions, and homeostasis of the intracellular environment, is a requirement for cell 
viability. Uptake of some charged dye molecules is also dependent on membrane 
potential (cationic dyes can accumulate in polarised cells, anionic dyes can accumulate 
in depolarised cells).437,464,465 Use of these dyes is technically challenging because outer 
membranes may have to be permeabilised to test the membrane potential of the inner 
membrane, and these dyes are fluorescent irrespective of location so may require wash 
steps and specific additives to define negative controls.437,464,465 Further, the 
mechanism of cell death would in theory impact on the time-dependence of observed 
changes in membrane potential.464 
4.4 Conceptualising cell viability & death 
in bacteria 
It is clear from the above review that defining bacterial viability or death is not 
straightforward. Consequently, several authors have proposed conceptualising a 
continuous spectrum of cell states between alive and dead, “perhaps defining one or 
more pathways by which [bacilli] are eliminated [in an] experimental system or 
host”.466 Two examples schematics are reproduced in figure 2.  The final determining 
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events in bacterial cell death – the “points of no return” on the different measurable 
dimensions of cell viability – are unknown. 
 
Figure 4-2. Continuous spectrum of live/dead cell states of bacteria. 
A. Ability to probe more microbial cell characteristics than just CFU formation means cells can 
be classified into more subpopulations than just “live” and “dead”. The route from live to 
dead can therefore be thought of to contain several steps, not all of which may occur in all 
cases. Reproduced from Davey 2011.467 B. Probes of cell state represented on 3 axes. The lower 
plot shows one of many possible pathways to death for mycobacteria. Reproduced from Davies 
2015.466 
 
 
4.5 Flow cytometry of mycobacteria 
Several reports of the use of flow cytometry to quantify viability of mycobacteria have 
been published (table 1). To summarise: 
• Previously used fluorescent stains include nucleic acid binding dyes (SYTOX-
green, SYTO-9, SYTO-BC, SYTO-16, SYBER-green I, propidium iodide, TO-
PRO-3 iodide, auramine-O) either to probe membrane integrity or in an attempt to 
stain all cells; esterase substrate dyes (fluorescein diacetate, calcein-violet); and 
membrane potential probes (diethyloxacarbocyanine iodide, rhodamine-123).  
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• Few studies have reported methods or justification for how bacilli have been 
separated from noise, i.e. how sensitivity and specificity have been optimised. 
Those that do have mostly used side and forward light scatter (SSC & FSC) to set 
thresholds/trigger levels, voltages, and gates to define what is a bacillus, along 
with a variety of negative controls and positive controls (e.g. beads) to assist with 
gating.   
• With only one exception,444 absolute bacilli counts have not been derived from 
FCM, instead batch measures of fluorescence (e.g. mean fluorescence signal), 
qualitative results (e.g. scatter-plots), or percentages are reported. No 
comparisons of flow counts to CFU exist. 
• Growth conditions, processing (e.g. washes and fixation), staining protocols, vary 
widely. In the few cases where the same stains have been used by different groups, 
results are contradictory; for example propidium iodide is reported to stain 0% of 
heat killed M. tuberculosis by one study,468 and 100% by another.469 
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Table 4-1. Flow cytometry of mycobacteria: prior literature. 
Ref 
Myco-
bacteria 
Purpose of the 
cytometry 
Stain Incubation Output 
Permeablisation, wash, 
fixation etc 
Flow parameters 
Hendon-
Dunn, 
2016.443 
H37Rv 
Develop rapid FCM 
tool for determining 
antibiotic activity 
against M.tb 
Calcein 
violet 
AM                         
SYTOX-
green 
60 min at 
RT 
%s in four populations 
defined by Calcein violet 
and SYTOX-green 
staining, across serial 
time points and 
concentrations of 
antimicrobials 
After staining, 2885g 
2min, resuspended in 
HBSS with 4% 
formaldehyde v/v 30min 
fixation time for sterility. 
Unstained controls used to set SSC FSC 
defined gate on 'bacteria'. Voltages in SG 
and CV-AM channels set such that 
unstained events were all in the first 
order of log scale histogram, all samples 
analysed on these settings. 
Hammond
, 2015.470 
M. 
smegmatis, 
marinum, 
fortuitum, 
bovis 
(BCG) 
To measure the 
proportion of lipid 
body +ve cells in in 
vitro cultures 
Nile red 
20min at 
RT, with 
agitation 
%s Nile red +ve and -ve 
over time points 
They probably washed 
with 100% ethanol, and 
then PBS 
Unknown 
Gonzalez, 
2012.471 
M. 
smegmatis 
mc2 155 
Defining growth 
curves  
SYTO 9; 
PI; 
SYTO 
BC       
25min RT Unclear 
None (not specifically 
mentioned) 
FSC and SSC "used to discriminate 
bacteria from background" 
Soejima, 
2009. 469 
H37Ra 
Live dead 
discrimination, 
method development 
SYTO9 
and PI 
unknown Unclear Unknown Unclear 
Qin, 
2008.472 
H37Ra 
Detection of M.tb in 
clinical specimens 
(spiked urine). 
Anti-
MTB 
conjugate
fluoresec
ent silica 
nanoparti
cles and 
1 h at 37oC 
for the 
conjugated 
nanoparticl
es, then 
15min RT 
for the 
Absolute counts are 
shown, but unclear how 
they were derived. 
None Unclear 
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SYBR 
green I 
SYBR-
green 
Shapiro, 
2008. 473 
M. 
smegmatis 
SOP for live dead 
discrimination with 
DiOC2(3) 
DiOC2(3
)                                               
TO-PRO-
3 iodide 
5 min at RT Qualitative plots  None 
FSC and SSC as trigger signal +/- 
'software gate' to exclude noise/debris. 
Detailed normalisation of signals to 
adjust for cell size. 
Shi, 
2007.449 
M. 
frederiksber
gense 
Comparing different 
markers of 
proliferation/viability 
PI; 
diOC6(3)
; Hoechst 
33342 
diCO6(3): 4 
min at 20oC       
PI: 10 min 
at 20oC                
Hoechst: 
45min at 
20oC 
% PI positive and 
diCO6(3) positive. 
Proportions with 
different chromosome 
numbers as a marker of 
physiological / growth 
state. 
Various wash steps; no 
fixation/permeabilisation. 
FSC and SSC "trigger signal for first 
observation point", amplification on 
linear or log scale dep on application. 
Beads and internal DAPI stained 
bacterial controls for alignment of FCM, 
max CV value 6%.  
Fredricks, 
2006.474 
35 clinical 
M.tb 
isolates; M 
bovis BCG. 
DST unknown unknown 
Aggregate measures only 
(no single cell counts) 
paraformaldehyde to final 
concentration of 1.4% 
Unclear 
DeCoster, 
2005. 475 
M.tb 
clinical 
isolates 
DST FDA 37oC 30min 
Ratios of mean 
fluoresence channel (cf 
controls) - summary 
measures, no true single 
cell data. 
None Unclear 
Akselband, 
2005. 447 
M.tb, M. 
bovis 
(BCG), M. 
avium 
DST 
Auramine
-O 
Cellswere 
incubated 
inside gel 
microdrops 
Aggregate measures only 
(no single cell counts) 
Washing and fixation 
carried out - all inside 
microdrops 
Light scatter thresholding to exclude 
'majority of unoccupied microdrops', a 
gate on remaining microdrop population 
applied before FL1 analysis. Time 0 
sample used to set voltage. 
Reis, 2004. 
476 
M.tb 
isolates 
DST FDA 
Norden 
method 
Aggregate measures only 
(no single cell counts) 
formaldehyde to final 
concentration 10% for 1 h 
Unclear 
Govender, 
2010. 477 
13 MDR-
TB 
DST 
SYTO16;  
PI 
SYTO16 
[10uM] 
Aggregate measures only 
(no single cell counts) 
Pellet resuspended in 250 
µl Isoflow sheath fluid. 
Unclear 
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isolates 
plus 
H37Rv 
30min; PI 
[20 µg/ml] 
for 60 min 
Vortex, needle 
emuslification. 
Burdz, 
2003. 478 
H37Ra 
and 
various 
respiratory 
tract 
bacteria 
Live / dead 
discrimination, 
testing sputum 
decontamination 
methods 
SYTO 9 
and PI; 
SYTO 
BC plus 
microsph
ere 
standard       
"as per 
manufactur
er 
instructions
" 
Absolute counts are 
made, but the data 
presented are the 'log-
kill' which is baseline log 
count - log count post 
decontamination… 
Multiple wash steps. Unclear 
James, 
2000. 442 
H37Rv 
Characterisation of 
the light scatter 
properties of 
continuously 
cultured M.tb 
None n/a Qualitative plots  
None (not specifically 
mentioned) 
Minimal detail 
Piuri, 
2009. 479 
M. 
smegmatis, 
M.tb 
MC(2)623
0 
DST 
In house 
fluoromy
ccobacter
iophages 
variable Qualitative plots  2% paraformaldehyde Minimal detail 
Norden, 
1995. 480 
H37Ra DST 
FDA 
250ng/m
L final 
conc 
30min at 
37oC 
Mean channel 
fluoresecnce and 'events 
per second' - but not 
validated as an absolute 
count 
Foramlin fixation 
"Initially, viable and heat-killed... 
differentiated from 7H9 particles by 
using FDA fuorescence. Live gating was 
performed ... during data acquisition to 
exclude all 7H9 particles" 
Bownds, 
1996. 481 
M. avium,  
fortuitum, 
gordonae, 
marinum  
DST 
FDA 
100ng/m
L final 
conc 
30min at 
37oC 
See Norden 1995 
method 
None See Norden 1995 method 
Kirk, 
1998. 482 
M. tb 
clinical 
isolates 
DST 
FDA 
250ng/m
30min at 
37oC 
Aggregate measures only 
(no single cell counts) 
None 
"M. tuberculosis cells were detected and 
differentiated from non-Mtb particles by 
FSC and SSC… background events and 
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L final 
conc 
electronoc noise eliminated by 
thresholding" 
Moore, 
1999. 483 
M.tb 
clinical 
isolates 
DST None n/a 
Same as Vena 2000 / 
based on Norden 1995 
~1% paraformaldehyde 
for 40 min 
Based on Norden 1995 
Vena, 
2000. 484 
MAC DST None n/a 
A ratio of events per unit 
time for condition versus 
control is given, but no 
validation of these as 
absolute counts 
200uL culture added to 
200uL PBS + 
paraformaldehyde (-
>final conc 1%), 
45minutes. 
"Electronic noise and background 
particles in the 7H9 medium excluded... 
by adjusting the threshold monitor listed 
on the WinBryte software program... [on 
FSC & SSC]" 
Ibrahim, 
1997. 485 
MAC 
Investigating growth 
cycle, including 
effects of isoniazid 
SYTO16 
Overnight 
at RT 
Essentially qualitative 
Pellet resuspended in ice-
cold 70% ethanol through 
a 24-gauge needle; stored 
at – 20oC. Washed 
filtered distilled water. 
Unclear 
Ryan, 
1995. 486 
M. bovis, 
M 
smegmatis 
DST 
Auramine
-O                                             
PI 
See 
Akselband
2005 
See Akselband 2005 See Akselband 2005 See Akselband 2005 
Yi, 1998. 
487 
M. tb 
Detection of M.tb in 
clinical specimens. 
Fluorosce
ine 
labelled 
Ab 
Variable 
Aggregate measures only 
(no single cell counts) 
Multiple wash steps Unclear 
Resnick, 
1985. 488 
M. 
smegmatis 
To detect changes in 
membrane potential 
Rhodami
ne 123 
60min (?at 
37oC) 
Aggregate measures only 
(no single cell counts) 
Washed twice in PBS Unclear 
Scott, 
2011.444 * 
M.tb 
Enumeration as part 
of GXP EQA pilot 
study 
Auromin
e O 
None: 
"immediatel
y analysed" 
Absolute counts from 
FCM 
All cultures inactivated 
by resuspension in 
PBS/GXP sample 
reagent mix for 2h; this 
then washed twice in 
PBS. 
Used 1uM beads to initially set light 
scatter thresholds and amp gains. Side 
scatter used to threshold flow on bacilli. 
FL1/SSC gating to define final bacilli 
population for counting. 
Studies identified by search PUBMED (mycobacter* AND cytometry)ALL FIELDS , plus references screen 
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* Flow cytometry method obtained by personal communication as not detailed in publication.  
M.tb = M. tuberculosis.  DST = Drug sensitivity testing. GXP = GeneXpert. EQA = External Quality Assurance. PI = propridium iodide. SYTO, SYTO , 
SYTOX are proprietry dye names. FDA = fluorescein diacetate. DiOC = diethyloxacarbocyanine iodide. RT = room temperature. FSC = forward 
scatter. SSC = side scatter. FL1 = fluorescence channel 1. Ab = antibody. CV = coefficient of variation. +ve = positive. -ve = negative. 
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Studies which have explicitly used flow cytometry to study ‘viable non-culturable’, or 
‘differentially culturable’ bacilli are rare. The leading example is a study by Hendon-
Dunn et al. which aimed to assess antibiotic effects against the whole population of M. 
tuberculosis in a broth culture rather than “just those bacteria that can grow in media 
post-exposure”.443  
It is worth reviewing the methodology and results of this seminal work in detail. H37Rv 
was grown in continuous culture using a chemostat system; the esterase substrate dye 
Calcein violet AM (CV-AM), and the membrane integrity probe SYTOX-green were 
used for flow cytometry. Signal thresholding / voltage manipulation strategy to define 
flow events as cells used unstained control samples to set a population gate around 
bacteria using FSC and SSC; voltages in the fluorescence channels were then adjusted 
so that histograms of unstained bacteria were contained in first order of log scale for 
fluorescence. Dual-staining of a variety of controls were used to define 4 functional 
subpopulations (P1 to P4) on CV-AM versus SYTOX-green fluorescence flow plots: 
• P1: CV-AM negative / SYTOX-green negative; gate set so >95% of unstained 
control cells were within P1. 
• P2: CV-AM positive / SYTOX-green negative; antibiotic free controls which were 
dual stained or CV-AM only; gate set on SYTOX-green so that all cells in antibiotic 
free controls were SYTOX-green negative, and so that CV-AM negative (as per P1) 
cells excluded.  
• P3: CV-AM positive / SYTOX-green positive; events which did not fall in any of 
the other 3 gates. 
• P4: CV-AM negative / SYTOX-green positive; heat-killed dual and SYTOX-green 
only stained; gate set so 100% of heat-killed cells were CV-AM negative, and so that 
SYTOX-green negative (as per P1) events excluded. 
P2 was interpreted as “live” cells; P4 as “dead cells. P3 was interpreted as cells which 
were damaged but still producing esterases. P1 was not normatively interpreted. The 
primary outputs for the analysis were percentages of events in each population by time 
and antibiotic condition (i.e. time-kill curves). As per the population definitions, almost 
100% of cells at time 0 in the time-kill curves were in P2. Over a 4-day time course, 
isoniazid at higher concentrations had profound depletion of %P2, with reciprocal rises 
in P3 and P4, e.g. at 8ug/ml by day 3 ~20% were P3, ~60% were P4, and only ~20% 
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remained in P2. Maximal effects of rifampicin in 4-day time-kill were less marked; e.g. at 
8ug/ml by day 3 ~20% were P3, ~20% were P4, and ~60% remained in P2. In follow-up 
experiments rifampicin did show time dependent and post-antibiotic effects unobserved 
by the 4-day time-kill. Also of note, and not discussed in the manuscript, is that the 
proportion of cells in P1 was consistently higher for rifampicin than isoniazid at all time 
points: up to a maximum of ~20% at rifampicin 0.128 to 32 ug/ml after 24hours 
exposure. This seems important, because if rifampicin kills bacilli through a route 
without a marked SYTOX-green positive phase, this killing wouldn’t be observed in P3 
or P4. The absence of a total cell denominator might bias the “percentages” in the plots: 
what if rifampicin caused cells to disintegrate more rapidly than isoniazid? This would 
render proportions observed in remaining cells hard to interpret. Indeed, Hendon-Dunn 
et al. also showed that their dual stained fluorescent profiles could differentiate 
antimicrobials by mechanism of action. An early (day-2) peak in %P3 followed by marked 
peak in %P4 was characteristic of cell-wall active compounds (isoniazid and a 
benzothiazinone), while intracellular acting (rifampicin, kanamycin and ciprofloxacin) 
had less dramatic rises in P3 and P4, but more marked increases in P1. Other important 
findings included that the mean CV-AM fluorescence of cells grown in continuous 
chemostat culture depended on growth rate, and that, while parallel CFU counts in the 
time-kill curves showed similar trends, there was a “lack of correlation” such that “flow 
cytometry analysis potentially captured information about cell populations that were 
unable to grow under standard conditions”.443 
 
4.6 Aims of current analysis 
1) To develop and validate a method of absolute counting of mycobacteria in vitro using 
FCM. 
2) Explore use of fluorescent dyes as probes of cell function to define subpopulations of 
bacilli in different physiological states. 
3) To compare this FCM method to CFU counts and optical density measures, both in 
normal broth cultures and in the presence of antimicrobials. 
4) To produce antimicrobial time-kill curves using these absolute counts and compare the 
dynamics of subpopulations defined by the different assays. 
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4.7 General methods 
To avoid repetition, the following methods apply to the experiments described in 
subsequent sections unless otherwise stated. 
4.7.1 Flow cytometer 
The majority of flow cytometry was carried-out on a BD Accuri C6™, a benchtop flow 
cytometer equipped with forward and side scatter detectors and four fluorescence 
detectors (FL1, 533/30 nm; FL2, 585/40 nm; FL3, > 670 nm; FL4, 675/25 nm) with 
fixed alignment and pre-optimised detector settings, and a non-pressurized fluidics 
system, and two lasers (488nm and 640nm). Data acquisition used BD Accuri C6™ 
software. Because the fluidics system uses a peristaltic pump mechanism, volume of 
sample processed can be derived directly. This volume, and the optical performance of 
the instrument, was regularly quality assured using fluorescent beads as per 
manufacturer protocol. Manual and extended cleaning cycles were performed at the 
beginning and end of each flow cytometry session with verification of low event rate in 
filtered PBS before each run. 
4.7.2 Broth culture conditions 
All broth was made using Middlebrook 7H9 media (211887 BD Diagnostics) and 
0.22um filtered deionized water according to manufacturer instructions. This was 
supplemented with 10% v/v Middlebrook OADC (212240 BD Diagnostics), 0.2% v/v 
glycerol and 0.15% v/v Tween 80 (lab stock). All broth was autoclaved prior to 
supplementation, and 0.22um filtered prior to use. 
Cultures were at 37oC in the dark with 150-200rpm agitation in 50ml sterile 
polyethylene conical flasks.  
4.7.3 CFU plating 
Middlebrook 7H10 (262710 BD Diagnostics) agar was prepared with 0.22um filtered 
deionized water according to manufacturer instructions, with v/v 0.5% glycerol added 
before autoclave sterilisation. When cooled to 45oC, v/v 10% ADC supplement was 
added and tri-segmented plates poured to depth 5mm.  
For CFU counting, 10-fold serial dilutions of samples were prepared in 96-well plates 
using 0.22um filtered 0.15% v/v Tween 80 sterile PBS. Each segment of a plate was 
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inoculated with 50uL of serial dilutions and spread using disposable, sterile loop 
spreaders. These were allowed to dry in a class-2 bio-safety cabinet for up to 2 hours 
before being incubated upside-down in double containment with polyethylene bags and 
boxes. CFU counts were performed with 3-fold technical replicates and counts averaged 
unless otherwise stated. Colony counts between 1 and 100 per segment were accepted 
and averages across dilutions were made where available (after adjustment for dilution). 
Counts were performed on 3 occasions (14, 21, and 28 days) to allow colonies to be 
counted before overgrowth. 
4.7.4 Antibiotic preparations 
 Primary stock dilutions of antibiotic powders (kindly donated by Professor Digby 
Warner) were made in 100% DMSO and frozen at-20oC wrapped in tinfoil. Fresh 
working dilutions were prepared in PBS prior to each experiment, 0.22nm filtered, and 
stored wrapped in tin foil at 2-5oC refrigeration.  
4.7.5 Screening fluorescent dyes for use in mycobacteria 
All fluorescent stains reported in prior literature to probe mycobacterial cell physiology 
and compatible with the excitation and emission ranges obtainable on the Accuri C6 
instrument were tested, including: 
• Fluorescein diacetate (FDA)  
• Calcein-AM (in lieu of calcein-violet which has emission and excitation spectra 
outwith the Accuri C6 range) 
• SYTOX-red 
• Acridine orange 
• Rhodamine 123 
• Baclight membrane potential kit (DiOC2(3)) 
In addition, stains not previously reported for use in mycobacteria were tested, 
including: 
• TOPRO-3 iodide 
• Live/Dead Fixable far red 
• SYBR-gold 
SYBR-gold has not, to my knowledge, been used for flow cytometry of any cell, or for 
physiology probing, but was tested because of its high sensitivity for fluorescent 
microscopy of mycobacteria (discussed in previous section).  
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All dyes were tested at a range of concentrations and incubation conditions, on live and 
heat-killed mid-log phase BCG at different ratios. Examples of flow plots from some of 
these tests are shown in figure 3. 
 
Figure 4-3. Example test runs of nine different fluorescent dyes on BCG broth 
cultures. 
For each dye, a fluorescence versus light-scatter plot is shown for 100% live mid-log phase M. 
bovis BCG (first column), 100% heat-killed bacilli from the same culture (third column) or a 
50/50 mix of the live and heat-killed (middle column). Only one specific iteration of processing 
conditions is shown for each (summarised in adjoining text), but a minimum of 50 different 
concentration/incubation parameters were tested for every dye. 
 
Dyes which showed the most consistent performance after optimisation were calcein-
AM and SYBR-gold. Of note, SYBR-gold showed extremely bright staining of cells, with 
mean FL1 fluorescence in heat-killed samples being approximately 1000-fold greater 
than unstained cell controls or stained cell-free broth controls. In addition, near perfect 
linearity of FCM counts across mixtures of live and heat-killed bacilli preparations were 
seen after SYBR-gold staining, such that, for example, SYBR-gold positive cell 
concentrations in 50/50 live dead mix preparations were always close to half those of 
100% heat-killed samples (figure 4). Like many commercial “live/dead” discrimination 
dyes which are excluded from cells with intact membranes, SYBR-gold fluoresces only 
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when bound to intracellular nucleic acid. The results are in keeping with SYBR-gold also 
acting as a membrane permeability probe, but in the current work it was found to give 
more reproducible results than any of the commercial membrane impermeant dyes 
tested (and is substantially cheaper).  
 
 
Figure 4-4. Linearity of SYBR-gold bacilli counts across different live / heat-killed 
cell preparation mixes. 
A mid-log phase 7H9/OADC broth culture of M. bovis BCG was split into two samples; one was 
heat killed at 65oC for 12 minutes. The two samples (“live” and “heat killed”) were mixed in 
the ratios shown before staining with SYBR-gold followed by FCM counting. 
 
 
Final, optimised, SOPs for calcein-AM and SYBR-gold staining of bacilli were: 
Calcein-AM 
1. Fresh 50μg vials (ThermoFisher, C3100MP) reconstituted in 50μL of DMSO daily 
for each experiment, further diluted to 200μL with PBS for “working stock”. 
2. 6μL of working stock added per 100μL of sample to be stained, with pipette mixing. 
3. Incubated in the dark at room temperature for 45-60 minutes before resuspension of 
bacilli with pipetting. 
4. Fluorescence remains stable for up to 2.5 hours (in dark). 
SYBR-gold 
1. Propriety stock is of unknown concentration (sold already in solution, ThermoFisher, S-
11494). Diluted 1000-fold in PBS, aliquoted and frozen at -20oC until use. After 
thawing further dilution (to 10-4) in PBS.  
2. 6μL of working stock added per 100μL of sample to be stained, with pipette mixing. 
3. Incubated in the dark at room temperature for 45-60 minutes before resuspension of 
bacilli with pipetting. 
4. Fluorescence remains stable for at least 24 hours (in dark). 
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4.8 Validation of thresholding and gating 
strategy for absolute cell counts 
All flow cytometers measure light signals (forward or side scattered light, or light 
passing through a specific wavelength filter corresponding to a specific fluorescence) 
generated by laser excitation of particles passing through a chamber with precisely 
controlled fluidics. Photodetectors convert these light signals (i.e. photons) into 
electronic signals (i.e. electrons). The voltage and amplification (gain) applied to this 
conversion of photons to electrons control how the electronic signal varies as a function 
of the light signal, but, within a given range, a brighter light signal results in a larger 
electronic signal. An analogue-to-digital converter (ADC) bins this (continuous) signal 
into a discrete ‘channel’ for data recording; what range of light signal a given channel 
represents depends in turn on the voltage and gain applied in the detector. A 
“threshold” is an electronic mechanism which causes the ADC to ‘ignore’ signals less 
than a specified value. Typically, this threshold is set on FSC, with the purpose of 
eliminating noise (e.g. physical debris and electronic noise) from data acquisition. The 
aim is to exclude noise without inadvertent exclusion of ‘real’ events of interest (i.e. 
cells). 
The Accuri C6 flow cytometer has a fixed dynamic range for voltage and gain, but allows 
thresholding on up to two signal values; these can be light scatter and/or fluorescence 
channels. The default threshold setting is FSC > 80,000, but any combination of two 
signals can be set as threshold for data acquisition by the user (for example, FSC 
>20,000 and SSC > 1000; or SSC>2000 and FL1>10,000 etc.).  
An important principle is that setting a lower threshold does not simply increase 
sensitivity and decrease specificity for ‘real’ events: there is an absolute limit to the 
number of events that can be registered and recorded by the photodetector and ADC in 
a given time period (equivalent to a refractory period of a neuron). Therefore, setting 
too low a threshold overwhelms the electronics and some real events are not 
recorded.438 
Optimal thresholding strategy depends on the experiment and has to be determined by 
trial-and-error. As mentioned previously in this chapter, thresholding is particularly 
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difficult and important in flow cytometry of bacteria because of the smaller size of the 
cells compared to eukaryotes.  
For the current work, the effect of thresholding on absolute counts of mycobacteria on 
the Accuri C6 system was investigated extensively. Mid-log phase BCG cultures were 
analysed after 2-fold dilution in 0.15% v/v Tween80 PBS solution. These were 
compared to identical preparation of cell-free 7H9 broth as a negative control. Matrices 
of threshold settings were screened. In each case a gate was set around an apparent 
discrete population of cells on a log(SSC) by log(FSC) plot, with the gate being set to 
maximise difference between the BCG broth and the negative control. The (optimised) 
ratio of events in the negative control to the events in the BCG broth was defined as the 
false discovery rate. The optimal thresholding strategy was defined as the settings which 
maximised the absolute count in the BCG broth gate, and minimised the false discovery 
rate, with the anticipation that these maxima and minima would be reliably modelled 
from the data.  
Several hundred combinations of combined FSC and SSC thresholding were assessed. 
In individual experiments, values which maximised counts were apparent (figure5), but 
false discovery rates were never less than 10%. More crucially, the apparent FSC/SSC 
threshold optima differed across biological replicates (i.e. new broth cultures of the same 
BCG isolate), with the impression that culture at different stages of growth had different 
FSC and SSC distributions (thus moving the optimal threshold level).  
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Figure 4-5. Example screening experiment for optimal SSC & FSC thresholding 
strategy. 
A matrix of threshold values for SSC [rows, SSC > 2000; 5000; 10000; 20000; 40000; 80000] 
and FSC [columns, FSC > 10; 100; 1000; 10000; 20000; 40000; 80000; 120000] tested on the 
same mid-log broth culture of BCG (unstained). In this experiment, the maximum apparent 
count of bacilli was given by threshold SSC>10000, FSC>100, indicated by darkest blue/ “1”. 
Other counts are shown as a proportion of this maximum, for example threshold SSC>2000 / 
FSC>40000 gave a count 93% of the maximum observed count. This shows that lower thresholds 
do not generally result in higher counts. The false discovery rate (events in ‘cell’ gate on a cell-
free negative control divided by cell count in equivalent gate on BCG sample) was above 10% for 
all thresholding conditions in the experiment. When similar matrices were repeated using new 
BCG cultures (biological replicates) the specific optimal threshold values were different. 
 
 
An alternative strategy of thresholding on fluorescence was assessed. Because cells 
stained with SYBR-gold were about 100 to 1000x brighter on FL1 than debris, choosing 
an optimal FL1 threshold value for these cells is straightforward. A thresholding 
strategy based on FL1, in heat-killed, SYBR-gold stained mid-log BCG, consistently 
reduced false discovery rate to <0.5%, while at the same time increasing absolute cell 
counts by more than a logarithm compared to thresholding on light scatter alone on the 
same samples (figure 6). Further, this strategy reduced the coefficient of variation 
between technical replicates, and gave near perfect linearity across serial dilutions of the 
same sample (figure 6). 
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Figure 4-6.  Comparison 3 thresholding strategies in heat killed and SYBR-gold 
stained mid-log phase BCG broth culture. 
A. Example FCM plots for three thresholding strategies (rows) applied to BCG broth culture 
(positive control, column 1) and cell free broth (cell-free negative control, column 2). Counts are 
extracted for the gated population (dashed red line), which is placed to maximise the count and in 
BCG broth and minimise the count in cell-free control. Recorded events in the low light scatter 
value thresholding (top row) are dominated by debris / noise, which can be seen as a dense 
population with low SSC and FSC values in lower left quadrant, equally apparent in the cell-free 
control. Higher light scatter thresholding (second row) excludes these events, but still records a 
substantial portion of higher SSC/FSC noise (seen in cell-free control), and the threshold level 
appears to bisect the ‘real’ cell population, i.e. losing cells from analysis. By contrast the 
thresholding based on fluorescence is qualitatively better, with very few false positive events in 
cell-free control, and a discrete cell population in BCG broth which is not artificially bisected. 
B. Greater internal consistency of the FL1/SSC thresholding strategy, with less error across 
serial dilutions of a BCG culture, is apparent. Quantitative evidence of improved absolute count 
validity includes a lower false discovery rate (FDR, defined as false positive cell count in cell-free 
control divided by paired cell count from broth); lower coefficient of variation (CV, calculated by  
standard deviation/mean from 5 technical replicates, averaged for 3 biological replicates); and 
higher R2 from linear fit across serial dilution series (one biological replicate as shown in figure; 
p<0.001 for F test comparing FL1/SCC to either FSC/SSC strategy) 
   
Thresholding based on fluorescence was therefore adopted for all subsequent 
experiments. This has the important implication that fluorescence negative cells could 
not be observed or counted. This is unusual for readers used to flow cytometry analysis 
of human cells, who expect to see % stain negative and % stain positive populations, 
typically combining one than one stain in the experiment to define multiple 
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subpopulations. Such an analysis will not be presented here. Instead, different 
preparations of the same culture are run in parallel to define subpopulations as follows: 
Table 4-2. Flow Cytometry defined cell populations. 
Cell Population Description 
HK Heat-killed SYBR-
gold stained total cell 
count denominator 
Sample is processed by incubation in water-bath at 60oC for 12 
minutes, followed by addition of SYBR-gold and incubation at 
room temperature for 10 to 60 minutes. This gives a total count of 
intact cells containing nucleic acid, used as a denominator for 
calculating proportions represented by subpopulations. 
Thresholding on SSC and FL1 (SYBR-gold fluorescence)  
CA Calcein-AM 
positive cells 
Live sample stained with calcein-AM incubated in dark for 
60 minutes at room temperature. This gives an esterase 
positive, or metabolically active, cell count, and an esterase 
negative cell count is derived by subtracting from the HK 
total cell count denominator. 
Thresholding on SSC and FL1 (Calcein-AM fluorescence) 
SG SYBR-gold positive 
cells 
Live (not heat-killed) sample stained with SYBR-gold and 
incubated in dark for 60 minutes at room temperature. This 
gives a cell-membrane permeant cell count, and a 
membrane-impermeant cell count is derived by subtracting 
from the HK total cell count denominator. 
Thresholding on SSC and FL1 (SYBR-gold fluorescence) 
 
This has the disadvantage of precluding observation of dual-staining characteristics, but 
the advantage of being able to use two FL1 / green fluorescent dyes, and, crucially, 
reliable absolute cell counts. 
 
4.9 Clumping in mycobacterial cultures 
can be observed and measured with FCM 
In all mycobacterial cultures tested (M. bovis BCG, M. tuberculosis, M. smegmatis), from 
early-log phase onwards a second population of events with higher FSC and SSC 
developed in flow plots (figure 7), becoming the dominant population in mid or late log 
phase. To investigate the nature of these distinct light-scatter populations, events gated 
on the two populations were sorted for downstream microscopy (figure 8 A&B). This 
demonstrated that the higher light-scatter population was composed of clumped cells, 
despite all cultures being grown in detergent (Tween 80 0.1% to 0.25%) and under 
agitation (150 to 200 rpm), and despite sonication prior to flow cytometry (figure 8 C).  
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Figure 4-7. Changing FSC/SSC region of mycobacteria during log-phase growth. 
2d-density plots of FSC v SSC on log scale for a culture of M. bovis BCG grown with v/v 0.15% 
Tween 80 at 180 rpm. Plots are from samples taken at 48, 96, 144, and 192 hours after culture 
was subbed from a log-phase starter culture into warmed broth; the samples are from early, early-
mid, late-mid and late log-phase. Samples were diluted 10-fold or 100-fold (later samples) in 0.25 
v/v Tween 80 PBS and sonicated for 60 seconds prior to flow cytometry. The tail of higher 
SSC&FSC events at 48-hours is seen to resolve into a second subpopulation by 96-hours, which 
continues to expand into a higher SSC&FSC region and become the predominant population by 
end of log-phase. 
 
 
Figure 4-8. Sorting populations of mycobacteria based on light scatter for 
downstream microscopy characterisation. 
A. Accuri C6 flow cytometry plot of mid-log phase culture of M. smegmatis stained with calcein-
AM. Grown in v/v 0.15% Tween 80 7H9 with 150 rpm agitation and diluted 10-fold in v/v 0.15% 
Tween 80 PBS prior to FCM. Data acquisition with threshold SSC>1000 and FL1>1000. Two 
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discrete populations of cellular events are seen one with lower (P1) and one with higher (P2) light 
scatter values. 
B. The same sample run on a Bio Rad S3 cell sorter with voltage and gain set to recreate Accuri 
C6 plot. P1 and P2 were sorted for downstream fluorescence microscopy. 
C. P1 was majority single cells or doublets, and P2 majority clumps. 
 
 
Clumping is a major determinant of total cell and CFU counts and can be limited by 
needle emulsification, but not vortex or sonication (figure 9). Consequently, needle 
emulsification increases both CFU and total FCM cell count of mycobacteria by an 
order of magnitude (over 2-fold in experiments performed for this thesis, figure 9B). 
As noted previously, FCM shows that clumping increases to become the norm during 
normal in vitro ‘planktonic’ growth of mycobacteria. The ability of needle emulsification 
to disrupt these clumps is limited in later stage cultures such that late log-phase cultures 
show extensive clumping despite emulsification (figure 10). Further, average size of 
clumps (approximated by mean FSC value) increases progressively in late stage cultures 
(figure 11), eventually producing clumps visible to the naked-eye. These clumps can be 
broken-up by more aggressive emulsification, but this results in structures which 
resemble debris rather than individual cells on microscopy. M. bovis BCG cultures grown 
in v/v 0.15% Tween 80 under agitation are predominantly clumps before reaching OD600 
of 0.5 and before broth is visibly different to cell-free broth.  
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Figure 4-9. Effect of vortex, sonication, and needle emulsification on FCM 
population and CFU counts. 
Mid-log phase culture of M. smegmatis grown in v/v 0.15% Tween 80 7H9 with 150 rpm agitation 
and diluted 10-fold in v/v 0.15% Tween 80 PBS and stained with calcein-AM prior to FCM on 
Accuri C6. Data acquisition with threshold SSC>1000 and FL1>1000. Samples were processed 
by 60 second vortex, or by 60 second vortex followed by 5-minutes sonication in water bath, or by 
both these methods followed by needle emulsification (12 passes through a double luer-lock 
ended, 25 Gauge, 4-inch, micro-emulsifying needle with a reinforcing bar (Cadence Inc.). 
A. Two discrete populations differentiated by light-scatter are seen: single cells (P1) and clumps 
(P2). Qualitatively, it can be seen that vortex and sonication processing have not disrupted 
clumps, but needle emulsification (far right plot) has shifted predominant P2 (clumps) t 
predominant P1 (single cells). 
B. Emulsification changes apparent cell counts by an order of magnitude; both CFU count and 
total flow cytometry count increased by half to one unit on log scale.The total P2 count doesn’t 
change much: larger clumps are partly replaced by smaller clumps, but the single cell count rises 
by more than 1 logarithm, and this results in the higher CFU / total FCM cell count. 
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Figure 4-10. Clumps not disrupted by emulsification eventually emerge in late log-
phase cultures. 
M. bovis BCG culture in v/v 0.15% Tween 80 7H9 with 150 rpm agitation and diluted 10-fold in v/v 0.15% 
Tween 80 PBS before heat-killed and stained with SYBR-gold. Samples were needle-emulsified (12 passes 
through a double luer-lock ended, 25 Gauge, 4-inch, micro-emulsifying needle) prior to FCM on Accuri 
C6; Data acquisition with threshold SSC>1000 and FL1>1000. Timepoints are days from inoculation into 
warmed broth from log phase starter culture. A long-tail of clumps, extending into the upper-right 
quadrant of higher SSC and FSC, emerges from around day 9, when OD600 was around 0.3. 
 
 
 
Figure 4-11. Quantification of clumping despite emulsification over growth phases. 
Four replicates of the data in figure 10 (i.e. 4 different cultures of BCG processed as per figure 10) had 
clumps and single cells quantified by flow cytometry: clumps defined as events with SSC and FSC values 
greater than a manually applied cut-off (similar to axes in figure 10). Four replicates shown with different 
colours. The ratio of clumps to single cells is suppressed by emulsification until late log-phase (~day 8), 
when both the number and size (approximated by mean FSC) of clumps rise rapidly. Line of best fit with 
95% CI band is a loess-regression line ignoring dependence by replicate. 
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Because preparation of single-cell suspensions is a basic requirement in many 
mycobacterial laboratory experiments, the effectiveness of a gold-standard method for 
single-cell preparation of mycobacteria was tested. This method, published by Saito et 
al., uses low g centrifugation to purportedly pellet clumps leaving single-cells in 
supernatant.489 Using FCM to quantify clumps and single-cells shows that, in fact, the 
ratio of clumps to singles is unaffected by this centrifuge processing (figure 12). 
 
Figure 4-12. Testing Saito 'centrifuge' method for single-cell preparation 
Three mid-log phase M. smegmatis cultures grown with 0.05% Tween80 (3 biological reps), processed 
three ways. Control sample: 10^-1 dilution in PBS/tween80 at 0.1%, no physical disruption. Emulsified 
sample: 10^-1 dilution in PBS/tween80 at 0.1% 12x needle emulsified. Centrifuge sample: 10ml + 5ml 
PBS/tween80 at 0.1%; spun in 15ml centrifuge tubes at 120 G for 8 min with no brake. Supernatant used 
for counts. (Saito et al. PNAS 2017 method). All samples heat-killed and stained with SYBR-gold as 
described previously, with thresholding on SSC and FL1. Three technical reps of each sample (x 3 
biological reps x 3 sample prep conditions  27 data points). A. Qualitatively, the FSC by SSc flow plots 
are similar for centrifuge method and control. B. The ratio of clumps to single cells is the same in the 
control and centrifuge preparations, but as expected much lower and with less variation across replicates 
with emulsification. Apparent cell counts are lower with centrifugation (due to loss of cells in pellet) and 
higher with emulsification (due to disruption of clumps). 
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4.10 Cell-subpopulation dynamics 
during antimicrobial free in vitro 
growth of mycobacteria 
The method development and insights described above resulted in a final FCM 
experimental method which can be used to examine dynamics of mycobacterial cell sub-
populations (figure 13).  Before assessing antimicrobial killing, the dynamics of in vitro 
growth in the absence of antimicrobials was defined for M. bovis BCG.   
 
Figure 4-13. Schematic of final FCM method. 
 
HK denominator counts were always the largest population. During log-phase CA+ and 
CFU counts were closely correlated and accounted for the majority of cells, with SG+ 
being a minority sub-population (figure 14). When entering stationary phase, both CA+ 
and CFU counts slowed more quickly than total cell count, then started to decline, with 
simultaneous rise in SG+ cells, in keeping with cell death (figure 14). Parallel rise in 
OD600 was more sigmoidal on a log scale (figure 15) with minimal detected change in 
OD until mid log-phase. Despite each of the four replicates being cultured in identical 
conditions, and subbed from the same original starter culture, differences in rate and 
maxima were apparent (figure 14 & 15). 
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Figure 4-14. CFU and FCM defined in vitro growth curves of M. bovis BCG. 
Four independent M. bovis BCG cultures in 50ml v/v 0.15% Tween 80 7H9 in 500ml tissue-
culture flasks with 150 rpm agitation (A – D) serially quantified by CFU counts & FCM counts 
between 2 and 15 days after inoculation into warmed broth from log phase starter culture. FCM 
samples diluted 10-fold in v/v 0.15% Tween 80 PBS before data acquisition on Accuri C6, 
threshold SSC>1000 and FL1>1000, and gating to maximise difference from cell-free stained 
broth & unstained cell controls. All samples were needle-emulsified (12 passes through a double 
luer-lock ended, 25 Gauge, 4-inch, micro-emulsifying needle) prior to FCM and CFU count. 
Counts adjusted by dilution factor and volume processed to log10 count per ml of original broth. 
 
 
Figure 4-15. Optical density defined in vitro growth curves of M. bovis BCG. 
Same four cultures (A-D) as shown in figure 14. Optical density measured on bench-top 
spectrometer at 600nm using undiluted samples and broth reference standard in 1ml cuvettes.  
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Figure 4-16. Sub-populations as a proportion of total cell count denominator. 
Same four cultures (A-D) as shown in figure 14. Proportions of total cell count (HK 
denominator) which were CA+ (left) CFU forming (middle) or SG+ (right) shown. Each of the 4 
replicates shown with different colour (A=red, B=green, C=blue, D=pink); line of best fit with 
95% CI band is a loess-regression line ignoring dependence by replicate. 
 
 
 Some subtle differences between CA+ and CFU count are made visible by representing 
counts as proportion of total cell count (i.e. divided by the HK denominator count, 
figure18). Proportion of cells which are CFU forming increases to a maximum at end of 
log-phase / early stationary phase; at this point a significant proportion of CFUs must 
not be CA positive. CFU proportion has a greater dynamic range than CA+ cells. 
Unlike proportion of cells which are CFU forming, proportion CA+ has significant 
correlation with the rate of growth of the whole population of cells, again suggesting that 
CFU forming behaviour is not simply a marker of metabolic activity (figure 19). 
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Figure 4-17. Rate of growth in broth culture correlates with proportion of cells 
CA+, but not proportion CFU positive. 
Rate of population growth was defined as the instantaneous rate of change of the HK total cell 
count (i.e. the slope of the tangent to the curve at a given timepoint). This measure correlated 
with proportion CA+ at this time point (adjusted R2 for model with different intercept by rep = 
0.04; adjusted R2 for same model including proportion CA+ = 0.51; proportion CA+ explains 
47% of variance in growth rate; p=4.7e-07). By contrast, the equivalent model for CFU 
proportion had R2 0.12 (p=0.11). 
 
Despite these differences, CA+ and CFU counts are highly correlated under in vitro 
broth growth conditions, such that CA+ FCM offers a reliable rapid surrogate of CFU 
count, with results in approximately 2 hours rather than 2-3 weeks for M. bovis BCG 
(figure 18).  
 
Figure 4-18. Correlation between CFU and CA+ counts under normal in vitro 
growth conditions. 
Data from experiments shown in figure 14. Line of best fit with 95%CI shown. Greatest residual 
variance is found for late-stage cultures (time since inoculation indicated by colour), so 
correlation would be higher if only log-phase cultures were compared. 
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Optical density, which is often used as a rapid surrogate of CFU count, has only 
moderate linear correlation with CFU on a log-log scale (figure 19), and is instead 
strongly related to the summed FSC of all events in flow cytometry analysis (including 
debris and clumps etc.). Since the distribution of FSC for particles in a broth culture 
depends on the stage of culture (late cultures have more clumps for example), the 
relationship between CFU and OD is actually non-linear, with dependence on culture 
stage and conditions. An OD600 = 1 culture diluted to have OD600 = 0.6, will have a very 
different CFU and cell density to a culture which has just reached OD600 = 0.6.  
 
 
Figure 4-19. Optical density is determined by total biomass in culture, with 
condition dependent correlation with CFU count. 
Data from figure 14 and 15 replotted to examine what determines optical density. OD600 shows 
some linear correlation with CFU count on a log-log plot (panel B), but is more closely correlated 
with total FCM cell count (HK denominator, panel C). When the HK count is weighted by FSC 
(i.e. rather than counting the HK cells, the FSC values of all events are summed – so that a 
‘larger’ FSC event counts for more, and all events including debris are included, rather than just 
cells) gives the strongest correlation with OD (panel D). 
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4.11 In vitro pharmacodynamics of 
mycobacteria by FCM & CFU counts 
Having established growth dynamics of in vitro BCG cultures in the absence of 
antimicrobials, the FCM method was applied to pharmacodynamic time-kill analysis. M. 
bovis BCG grown in 500ml tissue culture flasks containing 0.15% v/v Tween 80 7H9 
medium was grown. When these had reached 200000 CA+ cells per ml density, the 
stock was split into 20ml aliquots in 50ml conical flasks to which antimicrobials were 
added to a range of final concentrations chosen to be multiples of the minimum 
inhibitory concentration (MIC) for that antimicrobial. Samples were immediately drawn 
for CFU counting and FCM counting and the remaining aliquots incubated at 37oC in 
the dark under 180 rpm agitation. Further samples were drawn after 1, 2, 3, and 5 days 
incubation with antimicrobials, giving 5 timepoints to define time-kill curves.  
As per the FCM methods established and validated previously, all samples were needle-
emulsified prior to FCM and CFU counts. FCM samples were diluted 2-fold or 10-fold 
in v/v 0.15% PBS solution. Data acquisition was with FL1>1000 and SSC>1000 
thresholding. Calcein-AM staining, SYBR-gold staining, and heat-killing followed by 
SYBR-gold staining was performed. CFU samples were diluted 2-fold in v/v 0.15% PBS 
solution and needle-emulsified, followed by washes to remove antimicrobials before 
serial dilution and plating. Sample processing method is summarised in figure 20. 
 
Figure 4-20. Sample processing for time-kill experiments. 
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4.11.1 Raw FCM data: qualitative FCM plots & clustering 
Raw FCM data plots from a single replicate are shown for calcein-AM stained bacilli in 
figure 21. All plots show the same volume of sample processed, such that the density of 
events (dots) represents their density in the original sample, comparable across plots. 
All plots from day 0 are therefore nearly identical, but differences emerge in a time and 
concentration dependent manner. The kanamycin plots, for example, show that at the 
lowest concentration (0.5x MIC) a large CA+ population of cells grows over the 5-day 
time course (FL1 on x axes is capturing calcein-AM activity); while at higher 
concentrations of kanamycin, the CA+ population is progressively eliminated, with 
falling numbers and intensity of FL1 events. A similar, but more dramatic, pattern is 
seen for rifampicin plots. Isoniazid and ethambutol, by contrast, are qualitatively 
different. For both these drugs, at all concentrations greater than MIC, FL1 activity has 
increased on day 1, with shifting of the CA+ population to the right of the vertical 
dashed line, followed by a more sudden loss of CA+ cells from day 3. Similar to 
rifampicin versus kanamycin, isoniazid has effects at 0.5xMIc but ethambutol does not.  
Raw FCM data plots from a single replicate are shown for heat-killed SYBR-gold stained 
bacilli in figure 22. These plots are capturing the total cell population in the samples, 
and only one drug concentration is shown (4x MIC) for each antimicrobial. The total 
cell count is seen to be less influenced by antimicrobial action, but there are some 
qualitative differences by antimicrobial class. Rifampicin, and to a lesser extent 
kanamycin, cause a tail of lower FL1 events to develop extending left from the main cell 
bright-FL1 population on the right of the plot.  
All antimicrobials cause a rise in SG+ bacilli (cells with an abnormally permeant 
membrane) over time, but again there are qualitative differences by antimicrobial class 
(figure 23). Isoniazid and ethambutol result in a dense discrete region of SG+ cells, 
which may be disaggregating into two subpopulations, one with approximately double 
the FL1 intensity of the other (seen as two parallel, vertical ‘stripes’ of cells separated 
on the horizontal axis). This phenomenon is explored further in section 4.12. 
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Figure 4-21. Raw data FCM plots for CA+ bacilli by time & antimicrobial  condition 
Five concentrations in multiples of MIC (0.5x, 2x, 4x, 16x, 32x) are shown for four 
antimicrobials (rifampicin, kanamycin, isoniazid, ethambutol) over 5 timepoints (day 0, 1, 2, 3 & 
5) after addition of antimicrobials. Plots are log(SSC) by log(FL1); FL1 captures CA+ 
fluorescence.  
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Figure 4-22. Raw data FCM plots for heat-killed SYBR-gold stained bacilli (HK 
total cell count data) 
Only one concentration (corresponding to 4x MIC) for four antimicrobials is shown at 5 
timepoints (day 0, 1, 2, 3 & 5) after addition of antimicrobials. Plots are log(SSC) by log(FL1); 
FL1 captures SYBR-gold fluorescence, which stains all heat-killed bacilli containing nucleic acid. 
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Figure 4-23. Raw data FCM plots for SYBR-gold stained bacilli (not heat-killed 
prior to staining) 
Only one concentration (corresponding to 4x MIC) for four antimicrobials is shown at 5 
timepoints (day 0, 1, 2, 3 & 5) after addition of antimicrobials. Plots are log(SSC) by log(FL1); 
FL1 captures SYBR-gold fluorescence, which is a probe of membrane integrity in these bacilli 
(which have not been heat-killed). 
 
4.11.2 Classification of FCM events by clustering 
In order to produce time-kill curves, events have to be classified as positive for counting. 
This can be achieved by placing gates on two-dimensional flow plots using FCM 
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software. Alternatively, algorithmic clustering of the events by proximity on FCM 
measures can be used. This has the advantage of being able to use more than two 
dimensions to classify cells, and being more reproducible because it does not require 
user decisions on position of gates. A K-means clustering approach was used to classify 
all FCM events in the time-kill analysis (outlined in figure 24 & 25). 
 
 
Figure 4-24. K-means clustering classification ("gating") of FCM events. 
All FCM data from all antibiotic conditions were combined from one replicate of the time-kill 
experiments, which totalled millions of data points. These are plotted on a single combined plot 
for CA stained (A), HK cells (C) and SG cells (E). FCM measures for these data points – 
including FLI_H, FL1_A, SSC_H, FSC_H, and scaled ratio of FL1 to SSC – were used to 
define a multi-dimensional space in which events were clustered by their proximity in this space. 
For CA stained cells, 4 clusters were specified, and for SG and HK cells 2 clusters were 
specified. The result of this clustering is shown in panel B, D, F (only 1000 randomly selected 
events are shown to avoid over-plotting). This clustering was applied to the total dataset (all 
timepoints and replicates); for CA staining, events in cluster 1 or 2 were classified as CA+; for 
SG and HK, events in cluster 1 were classified as positive. This is equivalent to gating for event 
counting, but requires no user-dependent decisions about gate placement. 
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Figure 4-25. CA+ event clustering applied to new data 
The clustering algorithm from previous figure applied to selected concentrations at day 2 
timepoint from a different replicate of the time-kill experiment. CA+ events (cluster 1 and 2, 
light and dark green) are present in isoniazid (H), ethambutol (E) and no antibiotic control 
(CTRL) conditions, but substantially reduced by kanamycin and rifampicin in a concentration 
dependent manner. The clustering makes this easier to see compared to the raw FCM plots 
shown previously, and allows the CA+ events to be counted based on their clustering. 
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4.11.3 Time-kill curves 
M. bovis BCG quantitative time-kill curves based on CFU count, CA+ count, SG+ count 
and total cell count (HK) are shown in figure 26. CFU, CA and SG as a proportion of 
total cell count are shown in figure 27.  
 
Figure 4-26. Time-kill curves for absolute counts. 
Time-kill curves for ethambutol, isoniazid, kanamycin, and rifiampicin (E, H, K, R), and a no 
antimicrobial control growth curve are shown. All antimicrobials were tested at 0.5, 2, 4, 16, and 
32x MIC; H and K were also tested at 64x MIC; R was also tested at 0.1, 64 and 128x MIC. The 
experiment was performed on three separate occasions with new M. bovis BCG cultures giving 
three replicates of each condition, except the no antimicrobial control which has six replicates. A 
loess regression line is fit to the data to show trend. 
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Figure 4-27. Time-kill curves based on proportions. 
Same data as previous figure, but CA, CFU and SG counts are now represented as proportions of 
the HK total cell count denominator. A loess regression line is fit to the data to show trend. 
 
 
The correlation between CA+ counts and CFU counts seen under nil antimicrobial 
growth conditions is lost when bacilli are exposed to antimicrobials. CFU counts decline 
more rapidly than CA+ counts under all antimicrobial conditions. CFU time-kill curves 
are linear or convex (on log scale) suggesting either mono or bi-exponential elimination; 
CA+ curves have a convex function for R and K, but a concave function for H and E 
where an initial increase in CA+ bacilli is seen around day 1. Overall, CFU forming 
behaviour is lost by many bacilli which are still intact and metabolically active according 
to FCM analysis.  
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SG+ counts rise under all antimicrobial conditions, but the rise is notably steeper and 
earlier for H & E compared to R & K. 
4.11.4 Modelling FCM pharmacodynamics 
Variation between replicates is notable on some plots, for example replicate A had 
overall lower proportion of CA+ events – including in drug free control – and a more 
profound collapse of CA+ counts by day 5, most clearly seen in the isoniazid conditions. 
There is also some variation in the starting inoculum between replicates in keeping with 
technical error. 
To extract summary measures of PD effects as assessed by different population counts, 
the time-kill data was modelled using a linear mixed-effects model, with a fixed effect of 
intercept, and random slopes for antibiotic condition and replicate. The model form 
was: 
log 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 ~ 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡  + (𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡 | 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛)  +  (𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡 | 𝑟𝑒𝑝) 
where random effects are in parentheses. This captures the crossed design (as opposed 
to nested design) where-by each replicate was assessed under each antimicrobial 
condition. This allowed the effect of replicate to be estimated using data across all 
conditions, and the effect of condition to be estimated using data across all replicates 
(using Restricted Maximum Likelihood). The antibiotic condition effect, defined as 
slope gradient for the time-kill curve, was then extracted, independent of replicate 
effect, from the model as a summary PD measure. The R package lme4 was used for this 
modelling.312 
Figures 28 to 31 show CA+ count, CFU count, HK (total-cell) count, & SG+ proportion 
time kill curves respectively. In each, panel A shows the raw data, with a linear 
regression applied to each replicate within each condition. Panel B shows the output – 
predicted counts or proportions – after fitting a linear mixed-effects model. All models 
are for data from day 0 to day 5, except proportion SG+ (figure 31 B) which was 
modelled over day 0 to 3 because data appeared non-linear outside of this range.  
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Figure 4-28. CA+ count time-kill data: raw (A) & modelled (B). 
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Figure 4-29. CFU count time-kill data: raw (A) & modelled (B). 
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Figure 4-30. HK (total-cell) count time-kill data: raw (A) & modelled (B). 
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Figure 4-31. SG+ count time-kill data: raw (A) & modelled (B). 
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Antimicrobial effects extracted from these models were related to drug concentration 
for each antimicrobial using a standard sigmoid Emax PK/PD model, of form: 
𝐸 =  
𝐸𝑚𝑎𝑥  ∙  𝐶
𝑛
𝐸𝐶50
𝑛 + 𝐶𝑛
 
Where E is the PD effect (the slope gradient estimates by mixed-effects modelling 
above), C is the drug concentration (known from experimental condition), and the 
remaining parameters are estimated from the data: Emax (maximum achievable effect of 
antimicrobial), EC50 (the drug concentration where half of Emax is obtained), and n (a 
scaling parameter). These models summarise PKPD by antimicrobial and by cell 
population under study, i.e. allow comparison of antimicrobial killing effects when 
assessed by the different systems (CFU counting and FCM cell population counting).  
 Relative effects and rank order of antimicrobials differed depending on the cell 
population under study (figure 32). Rifampicin and kanamycin had higher estimated Emax 
for elimination of CA+ cells, while ethambutol and isoniazid had greater estimated Emax 
for rendering bacilli SG+. Indeed, effect of rifampicin and kanamycin on proportion SG% 
did not seem to follow a dose-response relationship (figure 32, bottom row). This is in 
keeping with their known mechanisms of action: intracellular acting rifampicin and 
kanamycin have more effect on intracellular metabolic activity, while cell-wall acting 
isoniazid and ethambutol, intuitively, would disrupt membrane integrity. For both CFU 
count and total cell count (HK population), rifampicin had the highest estimated Emax 
and lowest EC50.  
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Figure 4-32. Sigmoid Emax models applied to CFU & FCM time-kill data. 
Effects normalised against no antibiotic control and, in CFU, CA+ and HK counts, effects are all 
plotted on a positive scale, i.e. so that more effect = more cell death, & lower bounded at 0. The 
relationship between drug concentration and effect follows a sigmoid function in all cases, except 
the effect of rifampicin and kanamycin on proportion of cells SG+. 
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4.12 Dual SG+ population 
As noted in figure 23, bacilli stained with SYBR-gold (without prior heat-killing) can be 
seen in some plots to have two populations separated by FL1, i.e. different SG+ 
brightness. This is most clearly seen for cultures treated with ethambutol or isoniazid. 
The brighter FL1 population has slightly higher SSC values, and approximately double 
fluorescence from SG staining of nucleic acid. This dual population is faintly visible in 
heat-killed SYBR-gold stained cells, but less clear perhaps due to disruption of nucleic 
acid structure by the action of heat. A detailed example is shown (figure 33). 
 
Figure 4-33. Example of dual SG staining population. 
Example is from a BCG culture after 2 days exposure to ethambutol at concentration 16xMIC, with data 
acquisition o Accuri C6 with thresholding on FL1>2000 and SSC>2000 (A). Same data but ‘zoomed-in’ 
on dual population of interest, with horizontal bars on approximate median of the two populations (B).  
The dual FL1 fluorescence is most easily seen on a 1-dimension density plot of log FL1.H where 2 peaks 
are clearly seen (C). Gating by simple geometric region of the two populations (D). 
 
Two possible explanations of this dual population were considered: 
1. It exists in all cultures to the same extent, but is made more visible by increased cell 
permeance to SYBR-gold caused by cell wall active antimicrobials. 
2. The dual population is a physiological response by bacilli, differentially induced by 
cell wall active versus intracellular acting antimicrobials. 
To investigate these explanations further, it was thought necessary to develop a method 
to routinely permeabilise bacilli membranes to SYBR-gold, without heat-killing 
disruption of nucleic acid structure, and without causing significant cell destruction. 
This would allow observation of any differential effect of antimicrobials independent of 
their permeabilization of the cell membrane, and without the ‘noise’ created by nucleic 
acid damage from heat-killing. 
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4.12.1 Development of a membrane permeabilization method 
Published methods for permeabilizing mycobacterial cell walls were reviewed; those 
with highest reported success and best description of validation490,491 were taken forward 
for testing and adaptation. Some example iterations of the method development are 
shown in figures 34 & 35, all experiments were performed on early to mid-log phase M. 
bovis BCG cultures grown as per the time-kill experiments detailed above. 
 
Figure 4-34. Permeabilization method development, experiment 3.4. 
8 methods (summarised in table) were tested in this iteration, all with and without prior 
paraformaldehyde / ammonium chloride fixation (8 x 2 = 16 conditions), and with 2.5 hour 
SYBR-gold incubation or 16 hour SYBR-gold incubation (16 x 2 = 32 conditions). Only the 
2.5hour incubation FCM plots are shown here as duration of SYBR-gold incubation had no 
observed effect.  Ethanol and hydrochloric acid at the concentrations and incubations tested in 
this replicate caused near complete destruction of the cells. In this replicate, lysozyme and 
detergent conditions tested (LZ, TX, CM) were most able to reveal the dual SG stain population 
of interest (purple arrows); the addition of prior fixation with paraformaldehyde / ammonium 
chloride (PFL NH4CL, lower row) caused cell destruction. Note that heat fixing (HK) allowed 
SG to stain cells, but the dual population is not seen, possibly due to heat disruption of nucleic 
acid structures. Red arrows show poorly staining cells or possibly cell debris. In subsequent 
iterations, different concentrations and incubation times and temperatures were investigated for 
lysozyme and triton-X-100. 
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Figure 4-35. Permeabilization method development, experiment 5.0 & 5.1. 
16 methods (A to L, and 3 reps of 4 conditions M to X)) tested using different wash, lysozyme and 
triton-X-100 concentrations and incubations. All resulted in a permeabilized cell population of interest 
with dual SG staining populations visible (A). Compared to a heat-killed control, which gives a reliable 
total cell count, methods with a lower lysozyme concentration but longer incubation times (e.g. 
method S and V), showed that up to 80% of cells could be permeabilized without cell destruction (B). 
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This led to a final method for reliable permeabilization of BCG bacilli without 
substantial cell loss, such that over 80% of bacilli could be SYBR-gold stained (compared 
to the heat-killed total cell count denominator gold standard). The final method used 
was: 
1. 500µl broth culture sample diluted to 1ml with PBS v/v 0.15%Tween 80, but no 
wash step. 
2. Needle emulsified (12 passes through a double luer-lock ended, 25 Gauge, 4-inch, 
micro-emulsifying needle). 
3. 500µl lysozyme added to final conc 0.1mg/ml. 
4. Incubated for 45 minutes at 37oC. 
5. 500µl triton-X-100 added to final concentration v/v 0.2%. 
6. Pelleted (16000 g , 5 min) and re-suspended in 500µl PBS-tween; 40µl working 
stock SYBR-gold added and incubated at room temperature for 2-4 hours. 
7. FCM with thresholding on FL1 and SSC. 
 
4.12.2 Differential dual SG staining population characteristics by 
antimicrobial action 
To investigate the effect of antimicrobials on the development of dual SG staining 
populations, mid-log phase M. bovis BCG cultures were grown under the same 
conditions described for the time-kill experiments above. Independent cultures with 
different antimicrobial conditions were set up, sampled at timepoints 2, 3 and 5 days 
after addition of antimicrobials. Samples were processed as per the permeabilization 
method outlined in the previous section.  
With standardised permeabilization of all bacilli (or about 80% of cells), all FCM plots 
demonstrated dual SG staining populations (figure 36).   
 
 
212 
 
 
 
Figure 4-36. Permeabilized BCG cells show dual SG staining under all antimicrobial 
conditions tested. 
Examples shown are from BCG cultures after 3 days exposure to 4 different antimicrobials 
(E=ethambutol, H=isoniazid, K=kanamycin, R=rifampicin) at concentrations 0.5, 2, 4, & 16 
xMIC. RH is rifampicin at these concentrations, but with isoniazid added as a second agent at a 
constant 2 xMIC in all cases. A no antibiotic control is also shown (CTRL). Dual SG stained 
populations are visible in all conditions after permeabilization (A). The 1-D density plots (B) 
show two peaks, but the relative height of these twin peaks differs by antimicrobial. 
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Gating bacilli the SG stained bacilli into two populations (P1 and P2 as per figure 33) 
allows quantitative comparison of the populations. Across all the antimicrobial 
conditions and the three timepoints sampled, mean FL1 fluorescence of P1 and P2 was 
11.1 and 11.8 respectively, meaning that on average P2 bacilli had almost exactly double 
the SG staining intensity of P1 bacilli [ exp(11.8) / exp(11.1) = 2.01 ], in keeping with 
them containing twice the amount of nucleic acid, which SG stains. 
The ratio of number of bacilli in P2 to number in P1 varied by antimicrobial. Bacilli 
treated with isoniazid or ethambutol increased the relative number of P2 bacilli 
compared to control and other antimicrobials (figure 37). Rifampicin, and to lesser 
extent, kanamycin, prevented the development of P2 bacilli (compared to control); 
bacilli treated with isoniazid also did not develop a larger P2 population when co-
exposed to rifampicin (figure 37). 
Some of the effects of antimicrobials on the dynamics of SG+ populations may have 
been partly time dependent (figure 38). 
4.12.3 Imaging characteristics of the dual SG+ bacilli populations 
To further explore the nature of the P1 and P2 cell populations, permeabilized SYBR-
gold stained cells from day 3 after treatment with rifampicin, isoniazid, or ethambutol 
were cell-sorted based on their P1 and P2 gate for downstream fluorescent microscopy. 
The log SSC.H by FL1 plots were recreated for these samples on a FACS Vantage to 
permit sorting.******* Sorted populations were then examined by fluorescent microscopy.  
P2 bacilli appeared to be longer, with more discrete SG positive regions; several P2 
bacilli had a V shape similar to that seen in binary fission prior to cell division 492(figure 
39).   
  
                                                             
******* With thanks to Mr Ronnie Dreyer from Division of Immunology University of Cape Town 
for access to and assistance with using the FACS Vantage for this experiment. 
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Figure 4-37. Ratio of P2 to P1 bacilli by antimicrobial condition. 
Each antimicrobial condition (n= 27) is an independent culture; each was sampled at 3 timepoints (day 2, 3 &5 
after addition of antimicrobials) giving 27*3 = 81 antimicrobial data points, plus two no antibiotic control cultures 
sampled at the three timepoints, giving 6 no antibiotic control (CTRL) data points. E=ethambutol, H=isoniazid, 
K=kanamycin, R=rifampicin at concentrations ranging from 0.1 to 64 xMIC. RH is rifampicin at range of 
concentrations, but with isoniazid added as a second agent at a constant 2 xMIC in all cases. Significance testing 
with pairwise t tests (all *** p-values remain <0.05 after Bonferroni correction for multiple comparison). 
Overlaid boxplots show median, IQR and range (bar, box, whiskers respectively). 
 
 
Figure 4-38. Ratio of P1 to P2 bacilli by antimicrobial and duration of exposure. 
Same data as figure 35 disaggregated by timepoint of sample. 
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Figure 4-39. Images of bacilli stained with SYBR-gold and sorted by P1 & P2. 
12 randomly selected images from microscopy of sorted P1 and P2 bacilli. 
 
To quantify these differences, images of bacilli were analysed in Image J / FIJI.493 An 
axis was drawn from one bacilli pole to another manually; the fluorescence intensity for 
each pixel on this axis, and its coordinates, were extracted as vectors (these vectors are 
plotted for each of 40 bacilli in figure 40). Local maxima (peaks) in fluorescence and the 
length of the bacilli were then derived from these vectors using custom written functions 
in R studio. 
On average P2 bacilli were just under twice the length of P1 bacilli (mean 4.01 versus 
2.45 μm; median 4.00 versus 2.52 μm respectively), and had almost exactly double the 
number of fluorescent peaks (mean 6.0 versus 3.2 peaks; median 5.5 versus 3.0 peaks 
respectively) (figure 40). Different degrees of smoothing altered the number of peaks, 
but the average ratio between P2 and P2 bacilli stayed approximately the same at ~2 
(data not shown). 
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Figure 4-40. Fluorescence along longitudinal axis of P2 & P1 bacilli. 
40 randomly selected bacilli images from antimicrobial treated (rifampicin, isoniazid or 
ethambutol), permeabilized, SG stained and sorted populations. Top rows (green) are bacilli 
from P2, bottom rows (red) are bacilli from P1. Images were analysed in Image J / FIJI to extract 
fluorescence intensity along the longitudinal axis. Each plot shows fluorescence intensity by 
distance (in uM) along bacilli axis. 
 
 
Figure 4-41. Number of fluorescent peaks and bacilli length by P1 & P2. 
Number of peaks in the bacilli axis plots shown in figure 40 were counted using a custom written 
function in R studio. In brief, a loess regression line was applied to the fluorescence intensity by 
axis position data for each image to smooth out small peaks and local maxima along this 
regression line were counted. The number of fluorescent peaks differed significantly between P1 
& P2 (left panel), as did bacilli length (right panel). P values are from Wilcox rank sum tests. 
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4.13 Discussion 
This chapter describes development and validation of an absolute counting method for 
in vitro broth cultures of mycobacteria using flow cytometry. The most novel aspects of 
this method are the use of fluorescence signals based on SYBR-gold staining to define 
which FCM events are bacilli. The method showed a negligible false discovery rate, 
minimal coefficient of variation between replicates, and near perfect linearity of counts 
across serial dilutions. In addition, methods for measuring and minimising clumping in 
samples, and the major impact of clumping on apparent numbers of bacilli (e.g. CFU 
counts), were demonstrated. 
Method development in laboratory science isn’t generally met with enthusiasm by basic 
scientists who are more interested in mechanism discovery; it is worth explicating why 
the method developments in this chapter are important. The establishment of these 
methods is important for several reasons. 
Firstly, much current work in research mycobacteriology is focussed on exploring 
phenotypic heterogeneity or sub-populations of bacilli with different physiological 
characteristics, such as the differentially culturable bacteria discussed at the start of this 
chapter. If the total cell count denominator is unknown in these experiments it makes 
the results harder to interpret. For example, showing that the most-probable number of 
bacteria in Rpf+ liquid culture is several-fold higher than CFU counts is interpreted as 
evidence of a predominant differentially culturable subpopulation.406,407 But if the 
different processing and culture systems disrupt clumped bacilli to different degrees, 
this would make these findings spurious.  
Similarly, if CFU-counts are regarded as equivalent to counts based on metabolic 
activity as assessed by fluorescent probes, comparisons between experimental conditions 
based on these two assays might be erroneous. For example, a recent study by 
Aljayyoussi et al. compared killing dynamics of first line TB drugs for extracellular 
versus intracellular GFP-expressing H37Rv M. tuberculosis bacilli.494 Extracellular bacilli 
kill was assessed by decline in CFU count, while intracellular killing was assessed by 
decline in GFP+ bacilli; rifampicin had greatest effect on intracellular bacilli which 
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helped these in vitro results correlate with clinical trial findings. But is this evidence that 
rifampicin has better intracellular killing, or that it has greater effect on GFP expression 
than other drugs? 
As a final example, consider M. tuberculosis multiples-of-infection (MOI) of immune cell 
models used by TB immunologists. These either rely on OD600 measurements of live 
cultures with dilution to required density, or on CFU counts of frozen aliquots.495,496 
Because the ratio of clumps to single-cells, and the ratio of CFU counts to total cell 
count, is uncontrolled and unobserved in these methods, MOI isn’t actually known with 
accuracy and will not be comparable across studies. Also shown in the current work, the 
‘gold-standard’ method for single-cell suspension preparation of bacilli using low g 
centrifugation does not work.  
The work presented in this chapter shows how to prepare single-cell suspensions of 
bacilli (using early-log phase cultures and needle emulsifying), and how to accurately 
quantify bacilli for downstream experiments using flow cytometry. It is also shown that 
calcein positive bacilli counts can be used as a highly accurate and rapid surrogate of 
CFU count, available within hours rather than weeks for slowly growing mycobacteria. 
This has the potential to greatly simplify some in vitro mycobacteria experimental 
protocols. 
Conversely, differences in CA+ and CFU counts – even in antibiotic-free cultures – 
were shown in this chapter. Proportion of cells which are CA+ correlates with 
instantaneous rate of growth of the whole population in a static culture (but CFU count 
does not). This compliments the findings of Hendon-Dunn et al. who showed that mean 
calcein fluorescence correlates with rate of growth in a continuous culture system.443 
This suggests that CFU formation is not simply a reflection of metabolic activity, but a 
more specific cell phenotype, possibly dependent on so far undefined factors rather than 
overall metabolic state. 
Correlation of CFU counts with CA+ counts is unequivocally lost at early timepoints 
after exposure to antimicrobials. FCM defined populations appear to give different 
‘windows’ on pharmacodynamic activity of anti-mycobacterial compounds. Intracellular 
acting antimicrobials (rifampicin, kanamycin) have more profound early effects on 
calcein activity, while cell-wall acting drugs (isoniazid, ethambutol) cause earlier marked 
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membrane damage assessed by SYBR-gold permeance. That FCM can distinguish 
antimicrobials by mechanism of action replicates the findings of Hendon-Dunn et al.,443 
but with the advance that proportions of cells are related to an absolute total cell count 
denominator. This is important, because differences were seen in the dynamics of this 
total cell count. Rifampicin appeared to cause greater complete cell destruction than 
other drugs; this effect would have been unobserved by the four cell populations defined 
by Hendon-Dunn et al.’s analysis.  
In summary, FCM allows different pathways of cell death to be observed, giving some 
support to the hypothesised spectrum of cell vitality reviewed at the start of this chapter 
(figure 42).  
 
 
Figure 4-42. Continuous spectrum of live/dead cell states of bacilli, as observed by 
CFU & fluorescent probes in FCM. 
Populations of cells defined by CFU and FCM are related to the schematic shown previously in 
figure 2. Loss of CFU formation is an early event in the pathway from unrestricted growth to 
irreversible cell death. Loss of metabolic activity (CA positivity) and membrane integrity (SG 
positivity) develop more slowly after exposure to antimicrobials, and differentially by 
antimicrobial mechanism of action (intracellular action drugs = dashed blue path; cell-wall 
activity drugs = dashed purple path).  Eventual cell destruction can also be assessed by FCM 
analysis. 
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Perhaps the major question is which pharmacodynamic window is the most important? 
In other words, do dynamics of FCM defined populations give substantive information 
about antimicrobial activity? Unfortunately, the current analysis cannot answer this 
question. The point of irreversible cell death on these pathways, and markers of bacillary 
drug tolerance and persistence, remain poorly defined.  The fact that different 
antibiotics have different effects on FCM defined subpopulations may be important, or 
may be an unhelpful complication.  
Nonetheless, the methods developed in this chapter could be useful tools for exploring 
mycobacterial pharmacodynamics further. One approach would be to assess if there are 
greater differences in time-kill dynamics between different clinical isolates when 
assessed by FCM compared to CFU counting. One previous report has suggested that 
time-kill characteristics of clinical isolates ex vivo are predictive of clinical outcome, and 
independent of isolate MIC.497 This could be further explored using the FCM 
methodology in this chapter. This would require overcoming a major technical difficulty 
of standardising growth in vitro for time-kill experiments. Cultures subbed from the 
same BCG starter culture – using identical broth, culture flasks and incubator – resulted 
in different growth curves when assessed with flow cytometry (for example random 
effects on %CA+ - figure 14). Rates of growth influence antimicrobial tolerance,498-501 
and this variation is a major weakness of the current analysis. Notably, use of a 
continuous culture chemostat (as per the Hendon-Dunn FCM study) can make growth 
conditions reproducible,442 but is resource intensive and available in few labs.  
Finally, a novel finding in the current analysis is that two populations of SYBR-gold 
staining bacilli are seen on FCM, one having double the fluorescence of the other. Drug 
exposure increased the relative abundance of the brighter SG+ population (P2), but with 
significant differences by antimicrobial. In particular, rifampicin demonstrated ability to 
suppress development of P2. Since SYBR-gold predominantly stains DNA it could be 
speculated that P2 bacilli have a higher complement of chromosome copies. This 
hypothesis is weakly supported by the fact the populations were discrete (and align to a 
log2 scale), and also by the results of imaging analysis, which suggested P2 bacilli were 
larger with more discrete SG+ regions, perhaps having arrested during binary fission 
prior to cleavage into two daughter cells.  
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Ploidy is harder to define for bacteria than eukaryotic cells, since bacteria are not 
consistently uni-nucleoid.502 Decoupling of chromosome replication and cell division is, 
however, reported for mycobacteria. For example, bacilli in stress conditions are found 
to be diploid.503 It is suspected that filamentous mycobacteria found in macrophages 
may be polyploid.504 TB researchers have further noted that elongation without division 
results in polyploid cell phenotypes of E. coli, which are capable of persistence and drug-
resistance mutation from a starting population of just 100 bacteria under some 
microenvironment conditions.504 It could be speculated that the P2 population which 
developed under antimicrobial exposure in the current work represents a specific 
persister phenotype, and that if these cells contain multiple chromosome copies they 
would have increased propensity for developing drug resistance. In this interpretation, 
the fact that, in relative terms, isoniazid induces but rifampicin supresses P2 numbers is 
of interest. The FCM system developed in this chapter offers a potential high-
throughput tool to investigate ploidy in mycobacterial pharmacodynamics. 
In summary, the FCM method developed in this chapter facilitates mycobacterial lab 
work, and adds to the evidence that culturable mycobacteria give only one window on 
pharmacodynamics. Both these conclusions are exploited in the next chapter, which 
describes the development novel methods of counting mycobacteria in blood, and their 
use in a clinical pharmacodynamic study of MTBBSI. 
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5 Pharmacodynamics of MTBBSI: 
development of biomarkers & a 
clinical study 
 
5.1 Introduction  
5.1.1 Rationale for developing PD biomarkers of MTBBSI 
MTBBSI is the mode of severe HIV-associated tuberculosis infection in adult inpatients. 
It is highly prevalent, and a strong, independent predictor of mortality. This is shown by 
the most detailed clinical study of severe HIV-associated TB to date (the KDHTB study, 
described in chapter 1), and by systematic review of all available unbiased TB blood 
culture data in previous publications (the individual patient data meta-analysis in chapter 
2). Yet MTBBSI has not been the subject of any interventional study.   
Surrogate biomarkers of clinical endpoints can facilitate interventional trials. Continuous 
biomarkers may have greater power to show difference between arms than a dichotomous 
outcome, increasing trial efficiency and accelerating development of therapeutic 
evidence-base.505-507 A leading example is the use of HIV viral load dynamics in assessing 
anti-retroviral drugs: the meteoric development of highly-active antiretroviral therapy – 
based on phase-2 trials with less than 50 patients per arm – would have been impossible 
without this biomarker.508,509 While HIV viral load is generally dichotomised in these trials 
(e.g. proportion with viral suppression by week 24), this is just a summary measure of a 
continuous variable. The justification for using HIV viral load as a biomarker was based on 
its kinetics as a continuous variable being able to predict clinical endpoints.509 Early phase 
2 trials of antiretroviral therapy used rate of change in viral load as the primary outcome 
measure,510-515 and were not powered for detecting proportion with viral suppression by a 
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given time point. Regulatory approval based on surrogate biomarkers is well established 
for life-threatening diseases.516 
Correlation of a biomarker with clinical outcome at the individual level is logically 
independent of correlation of that biomarker with outcome at group (or trial arm) 
level.517,518  This phenomenon emerges depending on the causal structure which gave rise 
to the correlation between biomarker and outcome. If a biomarker does not lie on the 
(direct) causal pathway between treatment and outcome, it may turn out to be a 
misleading surrogate.  
For example, cholesterol levels are linked to cardiovascular disease. Hormone 
replacement therapy and statins both reduce cholesterol. But, in RCTs, the former 
increases risk of cardiovascular disease, while the later reduces risk of cardiovascular 
disease.  
In short, a biomarker should have a biologically plausible – preferably mechanistic – 
relationship to the clinical outcome.519 In the search for sterilising cure of pulmonary 
tuberculosis, it is argued that bacteriological biomarkers (as opposed to host-response 
dynamics) – particularly those that might track persister organisms – are the most logical 
pharmacodynamic measure.520,521  
Based on the work presented in this thesis, I would make a similar bacteriological case for 
severe HIV-associated tuberculosis. If we accept that MTBBSI is the mode of infection in 
severe HIV related TB, and is also a marker of total bacilli load, and directly linked to 
mortality, then serial quantification of MTBBSI is a promising basis for a 
pharmacodynamic biomarker capable of potentiating an urgent interventional research 
response to this neglected condition.   
5.1.2 Chapter aims 
1. Develop new methods, and optimise existing methods, for identifying and quantifying M. 
tuberculosis bacilli in patient blood samples. 
2. Using these methods, report the pharmacodynamics of MTBBSI during the first 72-hours of 
standard anti-tuberculosis therapy.  
3. Relate these MTBBSI pharmacodynamic measures to mortality and major clinical variables 
known to associate with mortality. 
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5.1.3 Chapter outline 
Published methods for identifying mycobacteria in blood are reviewed for methodological 
insights. Previous attempts at quantifying M. tuberculosis in blood are rare, and no serial 
quantification has been described.  
Novel method development is then described. This largely relied on optimisation of 
protocols using spiked blood samples, facilitated by the in vitro bacilli counting methods 
developed in chapter 4. Two pilot studies using clinical samples were also completed, 
recruiting patients using the predictive modelling described in chapter 3. The following 
methods and their development are described: optimised Myco/F lytic blood culture; a 
protocol for use of GeneXpert-ultra on blood; and fluorescent microscopy using a novel 
mycobacterial dye, 4-N,N-dimethylaminonaphthalimide-trehalose (DMN-Tre). 
Finally, a sub-study nested within the KDHTB cohort study is described, in which blood 
bacilli burden was serially quantified at up to five timepoints after the start of anti-
tuberculosis therapy, in 28 patients predicted to have high risk of MTBBSI.  
 
5.2 Identifying & quantifying 
mycobacteria in blood: prior 
literature 
5.2.1 Culture 
The emergence of M. avium – M. intracellulare (MAI) as a significant opportunistic 
pathogen with the advent of AIDS in the early 1980s renewed interest in blood culture 
for mycobacteria. At that time no standard protocol for recovery of mycobacteria was 
established; over 20 different methods are described in the early case series of 
mycobacteraemia.112,307,522-526 The subsequent development of mycobacterial blood 
culture methods can be summarised as follows: 
• Initially, two main methods were in use: (1) lysis-centrifugation methods, in which a 
relatively large volume of blood (e.g. 5-10ml) is lysed and the pellet plated on solid 
media or inoculated into liquid culture; and (2) direct inoculation of radiometric 
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liquid culture systems, which had capacity for a smaller volume blood (e.g. 1-2ml). 
In head-to-head comparisons, lysis-centrifuge systems had best recovery of MAI, 
while direct inoculation had marginally lower recovery, but shorter time-to-
detection (TTD).526,527 
• Commercial systems which could culture larger volumes of blood for mycobacteria 
(e.g. 3-5ml) directly in liquid media without a lysis/concentration step were 
developed in the 1990s. Of these BACTEC Myco/F Lytic (MFL, BD Sparks, Md.) 
is the most common example still in production.  
The major advantage of the MFL system is the ability to detect fungi, mycobacteria and 
other bacteria from a single sample, without processing steps and the use of multiple 
broths. In direct comparisons, MFL has shown better recovery of M. tuberculosis from 
blood than lysis-centrifuge systems when the lysate/concentrate was plated on solid 
media, and equivalent recovery to lysis-centrifuge systems when lysate/concentrate was 
inoculated into liquid media (table 1). This equivalence, and the convenience of MFL, 
has led to it being the most common system used in practice – 15 studies identified in 
the IPD meta-analysis in chapter 3 used MFL,15,21,24,59,127,128,144,308,323,327-332 while only 2 
older studies used lysis-centrifuge methods.120,324  
In principle, lysis-centrifuge methods could be used to culture greater volumes of blood 
than the maximum 5ml for MFL, or used to pre-process blood prior to MFL culture. 
Such a strategy has not been tested. In general, work to optimise blood culture methods 
in medical mycobacteriology has stagnated. By contrast, veterinary microbiologists have 
performed extensive work to optimise culture of Mycobacterium avium subspecies 
paratuberculosis (MAP) from cattle and sheep blood, showing, for example, that 
presence of whole blood or just red blood cells inhibits mycobacterial growth, and that 
lysis and wash steps can increase recovery.528,529 As shown in chapter 3 of this thesis, 
additional MFL cultures (even at same time point) increase detection of MTBBSI. In 
sum, a single MFL culture is convenient, but is unlikely to be optimal for identifying 
MTBBSI.  
Also of note, no studies to date have performed serial cultures of blood during anti-
tuberculosis treatment.  
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Table 5-1. Direct comparisons of MFL & alternative culture methods for recovery of 
M. tuberculosis from blood. 
Ref Comparator 
Comparator 
blood 
volume 
Positive 
by both 
method 
MFL 
positive 
only 
Comparator 
positive 
only 
Martinez-
Sanchez 
2000 306 
In house lysis-centrifuge 
method; concentrate inoculated 
to solid and liquid media. 
Not clear 2 2 0 
Crump 
2011 303 
BacT/Alert MB liquid culture 
system 
4-6ml 12 8 2 
Crump 
2011 303 
Isolator 10 lysis-centrifugation 
system with concentrate plated 
on 7H10 agar 
4-6ml 9 7 0 
Ref Comparator 
Comparator 
blood 
volume 
Positive 
by any 
method 
MFL 
positive 
Comparator 
positive 
Archibald 
2000 302 
Isolator 10 lysis-centrifugation 
system with concentrate 
inoculated in SC-AFB liquid 
culture system 
5ml 33 27 25 
Archibald 
2000 302 
Isolator 10 lysis-centrifugation 
system with concentrate plated 
on 7H11 agar 
5ml 33 27 13 
 
5.2.1.1 Quantification of MTBBSI with culture 
While associated with poorer recovery of mycobacteria from blood, lysis-concentration 
and plating of the concentrate on solid media allows CFU counting. This was the basis 
of the only two published attempts at quantifying bacilli in blood in MTBBSI. Crump et 
al. found <1 to 150 (median 40) CFU per ml of blood in 9 patients with MTBBSI; CFU 
count correlated moderately with TTD in liquid culture (r=-0.49, p=0.262),303 and CD4 
count (Kendal τ = -0.33, p=0.45).59 Munseri et al. showed a range of 1 to 23 (median 3) 
CFU/ml of blood, in 21 MTBBSI patients, although the majority of samples were 
processed more than 7 days after collection.308 
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5.2.2 Microscopy 
The first account of M. tuberculosis visualised on microscopy of blood was from post 
mortems performed by Anton Weichselbaum††††††† in the 1880s.530 A flurry of early 20th 
century reports that M. tuberculosis was visible on microscopy in a majority of TB 
patients’ blood531-533 ‡‡‡‡‡‡‡ were subsequently explained by the finding that acid-fast 
environmental bacilli were present in the distilled water used to prepare microscopy 
slides in these labs.534  
Again, the emergence of MAI in the early AIDS epidemic renewed interest in 
identifying mycobacteraemia, including by microscopy. Eng et al. detected AFB by 
fluorescent microscopy of the buffy coats of 13/14 and 0/1 patients with MAI and M. 
tuberculosis blood culture positive disease respectively.113 In 16 patients with MAI-
positive blood cultures, Ruf et al. reported acid-fast bacilli in the buffy coat (13/16) and 
whole-blood lysed cell pellet (4/16), but 0/4 patients with M. tuberculosis blood culture 
had positive microscopy by either method.307 Godwin et al. described acid-fast ‘rod 
shaped inclusions’ in monocytes and neutrophils of peripheral blood smear in 4/16 
patients with bone marrow culture positive MAI infection.535 Subsequent studies 
suggested 4% sensitivity of acid-fast microscopy of blood lysate, and 35% sensitivity of 
acid-fast microscopy of buffy coat compared to culture for MAI bacteraemia.536,537 
There is a single case report of detection of M. tuberculosis bacilli on blood microscopy 
from an HIV positive patient, using acid-fast staining of a whole blood lysate pellet.538 
5.2.3 Nucleic acid amplification 
A substantial number of attempts at M. tuberculosis PCR on blood, either specifically for 
patients suspected of having MTBBSI or in general TB populations, have been 
published, with wide variation in reported sensitivity (table 2). Unsurprisingly, studies 
which have focussed on PLWHIV at risk of MTBBSI have generally higher rates of PCR 
positivity in blood. Reported sensitivity of blood PCR in patients known to be TB blood 
culture positive have ranged from 5/25 (0.20, 95%CI 0.08 to 0.41)539 up to 11/13 (0.85, 
95%CI 0.54 to 0.97).122 Notably, all studies have identified M. tuberculosis in blood of 
                                                             
††††††† Who is more famous for discovering Neisseria meningitidis when examining the 
cerebrospinal fluid of meningitis patients. 
‡‡‡‡‡‡‡ Including one from Dr Charles Forsyth, pathologist to Liverpool Hospital for 
Consumption and Diseases of the Chest. 
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patients who are blood culture negative, in keeping with potential limited sensitivity for 
both techniques. Estimates for the limit of detection from spiking blood ex vivo are 
around 5 CFU/ml;540,541 as shown in chapter 4 of this thesis, the ratio of CFU to total 
cell count is highly dependent on growth conditions so these figures are 
methodologically flawed. 
PCRs have generally been run on extracted PBMCs,122,539,542 or on lysis-centrifuge 
concentrates,15,543,544 or without pre-processing of blood prior to use in a commercial 
blood DNA extraction kit.541,545 There is no clear pattern between studies to suggest 
which blood processing step is optimal (table 2), and no head-to-head comparisons of 
methods exist. The widespread belief that bacteraemic bacilli are intracellular and 
therefore concentrated in PBMC extractions is, to my knowledge, an assumption 
without direct evidence. Whole blood contains several known inhibitors of PCR, notably 
haem,546 but also non-target (human) DNA and anticoagulants used in blood collection 
tubes.547 It is surprising, then, that little attention has been given to optimisation of lysis 
and wash steps prior to PCR for M. tuberculosis in blood, which has been successful for 
blood PCR for other pathogens.548 
Most of the studies have used labour intensive DNA elution and PCR SOPs, unfeasible 
in most high-MTBBSI burden settings. The exception is the attempt to test blood in the 
Xpert system after a single lysis-centrifugation step by Banada and colleagues.540 Blood 
was mixed with a high-concentration red cell lysis buffer containing sucrose, magnesium 
chloride, Tris HCl and detergent. The ratio of blood to lysis buffer used was 85:15; the 
relatively low volume of lysis buffer being chosen to potentially lyse large volumes of 
blood in prefilled collection tubes. The authors reported no increase in the internal 
control CT values with higher blood volumes, arguing this showed that PCR-inhibitors 
were not present. This seems unlikely, and no blood-free control data is presented. In a 
subsequent test on clinical samples, 27% of those tested had invalid results or errors; 4/9 
were blood culture positive / Xpert negative, 4/9 were blood culture negative / Xpert 
positive, and 5 patients were positive by both tests.15 This gives a sensitivity against 
culture of 0.44, but given blood culture is an imperfect reference, it could also be argued 
that the Xpert method may be as sensitive as blood culture (p=1 by McNemar’s test for 
difference). In short, although these results are often described as showing poor 
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sensitivity of PCR and haven’t been followed-up, I think they are actually promising, 
and with significant room for optimisation of centrifuge-lysis method. 
Table 5-2. Selected blood PCR studies for TB diagnosis. 
Reference Study population PCR method Blood processing PCR positive 
Feasey 2013 15 104 HIV+ 
inpatients with 
suspected TB 
Xpert 18ml blood underwent lysis-
centrifuge concentration with 
pellet resuspended in 1ml PBS 
(based on Banada 2013) & added 
to Xpert with buffer. 
10/104; 5/9 
patients 
with 
positive 
MTB BC 
Shenai 2013 
544 
24 HIV 
negative PTB 
patients 
Xpert 10 ml blood concentrated into 2ml 
sample by RBC lysis centrifugation 
protocol (based on Banada 2013) & 
added to Xpert with buffer. 
 2/24 
Rebollo 2006 
539 
57 patients 
diagnosed with 
TB (43 micro 
confirmed; 25 
HIV+) 
In house PCR based 
on IS6110 
amplification. 
PBMCs from 5ml blood, washed 
2x in PBS, lysed in Tris-HCl and 
proteinase K, and DNA eluted. 
18/57; 5/25 
HIV+ 
patients 
with 
positive 
MTB BC 
Bwanga 2015 
541 
31 HIV+ 
inpatients with 
suspected 
MTBBSI 
FluoroType MTB 
commercial PCR 
based on IS6110 
amplification 
9ml blood underwent selective 
elution of MTB DNA using a 
commercial kit without prior blood 
processing. 
6/31; 5/7 
with 
positive 
MTB BC 
Richter 1996 
122 
158 inpatients 
with EPTB (103 
HIV+) 
In house PCR based 
on IS986 
amplification. 
PBMCs from 2ml blood, lysed in 
Tris-HCl and proteinase K, and 
DNA eluted. 
23/158; 
11/13 
HIV+ 
patients 
with 
positive 
MTB BC 
(buffy coat 
culture) 
Folgueira 
1996 542 
32 inpatients 
with confirmed 
TB (11 HIV+) 
In house PCR based 
on IS6110 
amplification. 
PBMCs from 5ml blood, washed 
2x in PBS, lysed in Tris-HCl and 
proteinase K, and DNA eluted. 
16/32; 9/11 
HIV+ 
Crump 2012 
543 
25 patients with 
positive MTB 
BC (all HIV+) 
In house PCR based 
on mycobacterial 
16S rRNA gene 
amplification. 
5ml blood concentrated to 0.3ml 
with lysis-centrifuge steps tube 
before DNA elution. 
9/25 
Hajiabdolbaghi 
2014 545 
190 inpatients 
with TB (45 
HIV+) 
In house PCR based 
on amplification of 
IS1081 
3ml blood had total DNA eluted 
with QIAGEN commercial kit 
without any additional prior 
processing of blood. 
78/190; 
26/45 
HIV+ 
MTB BC = M. tuberculosis blood culture (by MFL or other system) 
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5.3 Development of methods for 
identifying & quantifying bacilli in 
blood 
In this chapter, I describe three methods that were developed or optimised for blood: 
microscopy, Xpert PCR, and MFL culture. The process of method development was 
iterative, including using data from both clinical pilots and the larger sub-study. The 
work is presented by method rather than chronologically. For convenience, the clinical 
pilots and sub-study design are summarised in figure 1 and referred to in subsequent 
text.  
In pilot one, 16 patients were recruited who were predicted to have high risk of 
MTBBSI according to the machine learning models described in chapter 2. At each of 
four timepoints – 0h (prior to first dose of TB therapy), 4-12h, 24 h and 48 hours after 
first dose of TB therapy – two blood samples were taken at the same venesection. The 
first (5ml) was inoculated directly into a Myco/F Lytic (MFL) bottle. The second (5ml) 
was collected in a sterile sodium heparin tube, then centrifuged (3000G, 25min) to 
pellet cells and remove plasma, with inoculation of the cell pellet into an MFL bottle. 
In pilot two, 15ml of blood was taken at a single timepoint immediately prior to start of 
TB therapy in sodium heparin tubes. This combined sample was centrifuged (1800G, 
25min) to separate red cells, buffy coat, and plasma. Plasma and red cell pellet were 
inoculated separately into MFL bottles for culture. The buffy coat was split with ¼ being 
inoculated into MFL bottle; ¼ being inoculated into MFL with the addition of culture 
filtrate; ¼ stored at -20oC for downstream Xpert-ultra processing (described in section 
5.3.3); and ¼ being processed for DMN-trehalose microscopy (described in section 
5.3.1). 
In the main sub-study 28 patients were recruited; the study design is described in detail 
in section 5.4. In brief, at each of the 5 timepoints shown, 4 blood samples in sodium 
heparin tubes (each ~4.5ml) were collected. One was processed to remove plasma with 
culture of the cell pellet in MFL system (as per pilot 1). The remaining three samples 
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underwent red cell lysis and water lysis / wash, before MFL culture, DMN-trehalose 
microscopy, and storage for downstream Xpert-ultra processing. 
Figure 5-1. Two pilots & sub-study used to develop methods to identify &quantify 
MTBBSI. 
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5.3.1 Blood microscopy 
5.3.1.1 Initial attempts demonstrate parameters for optimisation 
The method for processing blood for microscopy was based on a publication by Sage & 
Neece549 describing selective lysis and concentration of blood spiked with bacteria on a 
0.6µM polycarbonate filter.§§§§§§§ Their lysis buffer contained tricine, Rhozyme 41 (a 
broad activity protease derived from A. oryza historically used by the food industry), 
NaOH, and Tween 20; this lysis buffer was developed to selectively lyse all human cells 
in blood, while not damaging bacteria.550-552 Sage & Neece successfully concentrated up 
to 1ml of blood on a 3mm2 polycarbonate membrane using vacuum suction.  
Rhozyme 41 is no longer commercially available, so initial selective lysis and 
concentration attempts adopted the method described by Bower et al. for isolating MAP 
from cattle and sheep blood. Briefly, 9 ml of whole blood was collected from healthy 
volunteers in sodium heparin tubes, centrifuged at 1455 g for 20 min with slow brake, 
and buffy coat extracted by pipetting. This was then pelleted at 200g for 5min in 1.5ml 
Eppendorf, and resuspended in 400µl of PBS. To this was added 12ml erythrocyte lysis 
buffer (0.83% w/v NH4Cl, 0.1% w/v KHCO3, 0.01M EDTA pH 7.5) and the solution 
incubated at room temperature for 10 min to allow lysis of the erythrocytes. This was 
then pelleted at 300g for 10 minutes and resuspended in 1.5ml distilled water. 
The Sage & Neece method for concentration of lysate on filter using air pressure risks 
aerosol formation so couldn’t be used for pathogenic mycobacteria. Instead, a centrifuge 
ultrafiltration holder, which fits standard 30mm centrifuge tubes, was used, allowing up 
to 2ml of liquid to be filtered through a 13mm polycarbonate filter using centrifugal 
force with three levels of containment (UFREU1301, Sterlitech, Kent WA). This filter 
holder is reusable as it can be sterilised. 13mm, 0.6µm, black polycarbonate membrane 
filters designed to fit this holder were used (PCTB0613100, Sterlitech, Kent 
WA).******** Filters were mounted using 50% glycerol on 20mm glass bottom cell culture 
dishes (801001, Whitehead Scientific, Cape Town), which were sealed by attaching the 
                                                             
§§§§§§§ I acknowledge Dr Howard Shapiro for sending me this paper in response to a question on 
the Purdue Cytometry Discussion List. 
******** I acknowledge Mr Kensen Hirohata of Sterlitech Corporation for his extensive expert 
advice on filter systems. 
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lid with cyanoacrylate (Superglue) before removal from the biosafety hood for 
microscopy. 
The sealed cell culture dishes were further mounted in a custom made aluminium 
holder to allow attachment to the microscopy stage (figure 2).†††††††† All microscopy 
was performed on a Zeiss Axio Observer 7 using the Plan-Apochromat 100x/1.4 Oil 
objective and 10x ocular lens giving 1000x magnification. 
 
 
Figure 5-2. Visualisation of a 13mm filter membrane sealed in a 20mm tissue 
culture dish secured on microscope stage using custom machined aluminium holder. 
                                                             
†††††††† I acknowledge Professor Robin Wood of University of Cape Town for machining this 
aluminium holder in his metal-workshop. 
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Figure 5-3. Centrifuge filter holder (right). 
In this example, blood lysate (red) in the top compartment has incompletely filtered through the 
filter membrane into the lower chamber. 
 
Initial attempts at microscopy were performed on volunteer blood spiked with 10^6/ml 
of M. bovis BCG (total cell count, using flow cytometry counting method described in 
chapter 4). Lysate was stained with SYBR-gold and heated at 65oC for 12 minutes before 
concentration on membrane filters. SYBR-gold has been shown to have higher 
sensitivity for mycobacteria in acid-fast staining than other more established dyes.384 
These were washed with 2 passes of acid-alcohol solution through the filter (0.5% HCl in 
70% isopropanol).  
Initial attempts were unsuccessful. Less than 5% of the lysate passed through the 
membrane after 30minutes centrifugation at 2000g (the maximum force supported by 
the filtration device). When filters were examined under microscope, they were found to 
be saturated with SYBR-gold stained cellular debris, with very few bacilli identified. 
This identified factors that needed to be optimised: 
1. Minimum centrifuge settings which result in complete pelleting of bacilli in 
solution. 
2. Lysis buffer, to render lysate maximally filterable through 0.6µm membrane, 
without destruction of bacilli. 
3. Staining procedure to maximise sensitivity and specificity of imaging.  
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5.3.1.2 Centrifuge parameters needed to reliably pellet mycobacteria 
Mycobacteria are said to settle to the bottom of cultures under the action of gravity 
when left on the bench top.553 Conversely, mycobacteria are said to have density less 
than water due to their lipid content, meaning they would not pellet in water under any 
g, and are even seen to accumulate on the surface of  liquid cultures under no 
agitation.554 Centrifuge methods described in the TB literature vary widely, ranging 
from 30 minutes at 1g, to 6000g for 15 minutes.555 The WHO recommends 3000g for 15 
minutes for sputum preparations without citing a source.556 The limited published data 
are contradictory, suggesting 3000g for 15 minutes, 2000g for 20 minutes, or 3200g for 
22 minutes are necessary to achieve effective sedimentation of mycobacteria.557,558 This 
certainly implies that the typically low g methods for preparing buffy coat preparations 
may leave any free bacilli in the plasma fraction.  
Centrifuge time and g were tested with BCG using the flow cytometry counting method 
described in chapter 4 (figure 4). Recovery of bacilli from resuspended sediment 
compared to a non-centrifuged control had a mono-exponential relationship to time and 
g, with increased centrifugation needed when bacilli were suspended in 50/50 
plasma/PBS solution compared to PBS alone. For 5 minutes spin, >10000g was needed 
to recover >90% of bacilli, and >20minutes at 2000g. 
 
Figure 5-4. Centrifuge parameters to maximise recovery of bacilli in suspension. 
A. 5-minute centrifuge of aliquots of the same suspension of BCG bacilli in 50/50 plasma/PBS 
solution. Each aliquot centrifuged under different g, with subsequent removal of 90% of 
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supernatant and resuspension to stated volume by pipetting. One aliquot was not centrifuged, 
and quantified directly, to give the control count. Counting was performed by flow cytometry 
using the heat-kill SYBR-gold stain method described in chapter 4. B. Same data as in A, but with 
3 additional aliquots suspended in PBS (no plasma) – plasma increases centrifuge g needed to 
recover bacilli. C. Method as per A, but g held constant at 2000g, with centrifuge time varied. 
 
5.3.1.3 Selective lysis methods 
Based on several published selective lysis methods,548-552 permutations of different 
detergent and enzyme-based lysis buffers were iteratively tested for ability to render 
healthy volunteer blood samples filterable through the 0.6µm polycarbonate membranes. 
Initial lysis of buffy coat extract using erythrocyte lysis buffer in ratio >10:1, followed by 
24 hour incubation in MFL buffer (which contains detergents), then a more aggressive 
lysis step with buffer containing v/v 1% triton-X-100 and 1% Tween 80 plus 1mg/ml 
proteinase-K incubated at 37oC for 25 minutes was found to result in >90% filtration of 
lysate through the filter membrane (figure 5 & 6).  
To check if this lysis procedure caused significant loss or destruction of bacilli, pure in 
vitro cultures of BCG (not spiked in blood) were quantified by the flow cytometry 
method described in chapter 4, before and after being processed using the same buffers 
and incubations developed for blood samples. This showed that 85-90% of bacilli were 
recovered after processing using the selective lysis steps (data not shown). 
 
 
Figure 5-5. Example experiment testing different detergent & enzyme conditions of 
blood lysis buffer. 
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In these experiments 3.5ml of heparinised blood was collected from healthy volunteers, spun at 
1800g for 10 minutes to separate cell layers, with the buffy coat extracted by pipetting. Extracted 
buffy coat (~0.5ml) was combined with 3ml of MFL broth and incubated in sodium heparin tubes 
for 24 hours at 37oC. These samples were then treated with 12ml of lysis buffer, the constituents 
of this lysis buffer being varied. In A, twelve conditions were tested: 4 different detergents at 3 
concentrations (concentrations on x axis are v/v percentages); all contained 18mg of proteinase-
K (for final concentration 1.2 mg/ml) and were incubated at room temperature for 20 minutes. In 
B, nine conditions were tested: 3 concentrations of proteinase K (amount on x axis is mg added to 
15ml volume) incubated for 20 minutes at 3 different temperatures; all contained v/v 2.5% 
Tween 80. After lysis samples were pelleted at 4600g for 10 minutes and re-suspended in 1 ml of 
PBS before attempted filtration with the centrifuge-filtration system. The total volume which 
passed through the filter was measured to assess how effective the different lysis conditions had 
been. 
 
 
Figure 5-6. Summary of iterative development of selective lysis method. 
Method development over time from earlier attempts (bottom) to later attempts (top). Factors 
that made major differences to filterability of blood lysate were use of a large volume for initial 
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lysis step, inclusion of proteinase-K in lysis buffer, and use of more than one detergent with 
different mechanisms of action (e.g. Triton-X-100 plus Tween 80). 
 
5.3.1.4 Staining procedure & choice of dye 
As described above, initial tests of blood microscopy with BCG-spiked blood used 
SYBR-gold staining, which was associated with sub-optimal results due to poor 
specificity of the dye with excessive staining of cell debris. Optimised acid-alcohol wash 
steps and counter staining procedures marginally improved the performance (data not 
shown), but the performance was radically improved by use of a novel dye, 4-N,N-
dimethylamino-1,8-naphthalimide–conjugated trehalose (DMN-Tre), developed by the 
Bertozzi lab at Stanford.559 This probe is metabolised by actinobacteria (including 
mycobacteria) to a trehalose mycolate and incorporated into the outer membrane of the 
bacilli, which specifically increases the molecule’s fluorescence activity over 700-fold.559 
This means the dye has high specificity for mycobacteria (without staining typical gram-
negative and gram-positive bacteria found in clinical samples), reports only 
metabolically active mycobacteria, and can be used without wash steps.559 DMN-tre dye 
was gifted by the Bertozzi lab for the current work.‡‡‡‡‡‡‡‡ Initial tests of DMN-tre 
showed >100-fold improved detection of bacilli in spiked blood samples (figure 7). 
                                                             
‡‡‡‡‡‡‡‡ I acknowledge Professor Carolyn Bertozzi, and Dr. Mireille Kamariza who invented 
DMN-tre, and manually produced the aliquots of dye used in this research (DMN-tre is not 
currently commercially available; the current work would not have been possible without their 
generous assistance).  
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Figure 5-7. Initial test of DMN-tre staining of BCG spiked blood versus SYBR-gold 
staining. 
Two 9 ml samples of whole blood collected from healthy volunteers in sodium heparin tubes, 
spiked with 3*10^5 BCG bacilli and incubated under agitation for 4 hours at 37oC. Centrifuged at 
2000g for 25 min, buffy coat extracted by pipetting (~1.5ml). 12.5ml erythrocyte lysis buffer 
(0.83% w/v NH4Cl, 0.1% w/v KHCO3, 0.01M EDTA pH 7.5) added and incubated at room 
temperature for 30 min, then pelleted at 3000g for 25 minutes. Both samples resuspended in 5ml 
of MFL broth in sodium heparin tubes; one tube had 10µL of 100mM DMN-tre added (final 
concentration 167 µM), then both incubated under agitation for 18 hours at 37oC, then pelleted 
at 3000g for 25 minutes. Resuspended in 30ml distilled water for 30 minutes at room 
temperature, pelleted at 3000g for 25 minutes and resuspended in 1ml PBS. The second sample, 
not previously stained with DMN-tre, was stained with SYBR-gold (60µL of 10^-4 dilution 
working stock added to 1ml, then heated at 65oC for 12 minutes). 200µL of each sample 
concentrated on membrane filter using the Sterlitech centrifuge system (which should equate to 
~500000 bacilli on membrane). In the SYBR-gold stained sample, occasional bacilli were visible 
at 100x magnification (two are visible in lower left panel, most fields of view contained no bacilli). 
In the DMN-tre sample, the number of visible bacilli were more than 100-fold more numerous 
(visible in most fields of view, lower right panel shows more than 40 bacilli). 
 
 
5.3.1.5 Optimised microscopy method tested in spiked samples & clinical sample pilot 
The optimised microscopy method is summarised below:  
Consumables 
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• RBC lysis buffer [155mM NH4Cl; 12mM NaHCO3; 0.1 mM EDTA] 
• Myco/F lytic broth [BD Bactec] 
• Lysis buffer 2 [DI H2O with 0.5% Triton-X-100 and 1% Tween80] 
• Proteinase K 
• 13mm, 0.6micron black Polycarbonate (PCTE) membrane filters [Sterlitech 
PCTB0613100]  
• Reusable centrifuge Ultrafiltration Holder, 13mm [ Sterlitech UFREU1301] 
Method 
1. 5ml of blood collected in sterile sodium heparin tube. Centrifuged at 1800g for 20 
minutes to separate cell layers from plasma; buffy coat extracted by pipetting. 
2. Add 45ml RBC lysis buffer to buffy coat, incubate at room temperature for 30 
minutes, inverting ~10 times during incubation to mix. 
3. Pellet at 3000g for 25min, re-suspend pellet by reverse pipetting in 1-2ml of RBC 
lysis buffer. 
4. Repeat this RBC lysis buffer lysis and wash (step 2 & 3). 
5. Re-suspend pellet in 5ml of MFL broth. 
6. Add 10µL of 100mM DMN-tre (final concentration 167 µM) and incubate under 
agitation for 18 hours at 37oC. 
7. Add 25ml of lysis buffer 2 which has been pre-warmed to 37oC 
8. Add 20mg of proteinase K to the sample / buffer solution. 
9. Incubate at 37oC for 25 minutes, inverting to mix every ~5minutes. 
10. Pellet at 3000g for 25min, re-suspend pellet by reverse pipetting in 2ml DIH2O. 
11. Spin sample through PCTE membrane in Ultrafiltration holder [1800G for 10min]. 
This was tested in volunteer blood samples (6ml) spiked with BCG bacilli at 100, 10, 1 
and 0 bacilli per ml. Another lab user labelled these tubes so that the operator was 
blinded to sample identity. Samples were then processed as per the above optimised 
method. In three replicates, the 100 bacilli/ml sample was distinguished from the 0 
bacilli control 3/3 times, the 10 bacilli/ml sample was distinguished from control 3/3 
times, and the 1 bacilli/ml sample was distinguished from control correctly 1/3 times. 
Further in vitro validations were not performed to accurately determine the limit of 
detection due to limited availability of DMN-tre (which is currently not being 
commercially produced). 
Instead, the method was next tested in clinical samples, in 5 patients from pilot 2 (figure 
1). In this pilot, five patients were recruited based on high predicted probability of 
MTBBSI (using the machine learning modelling and bedside prediction app developed 
in chapter 2). Microscopy was performed on samples in the 24 hours after patient 
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recruitment, i.e. before blood culture or Xpert results were available, so with operator 
blinded to blood culture status (but not to patient identifiers).  
Patients were classified as MTBBSI or not based on microscopy examination of blood. 
As with any microscopy, this is an operator dependent decision, as artefacts must be 
distinguished from bacilli based on morphology. Four out of five patients were judged to 
have bacilli on blood microscopy (figure 8); these same 4/5 patients were also 
subsequently blood culture positive and blood Xpert positive, meaning microscopy had 
full concordance with the other methods for identifying MTBBSI. Notably, one patient 
had more than 100,000 bacilli on the filter membrane, which would equate to >10^4 
bacilli per ml of the original blood sample. This patient also had the lowest TTD in MFL 
and lowest CT value on blood Xpert. 
Results from this pilot, and from other investigations further detailed below, suggested 
that the assumption that maximum numbers of bacilli would be found in the buffy coat 
was invalid. Therefore, before the microscopy technique was taken forward to the larger 
sub-study, it was adapted so that the whole blood sample was lysed in RBC lysis buffer 
(step 2 in method above), with the previous step for extracting buffy coat being 
abandoned. Surprisingly, this increased the adequacy of filtration of the subsequent 
lysate to >95% (data not shown).   
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Figure 5-8. DMN-tre microscopy images from pilot 2. 
Bacilli show variability in intensity of staining, variable lengths, and beaded appearance. 
Doublet cells and microcolonies are also seen, particularly in one patient (lower row) 
who had more than 100,000 bacilli on the filter membrane. One patient was classified as 
blood microscopy negative (Pt 853), an artefact which was closest to appearance of a 
bacilli is shown for this sample. 
 
 
5.3.2 MFL blood culture  
5.3.2.1 Pre-processing blood prior to MFL culture 
Blood sampling for culture at serial time points after start of TB therapy inevitably 
results in antimicrobial carry-over from blood into the culture broth. Taking blood for 
culture only at pre-dose time points was not always possible for logistic (imperfect 
control over time doses were administered in real-hospital environment) and design 
(timepoints less than 24 hours after dose) reasons. In addition, although free drug in 
plasma may have predictably low trough levels, this may not be true of intra-cellular 
concentrations, or bound drug.  
Therefore, methods for drug removal were investigated for patient blood samples in 
pilot 1 and the larger sub study (summarised in figure 1). In pilot 1, sixteen patients 
predicted to have high risk of MTBBSI underwent serial TB blood cultures over the first 
48 hours of treatment. At each sampling timepoint, a direct inoculation of 5ml blood 
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into an MFL bottle was made, and a 5ml sample of blood collected in parallel in sterile 
sodium heparin tubes. This second sample was centrifuged (25 min at 3,000g), and the 
resulting cell pellet (red cells and buffy coat) inoculated into an MFL bottle.  
This allowed comparison of direct inoculation to pellet inoculation. Pelleting before 
culture was associated with increased probability of positive culture, although the trend 
was not statistically significant (table 3). Conversely, pelleting was associated with an 
increase in time to detection in paired comparison (again not reaching statistical 
significance in this small sample) (figure 9).  
Table 5-3. Direct versus pellet MFL blood culture results from pilot 1 
Pairwise contingency by patient-timepoint, all timepoints 
 Pellet positive Pellet negative 
Direct positive 11 2 
Direct negative 7 31 
McNemar's test p =0.182 
Pairwise contingency by patient-timepoint, post-abx timepoints only 
 Pellet positive Pellet negative 
Direct positive 3 2 
Direct negative 5 28 
McNemar's test p =0.4497 
 
 
Figure 5-9. Time-to-detection in MFL for paired positive samples: direct versus cell 
pellet inoculation. 
Eleven pairs of samples positive by both direct inoculation and cell pellet inoculation. In 7/11 
samples pellet had longer TTD, in 3/11 direct had longer TTD and in 1/11 TTD was identical; 
mean difference 55 hours longer for pellet; p value from paired t-test. 
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 In the larger sub-study direct inoculation was not used. Instead a pair of samples from 
each time point were processed two ways; the first (~4ml) by pelleting as described for 
pilot 1. For the second MFL culture from each timepoint, 14ml of blood collected in 
sodium heparin tubes was lysed with addition of 32ml RBC lysis buffer [155mM NH4Cl; 
12mM NaHCO3; 0.1 mM EDTA], incubation at room temperature for 25 minutes, 
followed by centrifuging at 3000g for 25 minutes, resuspension of the pellet in 45ml of 
0.22µm filtered deionized water for 25 minutes at room temperature, followed by 
centrifuging at 3000g for 25 minutes and resuspension to ~5ml in sterile PBS solution. 
One-quarter of this lysate was inoculated into a second MFL bottle (equating to 3.5ml of 
the original blood sample). This allowed comparison of pellet culture to lysate culture 
(table 4), showing that lysate resulted in better recovery of mycobacteria, with the effect 
restricted to samples taken after start of antimicrobials. Again, a converse pattern was 
seen for TTD in MFL, with the pellet method having shorter TTD despite lower 
sensitivity for recovery of mycobacteria (figure 10). This implies that manipulation of 
sample prior to culture changes the relationship between number of bacilli and TTD. 
 
Table 5-4. Lysate versus pellet MFL blood culture results from sub-study 
Pairwise contingency by patient-timepoint, all timepoints 
 Pellet positive Pellet negative 
Lysate positive 18 23 
Lysate negative 11 59 
McNemar's test p =0.059 
Pairwise contingency by patient-timepoint, post-abx timepoints only 
 Pellet positive Pellet negative 
Lysate positive 9 18 
Lysate negative 6 50 
McNemar's test p =0.025 
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Figure 5-10. Time-to-detection in MFL for paired positive samples: blood lysate 
versus cell pellet inoculation. 
Eighteen pairs of samples positive by both blood lysate inoculation and cell pellet inoculation. In 
16/18 samples lysate had longer TTD, in 2/18 pellet had longer TTD; mean difference 6 days 
longer for lysate; p value from paired T-test. 
 
5.3.2.2 Serial MFL results in pilot 1 study 
Fourteen patients had at least 1 positive MFL blood culture, of these 13 had valid 
sample results from ≥24 hours after start of TB therapy, and 4/13 remained culture 
positive at one of these later timepoints (figure 11). All but 1 post 24-hour positive 
culture was from a pellet culture. TTD rose for all patients with positive cultures at 
more than one timepoint, except for two patients with MDR isolates (figure 12).  
In sum, pre-processing blood before MFL culture demonstrated that culture positive 
MTBBSI was detectable after start of treatment and could therefore be used for an in 
vivo time kill study. 
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Figure 5-11. Serial MFL culture results from pilot 1. 
Sixteen patients each had 2 cultures (rows) at timepoints relative to start of TB therapy 
(columns; prior to therapy=0h, and 4-12, 24, and 48h after first dose). Two patients had 
resistance to rifampicin (MDR) and were initially treated with standard therapy; five patients 
died by 12 weeks follow-up (last column). 
 
0h  4-12h 24h 48h
1 Direct 0 0 0 1
MDR Pellet 1 0 0 1
2 Direct 1 0 0 NA
Pellet 1 0 1 0
3 Direct 1 1 0 0
Pellet 1 0 0 0
4 Direct 1 1 0 NA
Pellet 1 1 0 NA
5 Direct 0 0 0 0
Pellet 0 0 0 0
6 Direct 0 NA NA NA
Pellet 1 NA NA NA
7 Direct 1 0 0 0
Pellet 1 1 0 0
8 Direct 0 0 0 0
Pellet NA 0 0 0
9 Direct 1 0 0 NA
Pellet 1 0 1 NA
10 Direct 1 1 0 0
MDR Pellet 1 1 0 0
11 Direct 0 0 0 0
Pellet 0 0 0 0
12 Direct 1 0 0 0
Pellet 1 0 0 0
13 Direct 0 0 0 0
Pellet 1 0 0 0
14 Direct 1 0 0 NA
Pellet NA 0 1 0
15 Direct 1 0 NA NA
Pellet 1 1 NA NA
16 Direct 0 1 0 0
Pellet 0 1 0 0
0 No growth at 42 days
1 MTB
NA No culture done
alive
alive
alive
alive
alive
alive
died
died
died
died
died
alive
alive
alive
alive
alive
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Figure 5-12. TTD from serial MFL culture results from pilot 1. 
Patients with positive MFL from more than one timepoint are shown with a line of best fit 
applied to their observed TTDs by time. Two patients with MDR-TB isolates shown in yellow. 
 
5.3.3 Xpert-ultra testing of processed blood 
Xpert MTB/RIF (Xpert) is a nearly fully automated cartridge based hemi-nested PCR 
assay ( products from the first PCR are used as the template in a second PCR, using 
different primers whose binding sites are ‘nested’ within the first set, thus increasing 
specificity) which amplifies five moieties on the rpoB gene of M. tuberculosis to detect the 
presence of bacilli and mutations responsible for the majority of rifampicin resistance. A 
next generation assay, Xpert MTB/RIF Ultra (Xpert-ultra) has been developed to have 
improved sensitivity. In addition to optimised cartridge fluids and chemistry, Xpert-
ultra incorporates two extra amplification targets.560 IS6110 and IS1081 are multicopy 
genes (copies vary between isolates, H37Rv for example has 16 copies of IS6110); 
Xpert-ultra labels both with the same fluorescent probe and measures combined signal 
to detect M. tuberculosis, while the five rpoB targets are probed separately to determine 
rifampicin resistance genotype.560 Xpert-ultra has improved limit of detection by 
approximately 1-logarithm compared to Xpert.338,560 
As discussed in chapter 4, Xpert rpoB probe CT values are at least semi-quantitative for 
intact bacilli number. As with the previous system, Xpert-ultra also gives an ordinal 
read-out on quantity based on CT values: high, medium, low, very low, & trace 
detection. The first 4 are bins of minimum rpoB CT value across the 5 probes; the 5th 
“trace” is samples where rpoB PCR was negative, but IS6110-IS1081 signal was 
detected. Because these genes are multicopy, this could in theory complicate 
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interpretation of their CT values as a read out of number of bacilli. Xpert-ultra 
cartridges, like their predecessors, also run an internal control PCR to assess PCR 
inhibition, but this value does not seem to be factored in when assigning ordinal category 
for bacilli quantity.§§§§§§§§  
As discussed above, previous attempts to use Xpert to detect MTBBSI have had poor 
sensitivity, and probably had sub-optimal pre-processing of blood (focussing instead on 
low volume lysis buffer for practical reasons). In addition, the new generation Xpert-
ultra has not been tested on blood. Therefore, Xpert-ultra testing of blood after more 
thorough lysis and washing was tested in the current analysis.  
5.3.3.1 Xpert-ultra testing of spiked blood samples 
A fully attenuated M. tuberculosis strain with auxotrophic mutations in leucine and 
pantothenate biosynthesis was grown and quantified in early-log phase growth using the 
calcein stained flow cytometry method described in chapter 4.********* Volumes of culture 
broth equating to range 60, 300, 600, 1200, and 4800 calcein positive (metabolically 
active) bacilli were inoculated into 6ml samples of volunteer blood collected in sodium 
heparin tubes (for final bacilli concentration 10, 50, 100, 200, 800 bacilli/ml). Samples 
were lysed in 40ml RBC lysis buffer for 30 minutes at room temperature then pelleted at 
3000g for 25minues. The pellet was resuspended in 45ml of 0.22µm filtered deionised 
water for 30 minutes at room temperature and re-pelleted as before; this pellet was 
resuspended in 2ml of sterile PBS and stored at -20oC until time of Xpert-ultra testing. 
After thawing at room temperature, the 2ml sample was centrifuged at 16000g for 10 
minutes, with removal of 1ml supernatant, and resuspension in remaining volume. This 
residual 1ml volume was mixed with 1ml of Xpert buffer, incubated at room 
temperature for 30 minutes, then pipetted into Xpert-ultra cartridges as per 
manufacturer instructions.  
Three replicates of each bacilli concentration were performed; M. tuberculosis was 
detected in all samples except one replicate of 10 bacilli/ml (negative result) and one 
                                                             
§§§§§§§§ I can’t find a citation for this, but have worked it out empirically from the raw data 
exports from Xpert-ultra machine. 
********* The ΔleuDΔpanCD double auxotroph M. tuberculosis was kindly gifted by Professor Digby 
Warner of the Molecular Mycobacteriology Research Unit, University of Cape Town and was 
used here as it can be processed safely in biosafety level 2 laboratory. 
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replicate of 50 bacilli/ml (error result). Log transformed bacilli concentration correlated 
with Xpert-ultra CT value (figure 13). This suggested that two high volume lysis step 
pre-processing of blood combined with Xpert-ultra testing was potentially highly 
sensitive for detecting MTBBSI. 
 
Figure 5-13. Xpert-ultra CT correlation with number of bacilli in spiked blood. 
CT values are for the combined IS6110-IS1081 probe. Internal control CT values were all less 
than 28 providing evidence that PCR inhibition was not significant. 
 
 
5.3.3.2 Pilot Xpert-ultra testing of patient blood samples 
Next, the above cell lysis and Xpert-ultra method was tested on clinical samples from 
pilot studies.   
Five samples were tested from pilot 2. Five patients were recruited based on high 
predicted probability of MTBBSI (using the machine learning modelling and bedside 
prediction app developed in chapter 2). Fifteen ml of blood was collected in sodium 
heparin tubes; buffy coat was extracted and lysed as described in steps 1-4 of method in 
section 5.3.1.5. One-quarter of the lysate (representing 3.75ml volume of original 
sample) was stored at -20oC until time of Xpert-ultra testing. After thawing at room 
temperature, lysate sample was made up to 15 ml volume with 0.22µm filtered deionised 
water, incubated for 30 minutes at room temperature, and pelleted at 3000g for 25 
minutes. Fourteen ml of supernatant was removed, pellet resuspended in residual 1ml 
volume and mixed with 1ml of Xpert buffer, incubated at room temperature for 30 
minutes, then pipetted into Xpert-ultra cartridges as per manufacturer instructions.  
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Four freezer stored whole blood samples (~5ml) from the KDHTB study were also 
processed using the same lysis steps (without buffy coat extraction, and without second 
freezing step after lysing). 
From the total of 9 samples, 1 gave no result on Xpert-ultra testing (error message); of 
the eight with valid results, 6/8 were positive and 2/8 were negative. These results were 
in complete concordance with the MFL culture results performed on samples from the 
same venesection, and CT values correlated with TTD in MFL (figure 14).  
 
Figure 5-14. Blood Xpert-ultra versus MFL results from clinical pilot testing. 
Xpert-ultra had 100% agreement with MFL results (left), and some evidence of correlation 
between CT value and TTD in MFL was also seen (right). 
 
 
5.3.3.3 Imputing CT values for trace detected blood samples 
As discussed above, Xpert-ultra ‘trace detected’ results are given for samples which are 
negative for rpoB PCRs but positive for the combined IS6110-IS1081 probe. By 
definition, then, trace detected samples don’t have a CT value for rpoB moieties, but do 
have a CT for the multicopy IS6110-IS1081 genes. To check if this CT value can be used 
quantitatively, the correlation between minimum rpoB CT and IS6110-IS1081 CT was 
assessed for samples with both available from the serial sub-study. This revealed a 
reasonably strong relationship between the two (figure 15), which was then used to 
impute minimum rpoB CT values for trace detected samples (hereafter referred to as 
Xpert-ultra CT values for convenience). 
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Figure 5-15. Comparing Xpert-ultra CT values based on rpoB & IS6110-IS1081 
probes. 
IS6110-IS1081 CT values are available for all positive samples (A), but rpoB CT values are not 
available for “trace detected” samples (B). IS6110-IS1081 CT correlates with rpoB CT for very-
low to high detected samples, with a notably non-linear relationship (C, aR2=0.80 for quadratic 
line of best fit shown). Trace-detected samples rpoB CT imputed using this relationship (D). 
 
 
5.3.4 Location of bacilli in MTBBSI 
Cellular location of mycobacteria is of importance from an immunological and PKPD 
perspective.103,494,561-564 As mentioned previously, many methods for identifying bacilli in 
MTBBSI use buffy coat / PBMC extraction, based on the assumption that most 
bacteraemic M. tuberculosis is intracellular. Also shown above was the finding that any 
free bacilli in plasma would not be expected to sediment in the buffy coat layer at the low 
g typically used for PBMC extraction methods. Therefore, whether bacilli in MTBBSI 
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are predominantly in white blood cells or extracellular is of fundamental and practical 
interest.  
In pilot 2, plasma, buffy coat, and red cell pellet from 5 patients were separated and 
cultured in different MFL bottles. Of these, only 1/5 grew M. tuberculosis from the buffy 
coat, while 4/5 cultures of the red cell pellet were positive. These results contradict the 
assumption that most bacilli are within white cells in MTBBSI.  
This finding was tested further with 10 samples from patients recruited to the sub-study. 
In each case, ~4ml of blood was syphoned for processing with Polymorphprep (Axis-
Shield / Alere Technologies, Oslo). Polymorphprep is an osmotic density gradient 
designed to separate both PBMCs and polymorphonucleocytes from erythrocytes. This 
is important because: (1) in simple centrifuge preparations of the buffy coat, 
granulocytes may colocalise with red blood cells below the buffy coat,565,566 and (2) 
neutrophils are the predominant phagocytic location of M. tuberculosis in at least some 
body compartments.567 Polymorphprep was therefore used as a gold standard method of 
ensuring neutrophils were captured in buffy coat preparations for these ten samples. 
The procedure is illustrated in figure 16. 
Extracted plasma, buffy coat preparation, and red cell pellet, were all processed with 3 
lysis-wash steps (two with filtered deionised water prior to storage at -20oC, one after 
thawing) prior to Xpert-ultra testing, as previously described for whole blood samples. 
This allowed comparison of Xpert-ultra CT values for the three blood compartments:  
red cell pellet; buffy coat preparation (which should contain >95% of all WBCs, but was 
generally contaminated with some RBCs); and plasma. The whole blood sample lysate 
processed in parallel for these samples is a further comparator, representing all 3 
compartments combined.   
Of these ten patient samples, most were positive from any compartment, with no 
statistically significant differences in recovery in any pairwise comparison (table 5). In 
particular, buffy coat layer did not have significantly higher recovery than plasma or red 
cell pellet. Cycle-threshold values, however, suggested that plasma had the lowest bacilli 
copy number (highest CT), and that whole blood lysate had the greatest bacilli copy 
number (lowest CT). Some patients had lower CT for buffy coat than red cell pellet, 
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while in others the reverse was seen; overall no significant difference between buffy and 
red cell pellet bacilli quantity was evident. 
 
 
Figure 5-16. Polymorphprep SOP. 
As shown in the manufacturer’s schematic (A), blood is layered on top of an equal volume of 
polymorphprep, spun at a low g for 30 minutes without brake. This should result in two 
erythrocyte free WBC layers corresponding to PBMCs and granulocytes (PMNs). The 
manufacturer acknowledge that separation is less complete when not using health volunteer 
blood (example from MTBBSI patient from current analysis shows not all RBCs sediment to red 
cell pellet, B). The 1/3 of the processed sample containing PBMC/PMC buffy coat should, 
however, contain >95% of white cells, i.e. >95% of phagocytosed bacilli, despite some 
contamination with RBCs. In turn, the top and bottom 1/3 (plasma and red cell pellet 
respectively) should be largely free of white blood cells. 
 
Table 5-5. Qualitative results Xpert-ultra for different blood compartments 
sample buffy plasma Rcp WBlysate 
1 M.tb detected M.tb detected M.tb detected M.tb detected 
2 Negative M.tb detected Negative M.tb detected 
3 M.tb detected M.tb detected M.tb detected Negative 
4 Negative M.tb detected Negative Negative 
5 M.tb detected M.tb detected M.tb detected M.tb detected 
6 M.tb detected M.tb detected M.tb detected M.tb detected 
7 M.tb detected M.tb detected M.tb detected M.tb detected 
8 M.tb detected Negative Negative M.tb detected 
9 M.tb detected M.tb detected M.tb detected M.tb detected 
10 M.tb detected M.tb detected M.tb detected M.tb detected 
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*Plasma, buffy, rcp (red cel pellet) = the three polymorphprep separated blood compartments 
(see figure 16). WBlysate = whole blood lysate, a second same volume sample from the same 
patient-timepoint processed complete, without separation of the components. 
 
Figure 5-17. Comparison Xpert-ultra CT values for different blood compartments. 
Each sample set (from the same patient timepoint, i.e. the same venesection) shown with 
individual colour. Line connect adjacent points only; if there is no CT value because the sample 
was negative, connecting line is interrupted. P-values are from paired t-tests from each pairwise 
comparison. Plasma, buffy, rcp (red cel pellet) = the three polymorphprep separated blood 
compartments (see figure 16). WBlysate = whole blood lysate, a second same volume sample 
from the same patient-timepoint processed complete, without separation of the components. 
 
 
Taken together, these results are not in keeping with the majority of bacteraemic bacilli 
being intracellular in MTBBSI. Rather, M. tuberculosis appears to be spread across blood 
compartments, including association with red cells (it is unknown if this association 
results from similar density-centrifugation properties or if it is in some way 
mechanistic). In sum, it seems likely that extra-cellular bacilli are common in MTBBSI. 
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5.4 KDHTB sub-study to characterise 
clinical pharmacodynamics of 
MTBBSI 
Having optimised existing methods and developed novel methods for identifying and 
quantifying MTBBSI, a cohort was recruited to  
• report the dynamics of MTBBSI over the first 72 hours of anti-tuberculosis 
chemotherapy (ATC); and 
• assess for association of MTBBSI pharmacodynamics with major clinical variables 
including mortality outcome.  
This cohort was recruited as a sub-study within the KDHTB parent study.  
5.4.1 Sub-study Methods 
5.4.1.1 Patient recruitment, inclusion and exclusion  
All patients in Khayelitsha Hospital emergency department, and patients admitted to 
medicine in the preceding 24-hours, were screened each morning Monday-Friday. All 
patients who were HIV positive and had at least one of thrombocytopenia, 
hyponatraemia < 130 mEp/L, haemoglobin < 10g/dL, raised creatinine, or CD4 count < 
150 cells/mm3 were formally screened including collection of urine for urine-LAM 
testing on site. Patients who had already received a dose of ATC, and patients with a 
non-tuberculosis diagnosis already made, were excluded. An updated version of the 
MTBBSI prediction model using variables [presence adenopathy or splenic micro-
abscesses, creatinine, sodium, white cell count, MCV, platelets, haemoglobin, CD4 
count, urine-LAM lateral flow result (0 to +4)] was constructed.††††††††† Patients with 
predicted probability of MTBBI > 0.6, and who gave informed consent, were recruited. 
Because of the nature of the study, a further exclusion criterion was patients who did not 
start TB therapy, which was at the discretion of (non-study) hospital doctors. In 
practice, all patients with predicted probability of MTBBSI > 0.5 were started on TB 
                                                             
††††††††† https://davidadambarr.shinyapps.io/MTBBSI_v2/  
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therapy during admission, but sometimes this was delayed by more than 24 hours after 
initial study screening, meaning that recruitment was also delayed to this time.  
5.4.1.2 Sample schedule & blood processing 
Blood was collected at five timepoints: 0h (prior to first does ATC), and 4, 24, 48 & 72 
hours after first does of ATC. At each time point 18ml of blood was collected in sterile 
sodium heparin tubes and transported to a laboratory at University of Cape Town. Five 
ml of blood was centrifuged at 3000g for 25 minutes to pellet all cells; this cell pellet was 
inoculated into a MFL bottle. The remaining blood (13ml) was split into 10ml and 3ml 
aliquots. Both were mixed with 30ml of 0.22µm filtered RBC lysis buffer [155mM 
NH4Cl; 12mM NaHCO3; 0.1 mM EDTA], incubated at room temperature for 30 
minutes with regular inversions to mix, then pelleted at 3000g for 25min. Both pellets 
were then resuspended in 45ml 0.22µm filtered deionised water, incubated at room 
temperature for 30 minutes with regular inversions to mix, then pelleted again at 3000g 
for 25min. The pellet from the10ml blood aliquot was resuspended in 5ml sterile PBS 
and divided as follows: 
• ½ (≡ 5ml of original blood sample) was inoculated into a second MFL bottle. 
• ½ (≡ 3.5ml of original blood sample) was stored at -20oC for downstream Xpert-ultra 
testing. 
The pellet from the 3ml blood aliquot was resuspended in 1ml sterile PBS and added to 
5ml of MFL broth in a 50ml sterile, disposable conical flask. 10µL of 100mM DMN-tre 
(final concentration 154 µM) was added and the sample incubated in dark and under 
agitation for 18 hours at 37oC. 
MFL cultures were transferred to the National Health Laboratory Service medical 
microbiology laboratory at Groote Schuur Hospital, and incubated within 24 hours of 
venesection. 
5.4.1.3 DMN-tre microscopy 
After incubation for 18 hours as above, samples were mixed with 30ml of detergent lysis 
buffer (0.22µm filtered deionised water with v/v 0.5% Triton-X-100 and 1% Tween80). 
18mg of proteinase-K was added to this volume, before incubation in the dark at 37oC 
for 30 minutes, with mixing at 15 minutes by gentle inversion. This was then pelleted at 
3000g for 25 minutes, and the pellet resuspended in 1.5ml 0.22µm filtered deionised 
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water by pipetting, before transfer to the centrifuge filtration device, with filtration at 
1800g for 10 minutes. The black polycarbonate membrane was mounted for microscopy 
as previously described. Each membrane was examined for 1 hour at 100x magnification. 
If bacilli were identified, 500 random fields were examined at 100x magnification to 
quantify bacilli on membrane. The effective surface area of the membranes was 
measured to be 2850 fields of view (FOV), by experiments with fluorescent beads 
counted by flow cytometry – data not shown here, so the bacilli count per ml could be 
calculated as: 
𝑏𝑎𝑐𝑖𝑙𝑙𝑖 𝑚𝑙−1 =  
𝑡𝑜𝑡𝑎𝑙 𝑚𝑖𝑐𝑟𝑜𝑠𝑐𝑜𝑝𝑦 𝑐𝑜𝑢𝑛𝑡
𝐹𝑂𝑉 𝑒𝑥𝑎𝑚𝑖𝑛𝑒𝑑
 ×
2850 𝐹𝑂𝑉
3𝑚𝑙
  
 
5.4.1.4 Xpert-ultra testing 
Batches of thawed samples were made up to a volume of 10ml by addition of 0.22µm 
filtered deionised water, then centrifuged at 4200G for 25 minutes. Supernatant volume 
9.3 ml was removed, leaving ~0.7ml sample, resuspended by pipetting. Xpert buffer 
(1.5ml) added for final volume ~2.2ml, and mixed by vigorous shaking 20 times, then 
incubated at room temperature for 10 minutes, followed by another 20 shakes and 
further 5-minute incubation, before adding to Xpert-ultra cartridges and processing as 
per manufacturer instructions.‡‡‡‡‡‡‡‡‡ Full results were outputted as .txt files and CT 
values extracted as described in section 5.3.3.3 using a custom R script. 
5.4.1.5 Collection of demographic, clinical & follow-up data 
All patients were examined by study clinicians at all sampling timepoints with clinical 
variables recorded on paper proformas. Blood and imaging results were extracted from 
electronic health records and the National Health Laboratory Service database, 
including all results recorded by routine care testing for 3 months after recruitment. 
Patients were formally followed-up by telephone call to ascertain 12-week survival by 
Mr M.K. Mpalali.  
   
                                                             
‡‡‡‡‡‡‡‡‡ I acknowledge Mr Avuyonke Balfour for assistance processing these samples, and to 
Professor Mark Nicol and Dr Slee Mbhele for access to Xpert machines. 
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5.4.2 Sub-study results  
5.4.2.1 Recruitment & cohort description  
Recruitment occurred Monday – Friday between 11/08/2017 and 21/11/2017, with 
serial blood sampling 7 days a week. Approximately 2500 patients underwent initial 
screening, 147 were formally screened (for a calculated predicted probability of 
MTBBSI > 0.56), and 28 met inclusion criteria.  
Patient history, examination, imaging results, and baseline blood results are summarised 
in tables 6 to 9.  Due to the enriched recruitment for MTBBSI, the cohort represented a 
markedly unwell population – all patients were tachycardic, tachyopnoeic, anaemic 
(median haemoglobin 6.5 g/dL), and profoundly immune-compromised (median CD4 
count 33 cells/mm3, 90% not currently taking anti-retrovirals). Functional impairment 
was nearly universal (26/28 ECOG score > 1). Within this severely unwell patient 
strata, variables associated with mortality included functional impairment, respiratory 
compromise (use of ancillary muscles of respiration, nasal flare, bilateral chest-X-ray 
disease, lower pulse oximetry saturation); renal compromise (higher creatinine & urea; 
lower bicarbonate & pH); lower haemoglobin, and higher AST. Patients who died had 
lower platelet counts, but this difference was not statistically significantly. By contrast, 
the fall in platelet count during admission (seen in nearly all patients) was significantly 
greater in those that died (table 10). 
Table 5-6. Patient presenting histories, summary by 12-week outcome. 
  n alive (N=20) died (N=8) Total (N=28) p value 
sex male 28 6 (30.0%) 3 (37.5%) 9 (32.1%) 1 
age 28       0.673 
   median   35.65 33.9 34.8   
   IQR   29.87, 39.70 31.97, 41.98 29.87, 39.88   
ARV status 28       0.956 
   Naïve  12 (60.0%) 5 (62.5%) 17 (60.7%)  
   Taking ARVs  2 (10.0%) 1 (12.5%) 3 (10.7%)  
   Prior not current   6 (30.0%) 2 (25.0%) 8 (28.6%)   
Cough 28 13 (65.0%) 7 (87.5%) 20 (71.4%) 0.467 
Fever 28 15 (75.0%) 5 (62.5%) 20 (71.4%) 0.843 
Night sweats 28 15 (75.0%) 5 (62.5%) 20 (71.4%) 0.843 
Weight loss 28 20 (100.0%) 8 (100.0%) 28 (100.0%) 1 
ECOG level 28       0.022* 
   1   2 (10.0%) 0 (0.0%) 2 (7.1%)   
   2   5 (25.0%) 0 (0.0%) 5 (17.9%)   
   3   7 (35.0%) 2 (25.0%) 9 (32.1%)   
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   4   6 (30.0%) 6 (75.0%) 12 (42.9%)   
n = number with complete observations. IQR = interquartile range. ECOG = Eastern Cooperative 
Oncology Group functional performance score. ARV = anti-retroviral. 
P-value from Wilcox Rank Sum or Fisher exact test as appropriate; except * which is from Chi-
squared test for a trend. 
 
Table 5-7. Baseline examination findings, summary by 12-week outcome. 
  n alive (N=20) died (N=8) Total (N=28) p value 
Walks unaided 28 7 (35.0%) 2 (25.0%) 9 (32.1%) 0.949 
Can self-feed 28 18 (90.0%) 5 (62.5%) 23 (82.1%) 0.242 
GCS<15 28 5 (25.0%) 2 (25.0%) 7 (25.0%) 1 
Wasting 28 12 (60.0%) 7 (87.5%) 19 (67.9%) 0.337 
Candidiasis 28 9 (45.0%) 4 (50.0%) 13 (46.4%) 1 
Oedema 28 5 (25.0%) 3 (37.5%) 8 (28.6%) 0.843 
Peripheral adenopathy 28 7 (35.0%) 1 (12.5%) 8 (28.6%) 0.467 
Flushed 28 8 (40.0%) 2 (25.0%) 10 (35.7%) 0.755 
Sweating on exam 28 7 (35.0%) 3 (37.5%) 10 (35.7%) 1 
Cool peripheries 28 6 (30.0%) 5 (62.5%) 11 (39.3%) 0.245 
Capillary refill >2sec 28 7 (35.0%) 5 (62.5%) 12 (42.9%) 0.365 
Doughy abdomen 28 3 (15.0%) 3 (37.5%) 6 (21.4%) 0.423 
Tender abdomen 28 6 (30.0%) 4 (50.0%) 10 (35.7%) 0.575 
Use ancillary muscles 28 5 (25.0%) 6 (75.0%) 11 (39.3%) 0.043 
Nasal flare 28 6 (30.0%) 6 (75.0%) 12 (42.9%) 0.08 
Full sentences 28 17 (85.0%) 6 (75.0%) 23 (82.1%) 0.938 
Heart rate / min 28    0.989 
   median  121.5 121.5 121.5  
   IQR  113.50, 128.00 117.50, 129.00 113.50, 128.00  
Systolic BP 28       0.697 
   median   113 108 111.5   
   IQR   100.50, 128.25 95.50, 114.50 99.00, 127.25   
Diastolic BP 28    0.43 
   median  70 71 70  
   IQR  63.50, 81.25 64.25, 82.25 63.50, 81.25  
Respiratory rate /min 28       0.553 
   median   30 32 31   
   IQR   26.00, 38.00 29.00, 37.00 26.00, 38.00   
Pulse oxygenation 28    0.008 
   median  97 94.5 96  
   IQR  95.75, 99.00 89.50, 96.50 95.00, 98.25  
Temperature oC 28       0.59 
   median   38.25 37.9 37.95   
   IQR   37.30, 39.25 37.17, 38.35 37.30, 38.75   
n = number with complete observations. IQR = interquartile range. BP = blood pressure. GCS = 
Glasgow Coma Scale. 
P-value from Wilcox Rank Sum or Fisher exact test as appropriate 
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Table 5-8. Imaging, sputum & uLAM findings, summary by 12-week outcome. 
  n alive (N=20) died (N=8) Total (N=28) p value 
CXR pleural effusion 28    0.592 
   Bilateral  1 (5.0%) 1 (12.5%) 2 (7.1%)  
   Unilateral  1 (5.0%) 1 (12.5%) 2 (7.1%)  
   None  18 (90.0%) 6 (75.0%) 24 (85.7%)  
CXR miliary 28 2 (10.0%) 3 (37.5%) 5 (17.9%) 0.242 
CXR bilateral infiltrate 28 10 (50.0%) 8 (100.0%) 18 (64.3%) 0.04 
CXR symmetrical infiltrate 28 5 (25.0%) 5 (62.5%) 10 (35.7%) 0.151 
CXR adenopathy 28 11 (55.0%) 5 (62.5%) 16 (57.1%) 1 
USS hepatomegaly 22 3 (18.8%) 0 (0.0%) 3 (13.0%) 0.578 
USS liver echogenic 22 8 (50.0%) 4 (57.1%) 12 (52.2%) 1 
USS splenomegaly 22 2 (12.5%) 0 (0.0%) 2 (8.7%) 0.861 
USS splenic micro-abscesses 22 13 (81.2%) 7 (100.0%) 20 (87.0%) 0.578 
USS kidney echogenic 22       0.243 
   Very increased   0 (0.0%) 1 (14.3%) 1 (4.3%)   
   Increased   11 (68.8%) 5 (71.4%) 16 (69.6%)   
   Normal   5 (31.2%) 1 (14.3%) 6 (26.1%)   
USS kidney CMD loss 22 2 (12.5%) 1 (14.3%) 3 (13.0%) 1 
USS frank ascities 22 1 (6.7%) 0 (0.0%) 1 (4.5%) 1 
USS pleural effusion 22 3 (20.0%) 2 (28.6%) 5 (22.7%) 1 
USS pericardial effusion >1cm 22 1 (6.7%) 1 (14.3%) 8 (36.4%) 1 
USS adenopathy 22 11 (68.8%) 5 (71.4%) 16 (69.6%) 1 
USS gall bladder oedema 22 3 (20.0%) 1 (14.3%) 4 (18.2%) 1 
uLAM 28    0.691 
   0  1 (5.0%) 0 (0.0%) 1 (3.6%)  
   1  5 (25.0%) 3 (37.5%) 8 (28.6%)  
   2  5 (25.0%) 1 (12.5%) 6 (21.4%)  
   3  5 (25.0%) 1 (12.5%) 6 (21.4%)  
   4  4 (20.0%) 3 (37.5%) 7 (25.0%)  
Sputum Xpert 28       0.684 
   MTB   5 (25.0%) 3 (37.5%) 8 (28.6%)   
   Negative   1 (5.0%) 0 (0.0%) 1 (3.6%)   
   No sputum obtained   14 (70.0%) 5 (62.5%) 19 (67.9%)   
n = number with complete observations. CXR = chest x-ray. USS = ultrasound scan of abdomen. 
Both performed as part of routine care, USS were all reported using a standardised template, 
CXRs all interpreted by the author. Small effusions were common but all were sub-clinical.  P-
vales from Fisher exact test. 
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Table 5-9. Baseline blood results, summary by 12-week outcome. 
  n alive (N=20) died (N=8) Total (N=28) p value 
log CD4 count 28 3.63 (0.83) 2.72 (1.67) 3.37 (1.17) 0.063 
pH 28 7.44 (0.08) 7.36 (0.11) 7.42 (0.10) 0.032 
HCO3 28 23.04 (5.72) 18.01 (5.86) 21.60 (6.11) 0.047 
Base Excess 28 -2.08 (6.75) -7.46 (7.86) -3.62 (7.36) 0.08 
log venous lactate 28 1.02 (0.51) 1.32 (0.51) 1.10 (0.52) 0.162 
pCO2 (venous) 28 4.10 (1.06) 3.90 (0.87) 4.05 (1.00) 0.632 
log glucose 28 1.94 (0.28) 1.92 (0.19) 1.93 (0.25) 0.854 
Haemoglobin* 28 7.53 (1.51) 5.47 (0.54) 6.94 (1.61) < 0.001 
MCV 28 80.69 (8.53) 77.01 (8.77) 79.64 (8.60) 0.316 
log platelet count 28 5.37 (0.57) 5.20 (0.41) 5.32 (0.52) 0.445 
log white cell count 28 1.97 (0.59) 1.69 (0.55) 1.89 (0.58) 0.256 
log sodium 27 4.85 (0.05) 4.84 (0.06) 4.84 (0.05) 0.674 
Potassium 27 4.26 (0.77) 4.15 (0.68) 4.23 (0.73) 0.722 
log urea 27 1.85 (0.78) 3.03 (0.75) 2.20 (0.94) 0.001 
log creatinine 28 4.54 (0.78) 5.34 (0.71) 4.77 (0.83) 0.018 
log albumin 14 2.89 (0.17) 2.88 (0.19) 2.88 (0.17) 0.898 
Alkaline phosphatase 12 160.17 (74.42) 187.00 (104.91) 173.58 (87.84) 0.62 
log ALT 21 3.53 (1.08) 3.71 (0.78) 3.60 (0.96) 0.685 
log AST 19 4.51 (1.02) 5.27 (0.78) 4.83 (0.98) 0.093 
log conjugated bilirubin 10 1.88 (0.31) 1.93 (0.91) 1.91 (0.64) 0.903 
Ferritin 8 1378.75 (242.50) 1304.25 (391.50) 1341.50 (304.10) 0.757 
n = number with complete observations. Mean (standard deviation) shown. Gas results are 
venous. Variables have been transformed to approximate normal distributions. P-value from t-
tests. Baseline values are defined as closest result to day of admission within a 7-day range. * 
Rather than baseline, haemoglobin results are the nadir haemoglobin during admission, because 
admission full blood counts overestimated haemoglobin due to haemoconcentration secondary to 
low extra-cellular fluid volumes.  
 
Table 5-10. Daily rate of change in platelet count, haemoglobin, & log creatinine 
during admission period. 
  n alive (N=20) died (N=8) Total (N=28) p value 
Platelet count change, cells/µL/day 21       0.008 
   Median   -2.64 -11.88 -4.1   
   IQR   -7.56, 3.67 -24.33, -6.82 -12.00, -0.08   
Haemoglobin change, g/dL/day 21    0.404 
   Median  -0.06 0.04 0.03  
   IQR  -0.20, 0.07 -0.11, 0.14 -0.22, 0.11  
Creatinine change, log µmol/L/day 24       0.417 
   Median   -0.08 -0.06 -0.08   
   IQR   -0.09, -0.06 -0.12, 0.04 -0.10, -0.02   
n = number with complete observations. IQR = interquartile range.  
P-value from Wilcox Rank Sum. Rate of change for each variable was calculated from slope of a 
line of best fit applied to data points from up to 14-days after admission. Residual variation in 
haemoglobin was marked due to the effects of haemodilution (all patients received IV fluids on 
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admission), blood transfusion (3 patients), and blood loss after blood anticoagulation due to 
venous thrombo-embolism (2 patients) 
 
 
5.4.2.2 Overall MTBBSI detection by method at all patient-timepoints 
28 patients by 5 timepoints is 140 sample time points. This gave a potential 140 DMN-
tre microscopy and blood Xpert-ultra samples, and 280 MFL culture samples (two at 
each patient-timepoint). Samples were not collected at 25 patient timepoints (10 
discharges or patient transfers where patient could not be located or brought back; 7 
declined samples; 5 missed due to time constraint; 3 because patient died before 
timepoint).  
Blood Xpert-ultra and DMN-microscopy had substantially higher detection rates 
(83/114 & 73/101 positive tests in valid samples, 72% for both) compared to MFL 
culture (71/226 valid results, 31%) (table 11 & 12).  
Overall agreement of tests across all patient-timepoints was moderate: 
• MFL ~ DMN-tre:    kappa = 0.37; p = 1.7e-05 
• MFL ~ blood Xpert-ultra:   kappa = 0.27; p = 1.0e-03 
• Blood Xpert-ultra ~ DMN-tre:   kappa = 0.34; p = 9.2e-05 
For comparison, no agreement with urine-Xpert-ultra result beyond chance was found 
for any of the three TB blood tests (95% confidence intervals for kappa all cross zero). 
 
Table 5-11. Available samples by method. 
method 
samples 
processed Potential 
technical 
failures* 
valid 
results 
M.tb 
detected negative 
M.tb 
quantified 
MFL blood 
culture 
229 280 5 226 71 155 69 
DMN-tre 
microscopy 
115 140 14 101 73 28 73 
Blood 
Xpert-ultra 
115 140 1 114 83 31 83 
*Technical failures for MFL = 2 contamination, 1 lost viability, 1 lost by lab, 1 discarded by 
accident. Technical failures for DMN = 2 contamination, 2 lost sample (filter caught in hood 
airflow), 1 discarded by accident, 9 had debris or some other fluorescence obscuring the fields of 
view. Technical failures for Xpert = 1 discarded by accident. 
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Table 5-12. Pairwise comparison of method for detecting MTBBSI across all patient 
timepoints. 
  
DMN-tre microscopy and blood Xpert had higher detection rates across all patient timepoints 
(top row of tables); and were similar to MFL culture when analysis was restricted to 0h 
timepoint, i.e. samples taken before anti-tuberculosis therapy was started. P-values from 
McNemar’s Chi-squared test for count data. 
 
5.4.2.3 MTBBSI detection by patient 
In total, 20/28 (71%) patients had at least one positive MFL blood culture; 22/28 (79%) 
had at least one positive DMN-tre microscopy sample; and 26/28 (93%) had at least one 
positive blood Xpert-ultra. Eighteen patients were positive by all three tests; 5 by two 
tests, 4 by one test, and 1 patient was negative on all tests at all time points.  
This aggregate (test positive on at least one timepoint = MTBBSI detected by that 
diagnostic), was used to calculate diagnostic performance. Compared to MFL blood 
culture as gold standard, blood Xpert-ultra had sensitivity 0.95 (95%CI 0.75 to 1.00) and 
specificity 0.12 (95%CI 0.00 to 0.53), and DMN-tre microscopy had sensitivity 0.95 
(95%CI 0.75 to 1.00) and specificity 0.62 (95%CI 0.24 to 0.91).  
If the gold standard was defined as MTBBSI detected by two or more diagnostics (at any 
timepoint), sensitivity was 0.87, 0.96, and 0.96, and specificity was 1.00, 1.00, and 0.20, 
for MFL, DMN-tre microscopy, and blood Xpert-ultra respectively (table 13).  
 
Table 5-13. Sensitivity & specificity of MTBBSI detection in patient for each 
diagnostic. 
DMN-tre 
positive
DMN-tre 
negative
Blood -Xpert-
ultra positive
Blood -Xpert-
ultra negative
DMN-tre 
positive
DMN-tre 
negative
MFL 
positive
42 3
MFL 
positive
46 6
Blood -Xpert-
ultra positive
61 13
MFL 
negative
30 25
MFL 
negative
36 23
Blood -Xpert-
ultra negative
11 12
p=6.0e-06 p=7.6e-06 p=0.838
DMN-tre 
positive
DMN-tre 
negative
Blood -Xpert-
ultra positive
Blood -Xpert-
ultra negative
DMN-tre 
positive
DMN-tre 
negative
MFL 
positive
16 0
MFL 
positive
16 3
Blood -Xpert-
ultra positive
16 2
MFL 
negative
4 5
MFL 
negative
4 4
Blood -Xpert-
ultra negative
4 2
p=0.134 p=1 p=0.838
Timepoint 0hours only (pre-antimicrobials):
All patient-timepoints:
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Gold standard = MTBBSI detected by ≥ 2 diagnostics (n=23)  
  Sensitivity (95%CI) Specificity (95%CI) 
MFL blood culture 0.87 (0.66 to 0.97) 1.00 (0.48 to 1.00) 
DMN-tre microscopy 0.96 (0.78 to 1.00) 1.00 (0.48 to 1.00) 
Blood Xpert-ultra 0.96 (0.78 to 1.00) 0.20 (0.01 to 0.72) 
Gold standard = MTBBSI detected by ≥ 1 diagnostics (n=27) 
  Sensitivity (95%CI) Specificity* (95%CI) 
MFL blood culture 0.74 (0.54 to 0.89) 1.00 (0.02 to 1.00) 
DMN-tre microscopy 0.81 (0.62 to 0.94) 1.00 (0.02 to 1.00) 
Blood Xpert-ultra 0.96 (0.81 to 1.00) 1.00 (0.02 to 1.00) 
* Specificity under this gold-standard is, by definition, equal to 1.00 (as if any diagnostic 
was positive patients are defined as having MTBBSI, so false positives are impossible) 
so is not meaningful. 
 
5.4.2.4 MTBBSI detection by timepoint 
Detection of MTBBSI by method over time and patient is shown in figure 18, and 
summarised across patients in figure 19. A marked decline in MFL culture positivity 
was seen by 4 hours after receipt of anti-tuberculosis chemotherapy, with continued 
decline out to 72 hours. In contrast, detection of TB in blood by DMN-tre microscopy 
and Xpert-ultra persisted to 72 hours, the last observed timepoint. 
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Figure 5-18. MTBBSI detection by method, patient & timepoint. 
uGXP = urine Xpert-ultra; MFL = MFL blood culture; GXP = blood Xpert-ultra; DMN = DMN-
tre microscopy. Each 4x5 block represents a different patient (n=28). 
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Figure 5-19. MTBBSI detection across patients by method & timepoint. 
 
5.4.2.5 Quantification of MTBBSI: univariate & bivariate distributions 
Distributions are shown for the three methods of quantifying MTBBSI, along with urine 
Xpert-ultra CT, in figure 20. These show patients’ DMN-tre bacilli count per ml has a 
positively skewed distribution, with a long tail extending into thousands of bacilli per ml. 
This long-tail of very high bacilli burden is not obvious from the TTD and CT 
distributions.  
Moderate to strong pairwise correlation between the three measures of bacilli burden 
were apparent, and were more pronounced than correlation of blood measures with 
urine Xpert-ultra CT value (figure 21). 
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Figure 5-20. MTBBSI quantification: distribution of maximum values by method. 
 
 
Figure 5-21. Pairwise correlations for MTBBSI quantification methods, & urine 
Xpert-ultra CT. 
In general patients have more than one measure on each method of quantification, so the 
maximum (DMN-tre count) or minimum (TTD and CT values) value by patient was extracted to 
summarise. Min = minimum; Max = maximum. 
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5.4.2.6 Time-kill curves for MTBBSI by method of quantification 
Quantitative values for MFL culture (time to detection, TTD), DMN-tre microscopy 
(log bacilli per ml blood), blood Xpert-ultra (CT value), and urine Xpert-ultra (CT value) 
over time by patient are shown from 0 to 72 hours in figures 22 to 25. In the majority, a 
line can be fit to available data by patient, and in most of these TTD and blood CT values 
increase, while DMN-tre bacilli per ml decrease. There is, however, marked variation in 
the intercept (which is generally the maximum or minimum value for each patient) and 
the slope of the fitted lines.   
In contrast to the blood time-kill curves, urine Xpert-ultra CT values were in most cases 
flat over the time course (figure 25). 
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Figure 5-22. TTD in MFL MTBBSI time-kill curve. 
Each patient is shown in different panel. In cases where cultures became negative (an initial 
positive test was followed by one or more negative tests, not including missing/invalid results), 
the first negative test was imputed at the limit of detection value (TTD = 42 days). Curves are 
modelled with a line of best fit on TTD scale. 
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Figure 5-23. Log DMN-tre+ bacilli per ml MTBBSI time-kill curve. 
Each patient is shown in different panel. In cases where DMN-tre microscopy became negative 
(an initial positive test was followed by one or more negative tests, not including missing/invalid 
results), the first negative test was imputed at the limit of detection value (= 1 bacilli per ml, 
rounded to nearest whole number). Curves are modelled with a line of best fit on log scale, 
representing a mono-exponential decline. 
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Figure 5-24.Blood Xpert-ultra CT value MTBBSI time-kill curve. 
Each patient is shown in different panel. In cases where blood Xpert-ultra became negative (an 
initial positive test was followed by one or more negative tests, not including missing/invalid 
results), the first negative test was imputed at the limit of detection value (CT = 50). Curves are 
modelled with a line of best fit on CT scale, which approximates a log2 scale (doubling cycle 
threshold), thus likely represents a mono-exponential decline. 
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Figure 5-25. Urine Xpert-ultra CT value MTBBSI time-kill curve. 
Each patient is shown in different panel. In cases where urine Xpert-ultra became negative (an 
initial positive test was followed by one or more negative tests, not including missing/invalid 
results), the first negative test was imputed at the limit of detection value (CT = 50). Curves are 
modelled with a line of best fit on CT scale, which approximates a log2 scale (doubling cycle 
threshold), thus likely represents a mono-exponential decline. 
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5.4.2.7 Pharmacodynamic summary measures extracted from time-kill curves 
To allow assessment for associations between MTBBSI pharmacodynamics and clinical 
outcomes, three summary measures of the time-kill curves were extracted. 
1. The minimum (CT and TTD) or maximum (DMN-tre bacilli count) observed value 
for each patient. 
2. The slope of the fitted line, extracted as the gradient parameter from an lmList() 
object generated using lme4 package in R. 
3. The area under the time-kill curve (AUC), representing overall exposure to the 
bacillaemia during the 72-hour period of observation. This was extracted using the 
trapezoid method from DescTools package in R. For this analysis, missing values due 
to negative tests were imputed with the limit of detection value; missing values due 
to invalid or missing test result were dropped. In the case of the patient who died 
before 72-hours follow-up, the 72-hour AUC was estimated by extrapolating the 
line of best fit to 72-hours. AUCs were calculated relative to the limit of detection 
value, e.g. for Xpert AUC was calculated between the curve and a constant CT value 
of 50 (method illustrated in figure 26) 
 
 
Figure 5-26. Deriving AUC PD summary for time-kill curves 
Shaded yellow area shows area between line connecting all points (not line of best fit) and limit of 
detection (LoD – dashed yellow line), and was calculated using trapezoid rule. This is actually 
area ‘above the curve’ where lower bacilli numbers result in higher measurement values (e.g. 
TTD, A).  It represents the total exposure to bacillaemia over the time period, for example, in 
DMN-tre bacilli counts per ml (B), the units would be log(bacill)•ml-1•hour-1 .  
 
 
In addition, a mixed-effects model, with random intercept and slope permitted by 
patient, was fitted with a fixed effect for timepoint, outcome, and the interaction 
time*outcome. The outcome term allows for a fixed (average) difference in time-kill curve 
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intercept by outcome, and the interaction term allows the slope to differ by outcome. 
The same model was also fitted but without outcome covariates, and the two models 
then compared using likelihood ratio tests. This tests the hypothesis that time-kill 
curves differed on average (in intercept and /or slope) between patients who survived 
and those that died (i.e. were residual sums of squares less when patient outcome was 
included as a covariate). This gives a single global test of time-kill curve function 
association with death. 
The results of PD summary measures and mixed-effects modelling are presented in table 
14 giving comparisons of patients who died to those that survived. In all cases, PD 
summary measures were more adverse in those that died, and several were statistically 
associated with death at alpha<0.05 or alpha<0.1, including MFL TTD slope, DMN-tre 
log bacilli/ml maximum and AUC, blood Xpert-ultra slope and AUC. Inclusion of 
outcome as a covariate in mixed-effects modelling of time-kill dynamics improved model 
fit for DMN-tre and blood Xpert-ultra data (at p = 0.059 and p=0.071 respectively). By 
comparison, none of the urine Xpert summary PD measures were statistically associated 
with mortality.  
In general, PD summary measures also correlated with important clinical variables. For 
example, AUC for log DMN-tre bacilli count per ml was associated with functional 
status, lactate, AST, renal function, extent of infiltrates on chest-x-ray, respiratory rate, 
pulse oximetry O2 saturation, platelet count (and possibly rate of platelet decline during 
admission), total white cell count and CD4 cell count (figure 27 & 28).  
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Table 5-14.  Pharmacodynamic summary measures association with outcome. 
MFL TTD    
PD summary measures Died, median (range) Survived, Median (range) P-value 
Minimum TTD value 21.5 (15 to 35) 24.5 (14 to 34) 0.9669 
Fitted gradient over 72hours 0.005 (0.002 to 0.008) 0.009 (0.000 to 0.060) 0.0758 
AUC, TTD value per hour over 27 hours 262 (0.5 to 899) 67.8 (2.4 to 559) 0.3200 
Mixed-effects model Intercept Slope   
Estimated fixed effect association of death -3.6 -0.08 0.1560 
log DMN-tre bacilli/ml 
    
  
PD summary measures Died, median (range) Survived, Median (range) P-value 
Maximum log bacilli/ml observed 4.5 (3.0 to 10.0) 3.4 (2.6 to 7.2) 0.0344 
Fitted gradient over 72hours   -0.02 (-0.06 to 0.26)   -0.04 (-0.09 to -0.01) 0.2571 
AUC, log bacilli/ml per hour over 27 hours 241 (0 to 591) 102 (0 to 418) 0.0989 
Mixed-effects model Intercept Slope   
Estimated fixed effect association of death 1.85 0.01 0.0594 
Blood Xpert 
    
  
PD summary measures Died, median (range) Survived, Median (range) P-value 
Minimum CT value 27.2 (21.4 to 34.9) 29.9 (21.4 to 37.1) 0.3305 
Fitted gradient over 72hours 0.03 (-0.23 to 0.09) 0.13 (-0.04 to 1.02) 0.0266 
AUC, CT value per hour over 27 hours 1401 (209 to 2040) 430 (5 to 2017) 0.0502 
Mixed-effects model Intercept Slope   
Estimated fixed effect association of death -2.54 -0.23 0.0712 
Urine Xpert 
    
  
PD summary measures Died, median (range) Survived, Median (range) P-value 
Minimum CT value 21.8 (21.0 to 27.5) 22.6 (20.6 to 35.6) 0.6110 
Fitted gradient over 72hours 0.01 (-0.01 to 0.07) 0.02 (-0.68 to 1.22) 0.7798 
AUC, CT value per hour over 27 hours 1697 (0 to 2039) 657 (0 to 2112) 0.3753 
Mixed-effects model Intercept Slope   
Estimated fixed effect association of death -6.3 -0.13 0.3005 
 
P-values for PD summary measure comparisons from Wilcox rank sum, comparing those that 
survived to those that died. P-values for mixed effects models compare a baseline model of form 
bacilli burden ~ timepoint + (timepoint | patient) to model of form bacilli burden ~ timepoint + 
outcome + timepoint*outcome + (timepoint | patient), where random effect is shown in parentheses, 
and bacilli burden is TTD, CT value or log DMN-tre bacilli count per ml, by likelihood ratio test.   
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Figure 5-27. Correlation of clinical variables with PD summary measures. 
Correlation of eight PD summary measures (columns; values by patient for maximum log DMN-
tre bacilli per ml, minimum blood Xpert-ultra CT, minimum urine Xpert-ultra CT, minimum 
TTD in MFL, and AUCs for these detection methods as described in text and figure 26) with 
clinical variables (rows) selected because of their suggested association with mortality (both in 
this sub-study or in the wider KDHTB cohort). These variables were transformed to 
approximate normal distributions (assessed by histograms and QQ plots) where appropriate, and 
correlations were by Pearson’s r (magnitude and direction indicated by colour in matrix plot). P-
values for the Pearson’s r test are indexed as shown. 
 
ECOG = Eastern Cooperative Oncology Group functional performance score; lactate_log = log 
venous lactate level; AST_log = log serum aspartate transaminase; creat_log = log serum 
creatinine; urea_log = log serum urea; CXR.inf.lobes = number of lobes with infiltrate seen on 
chest-x-ray; RR = respiratory rate per minute; sats = oxygen saturation on pulse oximeter; Hb = 
haemoglobin nadir during admission; plt_slope = Platelet count change, cells/µL/day during 
admission (see table 10); platelets_log = log platelet count; wcc_log = log white cell count; 
cd4_log = log CD4 cell count. 
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Figure 5-28. Correlation of clinical variables with AUC72h log DMN-tre bacilli per 
ml. 
These are the raw data for the correlations shown for DMN-tre AUC in the previous figure. Line 
of best fit with 95% confidence interval in shaded area, Pearson’s r and associated p value shown. 
 
ECOG = Eastern Cooperative Oncology Group functional performance score; lactate_log = log 
venous lactate level; AST_log = log serum aspartate transaminase; creat_log = log serum 
creatinine; urea_log = log serum urea; CXR.inf.lobes = number of lobes with infiltrate seen on 
chest-x-ray; RR = respiratory rate per minute; sats = oxygen saturation on pulse oximeter; Hb = 
haemoglobin nadir during admission; plt_slope = Platelet count change, cells/µL/day during 
admission (see table 10); platelets_log = log platelet count; wcc_log = log white cell count; 
cd4_log = log CD4 cell count. 
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5.4.2.8 DMN-tre microscopy bacilli morphology 
The majority of TB bacteria seen on microscopy of blood were single bacilli of length 2 – 
4 μm; most, but not all, had a beaded appearance or discontinuous DMN-tre staining 
(figure 29). Doublets, with v-shape arrangement at variable angle, were also common in 
higher bacilli burden patients, more commonly at early timepoints (figure 30). Bacilli of 
length greater than 4μm were not infrequent, sometimes up to 8-10μm, and sometimes 
with the appearance of budding or branching (figure 31, lower row), although these 
features are hard to distinguish from overlaying of more than one bacilli. Longer bacilli 
were more likely to be seen at later timepoints after starting anti-tuberculosis therapy 
(figure 33). Microcolonies of bacilli – clumps of more than 5 bacilli – were also seen 
(figure 32). Three patients had extensive microcolonies on baseline sample (more than 
one per field of view), all three of these patients died.  
 
Figure 5-29. DMN-tre microscopy of MTBBSI: single bacilli 2-4μm. 
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Figure 5-30. DMN-tre microscopy of MTBBSI: doublet bacilli 
 
Figure 5-31. DMN-tre microscopy of MTBBSI: single bacilli 4-10μm 
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Figure 5-32. DMN-tre microscopy of MTBBSI: microcolonies. 
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Figure 5-33. Bacilli length on DMN-tre microscopy by sample timepoint 
Stored microscopy images from five patients with high bacilli burden in blood were processed in 
FIJI/Image-J software. Bacilli length was measured manually along the longest axis using a 
segmented line. 850 bacilli were measured. The distribution of bacilli length shifts so that more 
bacilli from later timepoint samples were >4μm long (A). A mixed-effects model with random 
intercept by patient suggested a significant fixed effect of time on mean log2 bacilli length 
(estimated fixed-effect of time shown with black line, B) – comparing model with bacilli length 
allowed to vary by timepoint to a null model containing only random intercept by patient gives     
p < 2.2e-16 for the effect of time of bacilli length. 
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5.5 Discussion 
This chapter described the development of novel methods for identifying and 
quantifying blood bacilli, and provides evidence that these methods may provide a basis 
for a pharmacodynamic biomarker of treatment response in MTBBSI. Bacilli burden and 
rate of sterilisation of blood varied between patients, and there was evidence that 
summary measures of bacillaemia during the first 72-hours of anti-tuberculosis 
treatment (ATT) correlated with important clinical variables and mortality outcomes. 
The patient sample size was small and the significance tests relating the presented 
MTBBSI PD summary measures to outcome are borderline – none would remain 
significant at alpha <0.05 if corrected for multiple comparison, for example. 
Nevertheless, taken together, the results support the idea that blood bacilli load 
measured with these methods is likely to be causally related to outcome, and therefore a 
promising pharmacodynamic biomarker. Development of these methods could facilitate 
future interventional trials.  
Although the analysis was not designed to validate DMN-tre microscopy and optimised 
blood Xpert-ultra as diagnostics, both performed well against blood culture (both 95% 
sensitive for diagnosing culture positive MTBBSI in a given patient, and significantly 
outperforming MFL blood culture on a paired sample basis across patient-timepoints). 
The fact that most samples were taken after start of ATT may have underestimated 
blood culture sensitivity – carry over of antimicrobial bound to cellular receptors is 
possible despite the processing of blood to remove free antimicrobial. This is suggested 
by the marked drop in MFL positivity even by the 4-hour time point. However, in 
counterpoise, it should also be noted that, at each patient-timepoint, approximately 
double the volume of blood was allocated to MFL culture (2 x 5ml) as to Xpert-ultra (1 x 
5ml) or DMN-microscopy (1 x 3ml), which would have acted to overestimate relative 
MFL culture sensitivity. The blood Xpert-ultra method is particularly feasible as a 
diagnostic test in low resource settings which already have access to Xpert testing 
facilities. Additional processing time compared to sputum is less than 2 hours, with 
283 
 
 
negligible consumable costs. Blood is more easily and rapidly obtained than other patient 
samples for unwell patients in secondary care settings. Hypothetically, a blood-based 
diagnostic could shorten time to diagnosis even more than urine-based diagnostics. In 
the current analysis, blood Xpert-ultra had low specificity (0.20) compared to a 
composite gold-standard. This was because 4 patients had MTBBSI detected by Xpert-
ultra who were culture and DMN-tre microscopy negative on all samples (patients 864, 
874, 880, & 882 in figure 18). All these 4 patients were urine-LAM and urine-Xpert-
ultra positive for M. tuberculosis, so I would argue they were true positive blood-Xpert 
results for disseminated tuberculosis. The overall diagnostic utility of blood Xpert-ultra 
using the method developed in this thesis is currently being tested on stored whole blood 
from the full KDHTB cohort.  
In the current form, DMN-tre microscopy of blood is too labour intensive to be a 
practical diagnostic – requiring extensive (and relatively expensive) processing of blood. 
The technique is, however, a substantive innovation for understanding MTBBSI. The 
results presented in this chapter expand the estimates of bacilli burden in MTBBSI and 
show for the first time that some patients harbour sustained bacteraemia with 10^5 
bacilli per ml. This adds further credence to the idea that bacterial burden is likely to be 
mechanistically related to disease phenotype and outcome in severe HIV-associated TB. 
DMN-tre microscopy count on blood showed a different distribution to MFL TTD, 
correlated more closely with a range of clinical markers of disease severity, and was 
significantly associated with mortality. Bacteraemias in the range 10^5 cells/ml have not 
been described for most pathogens,568-573 but are seen in MAC disease.574 
DMN-tre microscopy also allowed characterisation of bacilli morphology in blood. In 
vitro, mycobacteria length is relatively heterogeneous in log phase, and on average 
shorter and more homogeneous in stationary phase.492 V-forms likely represent active 
growth and ‘snapping division’.492 Eum et al. measured TB bacilli length in cavity 
caseum, sputum, and bronco-alveolar lavage (BAL) fluid, finding bacilli were shortest in 
the former (mean 1.9, range 0.5 to 9μm) and longest in the later (mean 3.6, range 0.5 to 
9μm).567 They concluded that this showed intra-cavity bacilli were in stationary phase, 
while BAL/sputum bacilli were in log growth. The data presented here are the first 
measurement of bacilli length from blood (i.e. bacilli not destined to be expectorated), 
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and to my knowledge the first serial measure of bacilli length at different timepoints into 
ATT. The morphological features were in keeping with unrestricted, log-growth of 
bacilli. The shift to longer bacilli morphology with exposure to antibiotics is in keeping 
with a phenotypic response to ATT mediated through changes in the cell-cycle. This in 
turn echoes the flow cytometry data on cell length from in vitro time-kill curves 
presented in chapter 4.  There are, however, limitations to this analysis. Only five 
patients had enough bacilli imaged to allow distribution of cell sizes to be estimated at 
each timepoint, and the number of bacilli measured was uneven with fewer bacilli 
recorded at later timepoints. It is not always clear if an image shows one long bacilli or 
two short bacilli end-to-end. Finally, although the 18-hour incubation period with 
DMN-tre dye is less than a generation time for mycobacteria, some growth presumably 
has occurred ex vivo in these conditions. Despite this, the results show that MTBBSI 
provides an important window on bacilli phenotypes beyond the airway compartment, 
and supports further investigation of cell-cycle dynamics in relation to drug tolerance.504 
The blood microscopy technique requires complete lysis of human blood cells during 
processing. This unfortunately means the cellular location of bacilli was not visualised. 
However, detection of M. tuberculosis by Xpert-ultra was not significantly higher in 
granulocyte enriched buffy coat preparations compared to red cell pellets – a result not 
in keeping with most bacilli being intracellular. Indeed, the colocalization with red cells 
is surprising and doesn’t seem to occur in spiked samples (data not shown here). 
Despite substantial evidence that M. tuberculosis routinely accesses the blood stream to 
infect distal sites (discussed in chapter 1), little is known about how this occurs.103 
Cellular location of bacilli has implications for understanding the immune response in 
MTBBSI, not least in whole-blood host transcriptome analysis.575 Development of the 
DMN-tre blood microscopy method to preserve white blood cell integrity would be 
worthwhile. 
In conclusion, this chapter has demonstrated novel or optimised methods for identifying 
MTBBSI. These methods can be used to give unprecedented characterisation of 
MTBBSI and are promising biomarkers of treatment response. 
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6 Conclusion 
 
6.1 Main findings & call for interventional 
trials in MTBBSI 
Interventions with enhanced anti-tuberculosis bactericidal activity should be tested in 
patients with severe HIV-associated TB, and, specifically in patients with M. tuberculosis 
blood stream infection (MTBBSI). That is the central message of this thesis, combining 
several lines of evidence. 
The extent and magnitude of M. tuberculosis blood stream dissemination can explain a 
substantial proportion of variance in major clinical variables and risk of death. In chapter 
1, data from the KDHTB cohort study was analysed with respect to MTBBSI. This 
cohort study is the most detailed description of severe HIV-associated tuberculosis 
carried out to date. It was argued that TB blood culture, urine-LAM and urine-Xpert 
results – which strongly covary – all report on blood stream dissemination, and can be 
combined to deal with measurement error in all three tests. Aggregated results of these 
three tests – a “disseminated TB score” – was strongly related to all reduced-dimension 
representations of clinical variables, and to mortality, placing extent and magnitude of 
blood stream infection at the centre of structural models relating clinical phenotype to 
mortality in severe HIV-associated tuberculosis.  
This finding is supported by other work in the thesis. On systematic review of all 
previous studies performing unselected TB blood cultures in people living with HIV 
(IPD meta-analysis in chapter 3), positive TB blood culture had double the hazard ratio 
for death compared to blood culture negative HIV-TB patients, after adjustment for 
major confounders like CD4 count. 
In addition, the smaller sub-study presented in chapter 5 of novel methods for 
quantifying MTBBSI showed that several measures of bacilli burden exposure were 
associated with death, demonstrating a ‘dose-response’ relationship even in this stratum 
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of patients with most severe disease. In addition, this study gives direct evidence that 
the dynamics of bacterial load during initial antimicrobial treatment is a determinant of 
outcome.   
Each of these lines of evidence has limitations. Substantial variance in clinical 
observations and mortality is unexplained by disseminated TB score or MTBBSI; this 
could be due to noise (i.e. measurement error) or to differences in host response at a 
given bacterial load. The IPD meta-analysis successfully reduced apparent heterogeneity 
between studies, but substantial unexplained differences in MTBBSI-associated risk of 
death remained between studies. This is likely related to the marked differences in 
inclusion criteria and study populations across settings, and the included studies may 
not accurately reflect non-study hospital populations as a whole. The major weakness of 
the chapter 5 sub-study is that it is underpowered, particularly because multiple 
comparisons could not be adjusted for with the small sample size. 
Nonetheless, such a systematic and accurate measurement of systemic bacilli burden in 
tuberculosis has not previously been reported, and taken together, these results 
substantiate the long-held belief that bacilli numbers are a major axis of variation 
underlying tuberculosis pathophysiology.45-47 Just as latent tuberculosis is not a 
homogenous category, but probably a spectrum characterised by bacterial load,576,577 so 
too is severe HIV-associated disease at the other end of the tuberculosis gamut, where 
blood stream dissemination is the mode of infection. If bacilli burden and MTBBSI 
drives pathophysiology, more rapid clearance of MTB from blood is a rational 
interventional target.  
One objection to the above reasoning could be that MTBBSI is too rare an event to be 
the mode of infection in HIV-associated tuberculosis. In chapter 2 it was shown that a 
single TB blood culture under-estimates the point prevalence of blood culture positive 
disease by around one-third compared to multiple blood cultures. Since almost all 
studies have relied on a single blood culture, the previous estimates of MTBBSI 
prevalence are flawed. In chapter 3, all available individual patient data from studies 
performing unselected TB blood cultures were reanalysed with model-based adjustment 
for this, and other technical factors such as timing of antimicrobials. This showed that 
TB was more commonly cultured than not from the bloodstream of critically unwell 
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(WHO danger-sign positive) inpatients with HIV-associated tuberculosis and a CD4 
count less than 100 cells/mm3.§§§§§§§§§ This hypothesised patient population probably 
encompasses a majority of patients who die in hospital of HIV-associated 
tuberculosis.19,217 Notably, blood culture, the gold-standard diagnostic, may have poor 
sensitivity for MTBBSI. The in vitro work described in chapter 4 adds to the growing 
evidence that mycobacteria are often non-culturable under standard conditions yet are 
intact and metabolically active by other measures.403,404,407 Although not designed to 
assess diagnostic performance, the sub-study described in chapter 5 suggests the novel 
blood-processing method combined with Xpert-ultra testing has greater sensitivity for 
detecting MTBBSI than culture. This may be because of antimicrobial carry-over in 
blood culture despite plasma removal or lysis/wash prior to inoculation, but is currently 
being investigated in the wider KDHTB cohort using stored whole blood samples.  
As it stands, the evidence outlined suggests that bacillaemia has been under-ascertained 
due to simple technical reasons, and MTBBSI is highly prevalent in HIV-infected 
patients at highest risk of death. Patients with detectable TB in blood are a rational 
population in which to assess current and novel management strategies aimed at 
reducing persistently high inpatient HIV-associated mortality.  
This can be illustrated with the issue of empirical TB therapy in patients with advanced 
HIV infection. Evidence from the IPD meta-analysis suggested that delay of empirical 
treatment in HIV-associated TB by four days or more (a cut-off chosen to reflect the 
WHO algorithm for seriously unwell patients with suspected TB and non-diagnostic 
initial tests) was associated with greater mortality after adjustment for disease severity. 
Importantly, this effect was evident only for patients with MTBBSI, with a significant 
interaction between treatment delay and positive blood culture. This was also seen in 
the STAMP trial, which established that availability of urine-based rapid diagnostics 
decreased time to TB diagnosis amongst HIV-infected inpatients, and this resulted in a 
7-9% absolute mortality reduction in patients with CD4 count < 100/mm3 or 
haemoglobin <8d/dL.22 By contrast, the negative findings reported from trials of 
                                                             
§§§§§§§§§ Assumes two blood cultures are taken prior to start of antimicrobial therapy, and that the 
population in question has a uniform CD4 count distribution between 0 and 100. 
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presumptive TB therapy in people living with HIV349-351 can be understood by the 
exclusion of patients most likely to have had MTBBSI.  
As well as making a case for interventional trials focussed on MTBBSI, this thesis has 
developed tools to facilitate such studies. Presence of MTBBSI can be reliably predicted 
using the modelling approaches outlined and validated in chapter 2. DMN-trehalose 
microscopy of blood, and optimised blood processing methods combined with culture 
and Xpert-ultra testing, demonstrate potential as pharmacodynamic biomarkers which 
could maximise power.  
6.2 Secondary findings & future directions 
The ability of a novel flow cytometry to probe in vitro pharmacodynamics of 
mycobacteria was shown in chapter 4. The potential for high-throughput 
characterisation of phenotypic sub-populations would be a major advance if this method 
could be combined with DMN-trehalose staining in clinical samples. Differences in 
bacilli morphology (length and nucleic acid staining with SYBR-gold) were shown to 
define discrete sub-populations in an antimicrobial dependent manner in in-vitro 
cultures of M. bovis BCG. Distribution of bacilli length in blood samples appears to 
increase with antimicrobial exposure in clinical samples, as shown with manual 
measurement of DMN-trehalose microscopy images. As noted by leading molecular 
mycobacteriologists,504 morphology phenotype has been related to cell-cycle dynamics, 
drug-tolerance, and propensity to develop drug-resistance in other bacteria, and could 
be an important mechanism of poor treatment response in tuberculosis. The ability to 
label, cell-sort, and investigate ex vivo, bacilli with different morphological phenotypes 
from clinical samples could support basic science investigations in this area. Further, 
cytometry-based time-kill curves could better characterise drug tolerance between 
clinical isolates ex vivo. While minimum inhibitory concentration of (wild-type) TB 
isolates to first-line drugs may not be variable enough to be a major determinant of 
outcome,578 measures of bacteriocidal activity could be independent of bacteriostatic 
activity,497 and remain to be investigated in detail. Such an approach would be possible 
using the flow method, if technical difficulties about standardising in vitro culture can be 
overcome.  
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The systematic phenotyping of patients using the ‘disseminated TB score’ facilitates a 
rational approach to characterising host-response. Previously, immunological 
investigations of advance HIV-associated tuberculosis have attempted to adjust for 
bacteriological variation by crude stratification, such as pulmonary versus extra-
pulmonary disease. By contrast, systematic quantification of blood stream dissemination 
has better resolution of patients on a continuous scale, avoids ascertainment bias 
(diagnosis of extra-pulmonary disease in pulmonary TB patients is largely a function of 
how hard you look for extra-pulmonary disease), and other category errors (extra-
pulmonary disease can be paucibacillary and localised, or multibacillary and 
disseminated; merging all makes little sense clinically). In a planned analysis of KDHTB 
whole blood RNA, transcriptome data will be related to burden of MTBBSI using the 
disseminated TB score. 
Finally, it has been argued here that MTBBSI is the elephant in the room for severe 
HIV-associated TB, but that elephant is also increasingly spotted by researchers working 
on sepsis more generally. The finding that TB bacteraemia is the foremost 
microbiological diagnosis in patients with severe sepsis in cohorts127,332 and RCTs268,289 
from high HIV-burden settings, has led to calls to include TB in the sepsis research 
agenda.353  The analysis in this thesis supports the idea that MTBBSI is an informative 
model of sepsis. In support of recent developments in the understanding of sepsis 
pathophysiology,247,248,251 blood lactate is more closely related to inflammation (and 
bacilli load) than markers of macro-haemodynamic compromise in MTBBSI. If elevated 
lactate is caused by upregulated aerobic glycolysis from tuberculosis-induced 
inflammation,252,253 this finding could be corroborated by correlating 24-hour lactate 
production with extent of F-fluorodeoxyglucose uptake as measured by positron 
emission tomography (FDG-PET-CT) scanning in patients with HIV-associated TB and 
sepsis. Similarly, there is little evidence that the substantial proportion of MTBBSI 
patients with acute kidney injury (AKI) is the result of hypotension. Rather, a complex 
(and probably sub-acute) pathophysiology involving both depletion of extra-cellular fluid 
circulating volume from profound sodium and water depletion, and abnormalities of 
ADH regulation well established in tuberculosis, is suggested. The mortality-effect of 
highly-aggressive fluid resuscitation protocols in sepsis patients who predominantly 
have MTBBSI is understandable considering these findings.268,289 A next step could be 
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to establish how much AKI is attributed to functional, adaptive host-responses, and how 
much is related to direct pathological ‘hits’ capable of decompensating this response. It 
would be surprising if filtering blood volumes per day corresponding to tens of millions 
of TB bacilli did not have direct pathological sequalae on the kidney. This could be 
investigated with urine and blood biomarkers reporting renal cytotoxicity and ischaemia 
in MTBBSI patients,178 which could in turn be an important host-biomarker of 
treatment response in intervention trials.  
6.3 Conclusion 
In summary, MTBBSI is a common and specific form of HIV-associated tuberculosis 
seen in high-burden settings. It is patho-physiologically distinct from ‘classic’ 
pulmonary forms of tuberculosis and is responsible for disproportionate mortality. 
Despite this no interventional evidence-base exists for its management. The data and 
tools to remedy this neglect are now available.  
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8 Appendix 
8.1 Ethics approvals 
The sub-study described in chapter 5 was completed under an amendment to the 
KDHTB ethics approval by the Human Research Ethics Committee (HREC), 
University of Cape Town. The HREC submission protocol and approval documentation 
are attached below. 
 
Form FHS006: Protocol Amendment 
 
HREC office use only (FWA00001637; IRB00001938) 
  Approved    Type of review: Expedited    Full committee  
This serves as notification that all changes and documentation described below are approved. 
Signature Chairperson of the HREC  Date  
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Note: All major amendments must include a local PI Synopsis justifying the changes for the amendment.  
Please note that incomplete amendment submissions will not be reviewed.  
Comments from the HREC to the Principal Investigator: 
 
Note: The approval of this protocol amendment does not grant annual approval. Please complete the 
FHS016 / FHS017 form for annual approval at least one month before study expiration.  
 
Principal Investigator to complete the following:  
1. Protocol information 
Date (when submitting 
this form) 
11 July 2017 
HREC REF Number 057/2013 
Protocol title  
Defining interventions to reduce mortality in severe HIV-associated tuberculosis 
(Short title: KDH-TB study) 
Protocol number  
(if applicable)   
NA 
Principal Investigator Graeme Meintjes 
Department / Office 
Internal Mail Address 
 
CIDRI office, 1st floor, Wolfson Pavilion, IDM, FHS 
1.1 Is this a major or a minor amendment? (see FHS006hlp) 
Major (tick box)  Minor (tick box) 
  Major  ✓  Minor 
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1.2 Does this protocol receive US Federal funding? 
  Yes  
  
✓  No 
1.3 If the amendment is a major amendment and receives US 
Federal Funding, does the amendment require full committee 
approval? 
  Yes  
  
  No 
 
 
 
2. List of Proposed Amendments with Revised Version Numbers and 
Dates 
Please itemise on the page below, all amendments with revised version numbers and dates, which 
need approval.  
This page will be detached, signed and returned to the PI as notification of approval. Please add extra pages 
if necessary. 
Revised consent form “KDHTB_MTBBSI_serial_quantification.ICF_English.V3.0_12Jul2017” 
See section 4.1 
3. Protocol status (tick ✓) 
✓ Open to enrolment 
 No participants have been enrolled 
 
 
 
 
Closed to enrolment (tick ✓) 
Research-related activities are ongoing 
Research-related activities are complete, long-term follow-up only 
      Research-related activities are complete, data analysis only 
4. Proposed changes will affect: (tick ✓ all the categories that apply) 
 Protocol 
 
Study objectives, design (including investigator’s brochure, clinical activities, study length) 
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 
Study instruments, questionnaires, interview schedules 
✓ 
Sample size 
 
Recruitment methods 
✓ 
Eligibility criteria (inclusion and exclusion criteria) 
 
Drug/device (composition, amount, schedule, route of administration, combination with other 
drugs/devices, safety information) 
 
Data collection/ analysis 
 
Principal Investigator. (Please attach revised conflict of interest and PI declaration statements. Refer: 
sections 7 and 8.4 in the New Protocol Application Form FHS013) 
✓ 
Consent form and information sheet 
 
Recruitment materials (e.g. advertisements) 
 
Administrative (e.g. change in sponsor’s name, change in contact information) 
✓ 
Other. Please specify: 
• We want to take a higher volume of blood during scheduled venesections, for additional/novel 
detection of M. tuberculosis blood stream infection. 
 
 
4.1 In your opinion, will there be any increase in risk, discomfort or 
inconvenience to participants? 
✓  Yes 
 
  
  No 
If yes, please provide a detailed justification/explanation:  
 
Explanation 
The proposed amendment is to take a larger total volume of blood from individual patients.  
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We previously received HREC permission to collect blood at additional time points (6, 24, 48 and 72 hours 
after recruitment) [057/2013 amendment date 24/04/2016], and also to trial novel techniques to identify M. 
tuberculosis blood stream infection at a single time point [057/2013 amendment date 07/04/2017]. 
 
We now want to use the novel techniques (microscopy, polymerase-chain reaction (PCR) and modified 
culture protocol) in serial time point samples. However, this involves a higher total volume of blood being 
taken from patients. 
 
To off-set this we will not take the baseline blood samples specified in the original KDH-TB study protocol 
(~55ml of blood at baseline, 0 hours). Instead we propose taking 18ml of blood at 5 time points (0, 4, 24, 48, 
72 hours), totaling 90ml at 72 hours. 
 
Comparison of blood volumes in original protocol, 2016 amendment, and current proposed amendment:  
Protocol  Amendment Volume blood first 24h Total volume blood over 72h 
KDH-TB 057/2013 N/A (original protocol) 55ml 55ml 
KDH-TB 057/2013 24/04/2016 60ml 75ml 
KDH-TB 057/2013 Current proposal 36ml 90ml 
 
 
Justification and mitigation of risk, inconvenience, and discomfort 
• Repeated blood culture to determine sterilization of the blood compartment is a standard of care in 
other bacteraemic conditions such as infective endocarditis, and daily venesection is not uncommon 
among unwell inpatients. 
• Although from a different patient population, it has been shown that 100ml of blood venesectioned at 
a single time point is associated with a mean 0.7g/dL (SE for mean 0.1g/dL) haemoglobin drop in 
inpatients (Thavendiranathan et al 2005). This mean drop was smaller in patients with lower 
haemoglobin levels on admission, presumably because patients with higher haemoglobin levels lost 
more per ml venesected. Based on prior literature, Thavendiranathan et al. considered a clinically 
significant change in haemoglobin to be greater than 0.7-1.0 g/dL.  
• Therefore, we propose that patients with haemoglobin levels less than 5g/dL, or symptomatic 
anaemia in the range 5-8g/dL, will be excluded from this additional venesection, thus reducing risk 
of contribution to significant anaemia. Patients with clinical evidence of hypovolaemic shock will also 
be excluded. 
• To reduce inconvenience for participants we would coordinate this venesection to coincide with 
blood sampling for clinical indications (as directed by hospital doctors responsible for patient care). 
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• An additional meal with high dietary iron content would be provided each day to participants 
undergoing additional venesection, to offset any contribution to iron deficiency. 
 
Thavendiranathan, P., et al., Do blood tests cause anemia in hospitalized patients? The 
effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. Journal of general 
internal medicine, 2005. 20(6): p. 520-4. 
 
4.2 What follow-up action do you propose for participants who are already enrolled in the study? 
 
Inform current participants as soon as possible 
 
Re-consent current participants with revised consent/assent forms (append) 
✓ 
No action required 
 
Other. Please describe: 
 
5. Detailed description of the change(s) 
Please attach, for each amendment, a summary of all changes which clearly indicates: 
i. Old wording (e.g. strikethrough text, CHANGED FROM and CHANGED TO) 
ii. New wording (e.g. italicized, bold, tracked) 
iii. Detailed rationale/ justification/ explanation for each change 
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